******These references are the same as in file 1 but now the sequences are displayed**** => d que 14 42 SEA FILE=REGISTRY ABB=ON PLU=ON [G'SAR']A[G'SAR']['HYP'P]['HY P'P]YN/SQSFP L3 36 SEA FILE=HCAPLUS ABB=ON PLU=ON L2 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND (AY<2001 OR PY<2001 OR

=> d hitseq 14 tot

L4

ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN L4

TT 716607-51-1

> RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses) (amino acid sequence; rice nucleic acid mols. and encoded proteins and their uses for plant improvement)

RN 716607-51-1 HCAPLUS

CN Protein (Oryza sativa clone PAT MRT4530 21015C.1.pep fragment) (9CI) (CA INDEX NAME)

1 GGPLAPGGLF PLYKKPREKK APETAPRPKI PGEFGPRGRV GPGGYPFPEP SEO 51 PRKKKAPKRP EESPGEKKPP LLGGGPPYQG SRGGRRPPRK FPPPGWAIWG

101 GKNLFFFPRG GFFFFQKVPA PPQ

PRY<2001)

ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN L4

IT 651799-18-7

RL: PRP (Properties)

(unclaimed protein sequence; cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use)

651799-18-7 HCAPLUS RN

103: PN: US20040018970 SEQID: 102 unclaimed protein (9CI) (CA INDEX NAME) CN

SEQ 1 TGKVALVTGA SSGLGLAIAK RLAKEGAKVV VVDRREEKAE QVAAELKAEL 51 GDRALFIQLD VTDEEQVKAA VAQAVERLGD RLDVLVNNAG ILGPGPPFEE 101 LSEEDWERVI DVNLTGVFLL TQAVLPAMDH MLKRKGGRLV NISSVAGLNV

151 GVPGLSAYSA SKAAVIGLTR SLALELAPHG TGLRVNAVAP GGVDTDMTKA

201 LRSRLIEAKK KVREVADIAD PELEERITST ITPLGRYGVT PEEIANAVLF

251 LASDGASYSV TGQTLNVDGG L

ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN L4

IT 477095-44-6

> RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

477095-44-6 HCAPLUS RN

CN Protein (Mycobacterium avium clone MAV104574 essential) (9CI) (CA INDEX NAME)

SEQ 1 MNAPMSMQPR SRRPLRRAQL SDEVAGHLRA AIMSGELRPG TFIRLDETAA

51 ELGVSVTPVR EALLKLRGEG MVQLEPHRGX RGAAASPAKT SRTSSGCRRP

101 SPRSWPPRPP TTSPTPRSTS WIASTTRSPR RSGPATPRPS RASSSASTGS

151 STRPAAGSSW PGSCSTPPAT CRCWCTPPTR SGGGPPFDNH RQLIAASAPP

201 RHRRGDRAHG LAVHRRGGAA DRDARPHRDA EQPGVSSRPT ARRAA

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

IT 355151-33-6P 355151-45-0P 355151-46-1P

355151-47-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

RN 355151-33-6 HCAPLUS

CN D-Asparagine, glycyl-D-alanylglycyl-(4S)-4-hydroxy-D-prolyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 355151-45-0 HCAPLUS

CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-glutaminylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 355151-46-1 HCAPLUS

CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 355151-47-2 HCAPLUS

CN Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl)
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 463362-44-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(synthesis of peptides and medical uses of intracellular communication

facilitating compds.)

RN 463362-44-9 HCAPLUS

CN L-Aspartamide, glycyl-L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl- (9CI) (CA INDEX NAME)

NTE modified

SEO 1 GAGXPYN

Absolute stereochemistry.

L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

IT 444214-05-5

RL: PRP (Properties)

(unclaimed protein sequence; human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses)

RN 444214-05-5 HCAPLUS

CN 50: PN: WO02059315 SEQID: 102 unclaimed protein (9CI) (CA INDEX NAME)

SEQ 1 TGKVALVTGA SSGIGLAIAK RLAKEGAKVV VVDRREEKAE QVAAELKAEL

51 GDRALFIQLD VTDEEQVKAA VAQAVERLGD RLDVLVNNAG ILGPGPPFEE

101 LSEEDWERVI DVNLTGVFLL TQAVLPAMDH MLKRKGGRIV NISSVAGLNV

151 GVPGLSAYSA SKAAVIGLTR SLALELAPHG TGIRVNAVAP GGVDTDMTKA

201 LRSRLIEAKK KVREVADIAD PELEERITST ITPLGRYGVT PEEIANAVLF

251 LASDGASYSV TGQTLNVDGG L

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

IT 408552-03-4P

RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; nucleic acids and their encoded polypeptides from human tissues)

RN 408552-03-4 HCAPLUS

CN Protein (human clone WO0231111-SEQID-704) (9CI) (CA INDEX NAME)

SEQ 1 MGEPRAGAAL DDGSGWTGSE EGSEEGTGGS EGAGGDGGPD AEGVWSPDIE

51 QSFQEALAIY PPCGRRKIIL SDEGKMYGRN ELIARYIKLR TGKTRTRKQV

101 SSHIQVLARR KSREIQSKLK DQVSKDKAFQ TMATMSSAQL ISAPSLQAKL

151 GPTGPQASEL FQFWSGGSGP PWNVPDVKPF SQTPFTLSLT PPSTDLPGYE

- 201 PPQALSPLPP PTPSPPAWQA RGLGTARLQL VEFSAFVEPP DAVDSYQRHL
- 251 FVHISQHCPS PGAPPLESVD VRQIYDKFPE KKGGLRELYD RGPPHAFFLV
- 301 KFWADLNWGP SGEEAGAGGS ISSGGFYGVS SQYESLEHMT LTCSSKVCSF
- 351 GKQVVEKVET ERAQLEDGRF VYRLLRSPMC EYLVNFLHKL RQLPERYMMN
- 401 SVLENFTILQ VVTNRDTQEL LLCTAYVFEV STSERGAQHH IYRLVRD
- L4 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
- IT 429718-39-8

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(amino acid sequence; human nucleic acids and polypeptides and their diagnostic and therapeutic uses)

- RN 429718-39-8 HCAPLUS
- CN Protein (human clone WO0175067-SEQID-32147) (9CI) (CA INDEX NAME)
- SEO 1 XPRWGKPRAG AALDDGSGWT GSEEGSEEGT GGSEGAGGDG GPDAEGVWSP
 - 51 DIEQSFQEAL AIYPPCGRRK IILSDEGKMY GRNELIARYI KLRTGKTRTR
 - 101 KQVSSHIQVL ARRKSREIQS KLKALNVDQV SKDKAFQTMA TMSSAQLISA
 - 151 PSLQAKLGPT GPQVVQASEL FQFWSGGSGP PWNVPDVKPF SQTPFTLSLT
 - 201 PPSTDLPGYE PPQALSPLPP PTPSPPAWQA RGLGTARLQL VEFSAFVEPP
 - 251 DAVDSYQRHL FVHISQHCPS PGAPPLESVD VRQIYDKFPE KKGGLRELYD 301 RGPPPCLLPG QFWADLNWGP SGEEAGAGGS ISSGGFYGVS SQYESLEHMT
 - 351 LTCSSKVCSF GKQVVEKVET ERAQLEDGRF VYRLLRSPMC EYLVNFLHKL
 - 401 RQLPERYMMN SVLENFTILQ VVTNRDTQEL LLCTAYVFEV STSERGAQHH
 - 451 IYRLVRD
- L4 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
- IT 367620-13-1

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(amino acid sequence; nucleic acids encoding human bone marrow-expressed polypeptides)

- RN 367620-13-1 HCAPLUS
- CN Bone marrow-specific protein (human clone WO0179447-SEQID-38 precursor) (9CI) (CA INDEX NAME)
- SEQ 1 MQGDSKFSSQ GTGPPYQDLS TKSRIALNRA LLVAKGRTVN IYTDSKYAFA
 - 51 TLHAHGAIYK ERGLLTAGGK EIKEEILQLL EAVWAPDKVA VIHCKGHQTR
 - 101 GGIEAKGNRK ADREARQAAM SNSSTKKKTP TLLLLLEPSL PETPSYSPNE
 - 151 KAWFEQESGS YIQGGRWKFS DGRLAIPEAI APQFMKQFHQ GTHMGKTALE
 - 201 TLVGWHFYVP CLTAITRAVC EQCLTCAQNN PWQVPTQPPG IQETGATPCE
 - 251 NLLVDFTELP RARGYQYMLV FVCTFSGWVE AFPTRIEKAQ EVTRLLLKDI
 - 301 IPRFGLPLTL GSDNGPAFMA EVVQQLSQLL KIKWKLHIVY HPQSSGKVQW
 - 351 MNQTLKHLLK FCQEPHLRWD QVLPMGLSPS QVYPYQIDWA FTL
- L4 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
- IT 355151-33-6P 355151-45-0P 355151-46-1P

355151-47-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel antiarrhythmic peptides)

RN 355151-33-6 HCAPLUS

CN D-Asparagine, glycyl-D-alanylglycyl-(4S)-4-hydroxy-D-prolyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

SEQ 1 GAGXPYN

Absolute stereochemistry.

RN 355151-45-0 HCAPLUS

CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-glutaminylglycyl] (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 AGXPYQG

RN 355151-46-1 HCAPLUS

CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl] (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 AGXPYNG

RN 355151-47-2 HCAPLUS

CN Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl) (9CI) (CA INDEX NAME)

NTE cyclic

SEQ 1 AGPPYNG

ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN L4IT 295808-32-1 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (amino acid sequence; sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from human adult and fetal brain cDNA libraries) RN 295808-32-1 HCAPLUS CNProtein (human clone fj01441 gene KIAA1466 fragment) (9CI) (CA INDEX SEO 1 ETNPLRTOTL NISQREAGLY OKGSAEPGMO GDSKFSSQGT GPPYODLSTK 51 SRIALNRALL VAKGRTVNIY TDSKYAFATL HAHGAIYKER GLLTAGGKEI 101 KEEILQLLEA VWAPDKVAVI HCKGHQTRGG IEAKGNRKAD REARQAAMSN 151 SSTKKKTPTL LLLLEPSLPE TPSYSPNEKA WFEQESGSYI QGGRWKFSDG 201 RLAIPEAIAP QFMKQFHQGT HMGKTALETL VGWHFYVPCL TAITRAVCEQ 251 CLTCAONNPW OVPTOPPGIQ ETGATPCENL LVDFTELPRA RGYQYMLVFV 301 CTFSGWVEAF PTRIEKAQEV TRLLLKDIIP RFGLPLTLGS DNGPAFMAEV 351 VQQLSQLLKI KWKLHIVYHP QSSGKVQWMN QTLKHLLKFC QEPHLRWDQV 401 LPMAFLQVRC TLTKLTGLSP CEIVFGRPPP IINQVKGDLW ELGELTLKRQ 451 MQALGLAMQK IHGWVREKLP ISLTDPVHPF TPGDLVWVKK WNPTTLGPIW 501 DGPTL ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN L4IT 227783-92-8 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (amino acid sequence; complete genome sequence of Aeropyrum pernix K1) RN 227783-92-8 HCAPLUS 132Aa long protein (Aeropyrum pernix strain Kl gene APE1292) (9CI) CN (CA INDEX NAME) 1 MEVCHAQIVL LIPCRGGEHY VGVYRGGGHP EVYCHQEVQL PLGGGPPYNL SEQ 51 LDEAPVHLLA HRLGHRAPQQ VLQEVLVALA AAAEEVSPPD EHDPNPVLRG 101 VRVLYRQLQL AALQKVYHVL HGILPKPPSL RR L4ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN 193843-04-8, Cadherin 5 (mouse F-2 cell) IT RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (amino acid sequence; in vivo evidence of critical role of cadherin-5 in murine vascular integrity) 193843-04-8 HCAPLUS RN Cadherin 5 (mouse F-2 cell) (9CI) (CA INDEX NAME) CN*** STRUCTURE DIAGRAM IS NOT AVAILABLE *** 173432-45-6, Cadherin 5, prepro- (Mus musculus) RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

173432-45-6 HCAPLUS

RN

CN Cadherin 5, prepro- (Mus musculus) (9CI) (CA INDEX NAME)

```
1 MQRLTELATA LGAFLGLLAV AAMAGPNFPQ IDTPNMLPAH HRQKRDWIWN
SEQ
        51 QMHIDEEKNE SLPHYVKDQS NVNRQNAKYV LQGEFAGKIF GVDANTGNVL
       101 AYERLDREKV SEYFLTALIV DKNTNKNLEQ PSSFTVKVHD INDNWPVFSH
       151 QVFNASVPEM SAIGTSVIRV TAVDADDPTV AGHATVLYQI VKGNEYFSID
       201 NSGLIFTKIK NLDREKQAEY KIVVETQDAL GLRGESGTAT VMIRLEDIND
       251 NFPVFTQSTY TFSVPEDIRV GKPLGFLTVV DPDEPQNRMT KYSIMQGEYR
       301 DTFTIETDPK RNEGIIKPTK SLDYEVIQQY TFYIEATDPT IRYEYLSSTS
       351 GKNKAMVTIN VLDVDEPPVF ORHFYHFKLP ENOKKPLIGT VVAKDPDKAQ
       401 RSIGYSIRKT SDRGQFFRIT KQGNIYNEKE LDRETYAWYN LTVEANELDS
       451 RGNPVGKESI VQVYIEVLDE NDNPPEFAQP YEPKVCENAA QGKLVVQISA
       501 TDKDVVPVNP KFKFALKNED SNFTLINNHD NTANITVKYG OFNREHAKFH
       551 YLPVLISDNG VPSLTGTSTL TVGVCKCNEQ GEFTFCEEMA AQAGVSIQAL
       601 VAIFLCILTI TVITLLIILR RRIRKQAHAH SKSALEIHEQ LVTYDEEGGG
       651 EMDTTSYDVS VLNSVRGGST KPLRSTMDAR PAVYTQVQKP PRLAPGLHGG
       701 PREMATMIDV KKEEADNDGG GPPYDTLHIY GYEGAESIAE SLSSLSTNSS
       751 DSDIDYDFLN DWGPRFKMLA ELYGSDPQEE LII
    ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
L4
IT
    RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (amino acid sequence; a novel family of developmentally regulated
        mammalian transcription factors containing the TEA/ATTS DNA binding domain)
    181829-01-6 HCAPLUS
RN
    RNA formation factor TEF-5 (human fragment reduced) (9CI) (CA INDEX NAME)
CN
        1 GAGGDGGPDA EGVWSPDIEQ SFQEALAIYP PCGRRKIILS DEGKMYGRNE
SEQ
        51 LIARYIKLRT GKTRTRKQVS SHIQVLARRK SREIQSKLKD QVSKDKAFQT
       101 MATMSSAQLI SALSLQAKLG PTGPQASELF QFWSGGSGPP WNVPDVKPFS
       151 QTPFTLSLTP PSTDLPGYEP PQALSPLPPP TPSPPAWQAR GLGTARLQLV
       201 EFSAFVEPPD AVDSYQRHLF VHISQHCPSP GAPPLESVDV RQIYDKFPEK
       251 KGGLRELYDR GPPHAFFLVK FWADLNWGPS GEEAGAGGSI SSGGFYGVSS
       301 QYESLEHMTL TCSSKVCSFG KQVVEKVETE RAQLED
    ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
L4
    173432-45-6, Cadherin 5, prepro- (Mus musculus)
    173432-46-7, Cadherin 5 (Mus musculus)
    RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP
     (Properties); BIOL (Biological study); OCCU (Occurrence)
        (amino acid sequence; cDNA sequence and tissue distribution of murine
        vascular endothelial-cadherin in early stage development of
        cardiovascular system)
    173432-45-6 HCAPLUS
RN
    Cadherin 5, prepro- (Mus musculus) (9CI) (CA INDEX NAME)
CN
        1 MQRLTELATA LGAFLGLLAV AAMAGPNFPQ IDTPNMLPAH HRQKRDWIWN
SEQ
        51 QMHIDEEKNE SLPHYVKDQS NVNRQNAKYV LQGEFAGKIF GVDANTGNVL
       101 AYERLDREKV SEYFLTALIV DKNTNKNLEQ PSSFTVKVHD INDNWPVFSH
```

151 QVFNASVPEM SAIGTSVIRV TAVDADDPTV AGHATVLYQI VKGNEYFSID

```
10772774
      201 NSGLIFTKIK NLDREKQAEY KIVVETQDAL GLRGESGTAT VMIRLEDIND
      251 NFPVFTQSTY TFSVPEDIRV GKPLGFLTVV DPDEPQNRMT KYSIMQGEYR
      301 DTFTIETDPK RNEGIIKPTK SLDYEVIQQY TFYIEATDPT IRYEYLSSTS
      351 GKNKAMVTIN VLDVDEPPVF QRHFYHFKLP ENQKKPLIGT VVAKDPDKAQ
      401 RSIGYSIRKT SDRGQFFRIT KQGNIYNEKE LDRETYAWYN LTVEANELDS
      451 RGNPVGKESI VQVYIEVLDE NDNPPEFAQP YEPKVCENAA QGKLVVQISA
      501 TDKDVVPVNP KFKFALKNED SNFTLINNHD NTANITVKYG QFNREHAKFH
      551 YLPVLISDNG VPSLTGTSTL TVGVCKCNEQ GEFTFCEEMA AQAGVSIQAL
      601 VAIFLCILTI TVITLLIILR RRIRKQAHAH SKSALEIHEQ LVTYDEEGGG
      651 EMDTTSYDVS VLNSVRGGST KPLRSTMDAR PAVYTQVQKP PRLAPGLHGG
      701 PREMATMIDV KKEEADNDGG GPPYDTLHIY GYEGAESIAE SLSSLSTNSS
      751 DSDIDYDFLN DWGPRFKMLA ELYGSDPQEE LII
    173432-46-7 HCAPLUS
CN Cadherin 5 (Mus musculus) (9CI) (CA INDEX NAME)
        1 DWIWNOMHID EEKNESLPHY VKDQSNVNRQ NAKYVLQGEF AGKIFGVDAN
       51 TGNVLAYERL DREKVSEYFL TALIVDKNTN KNLEQPSSFT VKVHDINDNW
      101 PVFSHQVFNA SVPEMSAIGT SVIRVTAVDA DDPTVAGHAT VLYQIVKGNE
      151 YFSIDNSGLI FTKIKNLDRE KQAEYKIVVE TQDALGLRGE SGTATVMIRL
      201 EDINDNFPVF TQSTYTFSVP EDIRVGKPLG FLTVVDPDEP QNRMTKYSIM
      251 OGEYRDTFTI ETDPKRNEGI IKPTKSLDYE VIQQYTFYIE ATDPTIRYEY
      301 LSSTSGKNKA MVTINVLDVD EPPVFQRHFY HFKLPENQKK PLIGTVVAKD
      351 PDKAQRSIGY SIRKTSDRGQ FFRITKQGNI YNEKELDRET YAWYNLTVEA
      401 NELDSRGNPV GKESIVQVYI EVLDENDNPP EFAQPYEPKV CENAAQGKLV
      451 VQISATDKDV VPVNPKFKFA LKNEDSNFTL INNHDNTANI TVKYGQFNRE
      501 HAKFHYLPVL ISDNGVPSLT GTSTLTVGVC KCNEQGEFTF CEEMAAQAGV
      551 SIQALVAIFL CILTITVITL LIILRRRIRK QAHAHSKSAL EIHEQLVTYD
      601 EEGGGEMDTT SYDVSVLNSV RGGSTKPLRS TMDARPAVYT QVQKPPRLAP
      651 GLHGGPREMA TMIDVKKEEA DNDGGGPPYD TLHIYGYEGA ESIAESLSSL
      701 STNSSDSDID YDFLNDWGPR FKMLAELYGS DPQEELII
=> d his full
     (FILE 'HOME' ENTERED AT 13:10:47 ON 12 MAR 2007)
    FILE 'REGISTRY' ENTERED AT 13:11:19 ON 12 MAR 2007
    FILE 'LREGISTRY' ENTERED AT 13:13:27 ON 12 MAR 2007
             O SEA ABB=ON PLU=ON [G'SAR']A[G'SAR']['HYP'P]['HYP'P]YN/SQSFP
    FILE 'REGISTRY' ENTERED AT 13:15:31 ON 12 MAR 2007
            42 SEA ABB=ON PLU=ON [G'SAR']A[G'SAR']['HYP'P]['HYP'P]YN/SQSFP
    FILE 'HCAPLUS' ENTERED AT 13:17:13 ON 12 MAR 2007
            36 SEA ABB=ON .PLU=ON L2
            14 SEA ABB=ON PLU=ON L3 AND (AY<2001 OR PY<2001 OR PRY<2001)
```

FILE 'REGISTRY' ENTERED AT 13:18:16 ON 12 MAR 2007

O SEA ABB=ON PLU=ON L2 AND MEDLINE/LC

0 SEA ABB=ON PLU=ON L2 AND EMBASE/LC 0 SEA ABB=ON PLU=ON L2 AND BIOSIS/LC 0 SEA ABB=ON PLU=ON L2 AND CAOLD/LC

RN

SEQ

Ll

L2

L3

L4

L5

L6 L7L8

FILE 'STNGUIDE' ENTERED AT 13:18:53 ON 12 MAR 2007

FILE 'HCAPLUS' ENTERED AT 13:19:30 ON 12 MAR 2007

E US2004-772774/APPS

2 SEA ABB=ON PLU=ON US2004-772774/AP D SCAN

SEL RN L9

L9

FILE 'REGISTRY' ENTERED AT 13:20:34 ON 12 MAR 2007

107 SEA ABB=ON PLU=ON (159503-65-8/BI OR 355151-11-0/BI OR L10 355151-12-1/BI OR 355151-13-2/BI OR 355151-14-3/BI OR 355151-15 -4/BI OR 355151-16-5/BI OR 355151-17-6/BI OR 355151-18-7/BI OR 355151-19-8/BI OR 355151-20-1/BI OR 355151-23-4/BI OR 355151-25 -6/BI OR 355151-26-7/BI OR 355151-27-8/BI OR 355151-29-0/BI OR 355151-30-3/BI OR 355151-31-4/BI OR 355151-32-5/BI OR 355151-33 -6/BI OR 355151-34-7/BI OR 355151-35-8/BI OR 355151-36-9/BI OR 355151-37-0/BI OR 355151-38-1/BI OR 355151-39-2/BI OR 355151-40 -5/BI OR 355151-41-6/BI OR 355151-43-8/BI OR 355151-45-0/BI OR 355151-46-1/BI OR 355151-47-2/BI OR 355151-49-4/BI OR 355151-50 -7/BI OR 355151-51-8/BI OR 355151-52-9/BI OR 355151-53-0/BI OR 355151-54-1/BI OR 355151-55-2/BI OR 355151-56-3/BI OR 355151-74 -5/BI OR 81771-37-1/BI OR 111915-92-5/BI OR 133294-37-8/BI OR 212570-15-5/BI OR 355151-21-2/BI OR 355151-22-3/BI OR 355151-24 -5/BI OR 355151-28-9/BI OR 355151-42-7/BI OR 355151-44-9/BI OR 355151-48-3/BI OR 355151-57-4/BI OR 355151-58-5/BI OR 355151-59 -6/BI OR 355151-60-9/BI OR 355151-61-0/BI OR 355151-62-1/BI OR 355151-63-2/BI OR 355151-64-3/BI OR 355151-65-4/BI OR 355151-66 -5/BI OR 355151-67-6/BI OR 355151-68-7/BI OR 355151-69-8/BI OR 355151-70-1/BI OR 355151-71-2/BI OR 355151-72-3/BI OR 355151-73 -4/BI OR 355151-75-6/BI OR 355151-76-7/BI OR 35919-99-4/BI OR 366800-53-5/BI OR 463362-31-4/BI OR 463362-32-5/BI OR 463362-33 -6/BI OR 463362-34-7/BI OR 463362-35-8/BI OR 463362-36-9/BI OR 463362-37-0/BI OR 463362-38-1/BI OR 463362-40-5/BI OR 463362-42 -7/BI OR 463362-43-8/BI OR 463362-44-9/BI OR 463362-45-0/BI OR 463362-46-1/BI OR 463362-47-2/BI OR 463362-48-3/BI OR 463362-49 -4/BI OR 463362-50-7/BI OR 463362-51-8/BI OR 463362-52-9/BI OR 463362-53-0/BI OR 463362-54-1/BI OR 463362-55-2/BI OR 463362-56 -3/BI OR 463362-57-4/BI OR 463362-58-5/BI OR 463362-59-6/BI OR 463944-96-9/BI OR 476-70-0/BI OR 50-99-7/BI OR 501-36-0/BI OR 57381-26-7/BI OR 602-07-3/BI OR 7782-44-7/BI) 5 SEA ABB=ON PLU=ON L10 AND L2 L11

FILE 'STNGUIDE' ENTERED AT 13:21:01 ON 12 MAR 2007

FILE 'HCAPLUS' ENTERED AT 13:22:00 ON 12 MAR 2007 E LARSEN B/AU

L12 177 SEA ABB=ON PLU=ON ("LARSEN B"/AU OR "LARSEN B DUE"/AU OR "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR "LARSEN BJARNE DUE"/AU)

E PETERSEN J/AU

L*** DEL 0 S E3, E29, E122, E127, E129, E169, E175-E177.

L13

262 SEA ABB=ON PLU=ON ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR
"PETERSEN JOERGEN"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN
JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN"/AU OR "PETERSEN
JORGEN S"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN
JORGEN SOEBERG"/AU)
E MEIER E/AU

L14 118 SEA ABB=ON PLU=ON ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M

		M"/AU OR "ME OR "MEIER EI	TIER E P"/AU OR "MEIER E V"/AU OR "MEIER EDDI"/AU DDIE"/AU)
	•	E KJOLBYE A	'AU
L15	7		PLU=ON "KJOLBYE ANNE LOUISE"/AU
		E JORGENSEN	N/AU
L16	31	SEA ABB=ON	PLU=ON ("JORGENSEN N"/AU OR "JORGENSEN N R"/AU OR
		"JORGENSEN N	RYE"/AU OR "JORGENSEN NIKLAS R"/AU OR "JORGENSEN
		NIKLAS RYE"	AU)
		E NIELSEN M	'AU
L17	495	SEA ABB=ON	PLU=ON ("NIELSEN M"/AU OR "NIELSEN M S"/AU OR
		"NIELSEN M S	WEBER"/AU OR "NIELSEN MORTEN"/AU OR "NIELSEN
		MORTEN S"/AU	OR "NIELSEN MORTEN SCHAK"/AU)
		E MARTINS J	AU
L18	138	·	PLU=ON ("MARTINS J"/AU OR "MARTINS J B"/AU OR
			L"/AU OR "MARTINS JAMES"/AU OR "MARTINS JAMES
		B"/AU)	, , , , , ,
		E HOLSTEIN F	2/AU
L19	76		PLU=ON ("HOLSTEIN R"/AU OR "HOLSTEIN RATHLOU N
			OLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN RATHLOU
		•	OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)
L20	2	•	PLU=ON L12 AND L13 AND L14 AND L15 AND L16 AND
LLU	-	L17 AND L18	
L21	13		PLU=ON L12 AND (L13 OR L14 OR L15 OR L16 OR L17
1121	13	OR L18 OR L1	· · · · · · · · · · · · · · · · · · ·
L22	15		PLU=ON L13 AND (L14 OR L15 OR L16 OR L17 OR L18
1122	13	OR L19)	FEG-ON BIS AND (BI4 ON BIS ON BI6 ON BI7 ON BI6
L23	1		PLU=ON L14 AND (L15 OR L16 OR L17 OR L18 OR L19)
L23			PLU=ON L15 AND (L16 OR L17 OR L18 OR L19)
			PLU=ON L16 AND (L17 OR L18 OR L19)
L25		SEA ABB=ON	
L26			·
L27		SEA ABB=ON	PLU=ON L18 AND L19
L28	21		PLU=ON (L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR
	4	L26 OR L27)	DILLOW TOO AND AND AND OR DR COOL OF DRY COOL
L29	4	SEA ABB=UN	PLU=ON L28 AND (AY<2001 OR PY<2001 OR PRY<2001)
	ETTE HIGNO	THE MEDITALE	EMPACE DIOCIC DDUCII MDIVI EMEEDED AM 12 20 40
			EMBASE, BIOSIS, DRUGU, WPIX' ENTERED AT 13:29:40
	ON 12 MAR		DILL ON LADGEN DO /ALL
L30			PLU=ON LARSEN B?/AU
L31			PLU=ON PETERSEN J?/AU
			PLU=ON MEIER E?/AU
L33			PLU=ON KJOLBYE A?/AU
L34			PLU=ON JORGENSEN N?/AU
L35			PLU=ON NIELSEN M?/AU
L36			PLU=ON MARTINS J?/AU
L37			PLU=ON HOLSTEIN R?/AU
L38	2	SEA ABB=ON	PLU=ON L30 AND L31 AND L32 AND L33 AND L34 AND
		L35 AND L36	
L39	0	SEA ABB=ON	PLU=ON (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
			AND (ANTI(2A) ARRYTHMIC?)
L40	2	SEA ABB=ON	PLU=ON (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
			AND (ANTIARRYTHMIC?)
L41			PLU=ON (L38 OR L40)
L42	856		PLU=ON (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
			AND (PEPTIDE?)
L43			PLU=ON L42 AND (ARRYTHM?)
L44	4	SEA ABB=ON	PLU=ON (L43 OR L41)
	FILE 'STNG	UIDE' ENTEREI	O AT 13:33:02 ON 12 MAR 2007

FILE 'REGISTRY' ENTERED AT 13:34:05 ON 12 MAR 2007

		10772774
L45 L46 L47 L48		STRUCTURE UPLOADED STRUCTURE UPLOADED 0 SEA SSS SAM L46 0 SEA SSS FUL L46
	FILE	'STNGUIDE' ENTERED AT 13:35:38 ON 12 MAR 2007
L49	FILE	'BEILSTEIN' ENTERED AT 13:35:43 ON 12 MAR 2007 0 SEA SSS FUL L46
	FILE	'MARPAT' ENTERED AT 13:35:57 ON 12 MAR 2007
	FILE	'STNGUIDE' ENTERED AT 13:36:04 ON 12 MAR 2007
	FILE	'REGISTRY' ENTERED AT 13:38:12 ON 12 MAR 2007
	FILE	'STNGUIDE' ENTERED AT 14:02:36 ON 12 MAR 2007
L50	FILE	'REGISTRY' ENTERED AT 14:03:19 ON 12 MAR 2007 D QUE L46 D QUE L45 STRUCTURE UPLOADED D QUE L50
	FILE	'STNGUIDE' ENTERED AT 14:04:58 ON 12 MAR 2007
L51 L52 L53 L54		'REGISTRY' ENTERED AT 14:12:47 ON 12 MAR 2007 STRUCTURE UPLOADED STRUCTURE UPLOADED 50 SEA SSS SAM L52 D QUE L52 2075 SEA SSS FUL L52 SAVE L54 TELLER/A TEMP 0 SEA ABB=ON PLU=ON L54 AND L10
L56	FILE	'HCAPLUS' ENTERED AT 14:16:01 ON 12 MAR 2007 1861 SEA ABB=ON PLU=ON L54
	FILE	'STNGUIDE' ENTERED AT 14:16:08 ON 12 MAR 2007
L57 L58 L59	FILE	'REGISTRY' ENTERED AT 14:22:05 ON 12 MAR 2007 STRUCTURE UPLOADED 0 SEA SUB=L54 SSS SAM L57 4 SEA SUB=L54 SSS FUL L57
L60	FILE	'HCAPLUS' ENTERED AT 14:23:05 ON 12 MAR 2007 2 SEA ABB=ON PLU=ON L59 D BIB D BIB 2
L61 L62 L63 L64 L65	FILE	'REGISTRY' ENTERED AT 14:23:30 ON 12 MAR 2007 0 SEA ABB=ON PLU=ON L59 AND MEDLINE/LC 0 SEA ABB=ON PLU=ON L59 AND EMBASE/LC 0 SEA ABB=ON PLU=ON L59 AND BIOSIS/LC 0 SEA ABB=ON PLU=ON L59 AND CAOLD/LC 528 SEA ABB=ON PLU=ON L54 AND (ALA OR ALANIN? OR GLY OR GLYCINE OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DOAMINOBUT? OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)

	10//2//4
	FILE 'HCAPLUS' ENTERED AT 14:25:47 ON 12 MAR 2007
1.66	300 SEA ABB=ON PLU=ON L65
	DEL 598742 S L10
ъ	D SCAN L9
L67	···
	DMA)/RL
	D KWIC
L68	1 SEA ABB=ON PLU=ON L66 AND (?ARRYTHM? OR ?THROMB? OR OSTEOPORO
	SIS? OR CANCER?)
1.69	56 SEA ABB=ON PLU=ON (L67 OR L68)
L70	
L71	·
L72	·
	OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DOAMINOBUT?
	OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
	GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
	D KWIC
L73	
11/3	OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT?
,	
	OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
	GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
L74	38 SEA ABB=ON PLU=ON (L68 OR L72 OR L73)
L75	38 SEA ABB=ON PLU=ON L74 NOT (L29 OR L4 OR L9)
	FILE 'BEILSTEIN' ENTERED AT 14:32:13 ON 12 MAR 2007
L76	0 SEA SSS FUL L57
4,0	0 021 000 101 201
	FILE 'MARPAT' ENTERED AT 14:32:29 ON 12 MAR 2007
	FILE MARFAI ENIERD AT 14:52:29 ON 12 MAR 2007
	FILE 'REGISTRY' ENTERED AT 14:33:37 ON 12 MAR 2007
L77	0 SEA ABB=ON PLU=ON L65 AND L10
L78	0 SEA ABB=ON PLU=ON L10 AND SQL/CI
	FILE 'STNGUIDE' ENTERED AT 14:36:57 ON 12 MAR 2007
	FILE 'REGISTRY' ENTERED AT 14:38:24 ON 12 MAR 2007
L79	
L80	·
	84 SEA ABB=ON PLU=ON L10 AND SQL<10
L81	
L82	23 SEA ABB=ON PLU=ON L10 NOT L81
	23 SEA ABB=ON PLU=ON L10 NOT L81 D SCAN L82
L83	23 SEA ABB=ON PLU=ON L10 NOT L81 D SCAN L82 106 SEA ABB=ON PLU=ON L10 NOT O2/MF
	23 SEA ABB=ON PLU=ON L10 NOT L81 D SCAN L82
L83	23 SEA ABB=ON PLU=ON L10 NOT L81 D SCAN L82 106 SEA ABB=ON PLU=ON L10 NOT O2/MF
L83 L84 L85	23 SEA ABB=ON PLU=ON L10 NOT L81 D SCAN L82 106 SEA ABB=ON PLU=ON L10 NOT O2/MF 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3/MF
L83 L84 L85 L86	23 SEA ABB=ON PLU=ON L10 NOT L81 D SCAN L82 106 SEA ABB=ON PLU=ON L10 NOT O2/MF 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3/MF 103 SEA ABB=ON PLU=ON L85 NOT C19H21NO4/MF
L83 L84 L85 L86 L87	23 SEA ABB=ON PLU=ON L10 NOT L81 D SCAN L82 106 SEA ABB=ON PLU=ON L10 NOT O2/MF 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3/MF 103 SEA ABB=ON PLU=ON L85 NOT C19H21NO4/MF 103 SEA ABB=ON PLU=ON L86 NOT C9H7C12N5/MF
L83 L84 L85 L86 L87	23 SEA ABB=ON PLU=ON L10 NOT L81 D SCAN L82 106 SEA ABB=ON PLU=ON L10 NOT O2/MF 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3/MF 103 SEA ABB=ON PLU=ON L85 NOT C19H21NO4/MF 103 SEA ABB=ON PLU=ON L86 NOT C9H7C12N5/MF 102 SEA ABB=ON PLU=ON L87 NOT C20H19NO6
L83 L84 L85 L86 L87	23 SEA ABB=ON PLU=ON L10 NOT L81 D SCAN L82 106 SEA ABB=ON PLU=ON L10 NOT O2/MF 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3/MF 103 SEA ABB=ON PLU=ON L85 NOT C19H21NO4/MF 103 SEA ABB=ON PLU=ON L86 NOT C9H7C12N5/MF
L83 L84 L85 L86 L87	23 SEA ABB=ON PLU=ON L10 NOT L81 D SCAN L82 106 SEA ABB=ON PLU=ON L10 NOT O2/MF 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3/MF 103 SEA ABB=ON PLU=ON L85 NOT C19H21NO4/MF 103 SEA ABB=ON PLU=ON L86 NOT C9H7C12N5/MF 102 SEA ABB=ON PLU=ON L87 NOT C20H19NO6 101 SEA ABB=ON PLU=ON L88 NOT C6H12O6/MF
L83 L84 L85 L86 L87 L88	23 SEA ABB=ON PLU=ON L10 NOT L81
L83 L84 L85 L86 L87 L88 L89	23 SEA ABB=ON PLU=ON L10 NOT L81
L83 L84 L85 L86 L87 L88	23 SEA ABB=ON PLU=ON L10 NOT L81
L83 L84 L85 L86 L87 L88 L89	23 SEA ABB=ON PLU=ON L10 NOT L81
L83 L84 L85 L86 L87 L88 L89	23 SEA ABB=ON PLU=ON L10 NOT L81
L83 L84 L85 L86 L87 L88 L89	23 SEA ABB=ON PLU=ON L10 NOT L81
L83 L84 L85 L86 L87 L88 L89 L90 L91	23 SEA ABB=ON PLU=ON L10 NOT L81
L83 L84 L85 L86 L87 L88 L89	23 SEA ABB=ON PLU=ON L10 NOT L81
L83 L84 L85 L86 L87 L88 L89 L90 L91	23 SEA ABB=ON PLU=ON L10 NOT L81
L83 L84 L85 L86 L87 L88 L89 L90 L91	23 SEA ABB=ON PLU=ON L10 NOT L81 D SCAN L82 106 SEA ABB=ON PLU=ON L10 NOT O2/MF 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3/MF 103 SEA ABB=ON PLU=ON L85 NOT C19H21NO4/MF 103 SEA ABB=ON PLU=ON L86 NOT C9H7C12N5/MF 102 SEA ABB=ON PLU=ON L87 NOT C20H19NO6 101 SEA ABB=ON PLU=ON L88 NOT C6H12O6/MF FILE 'HCAPLUS' ENTERED AT 14:43:59 ON 12 MAR 2007 109 SEA ABB=ON PLU=ON L89 66 SEA ABB=ON PLU=ON L89 (6 SEA ABB=ON PLU=ON L89 (L) (THU OR BAC OR PAC OR DMA OR PKT)/RL 26 SEA ABB=ON PLU=ON L91 AND (AY<2001 OR PY<2001 OR PRY<2001) D QUE L73 20 SEA ABB=ON PLU=ON L91 AND (ALA OR ALANIN? OR GLY OR GLYCINE OR GLU OR GLUTAMIC? OR ASP OR ASPARAGINE OR GLN OR
L83 L84 L85 L86 L87 L88 L89 L90 L91	23 SEA ABB=ON PLU=ON L10 NOT L81
L83 L84 L85 L86 L87 L88 L89 L90 L91	23 SEA ABB=ON PLU=ON L10 NOT L81 D SCAN L82 106 SEA ABB=ON PLU=ON L10 NOT O2/MF 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3 104 SEA ABB=ON PLU=ON L83 NOT C14H12O3/MF 103 SEA ABB=ON PLU=ON L85 NOT C19H21NO4/MF 103 SEA ABB=ON PLU=ON L86 NOT C9H7C12N5/MF 102 SEA ABB=ON PLU=ON L87 NOT C20H19NO6 101 SEA ABB=ON PLU=ON L88 NOT C6H12O6/MF FILE 'HCAPLUS' ENTERED AT 14:43:59 ON 12 MAR 2007 109 SEA ABB=ON PLU=ON L89 66 SEA ABB=ON PLU=ON L89 (6 SEA ABB=ON PLU=ON L89 (L) (THU OR BAC OR PAC OR DMA OR PKT)/RL 26 SEA ABB=ON PLU=ON L91 AND (AY<2001 OR PY<2001 OR PRY<2001) D QUE L73 20 SEA ABB=ON PLU=ON L91 AND (ALA OR ALANIN? OR GLY OR GLYCINE OR GLU OR GLUTAMIC? OR ASP OR ASPARAGINE OR GLN OR
L83 L84 L85 L86 L87 L88 L89 L90 L91 L92 L93	23 SEA ABB=ON PLU=ON L10 NOT L81

L95 33 SEA ABB=ON PLU=ON L94 NOT (L4 OR L29) L96 14 SEA ABB=ON PLU=ON (L9 OR L4)

FILE 'STNGUIDE' ENTERED AT 14:46:29 ON 12 MAR 2007

D QUE L29

D QUE L44

D QUE L4

D QUE L60

FILE 'HCAPLUS, WPIX' ENTERED AT 14:46:57 ON 12 MAR 2007

18 DUP REM L29 L44 L4 L60 (6 DUPLICATES REMOVED)

ANSWERS '1-18' FROM FILE HCAPLUS

D OUE L29

D OUE L41

D QUE L29

D QUE L44

D QUE L95

L98 37 DUP REM L29 L44 L95 (4 DUPLICATES REMOVED)

ANSWERS '1-37' FROM FILE HCAPLUS

D IBIB ABS HITIND HITSTR RETABLE L98 TOT

D QUE L4

D IBIB ABS HITIND HITSTR RETABLE L4 TOT

D QUE L60

D IBIB ABS HITIND HITSTR RETABLE L60 TOT

FILE 'HCAPLUS' ENTERED AT 15:06:34 ON 12 MAR 2007

D QUE L4

D HITSEQ L4 TOT

FILE HOME

L97

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2007 HIGHEST RN 926007-42-3 DICTIONARY FILE UPDATES: 11 MAR 2007 HIGHEST RN 926007-42-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE LREGISTRY

LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Mar 2007 VOL 146 ISS 12 FILE LAST UPDATED: 11 Mar 2007 (20070311/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 9, 2007 (20070309/UP).

FILE MEDLINE

FILE LAST UPDATED: 10 Mar 2007 (20070310/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE

FILE COVERS 1974 TO 12 Mar 2007 (20070312/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 7 March 2007 (20070307/ED)

FILE DRUGU

FILE LAST UPDATED: 9 MAR 2007 <20070309/UP>

>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

- >>> FILE COVERS 1983 TO DATE <<<
- >>> THESAURUS AVAILABLE IN /CT <<<

FILE WPIX

FILE LAST UPDATED: 5 MAR 2007 <20070305/UP>
MOST RECENT THOMSON SCIENTIFIC UPDATE: 200716 <200716/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

- >>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<
- >>> New display format FRAGHITSTR available <<< SEE ONLINE NEWS and http://www.stn-international.de/archive/stn_online_news/fraghitstr_ex.pdf
- >>> IPC Reform reclassification data for the backfile is being
 loaded into the database during January 2007.
 There will not be any update date (UP) written for the reclassified
 documents, but they can be identified by 20060101/UPIC. <<<</pre>

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://scientific.thomson.com/support/patents/coverage/latestupdates/

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX PLEASE SEE

http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<

FILE BEILSTEIN
FILE LAST UPDATED ON JANUARY 10, 2007

FILE COVERS 1771 TO 2006.

FILE CONTAINS 9,780,003 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

- * PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.
- * SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE
- * ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE
- * ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.
- * FOR PRICE INFORMATION SEE HELP COST

NEW

* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE

SEARCHED, SELECTED AND TRANSFERRED.

* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

FILE MARPAT

FILE CONTENT: 1961-PRESENT VOL 146 ISS 11 (20070309/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES (COVERAGE TO THESE DATES IS NOT COMPLETE):

2007020715 25 JAN 2007 DE 102005032918 18 JAN 2007 EΡ 1743897 17 JAN 2007 JΡ 2007016265 25 JAN 2007 WO 2007012422 01 FEB 2007 GB 2427406 27 DEC 2006 FR 2888248 12 JAN 2007 RU 2291880 20 JAN 2007 CA 2551930 08 JAN 2007

Expanded G-group definition display now available.

Rebamipide protect the stomach against injury caused by NH2Cl, and (3) the mechanism underlying the protective action of irsogladine is partly mediated by endogenous nitric oxide while that of Rebamipide is in part mediated by endogenous prostaglandins.

CC 1-9 (Pharmacology)

57381-26-7, Irsogladine 90098-04-7, Rebamipide ΙT RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(protective effect of irsogladine on monochloramine-induced gastric mucosal lesions in rats compared to Rebamipide)

57381-26-7, Irsogladine IT

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(protective effect of irsogladine on monochloramine-induced gastric mucosal lesions in rats compared to Rebamipide)

57381-26-7 HCAPLUS RN

1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME) CN

RETABLE					
Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
=======================================	+====+	 -====	-=====	+======================================	-========
Badwey, J	1980	46	695	Ann Rev Biochem	
Dekigai, H	1995	40	1332	Dig Dis Sci	MEDLINE
Graham, D	1989	96	615	Gastroenterology	
Grisham, M	1986	251	G567	Am J Physiol	HCAPLUS
Grisham, M	1984	259	10404	J Biol Chem	HCAPLUS
Ishihara, K	1992	42	1462	Arzneimittelforschun	HCAPLUS
Ivy, K	1970	59	683	Gastroenterology	
Kato, S	1977	42	2156	Dig Dis Sci	
Klevanoff, S	1980	93	480	Ann Intern Med	
Marshall, B	1983	1	1273	Lancet	
Marshall, B	1983	1	965	Lancet	•
Murakami, M	1995	40	268	Dig Dis Sci	HCAPLUS
Murakami, M	1993	105	1710	Gastroenterology	HCAPLUS
Nishiwaki, H	1997	29	713	Gen Pharmacol	HCAPLUS
Okabe, S	1984	24	683	Pharmacometrics	
Svanes, K	1982	82	1409	Gastroenterology	HCAPLUS
Takeuchi, K	1989	49	235	Jpn J Pharmacol	HCAPLUS
Tepperman, B	1992	105	171	Br J Pharmacol	HÇAPLUS
Ueda, F	1984	34P	474	Arzneimittelforschun	,
Ueda, F	1984	34	478	Arzneimittelforschun	HCAPLUS
Whitehead, R	1972	25	1	J Clin Pathol	MEDLINE
Whittle, B	1990	99	607	Br J Pharmacol	HCAPLUS
Yamasaki, K	1987	142	23	Eur J Pharmacol	HCAPLUS
Yoshikawa, T	1993	43	363	Arzneimittelforschun	HCAPLUS

1998:714418 HCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER: 130:119294

Effects of an antiarrhythmic peptide on intercellular TITLE:

coupling via gap junctions

Dhein, Stefan; Gottwald, Michaela; Schaefer, Thomas; AUTHOR (S):

Muller, Andreas; Tudyka, Tatjana; Krusemann, Kathi;

Grover, Rajiv

Institute of Pharmacology, University of Cologne, CORPORATE SOURCE:

Cologne, D-50931, Germany

Gap Junctions, Proceedings of the International Gap SOURCE:

Junction Conference, 8th, Key Largo, Fla., July 12-17,

1997 (1998), Meeting Date 1997, 163-167.

Editor(s): Werner, Rudolf. IOS Press: Amsterdam,

CODEN: 66XYAX

DOCUMENT TYPE:

Conference English LANGUAGE:

We recently reported on a synthetic antiarrhythmic peptide (AAP10, NH2- GLY-AB ALA-GLY-HYP-PRO-TYR-CONH2) which was found to be effective against arrhythmia in the late ischemic period in isolated rabbit hearts. This peptide enhanced gap junctional current in pairs of adult guinea pig cardiomyocytes. In this study we wanted to investigate whether AAP10 acts on uncoupled guinea pig papillary muscles. After 30 min of equilibration at normoxic conditions the muscles were submitted to hypoxia with glucose free superfusion for 20 min with or without pretreatment with 10 nM AAP10. Under these conditions intracellular action potentials were recorded and the delay between stimulus and propagated action potential (stimulus-response interval, SRI) was evaluated. We found no effect of AAP10 under normoxic conditions on SRI or on action potential morphol. Resting membrane potential, amplitude, action potential duration, dU/dtmax were not altered. However, while in untreated muscles uncoupling occurred after 12 min, this was not the case in muscles treated with AAP10. In addnl. expts., we could demonstrate that uncoupling via 50 mM Na-propionate could be antagonized by 10 nM AAP10 without affecting other parameters than SRI. This AAP10 effect could be fully inhibited by 10 μM genistein and 1 μM bisindolylmaleimide I (a specific inhibitor of PKC), but not by 2 μM H8 (a specific PKA blocker) and not by 5 μM genistein. Using 14Clabeled AAP10 we found that the substance binds to membrane proteins but not to connexin 43. From these results we conclude that AAP10 can enhance intercellular coupling especially in situations with reduced coupling probably via a protein kinase C mediated mechanism.

1-8 (Pharmacology) CC

159503-65-8, AAP10 IT

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(effects of an antiarrhythmic peptide on intercellular coupling via gap junctions)

159503-65-8, AAP10 IT

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(effects of an antiarrhythmic peptide on intercellular coupling via gap junctions)

159503-65-8 HCAPLUS RN

retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) CN INDEX NAME)

Absolute stereochemistry.

RETABLE					
Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
	+=====	+====	+=====	+==============	-======================================
Aonuma, S	1980	28	3340	Chem Pharm Bull	HCAPLUS
Dhein, S	1997			Cardiac gap junction	
Dhein, S	1993	87	617	Circulation	HCAPLUS
Dhein, S	1995	92	I	Circulation	
Dhein, S	1996	94	Ι	Circulation	
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1997	2	51	J Clin Exp Cardiol	
Dhein, S	1994	350	174	11.00.01.71.	HCAPLUS
Echt, D	1991	324	781	New Engl J Med	MEDLINE
Kwak, B	1995	6	1707	Mol Biol Cell	HCAPLUS
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Manjunath, C	1987	142	228	Biochem Biophys Res	HCAPLUS
Muller, A	1993	88	11	Basic Res Cardiol	MEDLINE
Muller, A	1997	327	65	Eur J Pharmacol	MEDLINE
Muller, A	1997	356	76	Naunyn Schmiedeberg'	MEDLINE
Podrid, P	1985	29	33	Drugs	
Spray, D	1981	77	77	J Gen Physiol	MEDLINE
Takens-Kwak, B	1992	422	198	Pfluger's Arch	HCAPLUS
Weingart, R	1986	370	267	J Physiol (Lond)	MEDLINE

L98 ANSWER 17 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN 1997:278971 HCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER:

127:17689

TITLE:

Process for preparation of triazine derivatives by

cyclization

INVENTOR(S):

Yagishita, Kenichi; Sato, Toyozo; Yokogoshi, Kiyonori

PATENT ASSIGNEE(S): SOURCE:

Permachem Asia, Ltd., Japan Jpn. Kokai Tokkyo Koho, 3 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09087256 PRIORITY APPLN. INFO.:	A	19970331	JP 1995-276084 JP 1995-276084	19950920 < 19950920 <
OTHER SOURCE(S):	CASRE	ACT 127:17689		

The title compds., useful for prevention and treatment of ulcer (no data), are prepared in an industrial manner efficiently and economically. Thus, 2,5dichlorobenzamidine is reacted with NaN(CN)2 in (HOCH2)2 to give 90% 2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine.

IC ICM C07D251-18

ICS C07D251-18; A61K031-53

CC 28-14 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT 57381-26-7P 57381-27-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(process for preparation of triazine derivs. by cyclization)

IT 57381-26-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(process for preparation of triazine derivs. by cyclization)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 18 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:693510 HCAPLUS Full-text

DOCUMENT NUMBER: 128:18349

TITLE: N-oxidation of irsogladine by the CYP2C subfamily in

the rat, dog, monkey and man

AUTHOR(S): Nakamura, A.; Hirota, T.; Morino, A.; Shimada, T.;

Uematsu, T.

CORPORATE SOURCE: Research Laboratories, Nippon Shinyaku Co., Ltd.,

Kyoto, 601, Japan

SOURCE: Xenobiotica (1997), 27(10), 995-1003

CODEN: XENOBH; ISSN: 0049-8254

PUBLISHER: Taylor & Francis

DOCUMENT TYPE: Journal LANGUAGE: English

1. The metabolism of irsogladine (ISG) was studied in hepatic microsomes from the rat, dog, monkey and man, and marked species differences were observed in N-oxidation of ISG. The rank order of the activity of the N-oxidation was shown to be man < monkey < dog < rat. 2. Anti-NADPH-P 450 reductase antibody inhibited the formation of the N-oxidized metabolite of ISG (ISG-N-oxide) in hepatic microsomes from rats by 74%. Anti-CYP2C11 antibody also inhibited the formation of ISG-N-oxide in hepatic microsomes from rat by 73 %, whereas anti-CYP2E1, 3A2 and 4A1 antibody did not inhibit N-oxidation Thus, CYP2C11 in the rat is at least partially responsible for the N-oxidation of ISG in the rat.

3. Anti-CYP2C11 antibody also inhibited the formation of ISG-N-oxide in hepatic microsomes from the dog and monkey by 61 and 46 % resp. Therefore, a isoform(s) similar to CYP2C11 partially contributed to the N-oxidation of ISG in the dog and monkey. In contrast, human CYP2C9, a member of the human CYP2C subfamily, did not catalyze the N-oxidation of ISG. 4. These findings show

that the marked species difference in the N-oxidation of ISG is caused by the difference in the catalytic properties of CYP2C among the species examined

CC 1-2 (Pharmacology)

Section cross-reference(s): 13

IT 57381-26-7, Irsogladine

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(N-oxidation of irsogladine by CYP2C subfamily in rat, dog, monkey and man)

IT 57381-26-7, Irsogladine

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(N-oxidation of irsogladine by CYP2C subfamily in rat, dog, monkey and man)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

RETABLE					
Referenced Author	Year	AOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
=======================================	+=====	+=====	+=====	+======================================	
Ando, T	1989	36	1221	Arzneimittel Forschu	•
Cashman, J	1993	21	492	Drug Metabolism and	
Chiba, K	1995	10	391	Xenobiotic Metabolis	!
Funae, Y	1993		221	Handbook of Experime	!
Gonzalez, F	1993		239	Handbook of Experime	:
Imaoka, S	1996	51	1041	Biochemical Pharmaco	•
Komori, M	1989	38	235	Biochemical Pharmaco	
Lowry, O	1981	193	265	Journal of Biologica	
Mani, C	1993	21	645	Drug Metabolism and	
Mani, C	1993	21	657	Drug Metabolism and	
Miura, T	1989	49	365	Japan Journal of Pha	
Nakashima, M	1984	34	492	Arzneimittel Forschu	!
Nedelcheva, V	1994	24	1151	Xenobiotica	HCAPLUS
Ohta, O	1983	996	142	Biochimica et Biophy	
Prough, R	1977	180	363	Archives of Biochemi	<u> </u>
Rodrigues, A	1994	22	788		HCAPLUS
Rouer, E	1987	15	524	Drug Metabolism and	
Shimada, T	1994	270	414	Journal of Pharmacol	
Smith, D	1991	23	355	Drug Metabolism Revi	!
Sugiyama, M	1989	36	1229	Arzneimittel Forschu	•
Uchida, T	1990	38	644	Molecular Pharmacolo	HCAPLUS
Ueda, F	1984	34	474	Arzneimittel Forschu	•
Ueda, F	1984	34	478	Arzneimittel Forschu	
Ueda, F	1991	57	321	Japan Journal of Pha	
Ueda, F	1994	271	397	Journal of Pharmacol	1
Weaver, R	1994	47	763	Biochemical Pharmaco	HCAPLUS
Zins, G	1965	150	109	Journal of Pharmacol	HCAPLUS

Zins, G | 1967 | 159 | 194 | Journal of Pharmacol |

L98 ANSWER 19 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1997:424142 HCAPLUS Full-text

DOCUMENT NUMBER: 127:130662

TITLE: Actions of the antiarrhythmic peptide AAP10 on

intercellular coupling

AUTHOR(S): Mueller, Andreas; Schaefer, Thomas; Linke, Werner;

Tudyka, Tatjana; Gottwald, Michaela; Klaus, Wolfgang;

Dhein, Stefan

CORPORATE SOURCE: Institute of Pharmacology, University of Koln, Koln,

D-50931, Germany

SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (

1997), 356(1), 76-82

CODEN: NSAPCC; ISSN: 0028-1298

PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

Disturbances in gap junction distribution and a decrease in the connexin43 content of the heart were shown to occur after myocardial infarction and in ischemic heart disease, resp. These changes are now thought to play an important role in the genesis of arrhythmias associated with these diseases. It is thought that agents that can increase cellular coupling might be beneficial in these situations. Recently, we presented data showing that the synthetic peptide AAP10 acts antiarrhythmically in a model of regional ischemia. The data suggested that AAP10 might act via an increase in cellular The goal of this study was to establish whether AAP10 can interact with cardiac gap junctions. Measurements of the stimulus-response-interval (SRI) in guinea pig papillary muscle showed that high concns. of AAP10 (1 μM) can decrease the SRI by about 10% under normoxic conditions. At lower concns. (10 nM) AAP10 had no effect on SRI under normoxic conditions but prevented the increase in the SRI induced by perfusion with hypoxic, glucose-free Tyrode's solution Double-cell voltage-clamp expts. confirmed that AAP10 can interact with cardiac gap junctions. 10 NM AAP10 could either diminish or reverse the run-down of gap junction conductance normally observed in pairs of guinea pig ventricular myocytes. During control gap junction conductance decreased with a rate of -2.5±2.0 nS/min. After application of 10 nM AAP10 gap junction conductance increased with a rate of $+1.0\pm0.7$ nS/min. After washout of AAP10 gap junction conductance decreased again with a rate not significantly different from control. Our results show that AAP10 does interact with gap junctions. Because no other effects of AAP10 on other electrophysiol. parameters could be found, this action on gap junctions might be the basis of AAP10's antiarrhythmic effect seen in previous studies.

CC 1-8 (Pharmacology)

IT 159503-65-8, AAP 10

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(actions of antiarrhythmic peptide AAP10 on intercellular coupling)

IT 159503-65-8, AAP 10

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(actions of antiarrhythmic peptide AAP10 on intercellular coupling)

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME).

Absolute stereochemistry.

L98 ANSWER 20 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1997:331424 HCAPLUS Full-text

DOCUMENT NUMBER:

127:44651

TITLE:

Increase in gap junction conductance by an

antiarrhythmic peptide

AUTHOR (S):

Mueller, Andreas; Gottwald, Michaela; Tudyka, Tatjana;

Linke, Werner; Klaus, Wolfgang; Dhein, Stefan Institute of Pharmacology, University of Koeln,

Gleueler Strasse 24, Koln, D-50931, Germany

CORPORATE SOURCE:

European Journal of Pharmacology (1997),

327(1), 65-72

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER:
DOCUMENT TYPE:
LANGUAGE:

Elsevier Journal English

Impaired cellular coupling is thought to be a very important factor for the AB genesis of cardiac arrhythmia. Cellular coupling is mediated by gap junctions. However, there are no therapeutic agents or exptl. substances yet that increase cellular coupling. In addition, it has been shown that most antiarrhythmic drugs available now possess serious adverse effects. Thus, there is an urgent need for new antiarrhythmic agents. Previous studies using epicardial mapping in isolated rabbit hearts provided indirect evidence supporting the hypothesis that a newly synthesized antiarrhythmic peptide (Gly-Ala-Gly -4Hyp-Pro-Tyr-CONH2 = AAP10) might act via an increase in cellular, i.e., gap junctional coupling. The aim of the present study was to test this hypothesis. Measurement of the stimulus-response interval in papillary muscle showed a decrease of about 10% after application of 1 μM AAP10. These results are compatible with the hypothesis of AAP10 acting on gap junctions. In order to prove this hypothesis, gap junction conductance was measured directly by performing double-cell voltage-clamp expts. in isolated pairs of guinea-pig myocytes. During a 10 min control period gap junction conductance slowly decreased with a rate of -2.5 ± 2.0 nS/min. After application of 10 nM AAP10 this behavior reversed and gap junction conductance now increased with $+1.0\pm0.7$ nS/min. Upon washout of AAP10 gap junction conductance again decreased with a rate similar to that under control conditions. Another important finding was that we could not detect any other actions of AAP10 on cardiac myocytes. All parameters of the transmembrane action potential remained unchanged and, similarly, no changes in the IV relationship of single cardiac myocytes treated with 10 nM AAP10 could be observed We conclude that AAP10 increases gap junction conductance, i.e., cellular coupling in the heart. This finding might be the first step towards the development of a new class of antiarrhythmic agents.

CC 1-8 (Pharmacology)

IT Antiarrhythmics

(antiarrhythmic peptide AAP10 (Gly-Ala-Gly

-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance) IT Cell junction

(gap junction, coupling; antiarrhythmic peptide AAP10 (Gly-Ala-Gly-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance)

IT 159503-65-8, AAP 10

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiarrhythmic peptide AAP10 (Gly-Ala-Gly

-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance 180268740)

IT 159503-65-8, AAP 10

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiarrhythmic peptide AAP10 (Gly-Ala-Gly

-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance 180268740)

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & & & \\ \text{Me} & & & \\ \text{NH} & & & \\ & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RETABLE					
Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
	+=====	+=====	+=====	+=================	+========
Aonuma, S	1980	28	3332	Chem Pharm Bull	HCAPLUS
Balke, C	1988	63	879	Circ Res	MEDLINE
Bastide, B	1993	73	1138	Circ Res	HCAPLUS
Cai, D	1994	41	217	IEEE Trans Biomed En	MEDLINE
Cole, W	1988	53	809	Biophys J	MEDLINE
de-Carvalho, C	1992	70	733	Circ Res	
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1994	350	174	Naunyn-Schmiedeberg'	HCAPLUS
Halliwell, J	1994]	17	Microelectrode Techn	[
Hamill, O	1981	391	85	Pflug Arch	MEDLINE
Jarolimek, W	1993	425	491	Pflug Arch	HCAPLUS
Kleber, A	1987	61	271	Circ Res	MEDLINE
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Merx, W	1977	94	603	Am Heart J	MEDLINE
Metzger, P	1985	366	177	J Physiol (London)	MEDLINE
Muller, A	1993	88	11	Basic Res Cardiol	MEDLINE
Page, E	1992	ļ	1003	The Heart and Cardio	
Peters, N	1993	88	864	Circulation	HCAPLUS

```
MEDLINE
                                          Circulation
                                   1742
                       11993 | 87
Saffitz, J
                                          J Cardiovasc Electro MEDLINE
                                   462
                       1994 | 5
Severs, N
                                                                MEDLINE
                                          Am J Pathol
                                   801
                       |1991 |139
Smith, J
                                                                MEDLINE
                                          Circulation
                       1994
                             90
                                   1103
Spach, M
                                                                MEDLINE
                                          J Gen Physiol
                       1981
                             177
                                   77
Spray, D
                                                                MEDLINE
                                           Basic Res Cardiol
                       |1993 |88
                                    167
Steendijk, P
                                                                MEDLINE
                       1990 258
                                          Am J Physiol
                                   C662
Veenstra, R
                                                                HCAPLUS
                                          |Biophys J
                        1992 | 63
                                   139
Wang, H
                                                                MEDLINE
                        1988 | 63
                                   172
                                          |Circ Res
Weingart, R
                                                                MEDLINE
                                          J Physiol (London)
                        1986 | 370
                                   1267
Weingart, R
                                                                MEDLINE
                                   942
                                          |Biophys J
                       1992 | 63
Wilders, R
L98 ANSWER 21 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN
                         1997:86895 HCAPLUS Full-text
ACCESSION NUMBER:
                         126:194926
DOCUMENT NUMBER:
                         Triazine derivatives inhibit rat hepatocarcinogenesis
TITLE:
                         but do not enhance gap junctional intercellular
                         communication
                         Hori, Takaaki; Asamoto, Makoto; Krutovskikh, Vladimir;
AUTHOR (S):
                         Iwahori, Yoshio; Maeda, Mitsuaki; Toriyama-Baba,
                         Hiroyasu; Takasuka, Nobuo; Tsuda, Hiroyuki
                         Chemotherapy Division, National Cancer Center Research
CORPORATE SOURCE:
                         Institute, Tokyo, 104, Japan
                         Japanese Journal of Cancer Research (1997),
SOURCE:
                         88(1), 12-17
                         CODEN: JJCREP; ISSN: 0910-5050
                         Japanese Cancer Association
PUBLISHER:
                         Journal
DOCUMENT TYPE:
                         English
LANGUAGE:
     We report here novel candidate chemopreventive agents active against exptl.
AΒ
     hepatocarcinogenesis. The triazine derivs. 6-(2-chlorophenyl)-2,4- diamino-
     1,3,5-triazine (2CPDAT), 6-(3-chlorophenyl)-2,4-diamino-1,3,5- triazine
     (3CPDAT), 6-(4-chlorophenyl)-2,4-diamino-1,3,5-triazine (4CPDAT), 6-(4-
     pyridyl)-2,4-diamino-1,3,5-triazine (PyDAT), and 6-(pyridine N-oxid-4-yl)-2,4-
     diamino-1,3,5-triazine (PyNODAT), synthesized in our laboratory, in addition
     to 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine (DCPDAT), or irsogladine,
     which is a widely used anti-ulcer drug, were investigated for potential
     chemopreventive effects in a rat liver medium-term bioassay system. A
     significant inhibitory influence on enzyme-altered liver foci was found for
     2CPDAT, 3CPDAT, 4CPDAT, and PyNODAT, but not for DCPDAT or PyDAT. The
     involvement of gap junctional intercellular communication in the inhibition
     was studied, but no change in gap junctional intercellular communication
     capacity in rat liver cells in vitro or in gap junction protein (connexin 32)
     expression in rat liver in vivo was noted. These results indicate that,
     although these irsogladine analogs exert inhibitory effects on rat liver
     carcinogenesis, their action is independent of modification of gap junctional
      intercellular communication.
     1-6 (Pharmacology)
CC
                                          33237-20-6 57381-26-7
                             29366-77-6
                 4514-54-9
IT
     4514-53-8
     187753-86-2
     RL: BAC (Biological activity or effector, except adverse); BSU
     (Biological study, unclassified); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (triazine derivs. inhibit hepatocarcinogenesis but do not enhance gap
        junctional intercellular communication)
     57381-26-7
IT
     RL: BAC (Biological activity or effector, except adverse); BSU
```

(Biological study, unclassified); THU (Therapeutic use); BIOL

(triazine derivs. inhibit hepatocarcinogenesis but do not enhance gap

(Biological study); USES (Uses)

junctional intercellular communication)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

RETABLE		·			
	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
	-====	}====-	+======	+================	-========
Asamoto, M	1991	4	322	Mol Carcinog	HCAPLUS
Bertram, J	1994	234	235	Methods Enzymol	HCAPLUS
Bertram, J	1989	18	562	Prev Med	HCAPLUS
Bex, V	1995	13	69	Cell Biochem Funct	HCAPLUS
Budunova, I	1994	10	71	Cell Biol Toxicol	HCAPLUS
Demilo, A	1981	29	82	J Agric Food Chem	HCAPLUS
El-Fouly, M	1987	168	422	Exp Cell Res	HCAPLUS
Hirose, Y	1996	87	549	Jpn J Cancer Res	HCAPLUS
Holder, J	1993	53	3475	Cancer Res	HCAPLUS
Hosokawa, T	1992	118	565	J Cancer Res Clin On	MEDLINE
Ito, N	1988	9	387	Carcinogenesis	HCAPLUS
Ito, N	1989	17	630	Toxicol Pathol	HCAPLUS
Jansen, L	1996	17	333	Carcinogenesis	HCAPLUS
Klaunig, J	1990	62	135	Lab. Invest	HCAPLUS
Krutovskikh, V	1991	12	1701	Carcinogenesis	HCAPLUS
Kumar, N	1986	103	767	J Cell Biol	HCAPLUS
Lalezari, I	1971	16	117	J Chem Eng Data	HCAPLUS
Loewenstein, W	1979	560	1	Biochim Biophys Acta	HCAPLUS
McKarns, S	1992	8	89	Cell Biol Toxicol	HCAPLUS
Mesnil, M	1986	165	391	Exp Cell Res	HCAPLUS
Murray, A	1979	91	395	Biochem Biophys Res	HCAPLUS
Murray, A	1982	7	587	Carcinogenesis	MEDLINE
Ogino, A	1980	23	437	J Med Chem	HCAPLUS
Ruch, R ~	1987	87	111	Toxicol Appl Pharmac	HCAPLUS
Saez, J	1989	257	1	Am J Physiol	<u> </u>
Sato, Y	1993	322	155	FEBS Lett	HCAPLUS
Satoh, K	1985	82	3964	Proc Natl Acad Sci U	:
Slaga, T	1981	213	1023	Science	HCAPLUS
Smyrl, N	1982	19	493	J Heterocycl Chem	HCAPLUS
Sumi, N	1986	36	251	Pharmacometrics	!
Trosko, J	1993	53	1	Life Sci	HCAPLUS
Tsushimoto, G	1983	12	721	Arch Environ Contam	HCAPLUS
Ueda, F	1984	34	478	Arzneim Forsch	HCAPLUS
Ueda, F	1991	57	321	Jpn J Pharmacol	HCAPLUS
Williams, G	1981	11	339	Cancer Lett	HCAPLUS
Yamasaki, H	1995	333	181	Mutat Res	HCAPLUS
Yotti, L	1979	206	1089	Science	HCAPLUS
Zhang, L	1991	12	2109	Carcinogenesis	HCAPLUS

L98 ANSWER 22 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1996:385934 HCAPLUS Full-text

DOCUMENT NUMBER:

125:41767

Synthesis and formulation of triazine derivatives as TITLE:

hepatitis remedies

INVENTOR(S): PATENT ASSIGNEE(S): Ueda, Fusao; Ozaki, Takayuki; Nakamura, Ken-ichi

Nippon Shinyaku Co., Ltd., Japan

SOURCE:

PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PAT	TENT NO.		KI	ID DATE	APPLICATION NO.		DATE	
	. -							
WO	9604914		A1	19960222	WO 1995-JP1577		19950808 <	
	W: AU,	BR, C	CA, CN,	FI, HU, JP,	KR, MX, NO, NZ, RU,	UA,	US, VN	
	RW: AT,	BE, C	CH, DE,	DK, ES, FR,	GB, GR, IE, IT, LU,	MC,	NL, PT, SE	
CA	2197091		A.		CA 1995-2197091		19950808 <	
AU	9531920		Α	19960307	AU 1995-31920		19950808 <	
AU	703263		B2	19990325				
EP	775487		A1	19970528	EP 1995-927992		19950808 <	
	R: AT,	BE, C	CH, DE,	DK, ES, FR,	GB, IT, LI, NL, PT,	SE		
CN	1155244		A	19970723	CN 1995-194521		19950808 <	
BR	9508539		Α	19971028	BR 1995-8539		19950808 <	
HU	77735		A2	19980728	HU 1997-355		19950808 <	
RU	2147233		C:	20000410	RU 1997-103983		19950808 <	
US	5962453		A	19991005	US 1997-776992		19970206 <	
PRIORITY	APPLN.	INFO.	:		JP 1994-185810	A	19940808 <	
					WO 1995-JP1577	W	1 19950808 <	

MARPAT 125:41767

OTHER SOURCE(S):

GI

A medicine useful as a hepatitis remedy is claimed which contains as the AB active ingredient a triazine derivative represented by general formula (I), a solvate thereof, or a salt thereof, wherein R1 and R2 represent each independently hydrogen or (un) substituted alkyl, aralkyl or alkenyl, or NR1R2 represents a cyclic amino group which may bear, in addition to the pertinent nitrogen atom, nitrogen, oxygen or sulfur as the ring atom and may be substituted, provided the case where NR1R2 represents NH2 is excluded. Studies in mouse and rat models of hepatitis indicate the remedial efficacy of various I.

ICM A61K031-53 IC

ICS A61K031-535; A61K031-54; A61K031-55

63-6 (Pharmaceuticals) CC

Section cross-reference(s): 1, 28

57381-26-7DP, derivs. 178105-27-6P 178105-28-7P 178105-29-8P IT 178105-31-2P 178105-32-3P 178105-48-1P 178105-57-2P 178105-59-4P 178105-60-7P 178105-61-8P 178105-65-2P 178105-85-6P 178105-91-4P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and formulation of triazine derivs. as hepatitis remedies) 51-35-4, 4-Hydroxyproline 56-40-6, Glycine, reactions 62-53-3, Aniline, reactions 64-04-0, Phenethylamine 74-89-5, Methylamine, reactions N, N-Dimethylformamide, reactions 100-36-7, N,N-Diethylethylenediamine 92-54-6, N-Phenylpiperazine 103-67-3, N-Methylbenzylamine 100-46-9, Benzylamine, reactions 103-76-4, N-(2-Hydroxyethyl)piperazine 107-15-3, 1,2-Ethanediamine, 108-18-9, Diisopropylamine 109-05-7, 2-Methylpiperidine reactions 109-85-3, 2-Methoxyethylamine 109-83-1, N-Methyl-N-(2-hydroxyethyl)amine 110-89-4, 110-85-0, Piperazine, reactions 109-96-6, 3-Pyrroline 111-42-2, Piperidine, reactions 110-91-8, Morpholine, reactions 111-49-9, Hexamethylenimine 123-75-1, Pyrrolidine, reactions 124-40-3, Dimethylamine, reactions 124-63-0, 123-90-0, Thiomorpholine 141-43-5, Ethanolamine, reactions 141-91-3, Methanesulfonyl chloride 2,6-Dimethylmorpholine 147-85-3, (s)-Proline, reactions 503-29-7, Azetidine 535-75-1, 2-Carboxypiperidine 598-41-4, Glycinamide 660-68-4, Diethylamine hydrochloride 841-77-0, 1-1499-56-5, trans-4-Hydroxy-L-proline methyl Diphenylmethylpiperazine 1664-40-0, N-Phenylethylenediamine 1758-46-9, 2038-03-1, 4-Morpholineethanamine 4360-51-4, 2-Phenoxyethylamine 5082-74-6, 3-Hydroxymethylpyrrolidine 5382-16-1, Cinnamylamine 5625-67-2, 2-Oxopiperazine 6457-49-4, 4-Hydroxypiperidine 4-Hydroxymethylpiperidine 6859-99-0, 3-Hydroxypiperidine 3-Amino-1-benzylpyrrolidine 19130-96-2, 1,5-Dideoxy-1,5-imino-D-glucitol 24252-67-3 27578-60-5, 2-Piperidinoethylamine 23356-96-9 20980-22-7 31252-42-3, 4-Benzylpiperidine 40499-83-0, 3-Hydroxypyrrolidine 41661-47-6, 4-Oxopiperidine 40807-61-2, 4-Hydroxy-4-phenylpiperidine 72351-36-1 55276-43-2 68832-13-3 45347-82-8, 3-Azetidinol 149366-79-0 178105-24-3 81530-73-6 103706-76-9 138304-74-2 149366-79-0 178105-25-4 178105-26-5 178105-46-9 178105-69-6 RL: RCT (Reactant); RACT (Reactant or reagent) (synthesis and formulation of triazine derivs. as hepatitis remedies) 57381-26-7DP, derivs. RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and formulation of triazine derivs. as hepatitis remedies)
57381-26-7 HCAPLUS

RN 57381-26-7 HCAPLUS CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

IT

IT

L98 ANSWER 23 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1996:203525 HCAPLUS Full-text DOCUMENT NUMBER: 124:278316

TITLE:

Inhibition of tumor growth and neovascularization by

an anti-gastric ulcer agent irsogladine

AUTHOR(S):

Ono, Mayumi; Kawahara, Naoyuki; Goto, Daisuke;

Wakabayashi, Yukihiro; Ushiro, Shin; Yoshida, Shigeo;

Izumi, Hiroto; Kuwano, Michihiko; Sato, Yashufumi

CORPORATE SOURCE:

School Medicine, Kyushu Univ., Fukuoka, 812-82, Japan Cancer Research (1996), 56(7), 1512-16

SOURCE:

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER:

American Association for Cancer Research

DOCUMENT TYPE:

Journal

LANGUAGE:

English

Irsogladine used clin. as an anti-gastric ulcer agent, at 10-6-10-4 M, AB , inhibited cell proliferation and tubular morphogenesis of vascular endothelial cells, but the proliferation of human epidermoid cancer of glioma cells was not inhibited by this drug, even at 10-4 M. In vivo studies demonstrated that p.o. administration of irsogladine significantly inhibited tumor growth of human glioma cells in mice, and histol. anal. showed a dramatic decrease of the neovascularization in the tumors. In mice transplanted with chambers containing human glioma cells or hepatic cancer cells, irsogladine also inhibited angiogenesis. These in vivo and in vitro assays demonstrate that irsogladine may be a unique and potent inhibitor of tumor angiogenesis.

1-6 (Pharmacology) CC

57381-26-7, Irsogladine IT

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibition of tumor growth and neovascularization by irsogladine)

57381-26-7, Irsogladine IT

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibition of tumor growth and neovascularization by irsogladine)

57381-26-7 HCAPLUS RN

1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME) CN

L98 ANSWER 24 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1996:387151 HCAPLUS Full-text

DOCUMENT NUMBER:

125:104423

TITLE:

Suppressing effects of 6-(2,5-dichlorophenyl)-2,4diamino-1,3,5-triazine and related synthetic compounds on azoxymethane-induced aberrant crypt foci in rat

AUTHOR (S):

Hirose, Yoshinobu; Tanaka, Takuji; Makita, Hiroki; Yang, Muzheng; Satoh, Kumiko; Hara, Akira; Maeda, Mitsuaki; Toriyama, Hiroyasu Baba; Mori, Hideki;

Tsuda, Hiroyuki

CORPORATE SOURCE:

First Dep. Pathol., Gifu Univ. Sch. Med., Gifu, 500,

SOURCE:

Japanese Journal of Cancer Research (1996),

87(6), 549-554

CODEN: JJCREP; ISSN: 0910-5050

PUBLISHER:

LANGUAGE:

Japanese Cancer Association

DOCUMENT TYPE:

Journal English

The modifying effects of dietary administration of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and 5 related compds. on the occurrence of azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) were investigated in rats. Male F344 rats were given s.c. injections of AOM (15 mg/kg body weight) once a wk for 3 wks to induce ACF. They also received a diet containing 200 ppm test compound for 5 wks, starting one wk before the first dosing of AOM. At the termination of the experiment, all of the compds. had caused a significant reduction in ACF frequency, which might by associated with suppression of the expression of proliferation biomarkers. The apoptotic index in the colonic mucosal epithelium of rats killed at 6 h after the first AOM exposure revealed no blocking activity of the compds.

CC 1-6 (Pharmacology)

IT 4514-53-8 4514-54-9 29366-77-6 33237-20-6 57381-26-7

178991-22-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compds. on azoxymethane-induced aberrant crypt foci in rat colon)

IT 57381-26-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compds. on azoxymethane-induced aberrant crypt foci in rat colon)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 25 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:750055 HCAPLUS Full-text

DOCUMENT NUMBER: 123:188182

TITLE: Irsogladine activates gap-junctional intercellular

communication through M1 muscarinic acetylcholine

receptor

AUTHOR(S): Ueda, Fusao; Ban, Keiko; Ishima, Tsuyoshi

CORPORATE SOURCE: Discovery Research Laboratories II, Nippon Shinyaku

Co. Ltd., Kyoto, 601, Japan

SOURCE: Journal of Pharmacology and Experimental Therapeutics

(1995), 274(2), 815-19

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

Irsogladine, an agent that protects gastric mucosa against various ulcerogenic AB stimuli through increasing cAMP in surface mucous cells, has been reported to dose-dependently (10-7 to 10-5 M) facilitate gap-junctional intercellular communication (GJIC) in gastric epithelial cells. The beta adrenergic agonist, isoproterenol, stimulates GJIC in resting cells and inhibits GJIC in cells activated by 3-isobutyl-1- methylxanthine. In this study, we investigated whether irsogladine acts on GJIC in a manner similar to that shown by isoproterenol. Irsogladine, which bound to M1 muscarinic acetylcholine receptors (mAChR), did not inhibit, but failed to further facilitate the 3-isobutyl-1-methylxanthine- enhanced GJIC, measured by Lucifier yellow transfer. The enhancement of GJIC by irsogladine was inhibited by the M1 mAChR antagonist, pirenzepine. A selective M1 mAChR agonist, McN-A-343, enhanced GJIC. Isoproterenol (10-8 to 10-6 M), which alone did not affect GJIC, inhibited the GJIC enhanced by 10-5 M irsogladine. Conversely, 10-10 to 10-6 M irsogladine, which alone did not affect GJIC, inhibited the GJIC enhanced by 10-5 M isoproterenol. McN-A-343 also converted the action of 10-5 M isoproterenol from facilitation to inhibition of GJIC. These results indicate that GJIC is heterologously down-regulated by crosstalk between M1 mAChR and beta adrenergic receptors. In addition, the effects of irsogladine and isoproterenol at low concns. suggest the involvement of another mechanism for down-regulating GJIC.

CC 1-9 (Pharmacology)

IT 57381-26-7, Irsogladine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor)

IT 57381-26-7, Irsogladine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 26 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1995:633350 HCAPLUS Full-text

DOCUMENT NUMBER:

123:74593

TITLE:

Effects of irsogladine, cimetidine and cetraxate on prostaglandin biosynthesis in cultured rabbit gastric

epithelial cells

AUTHOR (S):

Ueda, Fusao; Ideguchi, Kyoichi

CORPORATE SOURCE:

Discovery Res. Lab., Nippon Shinyaku Co. Ltd., Kyoto,

601, Japan

SOURCE:

Yakuri to Chiryo (1995), 23(2), 327-31

CODEN: YACHDS; ISSN: 0386-3603

PUBLISHER:

Raifu Saiensu Shuppan K.K.

DOCUMENT TYPE:

Journal Japanese

LANGUAGE:

The effects of antiulcer drugs on prostaglandin (PG) biosynthesis were investigated in 1-14C-arachidonic acid (AA)-prelabeled gastric epithelial cells. Irsogladine and cimetidine did not affect basal PG biosynthesis. Cetraxate decreased the release of polar substances (phospholipids and probably peptide leukotrienes) and increased AA release. All these antiulcer drugs inhibited norepinephrine-induced PGE2 biosynthesis. These results suggest that PGE2 is not important in gastric defense functions. In addition, the inhibition of PGE2 biosynthesis by the antiulcer drugs might be involved in their mechanisms for inhibiting gastric ulcers.

CC 1-9 (Pharmacology)

IT 34675-84-8, Cetraxate 51481-61-9, Cimetidine 57381-26-7,

Irsogladine

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(effects of irsogladine, cimetidine and cetraxate on prostaglandin biosynthesis in cultured rabbit gastric epithelial cells)

IT 57381-26-7, Irsogladine

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(effects of irsogladine, cimetidine and cetraxate on prostaglandin

biosynthesis in cultured rabbit gastric epithelial cells)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 27 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1995:954085 HCAPLUS Full-text

DOCUMENT NUMBER:

124:21526

TITLE:

Irsogladine inhibits ionomycin-induced decrease in intercellular communication in cultured rabbit gastric

epithelial cells

AUTHOR (S):

kameda, Yukiaki; Ueda, Fusao

CORPORATE SOURCE:

Res. Lab., Nippon shinyaku Co., Ltd., Kyoto, 601,

Japan

SOURCE:

Japanese Journal of Pharmacology (1995),

69(3), 223-8

CODEN: JJPAAZ; ISSN: 0021-5198

PUBLISHER:

Japanese Pharmacological Society

DOCUMENT TYPE:

Journal

LANGUAGE:

English

Effects of irsogladine on ionomycin-induced decreased in intercellular communication and increase in intracellular concentration of Ca2+ ([Ca2+]i) were investigated in cultured rabbit gastric epithelial cells. Ionomycin (10-7-10-16 M) transiently and concentrate-dependently inhibited intercellular communication concomitantly with the elevation of [Ca2+]i in the presence and

absence of extracellular Ca2+. Irsogladine (0-5 M), which has been shown to facilitate intercellular communication, suppressed the ionomycin-induced elevation of [Ca2+]i and decrease in intercellular communication. suppression of the ionomycin effects by irsogladine was independent of extracellular Ca2+. TMB-8 [8-(diethylamino)octyl-3,4,5- trimethoxybenzoate hydrochloride] (10-6 M) also suppressed the ionomycin-induced elevation of [Ca2+]i and decrease in intercellular communication. These results indicate that the ionomycin-induced decrease in intercellular communication may be due to Ca2+ mobilization from intracellular stores. Inhibitory effects of irsogladine and TMB-8 on the ionomycin-induced decrease in intercellular communication may be produced by suppressing Ca2+ mobilization.

1-9 (Pharmacology) CC

57381-26-7, Irsogladine IT

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(irsogladine inhibits ionomycin-induced decrease in intercellular communication in gastric epithelium)

57381-26-7, Irsogladine IT

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(irsogladine inhibits ionomycin-induced decrease in intercellular communication in gastric epithelium)

57381-26-7 HCAPLUS RN

1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME) CN

L98 ANSWER 28 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1995:126565 HCAPLUS Full-text

DOCUMENT NUMBER:

122:616

TITLE:

A new synthetic antiarrhythmic peptide reduces

dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia: a mapping study

AUTHOR (S):

Dhein, S.; Manicone, N.; Muller, A.; Gerwin, R.; Ziskoven, U.; Irankhahi, A.; Minke, C.; Klaus, W.

CORPORATE SOURCE:

Inst. Pharmakologie, Univ. Koln, Koln, D-50931,

SOURCE:

Naunyn-Schmiedeberg's Archives of Pharmacology (

1994), 350(2), 174-84

CODEN: NSAPCC; ISSN: 0028-1298

DOCUMENT TYPE:

Journal

LANGUAGE:

English

Common antiarrhythmic agents affect ionic membrane channels and thereby alter cellular elec. activity. Since this accounts for the proarrhythmic effects as well the authors tried to find new substances with different profiles of actions. A new antiarrhythmic peptide, H2, N-Gly- Ala-Gly-4 Hyp-Pro-Tyr-CONH2 (AAP 10), was synthesized using the Fmoc-strategy. This peptide was analyzed for its electrophysiol. profile of action in normal isolated rabbit hearts

perfused according to the Langendorff technique either under control conditions or after induction of a regional ischemia. For this purpose 256 channel epicardial mapping was employed allowing the determination of the time points of activation at each electrode thus identifying the origins of epicardial activation (so called breakthrough-points, BTP). Epicardial spread of activation was then described math. by activation vectors which gave direction and velocity of the epicardial activation wave at each electrode. Single heart beats were analyzed under control conditions and under treatment with AAP10 or under regional ischemia with or without AAP 10-pretreatment (10-8 mol./L). The authors calculated the percentage of similar vectors (VEC) with unaltered direction (deviation <5°) and the percentage of identical breakthrough points (deviation \leq 1 mm) compared to control conditions. addition, apparent epicardial velocities, total activation time of a given region and activation-recovery interval (ARI) as well as dispersion of ARI (i.e. standard deviation of ARI) and distribution of ARI were analyzed. Under control conditions treatment with AAP 10 (10-10 to 3+10-7 mol/L) led to a significant decrease in ARI-dispersion without alteration of any of the other parameters under investigation. Left ventricular regional ischemia resulted in a marked alteration of the activation patterns (a significant decrease in vector-field- and breakthrough point-similarity) which could be significantly inhibited by pretreatment with AAP10. In addition, the authors found that AAP10 depressed the increase in ARI-dispersion during the first minutes of ischemia and accelerated normalization of ARI-dispersion during reperfusion. In addnl. expts., it could be shown that AAP 10 did not alter action potential duration maximum dU/dt, amplitude or resting membrane potential of isolated guinea pig muscles using a common intracellular action potential recording technique. From these results it is concluded that (a) AAP 10 inhibits ischemia induced alterations of the activation pattern (b) that it decreases ARI-dispersion (c) that this effect seems not to be due to an action on ionic channels (d) that the effect of AAP 10 may be due to an improvement of cellular coupling and finally (e) that AAP 10 may be an interesting new approach to the problem of prophylaxis of ischemia-associated ventricular arrhythmias.

```
CC 1-8 (Pharmacology)
```

IT 159503-65-8

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(prevention of ischemia-associated ventricular arrhythmias by synthetic peptide AAP 10)

IT 159503-65-8

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(prevention of ischemia-associated ventricular arrhythmias by synthetic peptide AAP 10)

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$H_2N$$
 H_2N
 H_2N

L98 ANSWER 29 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1993:38951 HCAPLUS Full-text

DOCUMENT NUMBER:

118:38951

TITLE:

Preparation of 2,4-diamino-6-phenyl-1,3,5-triazine

derivatives as anticancer agents and anticancer

pharmaceutical compositions containing them

INVENTOR(S):

Mishina, Hitoshi; Ueda, Fusao

PATENT ASSIGNEE(S):

Nippon Shinyaku Co., Ltd., Japan

SOURCE:

PCT Int. Appl., 46 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 9211247	A1 19920709	WO 1991-JP1734	19911219 <
W: AU, BR, CA,	FI, HU, JP, KR,	NO, SU, US	
RW: AT, BE, CH,	DE, DK, ES, FR,	GB, GR, IT, LU, MC,	NL, SE
AU 9190979		AU 1991-90979	19911219 <
EP 563386	Al 19931006	EP 1992-901441	19911219 <
R: AT, BE, CH,	DE, DK, ES, FR,	GB, GR, IT, LI, LU,	
PRIORITY APPLN. INFO.:		JP 1990-413461	A 19901220 <
		JP 1991-96372	A 19910401 <
		WO 1991-JP1734	A 19911219 <

OTHER SOURCE(S):

MARPAT 118:38951

GI

The title compds. (I; R1, R2 = H, halo, amino, aralkylamino, NO2, alkyl, AΒ alkoxy, alkoxyalkyl, aralkyloxy, acyl; R3, R4 = H, nicotinoyl, Bz, alkoxy; n = 0, 1) are prepared An anticancer pharmaceutical composition contains I. Thus, a mixture of p-HOC6H4CN, PhCH2Cl, and K2CO3 in MeCN was refluxed for 5 h to give p-PhCH2OC6H4CN which was heated with dicyandiamide and KOH in diethylene glycol di-Me ether at 100° for 8 h to give I (R1 = 4-PhCH2O, R2 = R3 = R4 = H, n = 0). I.maleate (R1 = 2-Cl, R2 = 5-Cl, R3 = R4 = H, n = 0) (irsogladine) (II), administered to mice at 10 mg/kg p.o. per day from day 14 to 18 after implantation of human colon cancer WiDr cells, showed the tumor volume ratio (the tumor volume after 18 days/the initial volume) 1.52 vs. 2.00 (control) and 1.52 for cyclophosphamide administered at 10 mg/kg i.p. once on day 14. also enhanced the antitumor activity of 5-fluorouracil derivs., e.g. Mifurol and Sunfurol, and in vitro inhibited the uptake of 5-fluorouracil in MDCK cells. Clin. trials of II were also described. Tablet, powder, and injection solution formulations containing II were given.

IC ICM C07D251-18 ICS A61K031-53

CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

29366-71-0P 29366-73-2P 4514-54-9P 20317-65-1P 27374-29-4P IT 34095-30-2P 36303-44-3P 57381-26-7P, Irsogladine 30354-89-3P 57381-45-0P 57381-33-6P, Irsogladine maleic acid salt 68215-75-8P 65052-46-2P 57381-57-4P 57381-58-5P 59386-77-5P 145176-30-3P 116118-75-3P 145176-29-0P 81530-52-1P 81530-54-3P 145176-35-8P 145176-32-5P 145176-33-6P 145176-34-7P 145176-31-4P 145176-38-1P 145176-39-2P 145176-36-9P 145176-37-0P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as anticancer agent)

IT 57381-26-7P, Irsogladine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as anticancer agent)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 30 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1990:515835 HCAPLUS Full-text

DOCUMENT NUMBER: 113:115835

TITLE: Antiarrhythmic activity of a novel analog of AAP

AUTHOR(S): Kundu, Bijoy; Rizvi, Shaheena Yasmeen; Mathur, Krishna

Behari; Kar, Karunamoy

CORPORATE SOURCE: Div. Biopolym., Cent. Drug Res. Inst., Lucknow, 226

001, India

SOURCE: Collection of Czechoslovak Chemical Communications (

1990), 55(2), 575-80

CODEN: CCCCAK; ISSN: 0010-0765

DOCUMENT TYPE:

Journal

English LANGUAGE:

Antiarrhythmic peptide (AAP) analogs H-Gly-X-X1-Gly- Ala-Gly-OH [I; X-X1 = Sar-Pro (Sar = MeGly), Pro-Sar, Sar-Sar] have been synthesized in order to obtain peptides with enhanced antiarrhythmic activity. Their antiarrhythmic activity has been evaluated against aconitine induced arrhythmia in rats. I (X-X1 = Sar-Sar) is more active than AAP (I, X-X1 = Pro-Hyp). It is equipotent to the commonly used antiarrhythmic drug quinidine, so far as delay in the onset of ventricular tachycardia, ventricular fibrillation and cardiac arrest are concerned. Relationships of biol. activities of these peptides with their CD spectra are discussed. The spatial structure of I (X-X1 = Sar-Sar) attributed to Sar2-Sar3 linkage might be contributing to its higher antiarrhythmic activity.

34-3 (Amino Acids, Peptides, and Proteins) CC

Section cross-reference(s): 1

81771-37-1DP, Antiarrhythmic peptide (ox atrium), analogs IT 129165-01-1P 129164-97-2P 129164-98-3P 129164-99-4P 129165-00-0P 129165-02-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antiarrhythmic activity of)

81771-37-1DP, Antiarrhythmic peptide (ox atrium), analogs IT RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antiarrhythmic activity of)

81771-37-1 HCAPLUS RN

Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME) CN

Absolute stereochemistry.

HCAPLUS COPYRIGHT 2007 ACS on STN L98 ANSWER 31 OF 37

ACCESSION NUMBER: 1989:568091 HCAPLUS Full-text

DOCUMENT NUMBER:

Antiarrhythmic peptide has no direct cardiac actions TITLE:

Argentieri, T.; Cantor, E.; Wiggins, J. R. AUTHOR (S):

Berlex Lab., Inc., Cedar Knolls, NJ, 07927, USA CORPORATE SOURCE:

Experientia (1989), 45(8), 737-8 SOURCE:

CODEN: EXPEAM; ISSN: 0014-4754

Journal DOCUMENT TYPE: English LANGUAGE:

64

The electrophysiol., inotropic, and muscarinic effects of antiarrhythmic peptide (AAP) were examined in canine cardiac Purkinje fibers, ferret papillary muscle, and canine cardiac membranes, resp. Aside from a prolongation of time to peak force in papillary muscle, no biol. significant effects of AAP could be determined in any preparation, suggesting that its antiarrhythmic effects are not mediated by direct membrane actions.

CC 2-10 (Mammalian Hormones)

IT 81771-37-1, Antiarrhythmic peptide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(heart response to)

IT 81771-37-1, Antiarrhythmic peptide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(heart response to)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L98 ANSWER 32 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1989:147197 HCAPLUS Full-text

DOCUMENT NUMBER:

110:147197

TITLE:

Effect of N-3-(4-hydroxyphenyl)propionyl Pro-Pro-

Gly-Ala-Gly on

calcium-induced arrhythmias

AUTHOR (S):

Kohama, Yasuhiro; Kuwahara, Shigeki; Yamamoto, Koji;

Okabe, Masaru; Mimura, Tsutomu; Fukaya, Chikara;

Watanabe, Masahiro; Yokoyama, Kazumasa

CORPORATE SOURCE:

Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

SOURCE:

Chemical & Pharmaceutical Bulletin (1988),

36(11), 4597-9

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE:

Journal

LANGUAGE:

English

The present investigation was done to examine whether or not the presence of hydroxyproline in N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-Gly- Ala-Gly (HP-5) is essential for its antiarrhythmic activity. Pretreatment of mice with 10 mg/kg of [Pro2]-HP-5 provided better protection against calcium-induced arrhythmias than did pretreatment with HP-5. Thus, the prolyl residue was more favorable than the hydroxyprolyl residue for antiarrhythmic activity of these analogs.

CC 1-3 (Pharmacology)

Section cross-reference(s): 2, 34

IT 111915-92-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(antiarrhythmic activity of, structure in relation to)

IT 111915-92-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiarrhythmic activity of, structure in relation to)

RN 111915-92-5 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium), 1-deglycine-2-[1-[3-(4-hydroxyphenyl)-1-oxopropyl]-L-proline]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L98 ANSWER 33 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1988:16410 HCAPLUS Full-text

DOCUMENT NUMBER: 108:16410

TITLE: A new antiarrhythmic peptide, N-3-(4-

hydroxyphenyl)propionyl Pro-Hyp-Gly-

Ala-Glv

AUTHOR(S): Kohama, Yasuhiro; Okimoto, Naotsugu; Mimura, Tsutomu;

Fukaya, Chikara; Watanabe, Masahiro; Yokoyama,

Kazumasa

CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1987),

35(9), 3928-30

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal LANGUAGE: English

AB In order to increase the antiarrhythmic activity of the naturally occurring antiarrhythmic peptide (Pro-Hyp-Gly-Ala- Gly; (P-5)), P-5 analogs with 3 diffeent hydrophobic substituents, N-3-(4-hydroxyphenyl)propionyl (H), N-3-phenylpropionyl (I) and N-3-phenylpropyl (P), were prepared and their activities were evaluated in CaCl2-induced arrhythmias in mice. HP-5 showed potent antiarrhythmic activity at 1 mg/kg, i.v. and its potency was much higher than that of P-5 at 10 mg/kg, i.v. IP-5 showed similar potency to P-5, but PP-5 was inactive. Pro-Hyp-Gly-Ala, Pro-Hyp-Gly and Pro-Hyp with the substituent H, were also ineffective. Thus, 3-(4-hydroxyphenyl)propionylation of the imino nitrogen of Pro in P-5 led to increased potency.

CC 2-2 (Mammalian Hormones)

IT 111915-91-4DP, analogs 111915-92-5P 111915-93-6P
111915-94-7P 111915-95-8P 111915-96-9P 111915-97-0P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation and antiarrhythmic activity of, structure in relation to)

IT 111915-92-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (USES)

(preparation and antiarrhythmic activity of, structure in relation to)

RN 111915-92-5 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium), 1-deglycine-2-[1-[3-(4-hydroxyphenyl)-1-oxopropyl]-L-proline]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$HO_2C$$
 H
 HO_2C
 H
 HO_2C
 H
 HO_2C
 H
 HO_2C
 H
 HO

L98 ANSWER 34 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1984:133284 HCAPLUS Full-text

DOCUMENT NUMBER:

100:133284

TITLE:

Studies on heart. XXXIV. Inhibitory effect of antiarrhythmic peptide (AAP) on experimental

thromboses

AUTHOR(S):

Aonuma, Shigeru; Kohama, Yasuhiro; Makino, Toshitake;

Hattori, Kunihiro; Kawahara, Yusuke

CORPORATE SOURCE:

Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1984),

32(1), 219-27

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE:

Journal English

LANGUAGE:
AB The

The antithrombotic action of antiarrhythmic peptide (Gly -Pro-Hyp-Gly-Ala-[81771-37-1] was studied by using various in vivo thrombosis models. AAP (1, 10, or 100 mg/kg, i.v.; 10 mg/kg, i.p.; or 100 mg/kg, orally) significantly inhibited white thrombus formation on a silk thread in the extracorporeal shunt models in rats, its ED50 being about 30 mg/kg, i.v. (10 mg/kg, i.v.) was effective in protecting rats against the decrease in platelet count, against the incidence of electrocardiog. alterations (T-wave inversion and ST-segment depression) typical of myocardial ischemia, and against development of ectopic beats during coronary thromboembolism induced by i.v. infusion of ADP. The peptide (10 mg/kg, i.p.) was also effective in preventing thrombus formation in the lung and the decrease of platelet count induced by lactic acidosis in rats, and it (10 mg/kg, i.v.) clearly inhibited thromboembolic death induced by rapid i.v. injection of collagen in mice. Daily treatments with the peptide (10 mg/kg/d, i.p.) resulted in significant delay of the progression of gangrene and mummification in laurate-induced peripheral arterial occlusive disease in rats. AAP did not affect venous thrombus formation, blood flow through the carotid artery, plasma recalcification time or fibrinolytic activity in rats. It is likely that the potent antithrombotic action of AAP is mainly due to its anti-plateletaggregating action in vivo. Ticlopidine (100 mg/kg, orally) also showed a

comparatively wide antithrombotic spectrum, like AAP, in the present thrombosis models; but ticlopidine, like aspirin (50 mg/kg, s.c.), lacked activity against myocardial ischemia.

2-9 (Mammalian Hormones) CC

IT 81771-37-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (antithrombotic activity of)

81771-37-1 IT

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (antithrombotic activity of)

81771-37-1 HCAPLUS RN

Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME) CN

Absolute stereochemistry.

L98 ANSWER 35 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1983:482255 HCAPLUS Full-text

DOCUMENT NUMBER:

99:82255

TITLE:

Studies on heart. XXII. Inhibitory effect of an

atrial peptide (AAP) on several drug-induced

arrhythmias in vivo

AUTHOR (S):

SOURCE:

Aonuma, Shigeru; Kohama, Yasuhiro; Makino, Toshitake;

Hattori, Kunihiro

CORPORATE SOURCE:

Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

Yakugaku Zasshi (1983), 103(6), 662-6

CODEN: YKKZAJ; ISSN: 0031-6903

DOCUMENT TYPE:

Journal Japanese LANGUAGE:

The effect of an atrial peptide, Gly-Pro-4Hyp-Gly- Ala-Gly (AAP) [81771-37-1], on several drug-induced arrhythmias in anesthetized dogs, rats and mice was investigated. AAP (10 mg/kg, i.v.) significantly reversed the persistent arrhythmias consisting of atrio-ventricular (A-V) block, ectopic beat, and/or ventricular tachycardia induced by aconitine pretreatment prevented development of ventricular fibrillation in dogs and rats. AAP (10, 25 mg/kg, i.v.) prolonged onset time of A-V block or ectopic beat and onset time of ventricular tachycardia induced by aconitine infusion in mice. This peptide (10 mg/kg, i.v.) significantly prolonged the onset time of A-V block or ectopic beat induced by CaCl2 infusion and the time until ventricular fibrillation induced by ouabain infusion in mice, and shortened the duration of arrhythmia induced by ADP in rats, but did not affect the mouse epinephrine-induced arrhythmia. The peptide (25 mg/kg, i.v.) prolonged the QTc interval and had no effect on the PQ interval heart rate, respiratory rate, and blood pressure in dogs. AAP (1 g/kg, i.v.v., i.p., and orally) did not show acute toxicity in mice. AAP had antiarrhythmic activity with few side effects.

CC 1-8 (Pharmacology)

Section cross-reference(s): 2

IT 81771-37-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiarrhythmic activity of)

IT 81771-37-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antiarrhythmic activity of)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L98 ANSWER 36 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1980:157536 HCAPLUS Full-text

DOCUMENT NUMBER:

92:157536

TITLE:

Structure-activity study of antiulcerous and antiinflammatory drugs by discriminant analysis Ogino, Akio; Matsumura, Shingo; Fujita, Toshio

AUTHOR(S): CORPORATE SOURCE:

Res. Lab., Nippon Shinyaku Co., Ltd., Kyoto, 601,

Japan

SOURCE:

Journal of Medicinal Chemistry (1980),

23(4), 437-44

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE:

LANGUAGE:

Journal English

GI

The structure activity of 34 antiulcer benzoguanamines I (R = H, halogen, Me, NO2, SCF3, etc.; n = 0-2), and that of 22 antiinflammatory phenylacetic acids II (R = H, OH, Me, OEt, Ph, etc.; n = 0-2), and 24 aminouracils III (R1 = Et, Me, Ph, substituted Ph, etc.; R2 = alkyl, CH2CH2OH, etc.; NR3N4 = NHPr, NMe2, NHBu, morpholins, etc.) were studied in rats by discriminant anal. For antiulcer activity the drug effect was evaluated in terms of averaged ulcer indexes and the percent inhibition value against the injury was expressed relative to the averaged index of the control group; the error involved was <10%. For the antiinflammatory activity the inhibitory effect was represented as the percent value relative to the average volume of control; the error in the percent value was <10%. The discriminant variables were selected from the physicochem. parameters used to analyze the variation in hydrophobicity due to structural modifications. The potency scores divided into 3 groups for each of the 3 series of compds. were predicted with >80% accuracy.

CC 1-3 (Pharmacodynamics)

Section cross-reference(s): 22

4514-54-9 19338-12-6 91-76-9D, derivs. 4514-53-8 91-76-9 IT 30101-52-1 29366-72-1 29366-73-2 29366-77-6 29366-71-0 30530-44-0 30530-48-4 30530-43-9 30508-78-2 30508-75-9 57381-42-7 57381-35-8 57381-38-1 57381-40-5 57381-26-7 57381-54-1 57381-57-4 57381-46-1 57381-50-7 57381-45-0 65052-50-8. 65052-53-1 65052-49-5 65052-47-3 57381-60-9 72781-91-0 72775-80-5 72775-81-6 72775-79-2 65052-55-3 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiulcer activity of, discriminant anal. in evaluation of)

IT 57381-26-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiulcer activity of, discriminant anal. in evaluation of)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 37 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1975:606332 HCAPLUS Full-text

DOCUMENT NUMBER:

83:206332

TITLE:

Benzoguanamine derivatives

INVENTOR(S):

Murai, Hiromu; Ohata, Katsuya; Aoyagi, Yoshiaki; Ueda,

Fusao; Kitano, Masahiko; Takata, Satoshi; Tada,

Shinichi

PATENT ASSIGNEE(S):

Nippon Shinyaku Co., Ltd., Japan

SOURCE: Ger. Offe

Ger. Offen., 24 pp. CODEN: GWXXBX

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
APPLICATION NO.
                                                              DATE
                       KIND
                             DATE
    PATENT NO.
                            _____
                                                              _____
                      ----
                                        -----
    _____
                                                             19750218 <--
                                        DE 1975-2506814
    DE 2506814
                       A1
                             19750828
                       C3
                             19791115
    DE 2506814
                       B2
                             19790322
    DE 2506814
    JP 50111085
                     A
B
A
B
                                       JP 1974-19211
                                                             19740218 <--
                             19750901
                            19800131
    JP 55004751
                           19750901
19771129
                                        JP 1974-19212
                                                              19740218 <--
    JP 50111086
    JP 52046955
                                                              19750127 <--
                            19760629 US 1975-544176
                      Α
    US 3966728
                     A5 19771031 CH 1975-1300
                                                             19750204 <--
    CH 592638
                      A5 19771031 CH 1975-1301
                                                             19750204 <--
    CH 592639
                            19750819 SE 1975-1273
                                                             19750205 <--
    SE 7501273
                       Α
                                                              19750205 <--
    SE 425245
                             19820913
                                        SE 1975-1274
                       В
                    C 19821230
A 19751020 DK 1975-436
C 19790212
B 19780717 DK 1975-437
    SE 425245
                                                              19750207 <--
    DK 7500436
    DK 138268
                                                             19750207 <--
    DK 138116
                     B
C
    DK 138116
                            19781204
                      Α
                                       NL 1975-1574
                                                              19750211 <--
    NL 7501574
                            19750820
    NL 157901
                      В
                             19780915
                                                              19750211 <--
    NL 157902
                      В
                            19780915 NL 1975-1575
                     A1 19750912 FR 1975-4690
                                                              19750214 <--
    FR 2261009
                                                             19750218 <--
                            19750616 BE 1975-153471
    BE 825673
                      A1
                                                              19750218 <--
                            19770315 AT 1975-1200
    AT 7501200
                      A
                       В
                            19771110
    AT 339909
                            19770515 AT 1975-1197
                                                              19750218 <--
                       Α
    AT 7501197
                      В
                             19780110
    AT 340941
                                        JP 1974-19211 A 19740218 <--
JP 1974-19212 A 19740218 <--
PRIORITY APPLN. INFO.:
    For diagram(s), see printed CA Issue.
GI
    Triazines I (R = 2-Cl, 2-F, 2-Br, 3-Cl, R1 = 5-Cl; R = 2-Cl, R1 = 5-Br, 4-Cl,
AB
     3-C1, 6-C1, 5-F; R = 2-Br, 2-F, R1 = 5-F, 5-Br, 4-C1; R = 3-C1, R1 = 4-Br)
     were prepared by treating RR1C6H3CN with dicyandiamide or dihalobenzoic acid
     derivs. with biguanide. I inhibit ulceration. Thus 20 mg/kg I (R = 2-Cl, R1
     = 5-Cl) i.p. in rats gave total inhibition of Shay ulcers.
IC
    C07D
    28-21 (Heterocyclic Compounds (More Than One Hetero Atom))
CC
    57381-26-7P 57381-35-8P 57381-38-1P 57381-40-5P
IT
    57381-42-7P 57381-45-0P 57381-46-1P 57381-50-7P 57381-53-0P
    57381-54-1P 57381-55-2P
    RL: BAC (Biological activity or effector, except adverse); BSU
    (Biological study, unclassified); SPN (Synthetic preparation); BIOL
    (Biological study); PREP (Preparation)
       (preparation and antiulcer activity of)
    57381-26-7P
IT
    RL: BAC (Biological activity or effector, except adverse); BSU
    (Biological study, unclassified); SPN (Synthetic preparation); BIOL
    (Biological study); PREP (Preparation)
```

CN '1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

(preparation and antiulcer activity of)

57381-26-7 HCAPLUS

*******REFERENCES TO QUERY ON CLAIM 56, STRUCTURE WAS SEARCHED WITH LIMITATIONS GIVEN BY EXAMINER******

=> d que 14

L2 42 SEA FILE=REGISTRY ABB=ON PLU=ON [G'SAR']A[G'SAR']['HYP'P]['HY

P'P]YN/SQSFP

L3 36 SEA FILE=HCAPLUS ABB=ON PLU=ON L2

L4 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND (AY<2001 OR PY<2001 OR

PRY<2001)

=> d ibib abs hitind hitstr retable 14 tot

L4 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:546915 HCAPLUS Full-text

DOCUMENT NUMBER: 141:83631

TITLE: Rice nucleic acid molecules and encoded proteins and

their uses for plant improvement

INVENTOR(S): La Rosa, Thomas J.; Kovalic, David K.; Zhou, Yihua;

Cao, Yongwei; Wu, Wei; Boukharov, Andrey A.; Barbazuk,

Brad W.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S.

Ser. No. 837,604.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 27

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004123343	A1	20040624	US 2003-437963	20030514 <
US 2004123343	A1	20040624	US 2003-437963	20030514 <
PRIORITY APPLN. INFO.:			US 2000-197872P P	20000419 <
			US 2001-837604 A2	20010418
			US 2003-437963 A	20030514

AB The present invention provides 102,483 cDNA sequences and their encoded protein sequences from rice (Oryza sativa). Bioinformatic anal. identified putative functions and uses for the nucleic acids/polypeptides. The disclosed polynucleotides and polypeptides find use in production of transgenic plants to produce plants having improved properties. [This abstract record is one of forty-one records for this document necessitated by the large number of index

```
entries required to fully index the document and publication system
     constraints.].
     ICM A01H001-00
IC
         C12N015-82; C07H021-04; C12N009-24; C12N005-04
INCL 800278000; 435069100; 435200000; 435201000; 435419000; 536023200
     3-3 (Biochemical Genetics)
     Section cross-reference(s): 6, 11
                                                               716607-04-4
                                                716607-03-3
                                  716607-02-2
                   716607-01-1
     716607-00-0
IT
                                                               716607-09-9
                                                716607-08-8
                                  716607-07-7
     716607-05-5
                   716607-06-6
                                                               716607-14-6
                                                716607-13-5
                   716607-11-3
                                  716607-12-4
     716607-10-2
                                                               716607-19-1
                                  716607-17-9
                                                716607-18-0
                   716607-16-8
     716607-15-7
                                                               716607-24-8
                                  716607-22-6
                                                716607-23-7
     716607-20-4
                   716607-21-5
                                                716607-28-2
                                                               716607-29-3
                                  716607-27-1
     716607-25-9
                   716607-26-0
                                                               716607-34-0
                                                 716607-33-9
                   716607-31-7
                                  716607-32-8
     716607-30-6
                                                               716607-39-5
                                  716607-37-3
                                                 716607-38-4
                   716607-36-2
     716607-35-1
                                                               716607-44-2
                                                 716607-43-1
                   716607-41-9
                                  716607-42-0
     716607-40-8
                                                               716607-49-7
                                                 716607-48-6
                   716607-46-4
                                  716607-47-5
     716607-45-3
                                              716607-53-3
     716607-50-0 716607-51-1
                                716607-52-2
                                                 716607-57-7
                                                               716607-58-8
                                  716607-56-6
                   716607-55-5
     716607-54-4
                                                 716607-62-4
                                                               716607-63-5
                                  716607-61-3
                   716607-60-2
     716607-59-9
                                                 716607-67-9
                                                               716607-68-0
                                  716607-66-8
                   716607-65-7
     716607-64-6
                                  716607-71-5
                                                 716607-72-6
                                                               716607-73-7
                   716607-70-4
     716607-69-1
                                                 716607-77-1
                                                               716607-78-2
                                  716607-76-0
                   716607-75-9
     716607-74-8
                                                 716607-82-8
                                                               716607-83-9
                                  716607-81-7
                   716607-80-6
     716607-79-3
                                                               716607-88-4
                                                 716607-87-3
                                  716607-86-2
                   716607-85-1
     716607-84-0
                                                 716607-92-0
                                                               716607-93-1
                                  716607-91-9
                   716607-90-8
     716607-89-5
                                                 716607-97-5
                                                               716607-98-6
                                  716607-96-4
                   716607-95-3
     716607-94-2
                                                 716608-02-5
                                                               716608-03-6
                                  716608-01-4
                   716608-00-3
     716607-99-7
                                                 716608-07-0
                                                               716608-08-1
                                  716608-06-9
                   716608-05-8
     716608-04-7
                                                 716608-12-7
                                                                716608-13-8
                                  716608-11-6
                   716608-10-5
     716608-09-2
                                                 716608-17-2
                                                                716608-18-3
                   716608-15-0
                                  716608-16-1
     716608-14-9
                                                                716608-23-0
                                                 716608-22-9
                   716608-20-7
                                  716608-21-8
     716608-19-4
                                                                716608-28-5
                                                 716608-27-4
                                  716608-26-3
                   716608-25-2
     716608-24-1
                                                                716608-33-2
                                                 716608-32-1
                   716608-30-9
                                  716608-31-0
     716608-29-6
                                                                716608-38-7
                                                 716608-37-6
                                  716608-36-5
                   716608-35-4
     716608-34-3
                                                                716608-43-4
                                                 716608-42-3
                                  716608-41-2
                   716608-40-1
     716608-39-8
                                                                716608-48-9
                                  716608-46-7
                                                 716608-47-8
                   716608-45-6
     716608-44-5
                                                                716608-53-6
                                                 716608-52-5
                                  716608-51-4
                   716608-50-3
     716608-49-0
                                                                716608-58-1
                                                 716608-57-0
                                  716608-56-9
     716608-54-7
                   716608-55-8
                                                                716608-63-8
                                                 716608-62-7
                                  716608-61-6
     716608-59-2
                    716608-60-5
                                                 716608-67-2
                                                                716608-68-3
                                  716608-66-1
                   716608-65-0
     716608-64-9
                                                                716608-73-0
                                                 716608-72-9
                                  716608-71-8
                   716608-70-7
     716608-69-4
                                                                716608-78-5
                                                 716608-77-4
                                  716608-76-3
     716608-74-1
                   716608-75-2
                                                                716608-83-2
                                  716608-81-0
                                                 716608-82-1
     716608-79-6
                   716608-80-9
                                                                716608-88-7
                                                 716608-87-6
                                  716608-86-5
                   716608-85-4
     716608-84-3
                                                                716608-93-4
                                                 716608-92-3
                                  716608-91-2
                    716608-90-1
     716608-89-8
                                                                716608-98-9
                                  716608-96-7
                                                 716608-97-8
                    716608-95-6
     716608-94-5
                                                                716609-03-9
                                                 716609-02-8
                                  716609-01-7
     716608-99-0
                   716609-00-6
                                                                716609-08-4
                                                 716609-07-3
                                  716609-06-2
     716609-04-0
                   716609-05-1
                                                                716609-13-1
                                                 716609-12-0
                                  716609-11-9
     716609-09-5
                    716609-10-8
                                                                716609-18-6
                                                 716609-17-5
                                  716609-16-4
     716609-14-2
                    716609-15-3
                                                                716609-23-3
                                                 716609-22-2
                                  716609-21-1
     716609-19-7
                    716609-20-0
                                                                716609-28-8
                                                 716609-27-7
                                  716609-26-6
                    716609-25-5
     716609-24-4
                                                                716609-33-5
                                                 716609-32-4
                    716609-30-2
                                  716609-31-3
     716609-29-9
     716609-34-6
     RL: BSU (Biological study, unclassified); BUU (Biological use,
     unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
         (amino acid sequence; rice nucleic acid mols. and encoded proteins and
        their uses for plant improvement)
IT
     716607-51-1
```

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses) (amino acid sequence; rice nucleic acid mols. and encoded proteins and their uses for plant improvement)

716607-51-1 HCAPLUS RN

Protein (Oryza sativa clone PAT_MRT4530 21015C.1.pep fragment) (9CI) (CA CNINDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2004:80331 HCAPLUS Full-text

DOCUMENT NUMBER:

140:140710

TITLE:

cDNAs encoding human NOVX proteins and their

diagnostic and therapeutic use

INVENTOR(S):

Shimkets, Richard A.; Patturajan, Meera; Vernet, Corine A. M.; Casman, Stacie J.; Malyankar, Uriel M.; Shenoy, Suresh G.; Spytek, Kimberly A.; Gangolli, Esha

A.; Miller, Charles E.; Boldog, Ferenc L.; Li, Li; Taupier, Raymond J.; Kekuda, Ramesh; Smithson,

Glennda; Zerhusen, Bryan D.; Liu, Xiaohong; Colman, Steven D.; Tchernev, Velizar T.; Si, Jingsheng; Edinger, Shlomit R.; Stone, David J.; Sciore, Paul;

Millet, Isabelle; Rothenberg, Mark E.

PATENT ASSIGNEE(S):

USA

U.S. Pat. Appl. Publ., 240 pp., Cont.-in-part of U.S. SOURCE:

Ser. No. 28,248.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 173

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO. DATE
US 2004018970	A1	20040129	US 2002-107782 20020327 <
US 2003235882	A1	20031225	
US 2003203363	A1	20031030	US 2002-94466 20020307
CA 2440337		20020919	CA 2002-2440337 20020308
CA 2440345	A1	20020919	CA 2002-2440345 20020308
EP 1427749	A2	20040616	EP 2002-713788 20020308
	DE, DK	, ES, FR,	GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT,	LV, FI	, RO, MK,	CY, AL, TR
AU 2005200106	A1	20050210	AU 2005-200106 20050112 <
AU 2006201467			
PRIORITY APPLN. INFO.:			US 2000-256619P P 20001219 <
			US 2001-262959P P 20010119
			US 2001-272408P P 20010228
			US 2001-279344P P 20010328
			US 2001-285189P P 20010420
			US 2001-308039P P 20010726
			US 2001-311266P P 20010809
			US 2001-28248 A2 20011219
			AU 2000-37360 A3 20000309 <
			AU 2000-78680 A3 20001006 <
			US 2001-274191P P 20010308
			US 2001-274194P P 20010308
			US 2001-274281P P 20010308
			US 2001-274322P P 20010308
			US 2001-274849P P 20010309

```
P 20010312
US 2001-275235P
                   P 20010313
US 2001-275578P
                  P 20010313
US 2001-275579P
                 P 20010313
US 2001-275601P
                   P 20010314
US 2001-276000P
US 2001-276776P
                   P 20010316
                  P 20010319
US 2001-276994P
                 P 20010320
US 2001-277239P
US 2001-277321P
                 P 20010320
                  P 20010320
US 2001-277327P
                   P 20010320
US 2001-277338P
                   P 20010321
US 2001-277791P
US 2001-277833P
                   P 20010322
US 2001-278152P
                   P 20010323
US 2001-278894P
                  P 20010326
US 2001-278999P
                  P 20010327
                  P 20010327
US 2001-279036P
                  P 20010330
US 2001-279995P
                   P 20010330
US 2001-280233P
                   P 20010402
US 2001-280802P
                  P 20010402
US 2001-280822P
                 P 20010402
US 2001-280900P
US 2001-281194P
                  P 20010404
US 2001-283675P
                  P 20010413
                  P 20010430
US 2001-287424P
                   P 20010502
US 2001-288066P
                   P 20010502
US 2001-288148P
                   P 20010503
US 2001-288342P
US 2001-288528P
                  P 20010503
                  P 20010515
US 2001-291190P
               P 20010516
P 20010530
P 20010531
P 200105
US 2001-291099P
US 2001-291240P
US 2001-294485P
US 2001-294821P
US 2001-294889P
                  P 20010531
                  P 20010531
US 2001-294899P
                  P 20011031
US 2001-335302P
                  P 20011204
US 2001-338375P
```

```
AB The present invention provides cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use.
```

```
IC ICM C12Q001-68
ICS G01N033-53; C07K014-47; C12P021-02; C12N005-06; A61K038-17; C07K016-22; C07H021-04
```

INCL 514012000; 435069100; 435320100; 435325000; 530350000; 536023500; 530388150; 435006000; 435007100

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 13, 14

IT 651798-56-0 651798-57-1 651798-58-2 651798-64-0 651798-65-1 651798-66-2 651798-73-1, Protein NOV4b (human) 651798-79-7 651798-80-0 651798-81-1 651798-87-7 651798-93-5 651798-94-6 651799-00-7 651799-01-8 651799-07-4 651799-12-1 651799-18-7 651799-23-4 651799-29-0

RL: PRP (Properties)

(unclaimed protein sequence; cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use)

IT 651799-18-7

RL: PRP (Properties)

(unclaimed protein sequence; cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use)

RN 651799-18-7 HCAPLUS

103: PN: US20040018970 SEQID: 102 unclaimed protein (9CI) (CA INDEX NAME) CN

```
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN 2002:781492 HCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER:

138:1096

TITLE:

Essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and

antibiotic screening

INVENTOR(S):

Wang, Liangus; Zamudio, Carlos; Malone, Cheryl; Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.; Yamamoto, Robert; Forsyth, R. Allyn; Xu, H. Howard

PATENT ASSIGNEE(S):

PCT Int. Appl., 1766 pp.

Elitra Pharmaceuticals, Inc., USA

SOURCE:

DOCUMENT TYPE:

CODEN: PIXXD2 Patent

LANGUAGE:

English

22

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
APPLICATION NO.
                       KIND DATE
    PATENT NO.
                              -----
                                         ______
                        <del>- - - -</del>
     -----
                               20021003 WO 2002-XO9107
                                                               20020321
    WO 2002077183
                        A2
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
            LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
            PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
            UG, US, UZ, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
            CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                               20020523 US 2001-815242
                                                               20010321 <--
    US 2002061569
                        A1
                                                                20020321
                                          WO 2002-US9107
                               20021003
    WO 2002077183
                        A2
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
            CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                                           A 20010321
                                          US 2001-815242
PRIORITY APPLN. INFO.:
                                                             A 20010906
                                          US 2001-948993
                                                             P 20011025
                                          US 2001-342923P
                                          US 2002-72851
                                                             A 20020208
                                          US 2002-362699P
                                                            P 20020306
                                          WO 2002-US9107
                                                            A 20020321
                                          US 2000-191078P
                                                            P 20000321 <--
                                          US 2000-206848P
                                                            P 20000523 <--
                                                            P 20000526 <--
                                          US 2000-207727P
                                                             P 20001023 <--
                                          US 2000-242578P
                                                             P 20001127 <--
                                          US 2000-253625P
                                                            P 20001222 <--
                                          US 2000-257931P
                                                           P 20010216
                                          US 2001-269308P
     The sequences of antisense nucleic acids which inhibit the proliferation of
AΒ
```

prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified

for which expression inhibits proliferation or is required for proliferation in Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium, and Staphylococcus aureus. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than Staphylococcus aureus, Salmonella typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in [This abstract record is one of twenty records for this other organisms. document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12N

IT

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 10 477094-57-8 477094-58-9 477094-59-0 477094-60-3 477094-61-4 477094-63-6 477094-64-7 477094-65-8 477094-66-9 477094-62-5 477094-69-2 477094-70-5 477094-71-6 477094-68-1 477094-67-0 477094-75-0 477094-76-1 477094-74-9 477094-73-8 477094-72-7 477094-78-3 477094-79-4 477094-80-7 477094-81-8 477094-77-2 477094-86-3 477094-84-1 477094-85-2 477094-83-0 477094-82-9 477094-91-0 477094-90-9 477094-88-5 477094-89-6 477094-87-4 477094-96-5 477094-94-3 477094-95-4 477094-93-2 477094-92-1 477094-99-8 477095-00-4 477095-01-5 477094-98-7 477094-97-6 477095-04-8 477095-05-9 477095-06-0 477095-03-7 477095-02-6 477095-11-7 477095-10-6 477095-08-2 477095-09-3 477095-07-1 477095-15-1 477095-16-2 477095-14-0 477095-13-9 477095-12-8 477095-20-8 477095-21-9 477095-19-5 477095-18-4 477095-17-3 477095-25-3 477095-26-4 477095-22-0 477095-23-1 477095-24-2 477095-31-1 477095-29-7 477095-30-0 477095-27-5 477095-28-6 477095-35-5 477095-36-6 477095-34-4 477095-33-3 477095-32-2 477095-40-2 477095-41-3 477095-39-9 477095-37-7 477095-38-8 477095-45-7 477095-43-5 477095-44-6 477095-42-4 477095-50-4 477095-48-0 477095-49-1 477095-47-9 477095-46-8 477095-54-8 477095-55-9 477095-53-7 477095-52-6 477095-51-5 477095-59-3 477095-60-6 477095-57-1 477095-58-2 477095-56-0 477095-65-1 477095-63-9 477095-64-0 477095-62-8 477095-61-7 477095-69-5 477095-70-8 477095-68-4 477095-67-3 477095-66-2 477095-73-1 477095-74-2 477095-75-3 477095-72-0 477095-71-9 477095-80-0 477095-79-7 477095-78-6 477095-77-5 477095-76-4 477095-85-5 477095-84-4 477095-83-3 477095-82-2 477095-81-1 477095-90-2 477095-89-9 477095-88-8 477095-86-6 477095-87-7 477095-95-7 477095-94-6 477095-92-4 477095-93-5 477095-91-3 477096-00-7 477095-98-0 477095-99-1 477095-97-9 477095-96-8 477096-04-1 477096-05-2 477096-03-0 477096-02-9 477096-01-8 477096-10-9 477096-09-6 477096-08-5 477096-06-3 477096-07-4 477096-15-4 477096-14-3 477096-13-2 477096-11-0 477096-12-1 477096-20-1 477096-17-6 477096-19-8 477096-18-7 477096-16-5 477096-25-6 477096-24-5 477096-22-3 477096-23-4 477096-21-2 477096-29-0 477096-30-3 477096-28-9 477096-27-8 477096-26-7 477096-35-8 477096-33-6 477096-34-7 477096-32-5 477096-31-4 477096-37-0 477096-38-1 477096-39-2 477096-40-5 477096-36-9 477096-44-9 477096-45-0 477096-43-8 477096-42-7 477096-41-6 477096-49-4 477096-50-7 477096-47-2 477096-48-3 477096-46-1

```
477096-53-0
                                            477096-54-1
                                                          477096-55-2
    477096-51-8
                 477096-52-9
                                            477096-59-6
                                                          477096-60-9
    477096-56-3 477096-57-4 477096-58-5
                                            477096-64-3
                                                          477096-65-4
    477096-61-0 477096-62-1 477096-63-2
    477096-66-5 477096-67-6 477096-68-7
                                                          477096-70-1
                                            477096-69-8
                                            477096-74-5
                                                          477096-75-6
    477096-71-2 477096-72-3 477096-73-4
    477096-76-7 477096-77-8 477096-78-9 477096-79-0
                                                          477096-80-3
    477096-81-4 477096-82-5 477096-83-6 477096-84-7
                                                          477096-85-8
    477096-86-9 477096-87-0 477096-88-1 477096-89-2
                                                          477096-90-5
    RL: BSU (Biological study, unclassified); BUU (Biological use,
    unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological
    study); USES (Uses)
       (amino acid sequence; essential genes in microorganisms and their use
       as targets for antisense inhibition of proliferation and antibiotic
       screening)
    477095-44-6
    RL: BSU (Biological study, unclassified); BUU (Biological use,
    unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological
    study); USES (Uses)
       (amino acid sequence; essential genes in microorganisms and their use
       as targets for antisense inhibition of proliferation and antibiotic
       screening)
    477095-44-6 HCAPLUS
    Protein (Mycobacterium avium clone MAV104574 essential) (9CI) (CA INDEX
    NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
    ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
                        2002:754415 HCAPLUS Full-text
ACCESSION NUMBER:
DOCUMENT NUMBER:
                        137:263304
                        Synthesis of peptides and medical uses of
TITLE:
                        intracellular communication facilitating compounds
                        Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier,
INVENTOR(S):
                        Eddie; Kjolbye, Anne Louise; Jorgensen, Niklas Rye;
                       Nielsen, Morten Schak; Holstein-Rathlou, Niels-Henrik;
                       Martins, James B.
                        Zealand Pharmaceuticals A/S, Den.
PATENT ASSIGNEE(S):
                        PCT Int. Appl., 233 pp.
SOURCE:
                        CODEN: PIXXD2
                        Patent
DOCUMENT TYPE:
                       English
LANGUAGE:
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:
                              DATE APPLICATION NO. DATE
                       KIND
    PATENT NO.
                              -----
                                          ------
     -----
```

IT

RN

CN

L4

WO	2002	0770	17		A2		2002	1003	Ī	WO 2	002-1	JS57	73		20	0020	222	
WO	2002				A3		2003											
	W:	ΑE,	AG,	`AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	ВG,	BR,	BY,	ΒZ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
								IS,										
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ΤJ,	TM,	TN,	TR,	TT,	TZ,	
								ZA,										
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZM,	ZW,	AM,	ΑZ,	BY,	
								ΑT,										
								PT,										
								SN,										
WO	2001		-		A2			0830			001-1	DK12	7		2	0010	222 <-	-
_	2001				A 3		2002	0131										

```
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
            CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
            IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
            MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
            SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                         US 2001-792286
                                                                  20010222 <--
                               20030515
                         A1
    US 2003092609
                                           CA 2002-2439101
                                                                  20020222
                         A1
                               20021003
    CA 2439101
                                                                  20020222
                                           EP 2002-723240
                         A2
                               20031217
    EP 1370276
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                                                  20020222
                                           JP 2002-576275
                         T
                               20050303
    JP 2005506295
                                                                  20020222
                         Α
                               20060124
                                           BR 2002-7476
    BR 2002007476
                                                                  20030815
                         Α
                               20031020
                                           NO 2003-3641
    NO 2003003641
                                                                  20030822 <--
                                           US 2003-646294
                         A1
                               20050526
    US 2005113293
                                                                  20030822
                               20050527
                                           IN 2003-DN1336
    IN 2003DN01336
                         Α
                                                                  20040204 <--
                         A1
                               20050407
                                           US 2004-772774
    US 2005075280
                                           US 2001-792286
                                                               A 20010222
PRIORITY APPLN. INFO.:
                                                               A 20010222
                                           WO 2001-DK127
                                                               P 20010823
                                           US 2001-314470P
                                                               A 20000223 <--
                                           DK 2000-288
                                                               A 20000504 <--
                                           DK 2000-738
                                                               P 20001206 <--
                                           US 2000-251659P
                                                               W 20020222
                                           WO 2002-US5773
                         MARPAT 137:263304
OTHER SOURCE(S):
     The invention relates to novel peptides, including novel antiarrhythmic
AΒ
     peptides of linear or cyclic structure, having improved stability in vitro
     and/or in vivo, to compns. comprising these peptides, and to uses of the
     peptides for the preparation of medicaments. The invention also relates to
     the use of compds. that facilitate the intercellular communication for the
     preparation of medicaments for the treatment of a range of diseases
     characterized in impaired intercellular gap junctional communication.
     invention further relates to a method of treating diseases, such as bladder
     incontinence, disorders of alveolar tissue and bronchial tissue, impaired
     hearing due to diseases of the cochlea, endothelial lesions, diabetic
     retinopathy and diabetic neuropathy, ischemia of the central nervous system
     and spinal cord, dental tissue disorders including periodontal disease, kidney
     diseases leading to hypertension, and a method of preventing failures of bone
     marrow transplantation. Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D-Ala-Gly-NH2 (Hyp =
     hydroxyprolyl) was prepared by the solid-phase method and assayed for biol.
     activity. Graphs include those for relative cell-to-cell conductance, PI-
     turnover in neonatal rat cardiomyocytes, and ventricular APD90 dispersion.
     ICM C07K007-00
IC
     34-3 (Amino Acids, Peptides, and Proteins)
CC
     Section cross-reference(s): 1, 6, 63
     81771-37-1P, Antiarrhythmic peptide (cattle atrium)
                                                           111915-92-5P
IT
                                                 355151-13-2P
                                                                 355151-14-3P
                                  355151-12-1P
                   355151-11-0P
     159503-65-8P
                                                                 355151-19-8P
                                                  355151-18-7P
                                   355151-17-6P
                   355151-16-5P
     355151-15-4P
                                                                 355151-27-8P
                                                  355151-26-7P
                                   355151-25-6P
                   355151-23-4P
     355151-20-1P
                                   355151-31-4P
                                                  355151-32-5P
     355151-29-0P
                    355151-30-3P
                                                  355151-36-9P
                                   355151-35-8P
                    355151-34-7P
     355151-33-6P
                                                                 355151-41-6P
                                                  355151-40-5P
                                   355151-39-2P
                   355151-38-1P
     355151-37-0P
     355151-43-8P 355151-45-0P 355151-46-1P
                                  355151-50-7P
                                                 355151-51-8P
     355151-47-2P
                    355151-49-4P
                                                                 355151-56-3P
                                   355151-54-1P
                                                 355151-55-2P
     355151-52-9P
                   355151-53-0P
                                                                 463362-34-7P
                   463362-31-4P
                                   463362-32-5P
                                                  463362-33-6P
     355151-74-5P
                                  463362-37-0P
                                                  463362-38-1P
                                                                 463362-40-5P
                    463362-36-9P
     463362-35-8P
```

463944-96-9P

463362-42-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

212570-15-5 463362-43-8 463362-44-9 35919-99-4 366800-53-5 IT 463362-48-3 463362-46-1 463362-47-2 463362-45-0 463362-53-0 463362-54-1 463362-52-9 463362-50-7 463362-51-8 463362-55-2 463362-56-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

IT 355151-33-6P 355151-45-0P 355151-46-1P 355151-47-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

RN 355151-33-6 HCAPLUS

CN D-Asparagine, glycyl-D-alanylglycyl-(4S)-4-hydroxy-D-prolyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 355151-45-0 HCAPLUS

CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-glutaminylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 355151-46-1 HCAPLUS

CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 355151-47-2 HCAPLUS

CN Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl)
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 463362-44-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

RN 463362-44-9 HCAPLUS

CN L-Aspartamide, glycyl-L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2002:575239 HCAPLUS Full-text

DOCUMENT NUMBER:

137:136135

TITLE:

Human cDNA sequences and their encoded proteins and

diagnostic and therapeutic uses

INVENTOR(S):

Shimkets, Richard A.; Patturajan, Meera; Vernet, Corine A. M.; Casman, Stacie J.; Malyankar, Uriel; Shenoy, Suresh; Spytek, Kimberly A.; Gangolli, Esha; Miller, Charles; Boldog, Ferenc; Li, Li; Taupier, Raymond J., Jr.; Kekuda, Ramesh; Smithson, Glennda; Zerhusen, Bryan D.; Liu, Xiaohong; Colman, Steven D.; Tchernev, Velizar; Si, Jingsheng; Edinger, Schlomit;

Stone, David; Sciore, Paul; Millet, Isabelle;

Rothenberg, Mark

PATENT ASSIGNEE(S):

SOURCE:

Curagen Corporation, USA PCT Int. Appl., 363 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 173

PATENT INFORMATION:

PA'	PATENT NO.					KIND DATE			APPLICATION NO.						DATE				
												TOE O		20011219 <					
WO	2002	0593	15		A2		2002	0801	1	NO 21	00T-	0550	0 / 6		21	,,,,,,	219 (-		
WO	2002						2003												
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,		
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,		
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,		
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,		
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	ΤZ,	UA,		
		UG,	US,	UΖ,	VN,	YU,	ZA,	ZW											
	RW:							SD,											
								AT,											
		GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,		
		GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG									
AU	2002	2468	80		A1		2002	0806		AU 2	002-	2468	80		20	0011	219 <	-	
AU	2005	2001	06		A1		2005	0210	2	AU 2	005-	2001	06		20	0050	112 <	-	
AU	2006	2014	67		A1		2006	0504		AU 2	006-	2014	67		20	0060	107 <-	-	
PRIORIT										US 2	000-	2566	19P	:	P 20	0001	219 <-	-	

```
P 20010119
US 2001-262959P
                 P 20010228
US 2001-272408P
                 P 20010420
US 2001-285189P
                 P 20010726
US 2001-308039P
                  P 20010809
US 2001-311266P
                  A3 20000309 <--
AU 2000-37360
                  A3 20001006 <--
AU 2000-78680
                   W 20011219
WO 2001-US50076
```

Disclosed herein are 20 cDNA sequences that encode novel human polypeptides that are members of the following protein families: stabilin, CD44-like precursor/fascilin domain, polydom, transmembrane IIIb protein, serine proteinase, Wnt-7a protein, apical endosomal glycoprotein, ADAM13, leucinerich F box-containing protein, steroid-binding protein, steroid dehydrogenase, myosin heavy chain, and pancreatitis-associated protein. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

IC ICM C12N015-12

ICS C07K014-47
3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 13

IT 444213-89-2 444213-92-7 444213-96-1 444213-97-2 444213-98-3 444214-00-0 444214-01-1 444214-02-2 444214-03-3 444214-04-4

444214-05-5 444214-06-6 444214-07-7

RL: PRP (Properties)

(unclaimed protein sequence; human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses)

IT 444214-05-5

RL: PRP (Properties)

(unclaimed protein sequence; human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses)

RN 444214-05-5 HCAPLUS

CN 50: PN: WOO2059315 SEQID: 102 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2002:293812 HCAPLUS Full-text

DOCUMENT NUMBER:

136:290020

TITLE:

CC

Nucleic acids and their encoded polypeptides from

human tissues

INVENTOR(S):

Tang, Y. Tom; Liu, Chenghua; Zhou, Ping; Asundi, Vinod; Zhang, Jie; Zhao, Qing A.; Ren, Feiyan; Xue, Aidong J.; Yang, Yonghong; Wehrman, Tom; Drmanac,

Radoje T.

PATENT ASSIGNEE(S):

Hyseq, Inc., USA

SOURCE:

PCT Int. Appl., 357 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

127

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002031111	A2	20020418	WO 2001-US27760	20011011 <
WO 2002031111	A3	20021017		

```
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                           CA 2001-2425827
                                                                    20011011 <--
                                20020418
     CA 2425827
                          A1
                                                                    20011011 <--
                                            AU 2001-96235
    AU 200196235
                          Α
                                20020422
                                                                    20011011 <--
                                20030709
                                            EP 2001-977088
    EP 1325120
                          A2
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                                                 A2 20001012 <--
                                            US 2000-687527
PRIORITY APPLN. INFO.:
                                            WO 2001-US27760
                                                                 W 20011011
     The present invention provides novel nucleic acids, novel polypeptide
AB
     sequences encoded by these nucleic acids and uses thereof. Thus, 446 novel
     nucleic acids were obtained from cDNA libraries prepared from various human
     tissues and in some cases isolated from a genomic library derived from human
     chromosomes using standard PCR, SBH (sequencing-by-hybridization) sequence
     signature anal., and Sanger sequencing techniques. Novel contigs of the
     invention were assembled from sequences that were obtained from a cDNA library
     by the above methods, and in some cases sequences obtained from one or more
     public databases, using a recursive algorithm to extend the seed EST into an
     extended assemblage. Tissue expression profiles and nearest neighbor sequence
     homologies are provided. The sequences of this invention have applications in
     nucleic acid or polypeptide arrays, in the identification of binding mols.,
     and in treatment of diseases.
     ICM C12N
IC
     3-3 (Biochemical Genetics)
     Section cross-reference(s): 6, 13, 63
                                   408551-79-1P
                                                   408551-80-4P
                                                                  408551-81-5P
     408551-77-9P
                    408551-78-0P
IT
                    408551-83-7P
                                   408551-84-8P
                                                   408551-85-9P
                                                                  408551-86-0P
     408551-82-6P
                                                   408551-90-6P
                                                                  408551-91-7P
                                   408551-89-3P
     408551-87-1P
                    408551-88-2P
                                                   408551-95-1P
                                                                  408551-96-2P
     408551-92-8P
                                   408551-94-0P
                    408551-93-9P
                                                   408552-00-1P
                                                                  408552-01-2P
                                   408551-99-5P
     408551-97-3P
                    408551-98-4P
                                                 408552-05-6P
     408552-02-3P 408552-03-4P
                                 408552-04-5P
                                                   408552-09-0P
                                                                  408552-10-3P
                    408552-07-8P
                                   408552-08-9P
     408552-06-7P
                                                                  408552-15-8P
                                   408552-13-6P
                                                   408552-14-7P
                    408552-12-5P
     408552-11-4P
                                   408552-18-1P
                                                   408552-19-2P
                                                                  408552-20-5P
                    408552-17-0P
     408552-16-9P
                                                   408552-24-9P
                                                                  408552-25-0P
                                   408552-23-8P
                    408552-22-7P
     408552-21-6P
                                                                  408552-30-7P
                                   408552-28-3P
                                                   408552-29-4P
     408552-26-1P
                    408552-27-2P
                                                   408552-34-1P
                                                                  408552-35-2P
                                   408552-33-0P
                    408552-32-9P
     408552-31-8P
                                   408552-38-5P - 408552-39-6P
                                                                  408552-40-9P
     408552-36-3P
                    408552-37-4P
                                                                  408552-45-4P
                                   408552-43-2P
                                                   408552-44-3P
                    408552-42-1P
     408552-41-0P
                                                                  408552-50-1P
                    408552-47-6P
                                   408552-48-7P
                                                   408552-49-8P
     408552-46-5P
                                                                  408552-55-6P
                                   408552-53-4P
                                                   408552-54-5P
                    408552-52-3P
     408552-51-2P
                                                                  408552-60-3P
                                                   408552-59-0P
                                   408552-58-9P
                    408552-57-8P
     408552-56-7P
                                                                  408552-65-8P
                                   408552-63-6P
                                                   408552-64-7P
                    408552-62-5P
     408552-61-4P
                                                   408552-69-2P
                                                                  408552-70-5P
                                   408552-68-1P
                    408552-67-0P
     408552-66-9P
                                                   408552-74-9P
                                                                  408552-75-0P
                                   408552-73-8P
     408552-71-6P
                    408552-72-7P
                                                   408552-79-4P
                                                                  408552-80-7P
                                   408552-78-3P
                    408552-77-2P
     408552-76-1P
                                                                  408552-85-2P
                    408552-82-9P
                                   408552-83-0P
                                                   408552-84-1P
     408552-81-8P
                                   408552-88-5P
                                                   408552-89-6P
                                                                  408552-90-9P
                    408552-87-4P
     408552-86-3P
                                                   408552-94-3P
                                                                  408552-95-4P
                    408552-92-1P
                                   408552-93-2P
     408552-91-0P
     408552-96-5P
                                   408552-98-7P
                                                   408552-99-8P
                                                                  408553-00-4P
                    408552-97-6P
                    408553-02-6P
                                   408553-03-7P
                                                   408553-04-8P
                                                                  408553-05-9P
     408553-01-5P
                                   408553-08-2P
                                                                  408553-10-6P
                                                   408553-09-3P
                    408553-07-1P
     408553-06-0P
```

408553-13-9P

408553-12-8P

408553-11-7P

408553-15-1P

408553-14-0P

```
408553-20-8P
     408553-16-2P
                   408553-17-3P
                                  408553-18-4P
                                                 408553-19-5P
                                                                408553-25-3P
                                  408553-23-1P
                                                 408553-24-2P
     408553-21-9P
                   408553-22-0P
                                                 408553-29-7P
                                                                408553-30-0P
                                  408553-28-6P
     408553-26-4P
                   408553-27-5P
                                  408553-33-3P
                                                 408553-34-4P
                                                                408553-35-5P
     408553-31-1P
                   408553-32-2P
                                  408553-38-8P
                                                 408553-39-9P
                                                                408553-40-2P
     408553-36-6P
                   408553-37-7P
                   408553-42-4P
                                  408553-43-5P
                                                 408553-44-6P
                                                                408553-45-7P
     408553-41-3P
                                  408553-48-0P
                                                 408553-49-1P
                                                                408553-50-4P
                   408553-47-9P
     408553-46-8P
                                  408553-53-7P
                                                 408553-54-8P
                                                                408553-55-9P
                   408553-52-6P
     408553-51-5P
                                  408553-58-2P
                                                 408553-59-3P
                                                                408553-60-6P
                   408553-57-1P
     408553-56-0P
                                                 408553-64-0P
                                                                408553-65-1P
     408553-61-7P
                   408553-62-8P
                                  408553-63-9P
                                                                408553-70-8P
     408553-66-2P
                   408553-67-3P
                                  408553-68-4P
                                                 408553-69-5P
     408553-71-9P 408553-72-0P
                                  408553-73-1P
                                                 408553-74-2P
                                                                408553-75-3P
                                  408553-78-6P 408553-79-7P
                                                                408553-80-0P
     408553-76-4P 408553-77-5P
                                  408553-83-3P
                                                 408553-84-4P
                                                                408553-85-5P
                   408553-82-2P
     408553-81-1P
                                  408553-88-8P
                                                 408553-89-9P
                                                                408553-90-2P
                   408553-87-7P
     408553-86-6P
    RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
    unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical
     study); BIOL (Biological study); PREP (Preparation); USES (Uses)
        (amino acid sequence; nucleic acids and their encoded polypeptides from
        human tissues)
    408552-03-4P
    RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
     unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical
     study); BIOL (Biological study); PREP (Preparation); USES (Uses)
        (amino acid sequence; nucleic acids and their encoded polypeptides from
       human tissues)
     408552-03-4 HCAPLUS
    Protein (human clone WO0231111-SEQID-704) (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
    ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
                        2001:828442 HCAPLUS Full-text
ACCESSION NUMBER:
                        136:396989
DOCUMENT NUMBER:
                        Human nucleic acids and polypeptides and their
TITLE:
                        diagnostic and therapeutic uses
                        Drmanac, Rodoje T.; Liu, Chenghua; Tang, Y. Tom
INVENTOR(S):
PATENT ASSIGNEE(S):
                        Hyseq, Inc., USA
                        PCT Int. Appl., 103 pp.
SOURCE:
                        CODEN: PIXXD2
                        Patent
DOCUMENT TYPE:
LANGUAGE:
                        English
FAMILY ACC. NUM. COUNT:
                        127
PATENT INFORMATION:
                                                                  DATE
                                          APPLICATION NO.
                        KTND
                               DATE
    DATENT NO
```

IT

RN

CN

L4

PA:	LENI .	NO.			KIN.		DAIE			WEET)	TCAI.	TON						
					- 	-									-			
WO	2001	0750	67		A2		2001	1011	1	WO 2	001-	XF86	31		2	0010	330 <-	-
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,	
							DM,											
							JP,											
		LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PL,	PT,	RO,	RU,	
		SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VN,	
		YU,	ZA,	ZW														
	RW:	GH,	GM,	KE,	LS,	MW,	ΜŻ,	SD,	SL,	SZ,	TZ.,	UG,	ZW,	AT,	BE,	CH,	CY,	
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	
		ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG			
WO	2001	0750	67		A2		2001	1011	1	WO 2	001-1	JS86	31		2	0010	330 <-	-
WO	2001	0750	67		A3		2002	0404										
WO	2001	0750	67		A9		2002	1031										

```
20041014
    WO 2001075067
                          A8
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                                                A 20000331 <--
                                            US 2000-540217
PRIORITY APPLN. INFO.:
                                                                 A 20000823 <--
                                            US 2000-649167
                                            WO 2001-US8631
                                                                 W 20010330
     The present invention provides 30,368 nucleic acids and the 30,368 novel human
AB
     polypeptide sequences encoded by these nucleic acids. A plurality of novel
     nucleic acids are obtained from cDNA libraries prepared from various human
     tissues and in some cases isolated from a genomic library derived from human
     chromosomes using standard PCR, sequencing by hybridization signature anal.,
     and Sanger sequencing techniques. Nearest neighbor results are identified by
     sequence homol. searching. The invention also relates to therapeutic,
     diagnostic, and research utilities for these polynucleotides and proteins.
     [This abstract record is one of 10 records for this document necessitated by
     the large number of index entries required to fully index the document and
     publication system constraints.].
     ICM C12N
IC
     3-3 (Biochemical Genetics)
CC
     Section cross-reference(s): 6, 13, 63
                                                429717-77-1
                                                              429717-78-2
                                 429717-76-0
                   429717-75-9
     429717-74-8
IT
                                                              429717-83-9
                                 429717-81-7
                                                429717-82-8
                   429717-80-6
     429717-79-3
                                 429717-86-2
                                                429717-87-3
                                                              429717-88-4
                   429717-85-1
     429717-84-0
                                                              429717-93-1
                                 429717-91-9
                                                429717-92-0
                   429717-90-8
     429717-89-5
                                                429717-97-5
                                                              429717-98-6
                   429717-95-3
                                 429717-96-4
     429717-94-2
                                                429718-02-5
                                                              429718-03-6
                                 429718-01-4
                   429718-00-3
     429717-99-7
                                 429718-06-9
                                                429718-07-0
                                                              429718-08-1
                   429718-05-8
     429718-04-7
                                                429718-12-7
                                                              429718-13-8
     429718-09-2
                   429718-10-5
                                 429718-11-6
                                                429718-17-2
                                                              429718-18-3
                                 429718-16-1
     429718-14-9
                   429718-15-0
                                                429718-22-9
                                                              429718-23-0
                                 429718-21-8
                   429718-20-7
     429718-19-4
                                 429718-26-3
                                                429718-27-4
                                                              429718-28-5
                   429718-25-2
     429718-24-1
                                                429718-32-1
                                                              429718-33-2
                                  429718-31-0
     429718-29-6
                   429718-30-9
                                                              429718-38-7
                                 429718-36-5
                                                429718-37-6
     429718-34-3
                   429718-35-4
                                  429718-41-2
                                                429718-42-3
                   429718-40-1
     429718-39-8
                                                429718-46-7
                                                              429718-47-8
                                  429718-45-6
                   429718-44-5
     429718-43-4
                                                429718-51-4
                                                              429718-52-5
                                  429718-50-3
     429718-48-9
                   429718-49-0
                                                429718-56-9
                                                              429718-57-0
                   429718-54-7
                                 429718-55-8
     429718-53-6
                                                429718-61-6 429718-62-7
                                  429718-60-5
                   429718-59-2
     429718-58-1
                                                429718-66-1
                                                              429718-67-2
                   429718-64-9
                                  429718-65-0
     429718-63-8
                                                429718-71-8
                                                              429718-72-9
                                  429718-70-7
                   429718-69-4
     429718-68-3
                                  429718-75-2
                                                429718-76-3
                                                              429718-77-4
                   429718-74-1
     429718-73-0
                                                429718-81-0
                                                              429718-82-1
                                  429718-80-9
                   429718-79-6
     429718-78-5
                                                              429718-87-6
                                                429718-86-5
                                  429718-85-4
     429718-83-2
                   429718-84-3
                                                              429718-92-3
                                                429718-91-2
                   429718-89-8
                                  429718-90-1
     429718-88-7
                                                429718-96-7
                                                              429718-97-8
                                  429718-95-6
                   429718-94-5
     429718-93-4
                                                429719-01-7
                                                              429719-02-8
                                  429719-00-6
                   429718-99-0
     429718-98-9
                                                              429719-07-3
                                                429719-06-2
     429719-03-9
                                  429719-05-1
                   429719-04-0
                                                              429719-12-0
                                                429719-11-9
                                  429719-10-8
                   429719-09-5
     429719-08-4
                                                              429719-17-5
                                                429719-16-4
                                  429719-15-3
                   429719-14-2
     429719-13-1
                                                              429719-22-2
                                                429719-21-1
                   429719-19-7
                                  429719-20-0
     429719-18-6
                                                              429719-27-7
                                                429719-26-6
                   429719-24-4
                                  429719-25-5
     429719-23-3
```

429719-30-2

429719-35-7

429719-29-9

429719-34-6

429719-28-8

429719-33-5

429719-32-4

429719-37-9

429719-31-3

429719-36-8

```
429719-41-5
                                                             429719-42-6
                                 429719-40-4
                   429719-39-1
     429719-38-0
                                                             429719-47-1
                                               429719-46-0
                   429719-44-8
                                 429719-45-9
     429719-43-7
                                                             429719-52-8
                                               429719-51-7
                  429719-49-3
                                 429719-50-6
     429719-48-2
                                                             429719-57-3
                                 429719-55-1
                                               429719-56-2
     429719-53-9 429719-54-0
                                                             429719-62-0
                                               429719-61-9
                                 429719-60-8
     429719-58-4 429719-59-5
                                                             429719-67-5
     429719-63-1 429719-64-2
                                 429719-65-3
                                               429719-66-4
     429719-68-6 429719-69-7
                                               429719-71-1
                                                             429719-72-2
                                 429719-70-0
                                               429719-76-6
                                                             429719-77-7
                  429719-74-4
                                 429719-75-5
     429719-73-3
                                               429719-81-3
                                                             429719-82-4
     429719-78-8 429719-79-9
                                 429719-80-2
                               429719-85-7
                                               429719-86-8
                                                             429719-87-9
    429719-83-5 429719-84-6
    429719-88-0 429719-89-1 429719-90-4
                                               429719-91-5
                                                             429719-92-6
                                               429719-96-0
                                                             429719-97-1
    429719-93-7 429719-94-8 429719-95-9
                  429719-99-3 429720-00-3 429720-01-4
                                                             429720-02-5
     429719-98-2
     429720-03-6 429720-04-7 429720-05-8
                                               429720-06-9
    RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
    THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study);
    USES (Uses)
        (amino acid sequence; human nucleic acids and polypeptides and their
        diagnostic and therapeutic uses)
    429718-39-8
    RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
    THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (amino acid sequence; human nucleic acids and polypeptides and their
        diagnostic and therapeutic uses)
     429718-39-8 HCAPLUS
     Protein (human clone WO0175067-SEQID-32147) (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
    ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
                         2001:781081 HCAPLUS Full-text
ACCESSION NUMBER:
                         135:314493
DOCUMENT NUMBER:
                         Novel nucleic acids encoding human bone
TITLE:
                         marrow-expressed polypeptides
                         Ford, John E.; Boyle, Bryan J.; Tang, Y. Tom; Asundi,
INVENTOR(S):
                         Vinod; Yang, Yonghong; Liu, Chenghua; Drmanac, Radoje
                         Hyseq, Inc., USA
PATENT ASSIGNEE(S):
                         PCT Int. Appl., 203 pp.
SOURCE:
                         CODEN: PIXXD2
DOCUMENT TYPE:
                         Patent
                         English
LANGUAGE:
FAMILY ACC. NUM. COUNT:
                         127
PATENT INFORMATION:
                                            APPLICATION NO.
                                                                   DATE
     PATENT NO.
                         KIND
                                DATE
                                            ______
     ______
                         ----
                                _____
                                                                   20010418 <--
                                            WO 2001-US12607
    WO 2001079447
                         A2
                                20011025
    WO 2001079447
                         A8
                                20030724
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
             VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
```

KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,

GW, ML, MR, NE, SN, TD, TG

IT

RN

CN

```
20010418 <--
                               20011030
                                          AU 2001-55454
                         Α
    AU 200155454
                                                                 20020830 <--
                               20030619
                                          US 2002-232484
    US 2003113847
                         A1
                                                              A 20000418 <--
                                          US 2000-552929
PRIORITY APPLN. INFO.:
                                                              A 20001024 <--
                                          US 2000-695783
                                                              P 20001130 <--
                                          US 2000-250583P
                                                              A 20010126
                                           US 2001-770160
                                                              W 20010418
                                          WO 2001-US12607
     The present invention provides 67 novel bone marrow-expressed nucleic acids,
AΒ
     novel polypeptide sequences encoded by these nucleic acids, and uses thereof.
     The novel nucleic acids were assembled from expressed sequence tags (ESTs)
     isolated mainly by sequencing by hybridization, Sanger sequencing techniques,
     and in some cases, sequences obtained from one or more public databases. A
     recursive algorithm was used to extend some of the seed ESTs into an extended
     assemblage, by pulling addnl. sequences from different databases. Clusters
     were identified which were expressed in bone marrow tissue cDNA libraries, but
     not in other tissues. The polynucleotides and polypeptides of the invention
     have uses in diagnosis and therapy, detecting bone-marrow cells or tissues,
     and in arrays to screen for binding agents.
    ICM C12N
IC
    3-3 (Biochemical Genetics)
CC
    Section cross-reference(s): 6, 13, 63
                                                           367620-06-2
                                367452-08-2
                                              367620-05-1
                  321453-13-8
    218776-18-2
IT
                                                           367620-11-9
                  367620-08-4
                                367620-09-5
                                             367620-10-8
     367620-07-3
     367620-12-0 367620-13-1 367620-14-2 367620-15-3
     367620-16-4 367620-17-5 367620-18-6 367620-19-7
                                                           367620-20-0
                                                           367620-49-3
     367620-21-1 367620-22-2 367620-47-1
                                             367620-48-2
                                                           367620-54-0
     367620-50-6 367620-51-7 367620-52-8
                                             367620-53-9
                                                           367620-59-5
     367620-55-1 367620-56-2 367620-57-3
                                             367620-58-4
                                                           367620-64-2
     367620-60-8 367620-61-9 367620-62-0
                                             367620-63-1
     367620-65-3 367620-66-4 367620-67-5
                                             367935-34-0
                                                           367935-37-3
     367935-43-1 367935-50-0 367935-54-4
                                              367935-57-7
                                                           367935-63-5
                                                           367943-61-1
     367935-65-7 367935-71-5 367935-78-2
                                              367935-81-7
     367943-64-4 367943-67-7
    RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
    unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical
     study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
        (amino acid sequence; nucleic acids encoding human bone
       marrow-expressed polypeptides)
IT
    367620-13-1
    RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
     unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical
     study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
        (amino acid sequence; nucleic acids encoding human bone
        marrow-expressed polypeptides)
RN
     367620-13-1 HCAPLUS
    Bone marrow-specific protein (human clone WO0179447-SEQID-38 precursor)
CN
     (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
    ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
                        2001:636085 HCAPLUS Full-text
ACCESSION NUMBER:
DOCUMENT NUMBER:
                        135:180957
                        Preparation of novel antiarrhythmic peptides
TITLE:
                        Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier,
INVENTOR(S):
                        Eddi; Kjolbye, Anne Louise; Jorgensen, Niklas Rye;
                        Nielsen, Morten Schak; Holstein-Rathlou, Niels-Henrik;
                        Martins, James B.
                        Zealand Pharmaceuticals A/S, Den.
PATENT ASSIGNEE(S):
                        PCT Int. Appl., 189 pp.
```

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE: FAMILY ACC. NUM. COUNT:

2

PATENT INFORMATION:

```
APPLICATION NO.
                                                                 DATE
                             DATE
                        KIND
    PATENT NO.
                                         _____
                                                                 -----
    _____
                       _ - - -
                             -----
                                        WO 2001-DK127
                                                                 20010222 <--
    WO 2001062775
                        A2
                               20010830
                        A3
                               20020131
    WO 2001062775
        W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
            CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
            IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
            MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
            SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                                               20010222 <--
                        A1 20010830 CA 2001-2385659
    CA 2385659
                                        EP 2001-907393
                                                                 20010222 <--
                               20020731
                         A2
    EP 1226160
                               20041215
    EP 1226160
                         B1
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                        JP 2001-562556
                             20030930
                        Т
    JP 2003528826
                                        AT 2001-907393
ES 2001-1907393
                                                                 20010222 <--
                         Т
                               20050115
    AT 284896
                                                                 20010222 <--
                       T3 20050416
    ES 2228807
                     T 20050429 PT 2001-907393
B2 20050602 AU 2001-35362
A1 20021003 CA 2002-2439101
                             20050429 PT 2001-907393
                                                                 20010222 <--
    PT 1226160
                                                                 20010222 <--
    AU 781674
                                                                 20020222
                                        CA 2002-2439101
    CA 2439101
                                        WO 2002-US5773
                                                                 20020222
                        A2
                              20021003
    WO 2002077017
                              20031009
                        A3
    WO 2002077017
           AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
            GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
            GN, GQ, GW, ML, MR, NE, SN, TD, TG
                              20031217 EP 2002-723240
                         A2
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                               20050303 JP 2002-576275
    JP 2005506295
                        T
                                                                 20020222
                        Α
                                          BR 2002-7476
    BR 2002007476
                               20060124
                             20031020
                                          NO 2003-3641
                                                                 20030815
    NO 2003003641
                       Α
                     A1 20050526
A1 20050407
A1 20050929
                                                                 20030822 <--
                                          US 2003-646294
    US 2005113293
                                                                 20040204 <--
                                        US 2004-772774
    US 2005075280
                                                                 20050902 <--
                                        AU 2005-205785
    AU 2005205785
                                           DK 2000-288
DK 2000-738
                                                             A 20000223 <--
PRIORITY APPLN. INFO.:
                                                            A 20000504 <--
                                           US 2000-251659P
US 2001-792286
WO 2001-DK127
                                                             P 20001206 <--
                                                              A 20010222
                                           WO 2001-DK127
                                                              W 20010222
                                           US 2001-314470P P 20010823
WO 2002-US5773 W 20020222
```

MARPAT 135:180957 OTHER SOURCE(S):

Peptides X-A-B-Y and cyclo(X-A-B-Y) [A and B represents chemical moieties having an amino group (radical) and a carboxy group; X represents a peptide

sequence of 1 to 3 D- or L-amino acid residues or an N-terminal modification of the group A-B when Y represents a C-terminal peptide sequence of 2 to 5 Dor L-amino acid residues; X represents a peptide sequence of 2 to 5 D- or Lamino acid residues when Y represents a C-terminal peptide sequence of 1 to 3 D- or L-amino acid residues; for the linear peptide, X is optionally chemical modified at its N-terminal and has an optional linking group comprising 0-8 backbone atoms] and their mirror image or a retro analogs or pharmaceutically acceptable derivs. were prepared for treating cardiac arrhythmias. Thus, Ac-D-Tyr-D-pro-D-4Hyp-Gly- D-Ala-Gly-NH2 (4Hyp = 4-hydroxyprolyl) was prepared by the solid-phase method using TentaGel-S-Ram and examined for biol. activity [assays included effect on gap junction intercellular communication (GJIC) in cardiomyocytes, binding to tissue prepns. of murine heart, and effect on cAMP formation in CHO cells].

ICM C07K007-00 IC

34-3 (Amino Acids, Peptides, and Proteins) CC Section cross-reference(s): 1, 63

81771-37-1P, Antiarrhythmic peptide (cattle atrium) 159503-65-8P IT 355151-17-6P 355151-14-3P 355151-15-4P 355151-16-5P 355151-11-0P 355151-22-3P 355151-19-8P 355151-20-1P 355151-21-2P 355151-18-7P 355151-26-7P 355151-27-8P 355151-25-6P 355151-23-4P 355151-24-5P 355151-32-5P 355151-29-0P 355151-30-3P 355151-31-4P 355151-28-9P 355151-34-7P 355151-35-8P 355151-36-9P 355151-33-6P 355151-38-1P 355151-39-2P 355151-40-5P 355151-42-7P 355151-37-0P 355151-44-9P 355151-45-0P 355151-46-1P 355151-49-4P 355151-50-7P 355151-47-2P 355151-48-3P 355151-53-0P 355151-54-1P 355151-55-2P 355151-52-9P 355151-51-8P 355151-60-9P 355151-58-5P 355151-59-6P 355151-56-3P 355151-57-4P 355151-65-4P 355151-64-3P 355151-62-1P 355151-63-2P 355151-61-0P 355151-70-1P 355151-68-7P 355151-69-8P 355151-67-6P 355151-66-5P 355151-73-4P 355151-74-5P 355151-72-3P 355151-71-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel antiarrhythmic peptides)

355151-33-6P 355151-45-0P 355151-46-1P ΙT

355151-47-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel antiarrhythmic peptides)

355151-33-6 HCAPLUS RN

CN

D-Asparagine, glycyl-D-alanylglycyl-(4S)-4-hydroxy-D-prolyl-D-prolyl-Dtyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

355151-45-0 HCAPLUS RN Cyclo[L-alanylqlycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-CN glutaminylglycyl] (9CI) (CA INDEX NAME) *** STRUCTURE DIAGRAM IS NOT AVAILABLE *** 355151-46-1 HCAPLUS RN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-CN asparaginylglycyl] (9CI) (CA INDEX NAME) *** STRUCTURE DIAGRAM IS NOT AVAILABLE *** 355151-47-2 HCAPLUS RN Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl) CN (CA INDEX NAME) (9CI) *** STRUCTURE DIAGRAM IS NOT AVAILABLE *** ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN L42000:325646 HCAPLUS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: 133:247911 Prediction of the coding sequences of unidentified TITLE: human genes. XVII. the complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro Nagase, Takahiro; Kikuno, Reiko; Ishikawa, Ken-Ichi; AUTHOR(S): Hirosawa, Makoto; Ohara, Osamu Kazusa DNA Research Institute, Chiba, 292-0812, Japan CORPORATE SOURCE: DNA Research (2000), 7(2), 143-150 SOURCE: CODEN: DARSE8; ISSN: 1340-2838 Universal Academy Press PUBLISHER: DOCUMENT TYPE: Journal English LANGUAGE: To provide information regarding the coding sequences of unidentified human AB genes, the authors have conducted a sequencing project of human cDNAs which encode large proteins. The authors herein present the entire sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from two sets of size-fractionated human adult and fetal brain cDNA libraries. sizes of the inserts and corresponding open reading frames of cDNA clones analyzed here were 4.4 kb and 2.6 kb (856 amino acid residues), resp. Database searches of the predicted amino acid sequences classified 53 predicted gene products into the following five functional categories: cell signaling/communication, nucleic acid management, cell structure/motility, protein management and metabolism It was also revealed that homologues for 32 KIAA gene products were detected in the databases, which were similar in sequence through almost their entire regions. Addnl., the chromosomal loci of the genes were determined by using human-rodent hybrid panels unless their chromosomal loci were already assigned in the public databases. The expression levels of the genes were monitored in spinal cord, fetal brain and fetal liver, as well as in 10 human tissues and 8 brain regions, by reverse transcription-coupled polymerase chain reaction, products of which were quantified by ELISA. 3-3 (Biochemical Genetics) CC 295808-13-8 295808-14-9 295808-12-7 IT 295808-10-5 295808-11-6 295808-19-4 295808-17-2 295808-18-3 295808-15-0 295808-16-1 295808-24-1 295808-22-9 295808-23-0 295808-20-7 295808-21-8 295808-29-6 295808-25-2 295808-26-3 295808-27-4 295808-28-5 295808-30-9 295808-31-0 *295808-32-1* 295808-33-2 295808-38-7 295808-34-3 295808-35-4 295808-36-5 295808-37-6 295808-39-8 295808-40-1 295808-41-2 295808-42-3 295808-43-4 295808-44-5 295808-45-6 295808-46-7 295808-47-8 295808-48-9

295808-52-5

295808-53-6

295808-50-3

295808-51-4

295808-49-0

```
295808-58-1
                                        295808-57-0
                          295808-56-9
             295808-55-8
295808-54-7
                                                     295808-63-8
                          295808-61-6
                                        295808-62-7
295808-59-2
             295808-60-5
                                        295808-67-2
                                                     295808-68-3
295808-64-9 295808-65-0
                          295808-66-1
                                        295808-72-9
                                                     295808-73-0
295808-69-4 295808-70-7
                          295808-71-8
                                                     295808-78-5
295808-74-1 295808-75-2
                                        295808-77-4
                          295808-76-3
295808-79-6
                          295808-81-0
                                        295808-82-1
                                                     295808-83-2
             295808-80-9
             295808-85-4
                          295808-86-5
                                        295808-87-6
                                                     295808-88-7
295808-84-3
                                        295808-92-3
                                                     295808-93-4
295808-89-8
             295808-90-1
                          295808-91-2
                                                     295808-98-9
295808-94-5 295808-95-6
                          295808-96-7
                                        295808-97-8
                                                     295809-03-9
                          295809-01-7
                                        295809-02-8
295808-99-0 295809-00-6
                                        295809-07-3
                                                     295809-08-4
                          295809-06-2
295809-04-0
             295809-05-1
295809-09-5
```

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from human adult and fetal brain cDNA libraries)

IT 295808-32-1

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from human adult and fetal brain cDNA libraries)

RN 295808-32-1 HCAPLUS

CN Protein (human clone fj01441 gene KIAA1466 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

_				_
D	Tr'	בסיז	ЮI	. H.

Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
=======================================	+=====-	+=====	+======	+====================================	+=======
Anon	1998	282	2012	Science	
Bateman, A	1999	27	260	Nucleic Acids Res	HCAPLUS
Bleasby, A	1994	22	3574	Nucleic Acids Res	HCAPLUS
Deguchi, M	1998	273	26269	J Biol Chem	HCAPLUS
Dunham, I	1999	402	489	Nature	HCAPLUS
Goffeau, A	1996	274	546	Science	HCAPLUS
Gyapay, G	1996	5	339	Hum Mol Genet	HCAPLUS
Hirosawa, M	1999	6	329	DNA Res	HCAPLUS
Ishikawa, K	1997	4	307	DNA Res	HCAPLUS
Kikuno, R	2000	28	331	Nucleic Acids Res	HCAPLUS
Nagase, T	1998	5	277	DNA Res	HCAPLUS
Nagase, T	1998	5	31	DNA Res	HCAPLUS
Nagase, T	2000	7	65	DNA Res	HCAPLUS
Nomura, N	1994	1	27	DNA Res	HCAPLUS
Ohara, O	1997	4	53	DNA Res	HCAPLUS
Taguchi, A	1996	35	31	Brain Res Mol Brain	HCAPLUS

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS ON STN ACCESSION NUMBER: 1999:379001 HCAPLUS Full-text

DOCUMENT NUMBER:

TITLE:

131:54612
Complete genome sequence of an aerobic

AUTHOR (S):

hyper-thermophilic crenarchaeon, Aeropyrum pernix Kl Kawarabayasi, Yutaka; Hino, Yumi; Horikawa, Hiroshi; Yamazaki, Syuji; Haikawa, Yuji; Jin-No, Koji; Takahashi, Mikio; Sekine, Mitsuo; Baba, Sin-Ichi; Ankai, Akiho; Kosugi, Hiroki; Hosoyama, Akira; Fukui, Shigehiro; Nagai, Yoshimi; Nishijima, Keiko; Nakazawa, Hidekazu; Takamiya, Minako; Masuda, Sayaka; Funahashi,

Tomomichi; Tanaka, Toshihiro; Kudoh, Yutaka; Yamazaki, Jun; Kushida, Norihiro; Oguchi, Akio; Aoki, Ken-ichi; Kubota, Kenji; Nakamura, Yoshinobu; Nomura, Norimichi;

Sako, Yoshihiko; Kikuchi, Hisasi

CORPORATE SOURCE:

National Institute of Technology and Evaluation,

Tokyo, 151-0066, Japan

SOURCE:

DNA Research (1999), 6(2), 83-101, 145-152

CODEN: DARSE8; ISSN: 1340-2838

PUBLISHER:

Universal Academy Press

Journal

DOCUMENT TYPE: LANGUAGE:

English

The complete sequence of the genome of an aerobic hyper-thermophilic AB crenarchaeon, Aeropyrum pernix K1; which optimally grows at 95°, was determined by the whole genome shotgun method with some modifications. entire length of the genome was 1,669,695 bp. The authenticity of the entire sequence was supported by restriction anal. of long PCR products, which were directly amplified from the genomic DNA. As the potential protein-coding regions, a total of 2694 open reading frames (ORFs) were assigned. By similarity search against public databases, 633 (23.5%) of the ORFs were related to genes with putative function and 523 (19.4%) to the sequences registered but with unknown function. All the genes in the TCA cycle except for that of α -ketoglutarate dehydrogenase were included, and instead of the α ketoglutarate dehydrogenase gene, the genes coding for the 2 subunits of 2oxoacid:ferredoxin oxidoreductase were identified. The remaining 1538 ORFs (57.1%) did not show any significant similarity to the sequences in the databases. Sequence comparison among the assigned ORFs suggested that a considerable member of ORFs were generated by sequence duplication. genes identified were a single 16S-23S rRNA operon, two 5S rRNA genes, and 47 tRNA genes including 14 genes with intron structures. All the assigned ORFs and RNA coding regions occupied 89.12% of the whole genome. The data presented in this paper are available on the internet homepage

(http://www.mild.nite.go.jp). 3-3 (Biochemical Genetics) CC

```
Section cross-reference(s): 6, 10
```

```
227780-21-4
                                              227780-20-3
                                227780-19-0
    227780-17-8
                  227780-18-9
IT
                                                            227780-26-9
                                              227780-25-8
                                227780-24-7
    227780-22-5
                  227780-23-6
                                              227780-30-5
                                                            227780-32-7
                  227780-28-1
                                227780-29-2
    227780-27-0
                                              227780-49-6
                                                            227780-50-9
                                227780-45-2
                  227780-35-0
    227780-34-9
                                                            227780-55-4
                                227780-53-2
                                              227780-54-3
    227780-51-0
                  227780-52-1
                                              227780-63-4
                                                            227780-68-9
                                227780-59-8
                  227780-57-6
    227780-56-5
                                              227780-72-5
                                                            227780-73-6
                                227780-71-4
    227780-69-0
                  227780-70-3
                                              227780-77-0
                                                            227780-78-1
                                227780-76-9
                  227780-75-8
    227780-74-7
                                                            227781-14-8
                                227781-12-6
                                              227781-13-7
                  227781-11-5
    227780-92-9
                                                            227781-19-3
                                227781-17-1
                                              227781-18-2
                  227781-16-0
    227781-15-9
                                              227781-23-9
                                                            227781-24-0
                                227781-22-8
                  227781-21-7
    227781-20-6
                                                            227781-62-6
                                              227781-54-6
                                227781-45-5
                  227781-33-1
    227781-25-1
                                                            227781-79-5
                                              227781-78-4
                  227781-76-2
                                227781-77-3
    227781-74-0
                                                            227781-91-1
                                              227781-88-6
                                227781-83-1
                  227781-81-9
    227781-80-8
                                                            227782-15-2
                                              227782-05-0
                                227782-00-5
                  227781-96-6
    227781-95-5
                                                            227782-20-9
                                              227782-19-6
                                227782-18-5
                  227782-17-4
    227782-16-3
                                                            227782-28-7
                                              227782-27-6
                                227782-26-5
                  227782-25-4
    227782-24-3
                                                            227782-33-4
                                              227782-32-3
                                227782-31-2
                  227782-30-1
    227782-29-8
                                              227782-37-8
                                                            227782-38-9
                                227782-36-7
                  227782-35-6
    227782-34-5
                                                            227782-43-6
                                              227782-42-5
                                227782-41-4
                  227782-40-3
    227782-39-0
                                              227782-47-0
                                                            227782-48-1
                                227782-46-9
                  227782-45-8
    227782-44-7
                                                            227782-53-8
                                              227782-52-7
                                227782-51-6
                  227782-50-5
    227782-49-2
                                                            227782-58-3
                                              227782-57-2
                  227782-55-0
                                227782-56-1
    227782-54-9
                                                            227782-63-0
                  227782-60-7
                                227782-61-8
                                              227782-62-9
    227782-59-4
                                              227782-70-9
                                                            227782-71-0
                  227782-66-3
                                227782-69-6
    227782-65-2
                                                            227782-78-7
                                227782-74-3
                                              227782-75-4
                  227782-73-2
    227782-72-1
```

```
227782-82-3
                                       227782-83-4
                                                    227782-89-0
            227782-81-2
227782-79-8
                         227782-95-8
                                       227782-97-0
                                                    227783-01-9
            227782-94-7
227782-93-6
                          227783-19-9
                                       227783-20-2
                                                    227783-21-3
227783-11-1
            227783-18-8
227783-22-4 227783-23-5
                                       227783-25-7
                                                    227783-27-9
                         227783-24-6
                                       227783-33-7
                                                    227783-34-8
227783-29-1 227783-31-5
                         227783-32-6
                                       227783-38-2
                                                    227783-39-3
227783-35-9 227783-36-0 227783-37-1
227783-40-6 227783-41-7
                                                    227783-44-0
                         227783-42-8
                                       227783-43-9
           227783-46-2 227783-47-3
                                       227783-48-4
                                                    227783-49-5
227783-45-1
                                                    227783-54-2
            227783-51-9 227783-52-0
                                       227783-53-1
227783-50-8
                                       227783-58-6
                                                    227783-59-7
227783-55-3 227783-56-4
                         227783-57-5
227783-60-0 227783-61-1
                         227783-62-2
                                       227783-64-4
                                                    227783-65-5
                                       227783-69-9
                                                    227783-70-2
227783-66-6 227783-67-7 227783-68-8
                                       227783-74-6
                                                    227783-75-7
            227783-72-4 227783-73-5
227783-71-3
227783-76-8 227783-77-9
                                       227783-79-1
                                                    227783-80-4
                         227783-78-0
            227783-82-6 227783-83-7
                                       227783-84-8
                                                    227783-88-2
227783-81-5
            227783-91-7 227783-92-8 227783-93-9
227783-90-6
                                                    227783-98-4
                                       227783-97-3
            227783-95-1
                         227783-96-2
227783-94-0
227783-99-5 227784-00-1
                                       227784-02-3
                                                    227784-03-4
                          227784-01-2
                                                    227784-08-9
227784-04-5 227784-05-6 227784-06-7
                                       227784-07-8
                                       227784-12-5
                                                    227784-13-6
227784-09-0 227784-10-3 227784-11-4
                                                    227784-18-1
227784-14-7 227784-15-8 227784-16-9
                                       227784-17-0
227784-19-2 227784-20-5 227784-21-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
```

(Biological study)

(amino acid sequence; complete genome sequence of Aeropyrum pernix K1) 227783-92-8 IT

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; complete genome sequence of Aeropyrum pernix K1) 227783-92-8 HCAPLUS

RN 132Aa long protein (Aeropyrum pernix strain K1 gene APE1292) (9CI) (CA CN INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RETABLE					1 1
Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
=======================================	+====-	 ====	 =====	+======================================	+========
Bult, C	1996	273	1058	Science	HCAPLUS
Ewing, B	1998	8	175	Genome Res	HCAPLUS
Ewing, B	1998	8	186	Genome Res	HCAPLUS
Hirata, R	1990	265	6726	J Biol Chem	HCAPLUS
Kane, P	1990	250	651	Science	HCAPLUS
Kawarabayasi, Y	ĺ		147	DNA Res	
Kawarabayasi, Y	1998	5	55	DNA Res	HCAPLUS
Klenk, H	1997	390	364	Nature	HCAPLUS
Lowe, T	1997	25	955	Nuc Acids Res	HCAPLUS
Nakamura, Y	1997	2	299	Microbial & Comparat	HCAPLUS
Niehaus, F	1997	204	153	Gene	HCAPLUS
Nomura, N	1998	180	3635	J Bacteriol	HCAPLUS
Peler, F	1992	89	5577	Proc Natl Acad Sci	
Perler, F	1997	25	1087	Nuc Acids Res	HCAPLUS
Pietrokovski, S	1994	3	2340	Protein Science	HCAPLUS
Riera, J	1990	94	475	Proc Natl Acad Sci	
Sako, Y	1996	46	1070	International Journa	MEDLINE
Smith, C	1987	236	1448	Science	HCAPLUS
Smith, D	1997	179	7135	J Bacteriol	HCAPLUS
Smith, T	1981	147	195	J Mol Biol	MEDLINE
Takagi, M	1997	63	4504	Appl Environ Microbi	HCAPLUS
Xu, M	1993	75	1371	Cell	HCAPLUS

Zhang, Q | 1996 | 120 | 587 | J Biochem | HCAPLUS

L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1997:474887 HCAPLUS Full-text

DOCUMENT NUMBER: 127:174474

TITLE: In vivo evidence of the critical role of cadherin-5 in

murine vascular integrity

AUTHOR(S): Matsuyoshi, Norihisa; Toda, Ken-Ichi; Horiguchi, Yuji;

Tanaka, Toshihiro; Nakagawa, Shinichi; Takeichi,

Masatoshi; Imamura, Sadao

CORPORATE SOURCE: Department of Dermatology, Graduate School of

Medicine, Faculty of Science, Kyoto University, Kyoto,

606-01, Japan

SOURCE: Proceedings of the Association of American Physicians

(1997), 109(4), 362-371

CODEN: PAAPFD; ISSN: 1081-650X

PUBLISHER: Blackwell DOCUMENT TYPE: Journal LANGUAGE: English

Vascular endothelial cell-cell adhesion is crucial for the regulation of AB vascular functions and is associated with many circulatory disorders. We isolated a rat monoclonal antibody (VECD1) recognizing the mouse vascular endothelial cell adhesion mol. and found that it inhibited vascular endothelial cell-cell association We sequenced a full-length cDNA of the antigen that was identical to mouse cadherin-5. L-cells transfected with its cDNA acquired cell-cell adhesiveness, and these transfectants reacted with VECD1 at cell-cell contact areas. We studied the role of mouse cadherin-5 in vascular functions. The addition of VECD1 antibody to a cultured vascular endothelial cell line (F-2) caused the detachment of each cell. Although normal F-2 cells formed tubular structures on Matrigel, VECD1 disturbed the tubulogenesis. VECD1 also increased the permeability through the F-2 cell layer. To clarify the in vivo function of mouse cadherin-5, we i.p. injected the hybridomas producing VECD1 into adult mice. Severe venous stasis and s.c. hemorrhage were induced within several days after the injection, resulting in the early death of the animals. These findings are evidence of an essential role of cadherin-5 in the regulation of vascular endothelial cell-cell adhesion in vivo.

CC 13-6 (Mammalian Biochemistry) Section cross-reference(s): 6

IT 193843-04-8, Cadherin 5 (mouse F-2 cell)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

IT 173432-45-6, Cadherin 5, prepro- (Mus musculus)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

IT 193843-04-8, Cadherin 5 (mouse F-2 cell)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

RN 193843-04-8 HCAPLUS

CN Cadherin 5 (mouse F-2 cell) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 173432-45-6, Cadherin 5, prepro- (Mus musculus)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); PRP (Properties); BIOL (Biological study)
 (in vivo evidence of critical role of cadherin-5 in murine vascular
 integrity)

RN 173432-45-6 HCAPLUS

CN Cadherin 5, prepro- (Mus musculus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2007 ACS ON STN ACCESSION NUMBER: 1996:556341 HCAPLUS Full-text

DOCUMENT NUMBER:

125:239971

TITLE:

A novel family of developmentally regulated mammalian

transcription factors containing the TEA/ATTS DNA

binding domain

AUTHOR (S):

Jacquemin, Patrick; Hwang, Jung-Joo; Martial, Joseph

A.; Dolle, Pascal; Davidson, Irwin

CORPORATE SOURCE:

Inst. Genetique Biologie Moleculaire Cellulaire,

College France, Illkirch, 163-67404, Fr. Journal of Biological Chemistry (1996),

271(36), 21775-21785

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER:

LANGUAGE:

SOURCE:

American Society for Biochemistry and Molecular

Biology

DOCUMENT TYPE:

Journal English

The authors describe the mol. cloning of two novel human and murine AB transcription factors containing the TEA/ATTS DNA binding domain and related to transcriptional enhancer factor-1 (TEF-1). These factors bind to the consensus TEA/ATTS cognate binding site exemplified by the GT-IIC and Sph enhansons of the SV40 enhancer but differ in their ability to bind cooperatively to tandemly repeated sites. The human TEFs are differentially expressed in cultured cell lines and the mouse (m) TEFs are differentially expressed in embryonic and extra-embryonic tissues in early post-implantation embryos. Strikingly, at later stages of embryogenesis, mTEF-3 is specifically expressed in skeletal muscle precursors, whereas mTEF-1 is expressed not only in developing skeletal muscle but also in the myocardium. Together with previous data, these results point to important, partially redundant, roles for these TEF proteins in myogenesis and cardiogenesis. In addition, mTEF-1 is strongly coexpressed with mTEF-4 in mitotic neuroblasts, while accentuated mTEF-4 expression is also observed in the gut and the nephrogenic region of the kidney. These observations suggest addnl. roles for the TEF proteins in central nervous system development and organogenesis.

CC 3-4 (Biochemical Genetics)

Section cross-reference(s): 6, 13

IT 181829-00-5 181829-01-6 181829-02-7 181829-03-8

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; a novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain)

IT 181829-01-6
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(amino acid sequence; a novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain)

RN 181829-01-6 HCAPLUS

CN RNA formation factor TEF-5 (human fragment reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:49097 HCAPLUS Full-text

DOCUMENT NUMBER: 124:137260

TITLE: Molecular cloning and expression of murine vascular

endothelial-cadherin in early stage development of

cardiovascular system

AUTHOR(S): Breier, G.; Breviario, F.; Caveda, L.; Berthier, R.;

Schnuerch, H.; Gotsch, U.; Vestweber, D.; Risau, W.;

Dejana, E.

CORPORATE SOURCE: Max-Planck-Institut physiologische klinische

Forschung, Bad Nauheim, Germany

SOURCE: Blood (1996), 87(2), 630-41

CODEN: BLOOAW; ISSN: 0006-4971

PUBLISHER: Saunders
DOCUMENT TYPE: Journal
LANGUAGE: English

An early step in the formation of the extraembryonic and intraembryonic vasculature is endothelial cell differentiation and organization in blood islands and vascular structures. This involves the expression and function of specific adhesive mols. at cell-to-cell junctions. Previous work showed that endothelial cells express a cell-specific cadherin (vascular endothelial [VE]cadherin, or 7B4/cadherin-5) that is organized at cell-to-cell contacts in cultured cells and is able to promote intercellular adhesion. In this study, we investigated whether VE-cadherin could be involved in early cardiovascular development in the mouse embryo. We first cloned and sequenced the mouse VEcadherin cDNA. At the protein level, murine VE-cadherin presented 75% identity (90%, considering conservative amino acid substitutions) with the human homolog. Transfection of murine VE-cadherin cDNA in L cells induced Ca++dependent cell-to-cell aggregation and reduced cell detachment from monolayers. In situ hybridization of adult tissues showed that the murine mol. is specifically expressed by endothelial cells. In mouse embryos, VEcadherin transcripts were detected at the very earliest stages of vascular development (E7.5) in mesodermal cells of the yolk sac mesenchyme. At E9.5, expression of VE-cadherin was restricted to the peripheral cell layer of blood islands that gives rise to endothelial cells. Hematopoietic cells in the center of blood islands were not labeled. At later embryonic stages, VEcadherin transcripts were detected in vascular structures of all organs examined, e.g., in the ventricle of the heart, the inner cell lining of the atrium and the dorsal aorta, in intersomitic vessels, and in the capillaries of the developing brain. A comparison with flk-1 expression during brain angiogenesis revealed that brain capillaries expressed relatively low amts. of VE-cadherin. In the adult brain, the level of VE-cadherin transcript was further reduced. By immunohistochem., murine VE-cadherin protein was detected at cell-to-cell junctions of endothelial cells. Overall, these data demonstrate that VE-cadherin is an early, constitutive, and specific marker of endothelial cells. This distinguishes this mol. from other cadherins and suggests that its expression is associated with the early assembly of vascular structures.

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 6, 13

IT 173432-45-6, Cadherin 5, prepro- (Mus musculus)

173432-46-7, Cadherin 5 (Mus musculus)

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)

(amino acid sequence; cDNA sequence and tissue distribution of murine vascular endothelial-cadherin in early stage development of cardiovascular system)

IT 173432-45-6, Cadherin 5, prepro- (Mus musculus)

173432-46-7, Cadherin 5 (Mus musculus)

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)

(amino acid sequence; cDNA sequence and tissue distribution of murine vascular endothelial-cadherin in early stage development of cardiovascular system)

RN 173432-45-6 HCAPLUS

CN Cadherin 5, prepro- (Mus musculus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 173432-46-7 HCAPLUS

CN Cadherin 5 (Mus musculus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*****BELOW ARE REFERENCES TO QUERY ON CLAIM 41, WHERE A AND B ARE EQUAL TO 1 NOT A RANGE OF 0-1*******

=> d que 160

L52

STR

Structure attributes must be viewed using STN Express query preparation.

L54 2075 SEA FILE=REGISTRY SSS FUL L52

L57 STR

Structure attributes must be viewed using STN Express query preparation.

4 SEA FILE=REGISTRY SUB=L54 SSS FUL L57 . L59 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L59 L60

=> d ibib abs hitind hitstr retable 160 tot

L60 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2006:465364 HCAPLUS Full-text

DOCUMENT NUMBER:

144:460820

TITLE:

Peptide antitumor agents Rosenberg, Martin Jay

INVENTOR(S):

New York University, USA

PATENT ASSIGNEE(S):

PCT Int. Appl., 44 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.					KIND DATE			APPLICATION NO.						DATE			
	WO	2006	0527	75					0518	WO 2005-US40078						20051104		
	WO																~-	~ **
		W:	ΑE,															
				CO,														
				GH,														
			ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	MW,	MX,
			MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,
				SK,														
	•		VN,	YU,	ZA,	ZM,	zw											
		RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	ΗU,	IE,
			ıs,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,
				CG,														
				KE,														
				KZ,														
	US	2006	2585	73	•	Al	•	2006	1116	1	US 2	005-3	2646	84		2	0051	031
		7173																
PRIO	RITY	Y APP	LN.	INFO	. :					1	US 2	004-	6262	20P		P 2	0041	108
AB						e is	olat	ed,	puri	fied	l per	tide	s, k	oiol.	act	ive	frag	ments and
•	an	alog	s of	the	pept	ides	hav	ring	anti	-tum	or a	ctiv	rity	in m	amma	ıls,	phar	maceutical

formulations comprising the peptides, fragments and analogs and methods of treating mammals suffering from tumors using such materials.

CC 1-6 (Pharmacology)

Section cross-reference(s): 34, 63

IT 886751-53-7P 886751-54-8P 886751-55-9P 886751-56-0P

886751-57-1P 886751-58-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide antitumor agents)

IT 886751-53-7P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide antitumor agents)

RN 886751-53-7 HCAPLUS

CN Cyclo[(2S)-2-amino-4-(methylsulfinyl)butanoyl-(2S)-2-amino-4-(methylsulfinyl)butanoyl-L-cysteinyl-L-valyl-L-threonyl-L-histidyl-L-cysteinyl-L-asparaginylglycylglycyl], cyclic (3→7)-disulfide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L60 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:615187 HCAPLUS Full-text

DOCUMENT NUMBER: 123:27638

TITLE: Peptides for neutralizing the toxicity of lipid A

INVENTOR(S): Porro, Massimo

PATENT ASSIGNEE(S): Biosynth S.r.L., Italy

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

E: Patent English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PA'	TENT :	NO.					DATE			APPL	ICAT:	ION 1	NO.		D	ATE		
	9503							0202		WO 1	994-1	EP24:	13		1	9940	721	
WO	9503 W:	AM,	AT,	AU,	BB,	BG,	BR,	BY,	CA,							FI, MN,		
	RW:	NL,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SI,	SK,	TJ,	TT,	UA,	US, LU,	UZ,	VN
		NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	ML,	MR,	NE,	SN,	TD,	TG
	5652															9930	726	
CA	2167	087			A1		1995	0202		CA 1	994-:	2167	087		1	9940	721	
	9474				Α		1995	0220		AU 1	994-	7460	2		1	9940	721	
AU	6839	20			B2		1997	1127										
EP	7113	07			A1		1996	0515		EP 1	994-	9242	72		1	9940	721	
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙE,	IT,	LI,	LU,	MC,	NL,	PT,	SE
JР	0950	3489			Т		1997	0408		JP 1	994-	5049	48		1	9940	721	
PRIORIT																9930		
										US 1	991-	6587	44		B2 1	9910	211	
										US 1	992-	8198	93		A2 1	9920	116	
										US 1	993-	4987	1		A2 1	9930	419	
																9940		
					_									3 4		1- 4	1-4	. + h ~

AB A peptide composition for neutralizing the toxicity of lipid A exhibits the formula: (1) (A)n (A= Lys, Arg; n=integer ≥7); (2) (AB)m (A as in (1); B= Val,

```
Leu, Ile, Tyr, Phe, Try; m=integer ≥3); or (3) (ABC)p (A=Lys, Arg; B, C=Leu,
     Ile, Tyr, Phe, Try; p=integer ≥2). The composition binds lipid-A of
     endotoxins and provides therapeutic and prophylactic uses. Novel 29 peptides
     capable of neutralizing the toxicity of lipid A are provided and their use on
     treating septic shock is claimed.
     ICM C07K014-00
IC
     ICS C07K007-00
     4-9 (Toxicology)
CC
     Section cross-reference(s): 1
                            38000-06-5, Polylysine 163912-71-8
     25104-18-1, Polylysine
                                               164123-03-9
                                                             164123-04-0
                 164123-01-7
                                 164123-02-8
     164123-00-6
                                                             164123-09-5
                                               164123-08-4
                   164123-06-2
                                 164123-07-3
     164123-05-1
     164123-10-8 164123-11-9 164123-12-0
                                                             164123-17-5
                                 164123-15-3
                                               164123-16-4
     164123-13-1 164123-14-2
                                                             164123-22-2
                                               164123-21-1
     164123-18-6 164123-19-7
                                 164123-20-0
     164123-23-3 164123-24-4 164176-08-3
                                               164176-09-4
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (peptides for neutralizing the toxicity of lipid A of endotoxins)
     164123-10-8 164123-11-9 164123-12-0
ΙT
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (peptides for neutralizing the toxicity of lipid A of endotoxins)
     164123-10-8 HCAPLUS
RN
     Cyclo(L-cysteinyl-L-lysyl-L-phenylalanyl-L-lysyl-L-cysteinyl-L-lysyl-L-
CN
     phenylalanyl-L-lysyl-L-phenylalanyl-L-lysyl), cyclic (1\rightarrow 5)-
     disulfide (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
     164123-11-9 HCAPLUS
RN
     Cyclo(L-cysteinyl-L-lysyl-L-leucyl-L-lysyl-L-cysteinyl-L-lysyl-L-leucyl-L-
     lysyl-L-leucyl-L-lysyl), cyclic (1→5)-disulfide (9CI) (CA INDEX
     NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN
     164123-12-0 HCAPLUS
     Cyclo(L-arginyl-L-arginyl-L-cysteinyl-L-arginyl-L-threonyl-L-arginyl-L-
CN
     {\tt cysteinyl-L-arginyl-L-phenylalanyl-L-lysyl), cyclic (3 \rightarrow 7)-disulfide}
     (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
=> d his full
     (FILE 'HOME' ENTERED AT 13:10:47 ON 12 MAR 2007)
     FILE 'REGISTRY' ENTERED AT 13:11:19 ON 12 MAR 2007
     FILE 'LREGISTRY' ENTERED AT 13:13:27 ON 12 MAR 2007
              0 SEA ABB=ON PLU=ON [G'SAR']A[G'SAR']('HYP'P]['HYP'P]YN/SQSFP
Ll
     FILE 'REGISTRY' ENTERED AT 13:15:31 ON 12 MAR 2007
             42 SEA ABB=ON PLU=ON [G'SAR'] A [G'SAR'] ['HYP'P] ['HYP'P] YN/SQSFP
L2
     FILE 'HCAPLUS' ENTERED AT 13:17:13 ON 12 MAR 2007
             36 SEA ABB=ON PLU=ON L2
L3
             14 SEA ABB=ON PLU=ON L3 AND (AY<2001 OR PY<2001 OR PRY<2001)
L4
     FILE 'REGISTRY' ENTERED AT 13:18:16 ON 12 MAR 2007
              O SEA ABB=ON PLU=ON L2 AND MEDLINE/LC
```

L5

L6 0 SEA ABB=ON PLU=ON L2 AND EMBASE/LC L7 0 SEA ABB=ON PLU=ON L2 AND BIOSIS/LC L8 0 SEA ABB=ON PLU=ON L2 AND CAOLD/LC

FILE 'STNGUIDE' ENTERED AT 13:18:53 ON 12 MAR 2007

FILE 'HCAPLUS' ENTERED AT 13:19:30 ON 12 MAR 2007 E US2004-772774/APPS

L9 2 SEA ABB=ON PLU=ON US2004-772774/AP
D SCAN
SEL RN L9

FILE 'REGISTRY' ENTERED AT 13:20:34 ON 12 MAR 2007

107 SEA ABB=ON PLU=ON (159503-65-8/BI OR 355151-11-0/BI OR L10 355151-12-1/BI OR 355151-13-2/BI OR 355151-14-3/BI OR 355151-15 -4/BI OR 355151-16-5/BI OR 355151-17-6/BI OR 355151-18-7/BI OR 355151-19-8/BI OR 355151-20-1/BI OR 355151-23-4/BI OR 355151-25 -6/BI OR 355151-26-7/BI OR 355151-27-8/BI OR 355151-29-0/BI OR 355151-30-3/BI OR 355151-31-4/BI OR 355151-32-5/BI OR 355151-33 -6/BI OR 355151-34-7/BI OR 355151-35-8/BI OR 355151-36-9/BI OR 355151-37-0/BI OR 355151-38-1/BI OR 355151-39-2/BI OR 355151-40 -5/BI OR 355151-41-6/BI OR 355151-43-8/BI OR 355151-45-0/BI OR 355151-46-1/BI OR 355151-47-2/BI OR 355151-49-4/BI OR 355151-50 -7/BI OR 355151-51-8/BI OR 355151-52-9/BI OR 355151-53-0/BI OR 355151-54-1/BI OR 355151-55-2/BI OR 355151-56-3/BI OR 355151-74 -5/BI OR 81771-37-1/BI OR 111915-92-5/BI OR 133294-37-8/BI OR 212570-15-5/BI OR 355151-21-2/BI OR 355151-22-3/BI OR 355151-24 -5/BI OR 355151-28-9/BI OR 355151-42-7/BI OR 355151-44-9/BI OR 355151-48-3/BI OR 355151-57-4/BI OR 355151-58-5/BI OR 355151-59 -6/BI OR 355151-60-9/BI OR 355151-61-0/BI OR 355151-62-1/BI OR 355151-63-2/BI OR 355151-64-3/BI OR 355151-65-4/BI OR 355151-66 -5/BI OR 355151-67-6/BI OR 355151-68-7/BI OR 355151-69-8/BI OR 355151-70-1/BI OR 355151-71-2/BI OR 355151-72-3/BI OR 355151-73 -4/BI OR 355151-75-6/BI OR 355151-76-7/BI OR 35919-99-4/BI OR 366800-53-5/BI OR 463362-31-4/BI OR 463362-32-5/BI OR 463362-33 -6/BI OR 463362-34-7/BI OR 463362-35-8/BI OR 463362-36-9/BI OR 463362-37-0/BI OR 463362-38-1/BI OR 463362-40-5/BI OR 463362-42 -7/BI OR 463362-43-8/BI OR 463362-44-9/BI OR 463362-45-0/BI OR 463362-46-1/BI OR 463362-47-2/BI OR 463362-48-3/BI OR 463362-49 -4/BI OR 463362-50-7/BI OR 463362-51-8/BI OR 463362-52-9/BI OR 463362-53-0/BI OR 463362-54-1/BI OR 463362-55-2/BI OR 463362-56 -3/BI OR 463362-57-4/BI OR 463362-58-5/BI OR 463362-59-6/BI OR 463944-96-9/BI OR 476-70-0/BI OR 50-99-7/BI OR 501-36-0/BI OR 57381-26-7/BI OR 602-07-3/BI OR 7782-44-7/BI)

FILE 'STNGUIDE' ENTERED AT 13:21:01 ON 12 MAR 2007

FILE 'HCAPLUS' ENTERED AT 13:22:00 ON 12 MAR 2007

5 SEA ABB=ON PLU=ON L10 AND L2

E LARSEN B/AU

L11

L12

L13

177 SEA ABB=ON PLU=ON ("LARSEN B"/AU OR "LARSEN B DUE"/AU OR "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR "LARSEN BJARNE DUE"/AU)

E PETERSEN J/AU

L*** DEL 0 S E3, E29, E122, E127, E129, E169, E175-E177.

262 SEA ABB=ON PLU=ON ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN JORGEN SOEBERG"/AU)

L14	118	E MEIER E/AU SEA ABB=ON PLU=ON ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M
		M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR "MEIER EDDI"/AU OR "MEIER EDDIE"/AU) E KJOLBYE A/AU
L15		SEA ABB=ON PLU=ON "KJOLBYE ANNE LOUISE"/AU E JORGENSEN N/AU
L16	31	SEA ABB=ON PLU=ON ("JORGENSEN N"/AU OR "JORGENSEN N R"/AU OR "JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU OR "JORGENSEN NIKLAS RYE"/AU) E NIELSEN M/AU
L17		SEA ABB=ON PLU=ON ("NIELSEN'M"/AU OR "NIELSEN M S"/AU OR "NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR "NIELSEN MORTEN S"/AU OR "NIELSEN MORTEN SCHAK"/AU) E MARTINS J/AU
L18		SEA ABB=ON PLU=ON ("MARTINS J"/AU OR "MARTINS J B"/AU OR "MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS JAMES B"/AU) E HOLSTEIN R/AU
L19		SEA ABB=ON PLU=ON ("HOLSTEIN R"/AU OR "HOLSTEIN RATHLOU N H"/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN RATHLOU NIELS H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)
L20		SEA ABB=ON PLU=ON L12 AND L13 AND L14 AND L15 AND L16 AND L17 AND L18 AND L19
L21		SEA ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19)
L22		SEA ABB=ON PLU=ON L13 AND (L14 OR L15 OR L16 OR L17 OR L18 OR L19)
L23	4	SEA ABB=ON PLU=ON L14 AND (L15 OR L16 OR L17 OR L18 OR L19)
L24		SEA ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR L19)
L25		SEA ABB=ON PLU=ON L16 AND (L17 OR L18 OR L19)
L26		SEA ABB=ON PLU=ON L17 AND (L18 OR L19)
L27	2	SEA ABB=ON PLU=ON L18 AND L19
L28		SEA ABB=ON PLU=ON (L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L27)
L29	4	SEA ABB=ON PLU=ON L28 AND (AY<2001 OR PY<2001 OR PRY<2001)
	FILE 'HCAP'	LUS, MEDLINE, EMBASE, BIOSIS, DRUGU, WPIX' ENTERED AT 13:29:40
L30	2579	SEA ABB=ON PLU=ON LARSEN B?/AU
L31		SEA ABB=ON PLU=ON PETERSEN J?/AU
L32	1629	SEA ABB=ON PLU=ON MEIER E?/AU
L33	42	SEA ABB=ON PLU=ON KJOLBYE A?/AU
L34		SEA ABB=ON PLU=ON JORGENSEN N?/AU
L35		SEA ABB=ON PLU=ON NIELSEN M?/AU
L36		SEA ABB=ON PLU=ON MARTINS J?/AU
L37		SEA ABB=ON PLU=ON HOLSTEIN R?/AU
L38		SEA ABB=ON PLU=ON L30 AND L31 AND L32 AND L33 AND L34 AND
	_	L35 AND L36 AND L37
L39	0	SEA ABB=ON PLU=ON (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
L40	2	SEA ABB=ON PLU=ON (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
.	-	L36 OR L37) AND (ANTIARRYTHMIC?) SEA ABB=ON PLU=ON (L38 OR L40)
L41		
L42		L36 OR L37) AND (PEPTIDE?)
L43	1	SEA ABB=ON PLU=ON L42 AND (ARRYTHM?)
L44	4	SEA ABB=ON PLU=ON (L43 OR L41)

FILE 'STNGUIDE' ENTERED AT 13:33:02 ON 12 MAR 2007 FILE 'REGISTRY' ENTERED AT 13:34:05 ON 12 MAR 2007 STRUCTURE UPLOADED L45 STRUCTURE UPLOADED L46 O SEA SSS SAM L46 L47 0 SEA SSS FUL L46 L48 FILE 'STNGUIDE' ENTERED AT 13:35:38 ON 12 MAR 2007 FILE 'BEILSTEIN' ENTERED AT 13:35:43 ON 12 MAR 2007 0 SEA SSS FUL L46 L49 FILE 'MARPAT' ENTERED AT 13:35:57 ON 12 MAR 2007 FILE 'STNGUIDE' ENTERED AT 13:36:04 ON 12 MAR 2007 FILE 'REGISTRY' ENTERED AT 13:38:12 ON 12 MAR 2007 FILE 'STNGUIDE' ENTERED AT 14:02:36 ON 12 MAR 2007 FILE 'REGISTRY' ENTERED AT 14:03:19 ON 12 MAR 2007 D QUE L46 D QUE L45 STRUCTURE UPLOADED L50 D QUE L50 FILE 'STNGUIDE' ENTERED AT 14:04:58 ON 12 MAR 2007 FILE 'REGISTRY' ENTERED AT 14:12:47 ON 12 MAR 2007 STRUCTURE UPLOADED L51 STRUCTURE UPLOADED L52 50 SEA SSS SAM L52 L53 D QUE L52 L54 2075 SEA SSS FUL L52 SAVE L54 TELLER/A TEMP O SEA ABB=ON PLU=ON L54 AND L10 L55 FILE 'HCAPLUS' ENTERED AT 14:16:01 ON 12 MAR 2007 1861 SEA ABB=ON PLU=ON L54 L56 FILE 'STNGUIDE' ENTERED AT 14:16:08 ON 12 MAR 2007 FILE 'REGISTRY' ENTERED AT 14:22:05 ON 12 MAR 2007 STRUCTURE UPLOADED L57 O SEA SUB=L54 SSS SAM L57 L58 4 SEA SUB=L54 SSS FUL L57 L59 FILE 'HCAPLUS' ENTERED AT 14:23:05 ON 12 MAR 2007 2 SEA ABB=ON PLU=ON L59 L60 D BIB D BIB 2 FILE 'REGISTRY' ENTERED AT 14:23:30 ON 12 MAR 2007 O SEA ABB=ON PLU=ON L59 AND MEDLINE/LC L61 O SEA ABB=ON PLU=ON L59 AND EMBASE/LC L62 O SEA ABB=ON PLU=ON L59 AND BIOSIS/LC L63 0 SEA ABB=ON PLU=ON L59 AND CAOLD/LC L64 528 SEA ABB=ON PLU=ON L54 AND (ALA OR ALANIN? OR GLY OR GLYCINE L65 OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DOAMINOBUT?

OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)

	FILE	'HCAPI	US' ENTERED AT 14:25:47 ON 12 MAR 2007	
L66		300	SEA ABB=ON PLU=ON L65	
L***	DEL 5	98742	S L10	
			D SCAN L9	OD.
L67		56	SEA ABB=ON PLU=ON L65 (L) (THU OR PKT OR BAC OR PAC	OR
			DMA)/RL	
		_	D KWIC SEA ABB=ON PLU=ON L66 AND (?ARRYTHM? OR ?THROMB? OR	OSTROPORO
L68		T	SIS? OR CANCER?)	OBIECTORO
L69		56	SEA ABB=ON PLU=ON (L67 OR L68)	
L70			SEA ABB=ON PLU=ON L69 AND (AY<2001 OR PY<2001 OR PR	Y<2001)
L71		48	SEA ABB=ON PLU=ON L69 AND (AY<2000 OR PY<2000 OR PR	Y<2000)
		38	SEA ABB=ON PLU=ON L70 AND (ALA OR ALANIN? OR GLY OR	GLYCINE
			OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DOA	MINOBUT?
			OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN	OR
			GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)	
			D KWIC	
L73		38	SEA ABB=ON PLU=ON L70 AND (ALA OR ALANIN? OR GLY OR	GLYCINE
			OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIA	
			OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN	OR
		2.0	GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE) SEA ABB=ON PLU=ON (L68 OR L72 OR L73)	
		38	SEA ABB=ON PLU=ON L74 NOT (L29 OR L4 OR L9)	
L75		30	SER RESON FEBRUARY HOT (SES ON ET ON ES,	
	FILE	BETTS	STEIN' ENTERED AT 14:32:13 ON 12 MAR 2007	
L76			SEA SSS FUL L57	
	FILE	'MARP	AT' ENTERED AT 14:32:29 ON 12 MAR 2007	•
			STRY' ENTERED AT 14:33:37 ON 12 MAR 2007	
L77			SEA ABBEON PLUEON L65 AND L10	
L78		0	SEA ABB=ON PLU=ON L10 AND SQL/CI	
	элга	STNG	JIDE' ENTERED AT 14:36:57 ON 12 MAR 2007	
	FILE		STRY' ENTERED AT 14:38:24 ON 12 MAR 2007	
L79			SEA ABB=ON PLU=ON L10 AND SQL	
L80			SEA ABB=ON PLU=ON L10 AND SQL?	
L81			SEA ABB=ON PLU=ON L10 AND SQL<10	
L82		23	SEA ABB=ON PLU=ON L10 NOT L81	
			D SCAN L82	
L83			SEA ABB=ON PLU=ON L10 NOT 02/MF SEA ABB=ON PLU=ON L83 NOT C14H12O3	
L84			SEA ABB=ON PLU=ON L83 NOT C14H12O3 SEA ABB=ON PLU=ON L83 NOT C14H12O3/MF	
L85 L86			SEA ABBEON PLUEON L85 NOT C19H21NO4/MF	
L87			SEA ABB=ON PLU=ON L86 NOT C9H7C12N5/MF	
L88			SEA ABB=ON PLU=ON L87 NOT C20H19NO6	
L89		-	SEA ABB=ON PLU=ON L88 NOT C6H12O6/MF	
	FILE		LUS' ENTERED AT 14:43:59 ON 12 MAR 2007	
L90			SEA ABB=ON PLU=ON L89	0.00
L91		66	SEA ABB=ON PLU=ON L89 (L) (THU OR BAC OR PAC OR DMA	OK
			PKT)/RL SEA ABB=ON PLU=ON L91 AND (AY<2001 OR PY<2001 OR PR	V-2001)
L92		26		.1 ~ 2 0 0 1 /
L93		20	D QUE L73 SEA ABB=ON PLU=ON L91 AND (ALA OR ALANIN? OR GLY OR	GLYCINE
נפת		20	OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIA	MINOBUT?
			ON 010 01 010111110, 011 1111 011 11111111	

OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)

L94 35 SEA ABB=ON PLU=ON (L92 OR L93)

L95 33 SEA ABB=ON PLU=ON L94 NOT (L4 OR L29)

L96 14 SEA ABB=ON PLU=ON (L9 OR L4)

FILE 'STNGUIDE' ENTERED AT 14:46:29 ON 12 MAR 2007

D OUE L29

D QUE L44

D QUE L4

D QUE L60

FILE 'HCAPLUS, WPIX' ENTERED AT 14:46:57 ON 12 MAR 2007

L97 18 DUP REM L29 L44 L4 L60 (6 DUPLICATES REMOVED)

ANSWERS '1-18' FROM FILE HCAPLUS

D QUE L29

D QUE L41

D QUE L29

D QUE L44

D QUE L95

L98 37 DUP REM L29 L44 L95 (4 DUPLICATES REMOVED)

ANSWERS '1-37' FROM FILE HCAPLUS

D IBIB ABS HITIND HITSTR RETABLE L98 TOT

D QUE L4

D IBIB ABS HITIND HITSTR RETABLE L4 TOT

D QUE L60

D IBIB ABS HITIND HITSTR RETABLE L60 TOT

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2007 HIGHEST RN 926007-42-3 DICTIONARY FILE UPDATES: 11 MAR 2007 HIGHEST RN 926007-42-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE LREGISTRY

LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE HCAPLUS

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Mar 2007 VOL 146 ISS 12 FILE LAST UPDATED: 11 Mar 2007 (20070311/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 9, 2007 (20070309/UP).

FILE MEDLINE

FILE LAST UPDATED: 10 Mar 2007 (20070310/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE

FILE COVERS 1974 TO 12 Mar 2007 (20070312/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENTFROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 7 March 2007 (20070307/ED)

FILE DRUGU

FILE LAST UPDATED: 9 MAR 2007 <20070309/UP>

>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <><

>>> THESAURUS AVAILABLE IN /CT <<<

FILE WPIX

FILE LAST UPDATED:

5 MAR 2007 <20070305/UP>

MOST RECENT THOMSON SCIENTIFIC UPDATE: 200716 <200716/DWSDERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

- >>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<
- >>> New display format FRAGHITSTR available <<< SEE ONLINE NEWS and

http://www.stn-international.de/archive/stn online news/fraghitstr ex.pdf

>>> IPC Reform reclassification data for the backfile is being
loaded into the database during January 2007.
There will not be any update date (UP) written for the reclassified
documents, but they can be identified by 20060101/UPIC. <<<</pre>

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.de/training center/patents/stn guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://scientific.thomson.com/support/patents/coverage/latestupdates/

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

http://www.stn-international.de/stndatabases/details/ipc reform.html and
http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX PLEASE SEE

http://www.stn-international.de/stndatabases/details/dwpi r.html <<<

FILE BEILSTEIN
FILE LAST UPDATED ON JANUARY 10, 2007

FILE COVERS 1771 TO 2006.

FILE CONTAINS 9,780,003 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

- * PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.
- * SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE
- * ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE
- * ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.
- * FOR PRICE INFORMATION SEE HELP COST

* FOR PRICE INFORMATION SEE RELF COST

* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.

* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

FILE MARPAT

FILE CONTENT: 1961-PRESENT VOL 146 ISS 11 (20070309/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES (COVERAGE TO THESE DATES IS NOT COMPLETE):

US 2007020715 25 JAN 2007
DE 102005032918 18 JAN 2007
EP 1743897 17 JAN 2007
JP 2007016265 25 JAN 2007
WO 2007012422 01 FEB 2007
GB 2427406 27 DEC 2006
FR 2888248 12 JAN 2007
RU 2291880 20 JAN 2007
CA 2551930 08 JAN 2007

Expanded G-group definition display now available.

chain nodes : 31 32 33 34 35 36 37 38 39 40 ring nodes : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 41 chain bonds : 2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35 ring bonds : 1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28 27-30 28-29 29-30 exact/norm bonds : 1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38 18-19 19-20 20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 21:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:Atom

Uploading 12.str

1

chain nodes :

31 32 33 34 35 36 37 38

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

24 25 26 27 28 29 30 41

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-

13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24

25-26 26-28

27-30 28-29 29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11

11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38

18-19 19-20

20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35

29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

20:Atom 21:Atom

22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom

31:CLASS 32:CLASS

33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

41:Atom

chain nodes :

31 32 33 34 35 36 37 38 39 40

ring nodes :

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-24

13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24

25-26 26-28

27-30 28-29 29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38

18-19 19-20

20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

20:Atom 21:Atom

22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom

31:CLASS 32:CLASS

33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

41:Atom

chain nodes :

31 32 33 34 35 36 37 38 39 40

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 41

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-

 $13 - 14 \quad 14 - 15 \quad 14 - 41 \quad 15 - 16 \quad 16 - 17 \quad 17 - 18 \quad 18 - 19 \quad 19 - 20 \quad 20 - 21 \quad 21 - 22 \quad 22 - 27 \quad 23 - 24$

25-26 26-28


27-30 28-29 29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38 18-19 19-20 20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 21:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS 33:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:Atom



chain nodes :

31 32 33 34 35 36 37 38 39 40

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-

14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28 27-30 28-29

29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20 20-21 20-37

21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom

22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS

chain nodes : 31 32 33 34 35 36 37 38 39 ring nodes : 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 2 3 4 5 6 7 8 9 24 25 26 27 28 29 chain bonds : 2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35 ring bonds : 1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28 27-30 28-29 29-30 exact/norm bonds : 1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20 20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS 33:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

Uploading 152.str

chain nodes :

31 32 33 34 35 36 37 38 39 40

ring nodes :

24 25 26 27 28 29 30

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-

14

14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28

27-30 28-29

29-30

exact/norm bonds :

 $1-2 \quad 1-23 \quad 2-3 \quad 2-31 \quad 3-4 \quad 4-5 \quad 5-6 \quad 5-32 \quad 6-7 \quad 7-8 \quad 8-9 \quad 8-33 \quad 9-10 \quad 10-11 \quad 11-25$

11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20

20-21 20-37

21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom


11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

20:Atom 21:Atom

22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom

31:CLASS 32:CLASS

33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS



chain nodes :

31 32 33 34 35 36 37 38 39 40

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-14

14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28 27-30 28-29

29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20 20-21 20-37

21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS

33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

chain nodes :

31 32 33 34 35 36 37 38 39 40

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 41

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-24

13-14 14-15 15-16 15-41 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24

25-26 26-28

27-30 28-29 29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 15-16 15-41 16-17 17-18 17-38 18-19 19-20

20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

=> d que 129

- 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
- 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS
- 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:Atom

******BELOW ARE INVENTOR RESULTS ALONG WITH INVENTOR REGISTRY NUMBERS LIMITED BY THERAPEUTIC USE*****

L12	-	SEA FILE=HCAPLUS ABB=ON PLU=ON ("LARSEN B"/AU OR "LARSEN B DUE"/AU OR "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR
L13	262	"LARSEN BJARNE DUE"/AU) SEA FILE=HCAPLUS ABB=ON PLU=ON ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR "PETERSEN JOERGEN"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN"/AU OR
		"PETERSEN JORGEN S"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN JORGEN SOEBERG"/AU)
L14	118	SEA FILE=HCAPLUS ABB=ON PLU=ON ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR
		"MEIER EDDI"/AU OR "MEIER EDDIE"/AU)
L15	7	SEA FILE=HCAPLUS ABB=ON PLU=ON "KJOLBYE ANNE LOUISE"/AU
L16	31	SEA FILE=HCAPLUS ABB=ON 'PLU=ON ("JORGENSEN N"/AU OR "JORGENSE
		N N R"/AU OR "JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU
		OR "JORGENSEN NIKLAS RYE"/AU)
L17	495	SEA FILE=HCAPLUS ABB=ON PLU=ON ("NIELSEN M"/AU OR "NIELSEN M
		S"/AU OR "NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR
		"NIELSEN MORTEN S"/AU OR "NIELSEN MORTEN SCHAK"/AU)
L18	138	SEA FILE=HCAPLUS ABB=ON PLU=ON ("MARTINS J"/AU OR "MARTINS J
		B"/AU OR "MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS
		JAMES B"/AU)
L19	76	SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLSTEIN R"/AU OR "HOLSTEIN
		RATHLOU N H"/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN
		RATHLOU NIELS H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)
L20	2	SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND L13 AND L14 AND L15
		AND L16 AND L17 AND L18 AND L19
L21	13	SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15 OR
		L16 OR L17 OR L18 OR L19)
L22	15	SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L14 OR L15 OR L16 OR
		L17 OR L18 OR L19)
L23	4	SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND (L15 OR L16 OR L17 OR
T 0.4	-	L18 OR L19)
L24	5	SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR L19)
L25	2	SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND (L17 OR L18 OR L19)
L26		SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L18 OR L19)
112 V	3	DER 11DE-MONTEDO RED-ON 110-ON E17 RAD (E10 ON E17)

```
2 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND L19
L27
L28
            21 SEA FILE=HCAPLUS ABB=ON PLU=ON (L20 OR L21 OR L22 OR L23 OR
                L24 OR L25 OR L26 OR L27)
L29
              4 SEA FILE=HCAPLUS ABB=ON PLU=ON L28 AND (AY<2001 OR PY<2001
                OR PRY<2001)
=> d que 144
L30
           2579 SEA LARSEN B?/AU
           5774 SEA PETERSEN J?/AU
L31
           1629 SEA MEIER E?/AU
L32
             42 SEA KJOLBYE A?/AU
L33
L34
            977 SEA JORGENSEN N?/AU
           5171 SEA NIELSEN M?/AU
L35
           2182 SEA MARTINS J?/AU
L36
L37
            595 SEA HOLSTEIN R?/AU
L38
              2 SEA L30 AND L31 AND L32 AND L33 AND L34 AND L35 AND L36 AND
              2 SEA (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37) AND
L40
                (ANTIARRYTHMIC?)
              4 SEA (L38 OR L40)
L41
            856 SEA (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37) AND
L42
                (PEPTIDE?)
L43
              1 SEA L42 AND (ARRYTHM?)
              4 SEA (L43 OR L41)
L44
=> d que 195
             42 SEA FILE=REGISTRY ABB=ON PLU=ON [G'SAR'] A [G'SAR'] ['HYP'P] ['HY
L2
                P'P]YN/SQSFP
             36 SEA FILE=HCAPLUS ABB=ON PLU=ON L2
L3
             14 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND (AY<2001 OR PY<2001 OR
L4
                PRY<2001)
            107 SEA FILE=REGISTRY ABB=ON PLU=ON (159503-65-8/BI OR 355151-11-
L10
                0/BI OR 355151-12-1/BI OR 355151-13-2/BI OR 355151-14-3/BI OR
                355151-15-4/BI OR 355151-16-5/BI OR 355151-17-6/BI OR 355151-18
                -7/BI OR 355151-19-8/BI OR 355151-20-1/BI OR 355151-23-4/BI OR
                355151-25-6/BI OR 355151-26-7/BI OR 355151-27-8/BI OR 355151-29
                -0/BI OR 355151-30-3/BI OR 355151-31-4/BI OR 355151-32-5/BI OR
                355151-33-6/BI OR 355151-34-7/BI OR 3.55151-35-8/BI OR 3.55151-36
                -9/BI OR 355151-37-0/BI OR 355151-38-1/BI OR 355151-39-2/BI OR
                355151-40-5/BI OR 355151-41-6/BI OR 355151-43-8/BI OR 355151-45
                -0/BI OR 355151-46-1/BI OR 355151-47-2/BI OR 355151-49-4/BI OR
                355151-50-7/BI OR 355151-51-8/BI OR 355151-52-9/BI OR 355151-53
                -0/BI OR 355151-54-1/BI OR 355151-55-2/BI OR 355151-56-3/BI OR
                355151-74-5/BI OR 81771-37-1/BI OR 111915-92-5/BI OR 133294-37-
                8/BI OR 212570-15-5/BI OR 355151-21-2/BI OR 355151-22-3/BI OR
                355151-24-5/BI OR 355151-28-9/BI OR 355151-42-7/BI OR 355151-44
                -9/BI OR 355151-48-3/BI OR 355151-57-4/BI OR 355151-58-5/BI OR
                355151-59-6/BI OR 355151-60-9/BI OR 355151-61-0/BI OR 355151-62
                -1/BI OR 355151-63-2/BI OR 355151-64-3/BI OR 355151-65-4/BI OR
                355151-66-5/BI OR 355151-67-6/BI OR 355151-68-7/BI OR 355151-69
                -8/BI OR 355151-70-1/BI OR 355151-71-2/BI OR 355151-72-3/BI OR
                355151-73-4/BI OR 355151-75-6/BI OR 355151-76-7/BI OR 35919-99-
                4/BI OR 366800-53-5/BI OR 463362-31-4/BI OR 463362-32-5/BI OR
                463362-33-6/BI OR 463362-34-7/BI OR 463362-35-8/BI OR 463362-36
                -9/BI OR 463362-37-0/BI OR 463362-38-1/BI OR 463362-40-5/BI OR
                463362-42-7/BI OR 463362-43-8/BI OR 463362-44-9/BI OR 463362-45
                -0/BI OR 463362-46-1/BI OR 463362-47-2/BI OR 463362-48-3/BI OR
                463362-49-4/BI OR 463362-50-7/BI OR 463362-51-8/BI OR 463362-52
```

		-9/BI OR 463362-53-0/BI OR 463362-54-1/BI OR 463362-55-2/BI OR 463362-56-3/BI OR 463362-57-4/BI OR 463362-58-5/BI OR 463362-59 -6/BI OR 463944-96-9/BI OR 476-70-0/BI OR 50-99-7/BI OR 501-36-0/BI OR 57381-26-7/BI OR 602-07-3/BI OR 7782-44-7/BI)
L12	177	SEA FILE=HCAPLUS ABB=ON PLU=ON ("LARSEN B"/AU OR "LARSEN B DUE"/AU OR "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR "LARSEN BJARNE DUE"/AU)
L13		SEA FILE=HCAPLUS ABB=ON PLU=ON ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR "PETERSEN JOERGEN"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN S"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN JORGEN SOBERG"/AU)
L14		SEA FILE=HCAPLUS ABB=ON PLU=ON ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR "MEIER EDDI"/AU OR "MEIER EDDIE"/AU)
L15		SEA FILE=HCAPLUS ABB=ON PLU=ON "KJOLBYE ANNE LOUISE"/AU
L16	31	SEA FILE=HCAPLUS ABB=ON PLU=ON ("JORGENSEN N"/AU OR "JORGENSE
		N N R"/AU OR "JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU OR "JORGENSEN NIKLAS RYE"/AU)
L17		SEA FILE=HCAPLUS ABB=ON PLU=ON ("NIELSEN M"/AU OR "NIELSEN M S"/AU OR "NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR "NIELSEN MORTEN SCHAK"/AU)
L18		SEA FILE=HCAPLUS ABB=ON PLU=ON ("MARTINS J"/AU OR "MARTINS J B"/AU OR "MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS JAMES B"/AU)
L19		SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLSTEIN R"/AU OR "HOLSTEIN RATHLOU N H "/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)
L20		SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND L13 AND L14 AND L15 AND L16 AND L17 AND L18 AND L19
L21		SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19)
L22		SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L14 OR L15 OR L16 OR L17 OR L18 OR L19)
L23		SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND (L15 OR L16 OR L17 OR L18 OR L19) SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR
L24		L19) SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND (L17 OR L18 OR L19)
L25		
L26		SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L18 OR L19)
L27		SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND L19
L28	21	SEA FILE=HCAPLUS ABB=ON PLU=ON (L20 OR L21 OR L22 OR L23 OR
		L24 OR L25 OR L26 OR L27)
L29		SEA FILE=HCAPLUS ABB=ON PLU=ON L28 AND (AY<2001 OR PY<2001 OR PRY<2001) SEA FILE=REGISTRY ABB=ON PLU=ON L10 NOT O2/MF
L83		SEA FILE=REGISTRY ABB=ON PLU=ON L83 NOT C14H12O3/MF
L85		•
L86		
L87		
L88		
L89 L91		SEA FILE=REGISTRY ABB=ON PLU=ON L88 NOT C6H12O6/MF SEA FILE=HCAPLUS ABB=ON PLU=ON L89 (L) (THU OR BAC OR PAC OR DMA OR PKT)/RL
L92	26	SEA FILE=HCAPLUS ABB=ON PLU=ON L91 AND (AY<2001 OR PY<2001 OR PRY<2001)
L93	20	SEA FILE=HCAPLUS ABB=ON PLU=ON L91 AND (ALA OR ALANIN? OR GLY OR GLYCINE OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT? OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)

L94 35 SEA FILE=HCAPLUS ABB=ON PLU=ON (L92 OR L93) L95 33 SEA FILE=HCAPLUS ABB=ON PLU=ON L94 NOT (L4 OR L29)

=> dup rem 129,144,195
PROCESSING COMPLETED FOR L29
PROCESSING COMPLETED FOR L44
PROCESSING COMPLETED FOR L45

PROCESSING COMPLETED FOR L95

L98 37 DUP REM L29 L44 L95 (4 DUPLICATES REMOVED)
ANSWERS '1-37' FROM FILE HCAPLUS

=> d ibib abs hitind hitstr retable 198 tot

L98 ANSWER 1 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1

ACCESSION NUMBER:

2002:754415 HCAPLUS Full-text

DOCUMENT NUMBER:

137:263304

TITLE:

Synthesis of peptides and medical uses of

intracellular communication facilitating compounds

INVENTOR(S):

Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier, Eddie; Kjolbye, Anne Louise; Jorgensen, Niklas Rye;

Nielsen, Morten Schak; Holstein-Rathlou, Niels-Henrik; Martins, James B.

PATENT ASSIGNEE(S):

Zealand Pharmaceuticals A/S, Den.

SOURCE:

PCT Int. Appl., 233 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PAT	CENT 1	NO.			KIN)	DATE		i	APPL	ICAT:	ION I	. 01		D	ATE	
,						-											
WO	2002	0770	17		A2		2002	1003	1	WO 2	002-1	US57	73		20	0020	222
WO	2002	0770	17		A 3		2003	1009									
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ĒS,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,
		UA,	UG,	US,	UΖ,	VN,	YU,	ZA,	ZM,	zw							
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	ΚZ,	MD,	RU,	TJ,	TM,	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,
		GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,
		GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG							
WO	2001	0627	75		A2		2001	0830	1	WO 2	001-1	DK12	7		20	0010	222 <
WO	2001	0627	75		A 3		2002	0131									
	W:	ΑE,	AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CR,	CU,
		CZ,	DE,	DK,	DM,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,
		IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,
		MD,	MG,	MK,	MN,	MW,	MX,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,
		SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VN,	YU,	ZA,	ZW	
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,
	,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG		
US	2003	0926	09		A1		2003	0515	1	US 2	001-	7922	86		2	0010	222 <
CA	2439	101			A1		2002	1003		CA 2	002-	2439	101		2	0020	222
EP	1370	276			A2		2003	1217		EP 2	002-	7232	40		2	0020	222
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR						

```
JP 2002-576275
    JP 2005506295
                        Т
                              20050303
                                                               20020222
                                         BR 2002-7476
    BR 2002007476
                        Α
                              20060124
                                                               20020222
                                         NO 2003-3641
                                                               20030815
    NO 2003003641
                        Α
                              20031020
                                         US 2003-646294
                                                               20030822 <--
    US 2005113293
                        A1
                              20050526
                              20050527
                                         IN 2003-DN1336
                                                               20030822
    IN 2003DN01336
                        Α
                                                               20040204 <--
    US 2005075280
                        A1
                              20050407
                                         US 2004-772774
                                                            A 20010222
PRIORITY APPLN. INFO.:
                                         US 2001-792286
                                         WO 2001-DK127
                                                            A 20010222
                                                          P 20010823
                                         .US 2001-314470P
                                         DK 2000-288
                                                            A 20000223 <--
                                         DK 2000-738
                                                            A 20000504 <--
                                         US 2000-251659P
                                                           P 20001206 <--
                                                           W 20020222
                                          WO 2002-US5773
```

OTHER SOURCE(S): MARPAT 137:263304

AB The invention relates to novel peptides, including novel antiarrhythmic peptides of linear or cyclic structure, having improved stability in vitro and/or in vivo, to compns. comprising these peptides, and to uses of the peptides for the preparation of medicaments. The invention also relates to the use of compds. that facilitate the intercellular communication for the preparation of medicaments for the treatment of a range of diseases characterized in impaired intercellular gap junctional communication. invention further relates to a method of treating diseases, such as bladder incontinence, disorders of alveolar tissue and bronchial tissue, impaired hearing due to diseases of the cochlea, endothelial lesions, diabetic retinopathy and diabetic neuropathy, ischemia of the central nervous system and spinal cord, dental tissue disorders including periodontal disease, kidney diseases leading to hypertension, and a method of preventing failures of bone marrow transplantation. Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D-Ala-Gly-NH2 (Hyp = hydroxyprolyl) was prepared by the solid-phase method and assayed for biol. activity. Graphs include those for relative cell-to-cell conductance, PIturnover in neonatal rat cardiomyocytes, and ventricular APD90 dispersion.

IC ICM C07K007-00

CC 34-3 (Amino Acids, Peptides, and Proteins) Section cross-reference(s): 1, 6, 63

L98 ANSWER 2 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2

ACCESSION NUMBER:

2001:636085 HCAPLUS Full-text

DOCUMENT NUMBER:

135:180957

TITLE:

Preparation of novel antiarrhythmic peptides

INVENTOR(S):

Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier, Eddi; Kjolbye, Anne

Louise; Jorgensen, Niklas Rye;

Nielsen, Morten Schak; Holstein-Rathlou,

Niels-Henrik; Martins, James B. Zealand Pharmaceuticals A/S, Den.

PATENT ASSIGNEE(S):

PCT Int. Appl., 189 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: LANGUAGE: Patent English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	E APPLICATIO	N NO.	DATE
WO 2001062775		10830 WO 2001-DK	127	20010222 <
WO 2001062775 W: AE, AL,		20131 , BA, BB, BG, BR, B	Y, CA, CH, C	N, CR, CU,
CZ, DE,	DK, DM, EE, ES,	, FI, GB, GD, GE, G	H, GM, HR, H	U, ID, IL,
· ·		, KR, KZ, LC, LK, L . NO. NZ. PL. PT. R	· · · · · · · · · · · · · · · · · · ·	

```
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                20010830
                                            CA 2001-2385659
    CA 2385659
                          A1
                                                                    20010222 <--
                                            EP 2001-907393
    EP 1226160
                          A2
                                20020731
                                                                    20010222 <--
    EP 1226160
                          В1
                                20041215
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    JP 2003528826
                          Т
                                20030930
                                            JP 2001-562556
                                                                    20010222 <--
    AT 284896
                          Т
                                20050115
                                            AT 2001-907393
                                                                    20010222 <--
    ES 2228807
                          Т3
                                20050416
                                            ES 2001-1907393
                                                                    20010222 <--
                          Т
                                20050429
                                            PT 2001-907393
    PT 1226160
                                                                    20010222 <--
    AU 781674
                          B2
                                20050602
                                            AU 2001-35362
                                                                    20010222 <--
    CA 2439101
                          A1
                                20021003
                                            CA 2002-2439101
                                                                    20020222
                          A2
                                20021003
                                            WO 2002-US5773
                                                                    20020222
    WO 2002077017
    WO 2002077017
                          A3
                                20031009
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
             GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                20031217
                                            EP 2002-723240
    EP 1370276
                          A2
                                                                    20020222
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    JP 2005506295
                                20050303
                                            JP 2002-576275
                                                                    20020222
                          Т
                                            BR 2002-7476
                                                                    20020222
    BR 2002007476
                          Α
                                20060124
                                20031020
                                            NO 2003-3641
                                                                    20030815
    NO 2003003641
                          Α
                                20050526
                                            US 2003-646294
                                                                    20030822 <--
    US 2005113293
                          A1
                          A1
                                20050407
                                            US 2004-772774
                                                                    20040204 <--
    US 2005075280
    AU 2005205785
                          A1
                                20050929
                                            AU 2005-205785
                                                                    20050902 <--
                                            DK 2000-288
                                                                 A 20000223 <--
PRIORITY APPLN. INFO.:
                                            DK 2000-738
                                                                 A 20000504 <--
                                                                 Ρ
                                            US 2000-251659P
                                                                    20001206 <--
                                            US 2001-792286
                                                                 A 20010222
                                            WO 2001-DK127
                                                                 W
                                                                    20010222
                                            US 2001-314470P
                                                                 Р
                                                                    20010823
                                            WO 2002-US5773
                                                                 W
                                                                    20020222
```

OTHER SOURCE(S): MARPAT 135:180957

AΒ Peptides X-A-B-Y and cyclo(X-A-B-Y) [A and B represents chemical moieties having an amino group (radical) and a carboxy group; X represents a peptide sequence of 1 to 3 D- or L-amino acid residues or an N-terminal modification of the group A-B when Y represents a C-terminal peptide sequence of 2 to 5 Dor L-amino acid residues; X represents a peptide sequence of 2 to 5 D- or Lamino acid residues when Y represents a C-terminal peptide sequence of 1 to 3 D- or L-amino acid residues; for the linear peptide, X is optionally chemical modified at its N-terminal and has an optional linking group comprising 0-8 backbone atoms] and their mirror image or a retro analogs or pharmaceutically acceptable derivs. were prepared for treating cardiac arrhythmias. Thus, Ac-D-Tyr-D-pro-D-4Hyp-Gly- D-Ala-Gly-NH2 (4Hyp = 4-hydroxyprolyl) was prepared by the solid-phase method using TentaGel-S-Ram and examined for biol. activity [assays included effect on gap junction intercellular communication (GJIC) in cardiomyocytes, binding to tissue prepns. of murine heart, and effect on cAMP formation in CHO cells].

ICM C07K007-00 IC

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63

L98 ANSWER 3 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2006:100738 HCAPLUS Full-text

DOCUMENT NUMBER:

144:198849

TITLE:

Novel dosage form comprising modified-release and

immediate-release active ingredients

INVENTOR(S):

Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil;

Gupta, Vinod Kumar

PATENT ASSIGNEE(S):

India

SOURCE:

U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S.

Ser. No. 630,446.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006024365	A1	20060202	US 2005-134633		20050519
IN 193042	A1	20040626	IN 2002-MU697		20020805
IN 2003MU00080	Α	20050204	IN 2003-MU80		20030122
IN 2003MU00082	A	20050204	IN 2003-MU82		20030122
US 2004096499	A1	20040520	US 2003-630446		20030729
PRIORITY APPLN. INFO.:			IN 2002-MU697	Α	20020805
			IN 2002-MU699	Α	20020805
	•		IN 2003-MU80	A	20030122
			IN 2003-MU82	Α	20030122
			US 2003-630446	A2	20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

INCL 424468000

CC 63-6 (Pharmaceuticals)

50-04-4, Cortisone acetate 50-02-2, Dexamethasone 50-06-6, IT Phenobarbital, biological studies 50-12-4, Mephenytoin 50-13-5, Meperidine hydrochloride 50-18-0, Cyclophosphamide 50-19-1, Hydroxyphenamate 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-28-2, Estra-1,3,5(10)-triene-3,17-diol (17 β)-, 50-27-1, Estriol biological studies 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline bromide 50-35-1, Thalidomide 50-36-2, Cocaine 50-53-3, Chlorpromazine, biological studies 50-52-2, Thioridazine 50-55-5, Reserpine 50-56-6, Oxytocin, biological studies 50-58-8, Phendimetrazine tartrate 50-59-9, Cephaloridine Lypressin 50-65-7, Niclosamide 50-76-0, Dactinomycin 50-78-2, Aspirin 51-05-8, Procaine hydrochloride 51-15-0, Pralidoxime Floxuridine chloride 51-21-8, Fluorouracil 51-30-9, Isoproterenol hydrochloride 51-40-1, Norepinephrine bitartrate 51-43-4, Epinephrine 51-55-8, Atropine, biological studies Propylthiouracil 51-56-9, 51-57-0, Methamphetamine hydrochloride Homatropine hydrobromide 51-83-2, Carbachol 52-01-7, Spironolactone 51-64-9, Dextroamphetamine 52-24-4, Thiotepa 52-49-3, Trihexyphenidyl hydrochloride 52-68-6, 52-76-6, Lynestrenol 52-86-8, Haloperidol 52-88-0,

52-89-1, Cysteine hydrochloride Methylatropine nitrate 53-03-2, Prednisone 53-16-7D, Estrone, esters 53-19-0, Mitotane 53-34-9, Fluprednisolone 53-39-4, Oxandrolone 53-43-0, Dehydroepiandrosterone 53-60-1, Promazine hydrochloride 53-73-6, Angiotensin amide 53-79-2, Puromycin 53-84-9, Nadide 53-86-1, 54-03-5, Hexobendine 54-05-7, Chloroquine 54-21-7, Indometacin Sodium salicylate 54-31-9, Furosemide 54-35-3, Penicillingprocaine 54-36-4, Metyrapone 54-42-2, Idoxuridine 54-64-8, Thimerosal 54-84-2, Cinanserin hydrochloride 54-85-3, Isoniazid 54-91-1, 55-03-8, Levothyroxine sodium 55-06-1, Liothyronine sodium Pipobroman 55-63-0, Nitroglycerin 55-86-7, Mechlorethamine hydrochloride 55-98-1, Busulfan 56-45-1, Serine, biological studies Isoflurophate 56-47-3, Desoxycorticosterone acetate 56-53-1, Diethylstilbestrol 56-75-7, Chloramphenicol 56-84-8, 56-59-7, Felypressin Aspartic acid, biological studies 56-87-1, Lysine, 56-89-3, Cystine, biological studies 56-94-0, biological studies 57-13-6, Urea, biological studies 57-41-0, Demecarium bromide Phenytoin 57-47-6, Physostigmine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-65-8, Thyromedan hydrochloride 57-66-9, 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological Probenecid 57-91-0, $17-\alpha$ Estradiol 57-94-3, Tubocurarine chloride studies 57-96-5, Sulfinpyrazone 58-08-2, Caffeine, biological studies 58-18-4, Methyltestosterone 58-22-0, Testosterone Pyrimethamine 58-25-3, Chlordiazepoxide 58-28-6, Desipramine hydrochloride Dipyridamole 58-33-3, Promethazine hydrochloride 58-38-8, 58-39-9, Perphenazine 58-54-8, Ethacrynic acid Prochlorperazine 58-55-9, Theophylline, biological studies 58-71-9, Cephalothin sodium 58-86-6, Xylose, biological studies 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-33-6, Pyrilamine maleate 59-52-9, Dimercaprol 59-87-0, 59-63-2, Isocarboxazid 59-67-6, Niacin, biological studies Nitrofurazone 59-92-7, Levodopa, biological studies 59-97-2, Tolazoline hydrochloride 60-13-9, Amphetamine sulfate 60-18-4, 60-23-1, Cysteamine Tyrosine, biological studies 60-29-7, Ether, 60-45-7, Fenimide 60-54-8, Tetracycline biological studies 60-80-0, Antipyrine 60-99-1, Methotrimeprazine Methimazole Papaverine hydrochloride 61-56-3, Sulthiame 61-57-4, Niridazole 61-68-7, Mefenamic acid 61-73-4, Methylene blue 61-75-6, Bretylium tosylate 61-76-7, Phenylephrine hydrochloride 61-90-5, Leucine, 62-51-1, Methacholine chloride 62-68-0, Proadifen biological studies 62-73-7, Dichlorvos 62-90-8, Nandrolone phenpropionate hydrochloride 63-12-7, Benzquinamide 63-05-8, Androstenedione 63-39-8, Uridine triphosphate 63-45-6, Primaquine phosphate 63-68-3, Methionine, 63-89-8, Colfosceril palmitate biological studies Phenylalanine, biological studies 63-92-3, Phenoxybenzamine 63-98-9, Phenacemide 64-31-3, Morphine sulfate hydrochloride 64-43-7, Amobarbital sodium 64-55-1, Mebutamate 64-77-7, Tolbutamide 64-86-8, Colchicine 65-28-1, Phentolamine mesylate 65-29-2, Gallamine 65-45-2, Salicylamide 66-75-1, Uracil mustard 66-76-2, triethiodide 66-81-9, Cycloheximide 67-20-9, Nitrofurantoin 67-43-6, Dicumarol Pentetic acid 67-45-8, Furazolidone 67-63-0, Isopropyl alcohol, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 67-73-2, Fluocinolone acetonide 67-92-5, Dicyclomine hydrochloride 67-95-8, Quingestrone 67-96-9, Dihydrotachysterol 68-22-4, 68-23-5, Norethynodrel 68-35-9, Sulfadiazine Norethindrone 68-89-3, Dipyrone 68-91-7, Trimethaphan camsylate Cycloserine 68-96-2, 17 Hydroxy progesterone 69-44-3, Amodiaquine hydrochloride 69-53-4, Ampicillin 69-57-8, Penicillingsodium 69-65-8, Mannitol 69-72-7, Salicylic acid, biological studies 69-74-9, Cytarabine hydrochloride 70-00-8, Trifluridine 70-10-0, Ticlatone

71-00-1, Histidine, biological studies Hexachlorophene 71-27-2, 71-58-9, Medroxyprogesterone acetate Succinylcholine chloride 71-63-6, 71-68-1, Hydromorphone hydrochloride 71-73-8, Thiopental Digitoxin 71-81-8, Isopropamide iodide 72-18-4, Valine, biological sodium 72-19-5, Threonine, biological studies 72-33-3, Mestranol studies 72-44-6, Methaqualone 73-09-6, Etozolin 73-22-3, Tryptophan, biological studies 73-31-4, Melatonin 73-32-5, Isoleucine, biological 73-48-3, Bendroflumethiazide 74-79-3, Arginine, biological studies 75-00-3, Ethyl chloride 75-19-4, Cyclopropane 76-38-0, studies 76-42-6, Oxycodone 76-43-7, Fluoxymesterone Methoxyflurane 76-57-3, Codeine 76-73-3, Secobarbital 76-74-4, Pentobarbital 76-90-4, Mepenzolate bromide 77-21-4, Glutethimide 77-26-9, Butalbital 77-36-1, Chlorthalidone 77-41-8, Methsuximide 77-27-0, Thiamylal 77-67-8, Ethosuximide 77-86-1, Trometamol 77-46-3, Acedapsone 78-11-5, Pentaerythritol tetranitrate 78-44-4, Carisoprodol 79-09-4. Propionic acid, biological studies 79-17-4, Pimagedine 79-57-2, Oxytetracycline 79-64-1, Dimethisterone 80-08-0, Dapsone 80-50-2, Anisotropine methylbromide 81-04-9, 1,5-Naphthalenedisulfonic acid 81-13-0, Dexpanthenol 81-23-2, Dehydrocholic acid 81-54-9, Purpurin 82-92-8, Cyclizine 83-43-2, Methylprednisolone 83-73-8, Iodoquinol 83-74-9, Ibogaine 84-17-3, Dienestrol RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (novel dosage form comprising modified-release and immediate-release active ingredients) 55268-75-2, Cefuroxime 55294-15-0, Muzolimine 55298-68-5, Neomycin palmitate 55453-87-7, Isoxepac 55560-96-8, Tixocortol pivalate 55694-87-6, Pentizidone sodium 55695-56-2, Cloroperone hydrochloride 55774-33-9, Azathioprine sodium 55721-11-4, Secalciferol 55779-18-5, 55837-29-1, Tiropramide 55837-27-9, Piretanide 55870-64-9, Pentisomicin 55881-07-7, Miokamycin 55905-53-8, Clebopride 55981-09-4, Nitazoxanide 56030-54-7, Sufentanil 56049-88-8, Indacrinone 56079-80-2, Ropitoin hydrochloride 56093-45-9, Selenium 56119-96-1, Furodazole 56187-89-4, Ximoprofen 56208-01-6, Pifarnine 56211-40-6, Torasemide 56219-57-9, Arildone 56281-36-8, Motretinide 56290-94-9, Medroxalol 56383-05-2, Zindotrine 56391-55-0, Octazamide 56391-57-2, Netilmicin sulfate 56420-45-2, 56430-99-0, Flumecinol 56470-64-5, Anordrin 56605-16-4D, Epirubicin Spiromustine, di-Ph derivs. 56611-65-5, Oxagrelate 56689-42-0, Repromicin 56689-44-2, Nitramisole hydrochloride 56717-18-1, Isotiquimide 56741-95-8, Bropirimine 56784-39-5, Ozolinone 56796-20-4, Cefmetazole 56917-29-4, Fluretofen 56980-93-9, Celiprolol 56995-20-1, Flupirtine 57010-32-9, Tiapamil hydrochloride 57041-67-5, 57067-46-6, Isamoxole 57109-90-7, Clorazepate dipotassium Naftopidil 57166-13-9, Napactadine hydrochloride Desflurane 57149-07-2, Naftopidil 57248-88-1, Pamidronate disodium 57262-94-9, Setiptiline 57285-09-3, Folliculostatin 57381-26-7, Irsogladine 57432-61-8, Methylergonovine maleate 57441-90-4, Nivimedone sodium 57540-79-1, Nisbuterol mesylate 57645-05-3, Sermetacin 57653-26-6, Fenobam 57666-60-1, Nitrafudam hydrochloride 57726-65-5, Nufenoxole 57773-63-4, Triptorelin 57773-65-6, Deslorelin 57775-22-1, Etoperidone 57781-15-4, Halopredone 57801-81-7, Brotizolam hydrochloride 57808-65-8, Closantel 57982-78-2, Budipine 57998-68-2, Diaziquone 58019-50-4, Menabitan hydrochloride 58019-65-1, Nabazenil Miltefosine 58152-03-7, Isepamicin 58167-78-5, Tandamine hydrochloride 58239-89-7, Moxazocine 58261-91-9, Mefenidil 58473-74-8, Cinromide 58493-49-5, Olvanil 58497-00-0, Procinonide 58503-79-0, Meobentine 58524-83-7, Ciprocinonide 58525-82-9, Azatyrosine 58712-69-9, Traxanox 58795-03-2, Apalcillin 58581-89-8, Azelastine sodium 58934-46-6, Lorcainide hydrochloride 58944-73-3, Sinefungin

58970-76-6, Ubenimex

IT

58957-92-9, Idarubicin

59017-64-0, Ioxaglic acid

59018-13-2, Ioxaglate meglumine 59070-06-3, Ticarcillin cresyl sodium 59122-46-2, Misoprostol 59160-29-1, Lidofenin 59170-23-9, Bevantolol 59179-95-2, Lorzafone 59227-89-3, Laurocapram 59263-76-2, Meptazinol hydrochloride 59333-90-3, Exaprolol hydrochloride 59467-96-8, Midazolam hydrochloride 59497-39-1, Naflocort 59653-73-5, Teroxirone 59703-84-3, Piperacillin sodium 59729-33-8, Citalopram 59733-86-7, 59756-39-7, Enolicam sodium 59794-18-2, Paulomycin Butikacin 59803-98-4, Brimonidine 59804-37-4, Tenoxicam 59831-63-9, Doconazole 59831-64-0, Milenperone 59831-65-1, Halopemide 59917-39-4, Vindesine 59937-28-9, Malotilate 59954-01-7, Pamatolol sulfate 60019-19-4, Iotetric acid 60050-95-5, Sulfoxamine 60084-10-8, Tiazofurin 60086-22-8, Clopipazan mesylate 60135-22-0, Flumoxonide 60142-96-3, Gabapentin 60166-93-0, Iopamidol 60200-06-8, Clorsulon 60207-31-0, Azaconazole 60209-20-3, Lycetamine 60282-87-3, Gestodene 60325-46-4, Sulprostone 60398-23-4, Iodoamiloride 60400-92-2, Proxicromil 60525-15-7, Zimelidine hydrochloride 60560-33-0, Pinacidil 60569-19-9, Propiverine 60607-34-3, Oxatomide 60607-35-4, Topterone 60628-96-8, Bifonazole 60653-25-0, Orpanoxin 60719-84-8, Amrinone 60719-85-9, Ciprefadol succinate 60762-57-4, Pirlindole 60857-08-1, Prostratin 60925-61-3, Ceforanide 60940-34-3, Ebselen 60976-05-8 61036-62-2, Teicoplanin 61177-45-5, Clavulanate potassium 61220-69-7, Tiopinac 61260-05-7, Prenalterol hydrochloride 61263-35-2, Meteneprost 61270-78-8, Cefonicid sodium 61318-91-0, Sulconazole nitrate 61325-80-2, Flumezapine 61379-65-5, Rifapentine 61380-27-6, Carfentanil citrate 61380-41-4, Lofentanil oxalate 61413-54-5, Rolipram 61444-62-0, Nifluridide 61477-94-9, Pirmenol hydrochloride 61481-30-9, Dicranin 61484-39-7, Pareptide sulfate 61489-71-2, Menotropin 61570-90-9, Tioxidazole 61622-34-2, Cefotiam 61825-94-3, Oxaliplatin 61849-14-7, Epoprostenol sodium 61869-08-7, Paroxetine 62013-04-1, Dirithromycin 62087-72-3, Pentigetide 62134-34-3, Butoprozine hydrochloride 62220-58-0, Bipenamol hydrochloride 62265-68-3, Quinfamide 62304-98-7, Thymalfasin 62435-42-1, Perfosfamide 62488-57-7 62571-86-2, Captopril 62571-87-3, Minaxolone 62587-73-9, Cefsulodin 62613-82-5, Oxiracetam 62625-19-8, Pirogliride tartrate 62658-63-3, Bopindolol 62666-20-0, Progabide 62732-44-9, Ipidacrine 62816-98-2, Ormaplatin 62851-43-8, Zidometacin 62893-20-3, Cefoperazone sodium 62928-11-4, Iproplatin 62929-91-3, Procaterol hydrochloride 62973-76-6, Azanidazole 62973-77-7, Parconazole hydrochloride 62989-33-7, Sapropterin 62996-74-1, 63119-27-7, Anitrazafen 63198-97-0, Viroxime 63204-23-9, Oxmetidine hydrochloride 63245-28-3, Etifenin 63251-39-8, Sulfinalol hydrochloride 63269-31-8, Ciramadol 63358-49-6, Aspoxicillin 63534-64-5, Iosulamide meglumine 63585-09-1, Foscarnet sodium 63590-19-2, Balanol 63590-64-7, Terazosin 63612-50-0, Nilutamide 63659-18-7, Betaxolol 63659-19-8, Betaxolol hydrochloride 63675-72-9, Nisoldipine 63774-77-6, Somatomedin B 63941-73-1, Ioglucol 63941-74-2, Ioglucomide 63950-06-1, Esorubicin hydrochloride 64019-93-8, Dipivefrin hydrochloride 64059-66-1, Cetaben sodium 64063-83-8, Picotrin diolamine 64092-48-4, Zomepirac sodium 64211-45-6, Oxiconazole 64221-86-9, Imipenem 64228-81-5, Atracurium besylate 64318-79-2, Gemeprost 64379-93-7, Cinflumide 64420-40-2, Etibendazole 64461-82-1, Tizanidine hydrochloride 64485-93-4, Cefotaxime sodium 64706-54-3, Bepridil 64808-48-6, Lobenzarit sodium 64872-77-1, Butoconazole nitrate 64924-67-0, Halofuginone hydrobromide 64953-12-4, Moxalactam disodium 65009-35-0, Lidamidine hydrochloride 65043-22-3, Indeloxazine hydrochloride 65052-63-3, Cefetamet 65057-90-1, Talisomycin 65093-40-5, Cytarabine ocfosfate 65141-46-0, 65222-35-7, Pazelliptine 65271-80-9, Mitoxantrone Nicorandil 65277-42-1, Ketoconazole 65322-72-7, Endralazine mesylate 65454-13-9, Lateritin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (novel dosage form comprising modified-release and immediate-release active ingredients)

IT 57381-26-7, Irsogladine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (novel dosage form comprising modified-release and immediate-release active ingredients)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 4 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2004:1036916 HCAPLUS Full-text

DOCUMENT NUMBER:

INVENTOR(S):

142:33307

TITLE:

Stable analogs of peptide and polypeptide therapeutics Bachovchin, William W.; Lai, Hung-Sen; Sanford, David

Coorge

PATENT ASSIGNEE(S):

Trustees of Tufts College, USA

SOURCE:

PCT Int. Appl., 83 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE			
WO 2004103390 WO 2004103390			WO 2004-US15488	20040517			
			n. nn na nn nu	D. D. G. G.			
•			BA, BB, BG, BR, BW,				
CN, CC	, CR, CU, (CZ, DE, DK,	DM, DZ, EC, EE, EG,	ES, FI, GB, GD,			
GE, GH	, GM, HR, 1	HU, ID, IL,	IN, IS, JP, KE, KG,	KP, KR, KZ, LC,			
LK, LR	, LS, LT,	LU, LV, MA,	MD, MG, MK, MN, MW,	MX, MZ, NA, NI,			
NO. NZ	OM. PG.	PH. PL. PT.	RO, RU, SC, SD, SE,	SG. SK. SL. SY.			
·			UG, US, UZ, VC, VN,				
· ·			NA, SD, SL, SZ, TZ,				
· ·							
		4	TM, AT, BE, BG, CH,				
EE, ES	, FI, FR, (GB, GR, HU,	IE, IT, LU, MC, NL,	PL, PT, RO, SE,			
SI, SK	, TR, BF, 1	BJ, CF, CG,	CI, CM, GA, GN, GQ,	GW, ML, MR, NE,			
SN, TD	, TG						
AU 2004240630	A1	20041202	AU 2004-240630	20040517			
	A1		CA 2004-2525574	20040517			
US 2005049177	Α1	20050303	US 2004-847220	20040517			
	A2		EP 2004-752496				
			GB, GR, IT, LI, LU,	NL, SE, MC, PI,			
IE, SI	, FI, RO, (CZ, EE, HU, PL, SK				
CN 1822851	A	20060823	CN 2004-80019850	20040517			
PRIORITY APPLN. INF	၁. :		US 2003-471411P	P 20030515			
			WO 2004-US15488	W 20040517			

- The present invention relates to compns. of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof. The peptide and polypeptide analogs are resistant to cleavage by proteinases, i.e., a serine proteinase, metalloproteinase, aspartic proteinase, or cysteine e proteinase. For example, two substitutions at the P'1 glutamic acid of GLP1-(7-37) were made to obtain GLP-1 (3DMA), wherein the P'1 substitution was 3-dimethylaspartate, and GLP-1-(BM), wherein the P'1 substitution was 3-butylmethylglycine. Both GLP-1 (3DMA) and GLP-1-(BM) displayed robust resistance to degradation by the serine protease dipeptidyl peptidase IV (DPP IV) and retained biol. activities of native glucagon-like peptide 1 (GLP-1). They both retained the ability to bind to GLP-1 receptors of COS-7 cells, as well as to potentiate GLP-1 signaling via the GLP-1 receptor to an extent indistinguishable from native GLP-1.
- IC ICM A61K038-00
- CC 2-10 (Mammalian Hormones)
 Section cross-reference(s): 1, 63
- 50-56-6D, Oxytocin, analogs 58-82-2D, Bradykinin, analogs IT α -Melanotropin (swine), analogs 1393-25-5D, Secretin, analogs 1405-97-6D, Gramicidin, analogs 2002-44-0D, analogs Ornipressin, analogs 9002-60-2D, Adrenocorticotropic hormone, analogs 9002-72-6D, Growth hormone, analogs 9002-76-0D, Gastrin, analogs 9002-79-3D, Melanocyte stimulating hormone, analogs 9004-10-8D, Insulin, 9007-12-9D, Calcitonin, analogs 9007-92-5D, Glucagon, analogs 9014-42-0D, Thrombopoietin, analogs 9011-97-6D, Cholecystokinin, analogs 9015-71-8D, Corticotropin-releasing factor, analogs 9034-39-3D, Growth hormone releasing factor, analogs 9034-40-6D, Gonadotropin-releasing 9034-50-8D, Vasotocin, analogs 9041-90-1D. hormone, analogs Angiotensin I, analogs 11000-17-2D, Vasopressin, analogs 11002-13-4D, 11096-26-7D, Erythropoietin, analogs Angiotensinogen, analogs 11128-99-7D, Angiotensin II, analogs 24305-27-9D, Thyrotropin-releasing 33507-63-0D, Substance P, analogs 39379-15-2D, hormone, analogs 40077-57-4D, Vasoactive intestinal octacosapeptide Neurotensin, analogs (swine), analogs 51110-01-1D, Somatostatin, analogs 52232-67-4D, Human parathyroid hormone (1-34), analogs 52906-92-0D, Motilin, analogs 55123-66-5D, Leupeptin, analogs 58569-55-4D, Met-enkephalin, analogs 58822-25-6D, Leu-enkephalin, analogs 59392-49-3D, GIP, analogs 59763-91-6D, Pancreatic polypeptide, analogs 60118-07-2D, Endorphin, 61912-98-9D, Insulin-like growth factor, analogs Epidermal growth factor, analogs 64190-70-1D, FMRF-amide, analogs 67382-96-1D, Melanin-concentrating hormone, analogs 69431-45-4D, δ -Sleep inducing peptide, analogs 70904-56-2D, Kyotorphin, analogs 74913-18-1D, Dynorphin, analogs 80043-53-4D, Gastrin-releasing peptide, 80448-90-4D, Dynorphin A (swine), analogs 80802-79-5D, Cecropin, analogs 81608-30-2D, Neuromedin C, analogs 81771-37-1D , Antiarrhythmic peptide, analogs 82785-45-3D, Neuropeptide Y, analogs 83150-76-9D, Octreotide, analogs 83335-41-5D, Dynorphin B (swine), 83652-28-2D, Calcitonin gene-related peptide, analogs 85637-73-6D, Atriopeptin, analogs 86933-74-6D, Neurokinin A, analogs 86933-75-7D, Neurokinin B (swine spinal cord), analogs 87616-84-0D, Growth hormone-releasing peptide 6, analogs 88526-44-7D, Paracelsin, 89105-94-2, Fibrinogen-binding inhibitor peptide GLP 1, analogs 89750-15-2D, Glucagon-like peptide II, analogs 97793-28-7D, Atriopeptin III, analogs 98084-68-5D, Atriopeptin I, 98084-69-6D, Atriopeptin II, analogs analogs 98824-26-1D, Calcitonin 99566-27-5D, Neuropeptide FF (cattle), gene-related peptide II, analogs 102577-25-3D, Neuromedin N, analogs 103131-69-7D, Kinetensin 103220-14-0D, Corticostatin, analogs (human), analogs 103370-86-1D, Parathyroid hormone related peptide, analogs 106021-96-9D, analogs 106388-42-5D, Peptide YY, analogs 106441-70-7D, Neuropeptide K, analogs 111745-44-9D, Neuromedin U, analogs 114471-18-0D, Brain natriuretic

peptide, analogs 115150-59-9D, Antagonist G, analogs 116243-73-3D, Endothelin, analogs 119418-04-1D, Galanin, analogs 122752-15-2D, Deltorphin I, analogs 122752-16-3D, Deltorphin II, analogs 127830-04-0D, C-type natriuretic peptide, analogs 128245-93-2D, analogs 133249-66-8D, Elafin, analogs 137061-48-4D, Pituitary adenylate cyclase activating polypeptide, analogs 140896-21-5D, Indolicidin, analogs 141801-26-5D, Endomorphin-2, analogs 141636-44-4, GR 83074 151039-33-7D, PD-142893, analogs 151039-37-1D, PD-145065, analogs 154835-90-2D, Adrenomedullin, analogs 168317-35-9D, Guamerin, analogs 169494-85-3D, Leptin, analogs 170713-75-4D, Nociceptin, analogs 180201-29-0D, analogs 186901-48-4D, Cortistatin 14, analogs 188627-80-7D, Eptifibatide, analogs 189388-22-5D, Endomorphin-1, analogs 309247-07-2D, analogs 800379-40-2 800379-41-3D, analogs RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (proteinase-resistant analogs of peptide and polypeptide therapeutics) 37259-58-8, Serine proteinase 37353-41-6, 9002-04-4, Thrombin 54249-88-6, Dipeptidyl peptidase IV Cysteine proteinase 78169-47-8, Aspartic proteinase 81669-70-7 RL: BSU (Biological study, unclassified); BIOL (Biological study) (resistance to; proteinase-resistant analogs of peptide and polypeptide therapeutics) 81771-37-1D, Antiarrhythmic peptide, analogs

IT

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(proteinase-resistant analogs of peptide and polypeptide therapeutics)

81771-37-1 HCAPLUS RN

IT

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L98 ANSWER 5 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:394338 HCAPLUS Full-text

DOCUMENT NUMBER: 140:400107

Compositions and methods for modulating connexin TITLE:

hemichannels for treating diseases

Jensen, Peter Holme; Larsen, Bjarne Due; Hansen, Lars INVENTOR(S):

Bo Laurenborg; Petersen, Jorgen Soberg; Neve, Soren;

Nielsen, Morten Schak; Meier, Eddi; Steiness, Eva

PATENT ASSIGNEE(S): Zealand Pharma A/S, Den.

U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. SOURCE:

Provisional Ser. No. 352,717.

CODEN: USXXCO

DOCUMENT TYPE: Patent

English LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

APPLICATION NO. PATENT NO. KIND DATE DATE

				-	
US 2004092429	A1	20040513	US 2003-353549		20030129
US 7153822	B2	20061226			
CN 1638790	A	20050713	CN 2003-804968		20030129
US 2007042964	Al	20070222	US 2006-501402		20060809
PRIORITY APPLN. INFO.:			US 2002-352717P	P	20020129
			US 2003-353549	A3	20030129

Disclosed are compns. and methods for modulating hemichannel function in a cell, tissue or organ. The invention also relates to useful screens for detecting such compds., particularly those capable of modulating connexin phosphorylation. Further provided are therapeutic methods for preventing or treating conditions impacted by undesired hemichannel function in a mammal such as heart arrhythmia. Rats subjected to myocardial infarction but treated with Compound 1 (Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D- Ala-Gly-NH2) for three weeks, had an improved cardiac function with less congestion in the left ventricle as demonstrated by a reduced left ventricular end-diastolic pressure.

IC ICM A61K038-17

INCL 514002000

CC 1-12 (Pharmacology)

Section cross-reference(s): 9

IT 355151-12-1 355151-50-7

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(peptide compns. and methods for modulating connexin hemichannels for treating diseases)

IT 355151-12-1 355151-50-7

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peptide compns. and methods for modulating connexin hemichannels for treating diseases)

RN 355151-12-1 HCAPLUS

CN Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 355151-50-7 HCAPLUS

CN L-Tyrosinamide, N-acetylglycyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RETABLE					
Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
=======================================	+=====	+=====	+=====	+===============	+=======
Abdullah, K	1999	10	35	Endocrine	HCAPLUS
Actions	1997	356	76	Naunyn Schmiedebergs	
Adibi	1982	1		US 4340592 A	HCAPLUS
Alexandre Stewart	2001			Abstract from Americ	
Alford, A	2001	208	L680	Am J Physiol Lung Ce	
Anon				1	
Anon	1993			DE 4122885 A1	HCAPLUS
Anon	1993			WO 9314777	HCAPLUS
Anon	1994			CA 2156618	HCAPLUS
Anon	1994			DE 4314260 A1	HCAPLUS
Anon	1994		1	WO 9403468	HCAPLUS
Anon	1994	Ì		WO 9412181	HCAPLUS
Anon	1994	j	ĺ	WO 9414817	HCAPLUS
Anon	1994	j	ĺ	WO 9415908	HCAPLUS
Anon	1995	İ	j	WO 9513069	HCAPLUS
Anon	1996	İ	İ	WO 9619494	HCAPLUS
Anon	1996	Ì	İ	WO 9621674 A1	HCAPLUS
Anon .	1996		İ	WO 9630395	HCAPLUS
Anon	1996		İ	WO 9633209	HCAPLUS
Anon	1997	•		WO 9705889	HCAPLUS
Anon	1998	<u> </u>	<u>.</u>	WO 9810653	HCAPLUS
Anon	1998	İ	j	WO 9831359	HCAPLUS
Anon	1999	<u> </u>		DE 19816932 A1	HCAPLUS
Anon	1999	İ	j	WO 9911606	HCAPLUS
Anon	1999	Ϊ	İ	WO 9931049	HCAPLUS
Anon	2000	<u> </u>	İ	WO 0075286	HCAPLUS
Anon	2001	ĺ	İ	WO 0100610 A1	HCAPLUS
Anon	2001	1	i	WO 0162775	HCAPLUS
Anon	2001	1	i	WO 0190085 A1	HCAPLUS
Anon	2001	i	i	WO 0192236 A1	HCAPLUS
Anon	2002]	i	WO 02077017 A2	HCAPLUS
Anon ·	2002	<u> </u>	İ	WO 02077017 .	HCAPLUS
Anon	2002	İ		WO 02101007 A2	HCAPLUS
Anon	2004	Ì	İ	WO 2004028466 A2	HCAPLUS
Anon	2004	i	Ì	WO 2004048400 A1	HCAPLUS
Ashino, Y	2000	279	L5	Am J Physiol Lung Mo	!
Audia	2005	i		US 6888022 B1	HCAPLUS
Bailey	2001	i	i I	US 6291640 B1	HCAPLUS
Bascom	1996		!	US 5492894 A	HCAPLUS
Beardslee, M	2000	87	656	Circ. Res.	HCAPLUS
Bennett, M	1991	6	305	Neuron	HCAPLUS
Beny	1994	266	H1465	Physiol Heart Circ P	
Black	2000			US 6136787 A	
Blasits, S	2000	440	710	Phlugers Arch	HCAPLUS
	,	1		1	

Bolanos	1996	166	2019	J Neurochem	1
Bommarius	2001	00 	2019 	US 6251625 B1	 HCAPLUS
Brudnak	2001	ł	! !	US 20040005304 A1	HCAPLUS
Bruzzone, R	1996	1 238	1 1	Eur. J. Biochem.	HCAPLUS
Bruzzone, R	1997	9	1	J Eur Neurosci	MEDLINE
Bursell	1992	111	287	Curr Eye Res	MEDLINE
Buysse	2003	 	1207	US 20030092634 A1	MEDDINE
Cai	2001	33	! 957	J Mol Cell Cardiol	HCAPLUS
Campos De Carvalbo	1994	5	686	Journal of Cardiovas	Į.
Carmeliet, E	1999	79	917	Physiol Rev	HCAPLUS
Castro Pineiro	2003		1	US 20030114387 A1	c.
Charash, W	1993	148	467	Am Rev Respir Dis	MEDLINE
Chatterjee	2004			US 20040102609 A1	
Chen	1996	<u> </u>	i	US 5492920 A	HCAPLUS
Chen, X	1998	111	263	Chem Biol Interact	
Christ, G	1996	79	631	Circ Res.	HCAPLUS
Christ, G	2000	12	s15	Int J Import Res	
Colarusso	2004	i		US 20040142876 A1	İ
Collier	2003	ĺ	ĺ	US 20030202989 A1	
Colwell, C	2000	43	379	J Neurobiol	MEDLINE
Cook	1973			US 3740438 A	HCAPLUS
Cotrina, M	2000	20	2835	J Neurosci	HCAPLUS
Cotrina, M	1998	95	15735	Proc Natl Acad. Sci.	HCAPLUS
Cowsar	2003	İ	j	US 20030228353 A1	ĺ
Cunha-Vaz	1975	59	649	Br J Ophthalmol	MEDLINE
Dankwardt	2002	ĺ	ĺ	US 20020169133 A1	ĺ
Darrow, B	1995	76		Circulation Research	HCAPLUS
Demuth	2002	·		US 20020049164 A1	
Demuth	2003			US 20030135023 A1	
Demuth	2004		1	US 20040171555 A1	
	•	•	!		!
Do Carmo, A	1998	67	569	Exp Eye Res	HCAPLUS
Do Carmo, A Drauz	1996	67	569 	Exp Eye Res US 5534538 A	HCAPLUS
Drauz Drauz	1996 1996			Exp Eye Res US 5534538 A US 5543397 A	
Drauz Drauz Duerig, J	1996 1996 2000	67 111	569 416	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol	HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan	1996 1996 2000 2000	1111	 416 	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A	HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K	1996 1996 2000 2000 1995	 111 10	 416 589	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa	HCAPLUS HCAPLUS HCAPLUS MEDLINE
Drauz Drauz Duerig, J Duggan Endo, K Eugenin	1996 1996 2000 2000 1995 2001	1111	 416 	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc	HCAPLUS HCAPLUS HCAPLUS MEDLINE HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda	1996 1996 2000 2000 1995 2001 2000	 111 10 98	 416 589 4190	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A	HCAPLUS HCAPLUS HCAPLUS MEDLINE HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M	1996 1996 2000 2000 1995 2001 2000 2001	 111 10	 416 589	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences	HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant	1996 1996 2000 2000 1995 2001 2000 2001 1998	 111 10 98	 416 589 4190	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A	HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001	 111 10 98	 416 589 4190	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1	HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 2004	 111 10 98	 416 589 4190	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1	HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 2004 1993	 111 10 98	 416 589 4190	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A	HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon Griffith	1996 1996 2000 2000 1995 2001 2000 2001 1998 2004 1993 2003	 111 10 98	 416 589 4190	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1	HCAPLUS HCAPLUS MEDLINE HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon Griffith Grubb	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 2004 1993 2003 1991	 111 10 98 69	 416 589 4190 247 	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A	HCAPLUS HCAPLUS MEDLINE HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon Griffith Grubb Guerineau, N	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 2004 1993 2003 1991 1998	 111 10 98 69 273	 416 589 4190 247 	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem.	HCAPLUS HCAPLUS MEDLINE HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon Griffith Grubb Guerineau, N Guerrero	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 2004 1993 2003 1991 1998 1997	 111 10 98 69 69 273 99	 416 589 4190 247 10389 1991	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem. J Clin Invest	HCAPLUS HCAPLUS MEDLINE HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon Griffith Grubb Guerineau, N Guerrero Gupta, P	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 2004 1993 2003 1991 1998 1997 1998	 111 10 98 69 273	 416 589 4190 247 	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem. J Clin Invest Blood	HCAPLUS HCAPLUS MEDLINE HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon Griffith Grubb Guerineau, N Guerrero Gupta, P Haefliger	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 2004 1993 2003 1991 1998 1997	 111 10 98 69 69 273 99 91	 416 589 4190 247 10389 1991 3724 190	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem. J Clin Invest	HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon Griffith Grubb Guerineau, N Guerrero Gupta, P	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 2004 1993 2003 1991 1998 1997 1998 2001	 111 10 98 69 69 273 99 91 60	 416 589 4190 247 10389 1991 3724	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem. J Clin Invest Blood Kidney Int	HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon Griffith Grubb Guerineau, N Guerrero Gupta, P Haefliger Hagendorff, A	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 1993 1997 1998 2001 1999	 111 10 98 69 69 273 99 91 60	 416 589 4190 247 10389 1991 3724 190	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem. J Clin Invest Blood Kidney Int Circulation	HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon Griffith Grubb Guerineau, N Guerrero Gupta, P Haefliger Hagendorff, A Hans-Ulrich	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 1993 1997 1998 2001 1999 2001	 111 10 98 69 69 273 99 91 60 99	 416 589 4190 247 10389 1991 3724 190 1508	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem. J Clin Invest Blood Kidney Int Circulation US 20010020006 A1	HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon Griffith Grubb Guerineau, N Guerrero Gupta, P Haefliger Hagendorff, A Hans-Ulrich Hansson, L Hashitani, H Haslanger	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 1993 2003 1991 1998 2001 1999 2001 1999 2001 2000	 111 10 98 69 69 273 99 91 60 99 36	416 589 4190 247 10389 1991 3724 190 1508	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem. J Clin Invest Blood Kidney Int Circulation US 20010020006 A1 Nutrition and Cancer	HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon Griffith Grubb Guerineau, N Guerrero Gupta, P Haefliger Hagendorff, A Hans-Ulrich Hansson, L Hashitani, H Haslanger Henriques, J	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 1998 2003 1991 1998 2001 1999 2001 2000 2001	111 10 98 69 69 273 99 91 60 99 36 530 23	416 589 4190 247 247 10389 1991 3724 190 1508 122 273 1112	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem. J Clin Invest Blood Kidney Int Circulation US 20010020006 A1 Nutrition and Cancer J Physiol US 5061710 A Eur Heart J	HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gordon Griffith Grubb Guerineau, N Guerrero Gupta, P Haefliger Hagendorff, A Hans-Ulrich Hansson, L Hashitani, H Haslanger Henriques, J Iguchi, Y	1996 1996 2000 2000 1995 2001 2000 2001 1998 2003 1991 1998 1997 1998 2001 1999 2001 2000 2001 1991 2002 1984	 111 10 98 69 69 99 91 60 99 36 530	416 589 4190 247 247 10389 1991 3724 190 1508 122 273	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem. J Clin Invest Blood Kidney Int Circulation US 20010020006 A1 Nutrition and Cancer J Physiol US 5061710 A Eur Heart J Arch Oral Biol	HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gluckman Gordon Griffith Grubb Guerineau, N Guerrero Gupta, P Haefliger Hagendorff, A Hans-Ulrich Hansson, L Hashitani, H Haslanger Henriques, J Iguchi, Y Jarvinen	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 1998 1997 1998 2001 1999 2001 2000 2001 1991 2002 1984 2005	111 10 98 69 69 273 99 91 60 99 36 530 23	416 589 4190 247 247 10389 1991 3724 190 1508 122 273 1112	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem. J Clin Invest Blood Kidney Int Circulation US 20010020006 A1 Nutrition and Cancer J Physiol US 5061710 A Eur Heart J Arch Oral Biol US 20050059608 A1	HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gluckman Gordon Griffith Grubb Guerineau, N Guerrero Gupta, P Haefliger Hagendorff, A Hans-Ulrich Hansson, L Hashitani, H Haslanger Henriques, J Iguchi, Y Jarvinen Jensen	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 1998 1997 1998 2001 1999 2001 2000 2001 1991 2002 1984 2005 2004	111 10 98 69 69 273 99 91 60 99 36 530 23 29 	416 589 4190 247 10389 1991 3724 190 1508 122 273 1112 489	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem. J Clin Invest Blood Kidney Int Circulation US 20010020006 A1 Nutrition and Cancer J Physiol US 5061710 A Eur Heart J Arch Oral Biol US 20050059608 A1 US 20040092429 A1	HCAPLUS HCAPLUS
Drauz Drauz Duerig, J Duggan Endo, K Eugenin Fukuda Fukumoto, M Gallant Gluckman Gluckman Gluckman Gordon Griffith Grubb Guerineau, N Guerrero Gupta, P Haefliger Hagendorff, A Hans-Ulrich Hansson, L Hashitani, H Haslanger Henriques, J Iguchi, Y Jarvinen	1996 1996 2000 2000 1995 2001 2000 2001 1998 2001 1998 1997 1998 2001 1999 2001 2000 2001 1991 2002 1984 2005	111 10 98 69 69 273 99 91 60 99 36 530 23	416 589 4190 247 247 10389 1991 3724 190 1508 122 273 1112	Exp Eye Res US 5534538 A US 5543397 A Brit J Haematol US 6017925 A J Gastroenterol Hepa Proc. Natl. Acad. Sc US 6162828 A Life Sciences US 5798442 A US 6187906 B1 US 6780848 B1 US 5223486 A US 20030105165 A1 US 5037957 A J Biol Chem. J Clin Invest Blood Kidney Int Circulation US 20010020006 A1 Nutrition and Cancer J Physiol US 5061710 A Eur Heart J Arch Oral Biol US 20050059608 A1	HCAPLUS HCAPLUS

Vottnor	1987	ı	l	US 4636492 A	HCAPLUS
Kettner	!] 	 	!	
Kettner	1987	j 1	ļ 1	US 4652552 A	HCAPLUS
Kitaura	1987			US 4666890 A	HCAPLUS
Klaunig, J	1990	62	135	Lab Investigation	HCAPLUS
Knuetter	2004	21	61	European Journal of	ļ
Koenig, W			ļ	Succinimidbildung be	
Kohner, E	1995	44	603	Diabetes	HCAPLUS
Kondo	2000	32	1859	J. Mol. Cell. Cardio	HCAPLUS
Kotake	2001	ł		US 6255285 B1	HCAPLUS
Kuhner	2003			US 20030050247 A1	ļ
Kuhner	2003			US 20030194445 A1	HCAPLUS
Kumar, N	1996	84	381	Cell	HCAPLUS
Kurtz	1997			US 5643955 A	HCAPLUS
Kwak, B	2001	12	831	Molec Biol Cell	HCAPLUS
Kyung-Sun Kang	2001	166	147	Cancer Letters	
Lagostena, L	2001	531	693	J Physiol	HCAPLUS
Lampe	2000	384	205	Archives of Biochemi	HCAPLUS
Larsen	2002	Ì	Ì	US 6353023 B1	HCAPLUS
Larsen	2002	İ	j	US 6410585 B1	HCAPLUS
Larsen	2003		İ	US 20030092609 A1	İ
Larsen	2005	İ	<i>'</i>	US 20050075280 A1	İ
Larsen	2005	· ·	İ	US 20050113293 A1	İ
Leoni	2002	ļ	į	US 6342481 B1	HCAPLUS
Levy, D	1999	260	207	Neurosci Lett	HCAPLUS
Li, F	2001	33	2145	J. Mol. Cell. Cardio	1
Lin, R	2001	154	815	The Journal Of Cell	•
Lipsky	1991	1 + 5 1	1	US 5047401 A	HCAPLUS
Lipsky	1993	¦	! !	US 5206221 A	HCAPLUS
Low, P	1991	 40	l 873	Diabetes	HCAPLUS
Lynch, J	1981	3	49	J Cardiovasc. Pharma	!
Madar	2004	3	1 4 3	US 20040121964 A1	MEDLINE
	2004	! !] 	Abstract from Americ	
Masaya Tanno	!	 262	1127	<u> </u>	
Masuda, M	2001	1202	137	Anat Rec	HCAPLUS
Meier, E	2001	100	1017	International Gap Ju	
Melman, A	2001	28	217	Urol Clinic North Am	•
Mohammad Hossain	2000	!	<u> </u>	Science's Stke, Pers	:
Morriello	1996		1	US 5492916 A	HCAPLUS
Morriello	1996	!	 	US 5494919 A	HCAPLUS
Morriello	1997		 	US 5622973 A	HCAPLUS
Munoz	1999			US 5872101 A	HCAPLUS
Murakami, S	2001	203	367	Anat Embryol	HCAPLUS
Myers	1993			US 5252560 A	HCAPLUS
Nadya Lumelsky	2001	292	1389	Science	
Nagy, J	1996	7	745	Cell Growth Diff	HCAPLUS
Nargund	1999	!		US 5877182 A	HCAPLUS
Nicolson, G	1998	85	473	Proc. Natl Acad Sci	ļ
Oku, H	2001	142	1915	Invest Ophthalmol Vi	
Orlic	2001	410	701	Nature	HCAPLUS
Oviedo-Orta	2001	15	768	FASEB	HCAPLUS
Oviedo-Orta	2000	99	578	Immunology	HCAPLUS
Pavia	1995			US 5446023 A	HCAPLUS
Pavia	1997	1		US 5637564 A	HCAPLUS
Pavia	1997		1	US 5650393 A	HCAPLUS
Penney	1999			US 5980913 A	HCAPLUS
Peters	1998	97	1746	Circulation	MEDLINE
Peters, N	1993	88	864	Circulation	HCAPLUS
Petersen, J	1991	258	1	J Pharmacol. Esp. Th	HCAPLUS
Phipps	2005	İ	İ	US 20050020482 A1	İ
Pitre, D	2001	303	67	Neurosci Lett	HCAPLUS
Pitt	2004	İ		US 20040235752 A1	İ
				•	

Polacek, D	1997	34	19	J Vasc Res	HCAPLUS
Posposilik	2005	34	1 1 3	US 20050107308 A1	LUCAPTOR
Powers	1996	!	<u> </u>	US 5514694 A	HCAPLUS
Powers	1997		}	US 5610297 A	HCAPLUS
Powers	1997		† 1	US 5650508 A	HCAPLUS
	2001		1 1	US 6235929 B1	HCAPLUS
Powers	!	l I] 		LUCAPTOS
Powers	2004	1140	 1063	US 20040127427 A1	
Quist, A	2000	148	H1960	J. Cell Biol	HCAPLUS
Rehman, J	1997	272	HIAGO	AM J Physiol	HCAPLUS
Repolles Moliner Riniker	1995	. <u> </u> 	!	US 5432159 A	
	1975	1	1	US 3862113 A	HCAPLUS
Ritzeler	2002		ļ ·	US 6358978 B1	HCAPLUS
Rodriguez	2004			US 20040167106 A1	
Rosendaal, M	1991	23	457	Tissue Cell	MEDLINE
Saffitz, J	1999	42	309	Cardiovascular Resea	!
Sakagami, K	1999	521	637	J Physiol (Lond)	HCAPLUS
Saunders, M	2001	61	1765	Cancer Res	HCAPLUS
Sawa Kostin	2001			Abstract from Americ	,
Schuster, A	2001	280	H1088	Am J Physiol Heart C	!
Sharma	2004		[US 20040167201 A1	HCAPLUS
Shigeto Kanno	2001		!	Abstract from Americ	:
Shinohara, K	2000	286	107	Neurosci Lett.	HCAPLUS
Simon	1998		!	US 5811387 A	HCAPLUS
Simon, A	1998	8	295	Curr Biol	HCAPLUS
Stammler	2002	ļ	<u> </u>	US 6384272 B1	HCAPLUS
Stevens, R	1999	2777	C448	Am J Physiol	
Sundstrom	2004			US 20040106560 A1	1
Szeto	2004]		US 20040029796 A1	ļ
Taugner, R	1980	206	65	Cell Tissue Res	MEDLINE
Teetz	1989		ļ	US 4797471 A	HCAPLUS
Teilman, S	2001			International Gap Ju	
Thiele	1997			US 5602102 A	HCAPLUS
Todt, I	2001	181	107	J Membrane Biol	HCAPLUS
Tomoko Nao	2001			Abstract from Americ	
Torikata, C	1985	52	399	Lab Invest	HCAPLUS
Tung	1998			US 5849711 A	HCAPLUS
Turner, W	1997	75	77	Pharmacol Therap	HCAPLUS
Vitale, M	2001	64	625	Biol Reporo	HCAPLUS
Wang	2001	281	C75	Am J Physiol Cell Ph	HCAPLUS
Wang	2002	55	25	Cardiovasc Res	HCAPLUS
Wang	2001	6A	111	Urology	ĺ
Wang, Y	1995	270	26581	The Journal Of Biolo	HCAPLUS
Weisheng Bao	2001	Í	j	Abstract from Americ	İ
Wolburg, H	1995	157	315	Int Rev Cytol	HCAPLUS
Wright, A	1998	80	89	Pharmacol Ther	HCAPLUS
Yamanaka, I	1997	72	166	:	HCAPLUS
Yeh	1997	17	3174	Arterioscle Thromb V	
Yoshida, M	1998	72	192	Arch Toxicol	HCAPLUS
Zhou, Z	1	102	959	Neuroscience	HCAPLUS
		-	,	1	,

```
L98 ANSWER 6 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2003:155086 HCAPLUS Full-text
```

DOCUMENT NUMBER:

138:188077

TITLE: Preparation of novel peptide conjugates INVENTOR(S): Larsen, Bjarne Due; Petersen, Jorgen

Soberg; Kapusta, Daniel R.; Harlow, Kenneth W.

PATENT ASSIGNEE(S):

Zealand Pharmaceuticals A/S, Den.

SOURCE:

U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S.

Provisional Ser. No. 298,186.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
				- -	
US 2003040472	A1	20030227	US 2001-882291		20010615 <
US 2006052284	A1	20060309	US 2005-102564		20050408 <
PRIORITY APPLN. INFO.:			DK 2000-944	Α	20000616 <
			DK 2000-1485	Α	20001005 <
			US 2000-251671P	P	20001206 <
			US 2001-298186P	P	20010613
			US 2001-882291	A1	20010615

OTHER SOURCE(S): MARPAT 138:188077

Disclosed are peptide conjugates R1-Z-A1-A2-A3-A4-A5-A6-Z'-R2 (A1, A4, R6 = Arg, Lys, His; A2 = Tyr, Trp, Phe; A3 = Tyr, Asn, Trp, Phe; A5 = Phe, Tyr, Trp, Leu, Val, Ile, where each amino acid residue in the hexapeptide may be in the L or D form; Z, Z' each represent a charged peptide chain of 4 to 20 amino acid residues having the D or L configuration or is missing, provided that not both Z and Z' are missing; R1 = H, acyl group; R2 is an amino group or OH) which are optionally further linked to a transport moiety, as well as their salts, hydrates, solvates, and C-terminally amidated or esterified derivs. Also provided are antibodies that specifically bind the peptide conjugates. The invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides. Thus, Ac-Arg-Tyr-Tyr-Arg-Trp-Lys-Lys-Lys-Lys-Lys-Lys-NH2 was prepared on TentaGel resin and assayed for antibody production

ICM A61K038-16

ICS A61K038-10; A61K038-08; C07K007-08; C07K007-06

INCL 514012000; 514013000; 514014000; 514015000; 530324000; 530325000; 530326000; 530327000; 530328000

34-3 (Amino Acids, Peptides, and Proteins) Section cross-reference(s): 1, 15, 63

L98 ANSWER 7 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2003:610285 HCAPLUS Full-text

DOCUMENT NUMBER:

139:144011

TITLE:

Compositions and methods for modulating connexin

hemichannels for disease treatment

INVENTOR(S):

Petersen, Jorgen Soberg; Neve, Soren; Nielsen, Morten

Schak; Meier, Eddi; Steiness, Eva; Jensen, Peter

Holme; Larsen, Bjarne Due; Hansen, Lars Bo Laurenborg

PATENT ASSIGNEE(S):

SOURCE:

Zealand Pharma A/S, Den. PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 2003063891	A1 20030807	WO 2003-DK56	20030129
W: AE, AG, AL	, AM, AT, AU, AZ,	BA, BB, BG, BR, BY, B	Z, CA, CH, CN,
CO, CR, CU	, CZ, DE, DK, DM,	DZ, EC, EE, ES, FI, G	B, GD, GE, GH,
GM, HR, HU	, ID, IL, IN, IS,	JP, KE, KG, KP, KR, K	Z, LC, LK, LR,
LS, LT, LU	, LV, MA, MD, MG,	MK, MN, MW, MX, MZ, N	O, NZ, OM, PH,
PL, PT, RO	, RU, SC, SD, SE,	SG, SK, SL, TJ, TM, T	N, TR, TT, TZ,
UA, UG, US	, UZ, VC, VN, YU,	ZA, ZM, ZW	

```
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                            CA 2003-2474788
     CA 2474788
                          Al
                                20030807
                                                                   20030129
     EP 1469875
                          A1
                                20041027
                                            EP 2003-701478
                                                                   20030129
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    BR 2003007279
                          Α
                                20041228
                                            BR 2003-7279
                                                                   20030129
     JP 2005516054
                          Т
                                20050602
                                            JP 2003-563580
                                                                    20030129
     CN 1638790
                          Α
                                20050713
                                            CN 2003-804968
                                                                   20030129
    NO 2004003590
                          Α
                                20040827
                                            NO 2004-3590
                                                                   20040827
PRIORITY APPLN. INFO.:
                                            US 2002-352717P
                                                                P
                                                                   20020129
                                                                W 20030129
                                            WO 2003-DK56
     Disclosed are compns. and methods for modulating hemichannel function in a
AB
     cell, tissue or organ. The invention also relates to useful screens for
     detecting such compds., particularly those capable of modulating connexin
     phosphorylation. Further provided are therapeutic methods for preventing or
     treating conditions impacted by undesired hemichannel function in a mammal
     such as heart arrhythmia. More preferred compds. suitable for use with the
     present invention include those represented by the following Formula (I,
     R1(NHR2(CH2)s(CO)p)aNHR3(CH2)t(CO)qNHR4COR5) wherein R1= H or Ac; R2,R4= a
     sidechain of one of the amino acids G, Y, D-Y, F and D-F; R3 = any amino acid
     sidechain; R5 = OH or NH2; and a, S, T, P and Q are integers and independently
     = 0 or 1. More specific compds. include those having the following Formula
     (II, R1-X1-X2-X3-R2) wherein X1 = 0, Ala, Gly, \beta-Ala, Tyr, D-Tyr, Asp; X2 is
     0, Ala-Gly-T4c-Pro, Ala-Sar-Hyp-Pro, Ala-Asn, D-Asn-D-Ala, D-Asn, Gly, Ala,
     D-Ala, \beta-Ala, Asn; X3 = Tyr, D-Tyr, Gly, or Phe; R1 = H or Ac, with the
     proviso that X1 and X2 are not both 0; and R2= OH, NH2.
```

IC ICM A61K038-08

CC

ICS A61P009-06 1-12 (Pharmacology)

355151-12-1 355151-50-7 ·IT

RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(immunoassay method for screening compds. that modulate connexin

hemichannel function for use in disease treatment)

355151-12-1 355151-50-7 ΙT

RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(immunoassay method for screening compds. that modulate connexin hemichannel function for use in disease treatment)

355151-12-1 HCAPLUS RN

Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-CN alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 355151-50-7 HCAPLUS

CN L-Tyrosinamide, N-acetylglycyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RETABLE

Referenced Author	Year	VOL PG	Referenced Work		Referenced
(RAU)	(RPY)	(RVL) (RPG)	(RWK)	.	File .
	=+====	+====+=====	+==============	===+=	=======
Henrik, H	2001		WO 0162775 A	H	CAPLUS
Holstein-Rathlou, N	2002		WO 02077017 A) H	CAPLUS

L98 ANSWER 8 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2003:241921 HCAPLUS Full-text

DOCUMENT NUMBER:

138:260539

TITLE:

Apparatus and method for flow electroporation of

biological samples

INVENTOR(S):

Dzekunov, Sergey M.; Lee, Hyung J.; Li, Linhong;

Singh, Vininder; Liu, Linda; Holaday, John W.

PATENT ASSIGNEE(S):

Maxcyte, Inc., USA

SOURCE:

U.S. Pat. Appl. Publ., 59 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003059945	A1	20030327	US 2002-80272	20020221
US 7029916	B2	20060418		`
PRIORITY APPLN. INFO.:			US 2001-269867P P	20010221
•			US 2001-269868P P	20010221

AB The present invention relates to methods and apparatus for the encapsulation of biol.-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biol.-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the phys. characteristics of the various cell populations in blood. Primary lymphocytes were suspended in B and K buffer (125 mM KCl, 15 mM NaCl, 1.2 mM MgCl2, 3 mM glucose, 25 mM Hepes, pH 7.4) and cell concentration was set from 1x107 cells/mL to 6x108 cells/mL together with DNA plasmid from 50 to 1 mg/mL. Electroporation, 2.3 kV/cm, 400 μs, 4 pulses for small volume expts. (15 μl) or 2.2 kV/cm, 1.6 ms, 1 pulse for large volume expts. (0.5 mL-2 mL) was performed at room temperature Following electroporation, cells were incubated in B&K buffer for 20 min at 37° C. for small volume expts., or diluted by 10+ volume of culture medium (RPMI-1640+10% fetal bovine serum+1% Pen-strep+2 mM

L-glutamine) for large volume expts. Cells were cultured in culture medium for various periods (up to 72 h) and the transfection efficiency was analyzed. Primary quiescence lymphocytes were shown refractory to retrovirus based gene transfer. HIV-based vector could transduce primary lymphocytes, but the efficiency is extremely low in the absence of HIV accessory genes. Other nonviral transfection methods also gave very low transfection efficiency. This is the first demonstration of high efficiency of transfection of primary lymphocytes by a non-viral method.

IC ICM C12M001-42 ICS C12N015-87 INCL 435461000; X43-528.52 63-7 (Pharmaceuticals) Section cross-reference(s): 3, 9 IT 50-35-1D, Thalidomide, derivs. 50-81-7D, Ascorbic acid, ethers, biological studies 52-01-7, Spironolactone 53-05-4, Tetrahydrocortisone 60-33-3, Linoleic acid, biological studies 60-54-8D, Tetracycline, derivs. 68-96-2, 17α-Hydroxyprogesterone 128-13-2, Ursodeoxycholic acid 145-63-1, Suramin 152-58-9, Cortexolone 302-79-4, Retinoic acid 362-07-2, 2-Methoxyestradiol 446-72-0, 465-21-4, Bufalin 566-35-8 1406-16-2D, Vitamin D, derivs. Genistein 2609-46-3, Amiloride 4431-00-9, Aurintricarboxylic acid 9001-91-6, 11096-26-7, 9061-61-4, NGF 10118-90-8, Minocycline Plasminogen 12772-57-5, Radicicol 19545-26-7, Wortmannin Erythropoietin 33069-62-4, Taxol 34031-32-8, Auranofin 37270-94-3, Platelet factor 4 37300-21-3, Pentosan polysulfate 38096-31-0, Diaminoanthraquinone 50903-99-6, L-NAME 57381-26-7, Irsogladine 62031-54-3, Fibroblast growth factor 62571-86-2, Captopril 62683-29-8, Colony 62996-74-1, Staurosporine 65646-68-6, Fenretinide stimulating factor 70563-58-5, Herbimycin A 79831-76-8, Castanospermine 81627-83-0, M-CSF 83869-56-1, GM-CSF 86090-08-6, Angiostatin 86102-31-0, TIMP 98724-27-7, Proliferin-related protein 99519-84-3 100827-28-9, Erbstatin 103909-75-7, 22-0xa-1 α , 25-dihydroxyvitamin D3 105219-56-5, WEB 2086 106096-93-9, Basic fibroblast growth factor 110124-55-5, MDL 27032 125697-92-9, Lavendustin A 126509-46-4, Eponemycin 127464-60-2, Vascular endothelial growth factor 129298-91-5, AGM-1470 130370-60-4, Batimastat 134633-29-7, Tecogalan 142186-14-9, FR-118487 143011-72-7, G-CSF 148717-90-2, sodium 154039-60-8, Marimastat 169494-85-3, Leptin 171784-03-5, Squalamine 171784-05-7, Louisianine C 171784-06-8, Louisianine D Louisianine A 187888-07-9, Endostatin 188417-67-6, CM101 204005-46-9, SU5416 271597-12-7, Myostatin RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (apparatus and method for flow electroporation of biol. samples) IT 57381-26-7, Irsogladine RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (apparatus and method for flow electroporation of biol. samples)

RN 57381-26-7 HCAPLUS

1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME) CN

			_
רים כו	תיח	ום	

RETABLE	1			1 - 6	1
	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	• •	(RWK)	File
Abatti	+====- 1992	+====- 39	+===== 43	+=====================================	MEDLINE
Achelpohl	!	3 3 	1 23	US 4440386 A	 MEDDIINE
	1984	!	 	Multi-Arc Scientific	J I
Andal Corp	11075	<u> </u>	 	:	LUCADITIC
Anon	1975	!		DE 2405119	HCAPLUS
Anon	1985	!		EP 0137504	HCAPLUS
Anon	1987	!	ļ	DE 3603029	HCAPLUS
Anon	1987	!	ļ	JP 62151174	
Anon	1987	!	ļ	JP 62171687	HCAPLUS
Anon	1987	!	ļ	JP 62228277	HCAPLUS
Anon	1987	!		JP 62265975	
Anon	1988	1	ļ	JP 63141587	
Anon	1988]	!	WO 8804322	
Anon	1989]	!	EP 0343783	HCAPLUS
Anon	1989	ļ	!	JP 1141582	
Anon	1989	ļ	!	WO 8902464	HCAPLUS
Anon	1989	ļ		WO 8903426	HCAPLUS
Anon	1990	ļ.		EP 0362758	HCAPLUS
Anon	1990	ļ	ļ	JP 2131584	
Anon	1990		ļ	JP 2131585	
Anon	1990		ļ.	JP 2186993	
Anon	1991	ļ	ļ	JP 3195485	HCAPLUS
Anon	1991	ļ	ļ	WO 9118103	HCAPLUS
Anon	1992	ļ .		EP 0472772	HCAPLUS
Anon	1992			JP 4027393	
Anon	1994	1		JP 6349068	
Anon	1994			AT 680890	
Anon	1994			WO 9421117	HCAPLUS
Anon	1995			JP 7180029	
Anon	1995			JP 7320720	
Anon	1996			DE 4440386	HCAPLUS
Anon	1996		1	WO 9628199	HCAPLUS
Anon	1997		1	EP 0798309	HCAPLUS
Anon	1998			CN 1195997	HCAPLUS
Anon	1998			WO 9824490	HCAPLUS
Anon	2001	l .		WO 0124830	HCAPLUS
Anon	2002			CA 2214800	HCAPLUS
Anon	1975		598	Preparation of certa	
Asakami	1990	9	892	J. Mater. Sci. Lett.	HCAPLUS
Baer	1992			US 5128257 A	HCAPLUS
Barsoum	1990			US 4956288 A	HCAPLUS
Behrndt	1991	A139	58	Materials Sciences a	HCAPLUS
Bertoncini	1992			US 5114681 A	HCAPLUS
Boulton	1981			US 4252628 A	HCAPLUS
Buican	1992			US 5100627 A	HCAPLUS
Busta	1992			US 5137817 A	HCAPLUS
CRC Press	1995		1650	Biological Buffers,	
Calvin	1992	1	1	US 5098843 A	HCAPLUS
Capizzi	1993	72	3495	Cancer	HCAPLUS
Casnig	1992	1	1	US 5134070 A	
Chang	1989	1	1	US 4822470 A	HCAPLUS
Chang	1990			US 4970154 A	HCAPLUS
Chassy	1988	<u> </u> .6	303	Trends in Biotechnol	HCAPLUS
Coll	1992		1	Metallurgical and Tr	1
Dower	1990	1.		US 4910140 A	HCAPLUS
Dunican	1998	7	1067	BIO/Technology	
Dzekunov	2003	1	[US 20030073238 A1	1

Declare	10004	1	1	US 20040197883 A1	t
Dzekunov	2004				j 1
Egorov	1991	29	705	Sov. Powder Metall M	•
Einck	1998	ļ	357	Tissue Oxygenation i	i
Firth	1993	ŀ	ļ	US 5232856 A	HCAPLUS
Franco	1984			US 4478824 A	HCAPLUS
Franco	1990		ļ	US 4931276 A	HCAPLUS
Gersonde	1980	46	81	Biblthca Haemat.	
Gersonde	1979	39	1	Blut, Improvement of	
Gersonde	1982		277	Origins of Cooperati	HCAPLUS
Gersonde	1982	22	279	Toxicology	HCAPLUS
Goodrich	1989	Ì	1	US 4874690 A	HCAPLUS
Goodrich	1991	İ	Ì	US 5043261 A	HCAPLUS
Gossling	1960	İ	ĵ	US 2955076 A	İ
Hibi	1989	ĺ	Î	US 4800163 A	İ
Hilliard	1987	i	İ	US 4695547 A	HCAPLUS
Hilliard	1989	i	<u> </u>	US 4882281 A	HCAPLUS
Hirai	1987	40	607	J. of Antibiotics	HCAPLUS
Hofmann	1996		007	US 5501662 A	
Hofmann	1996	1	<u> </u>	US 5545130 A	l
Hofmann	1997	1	! !	US 5676646 A	}
	1986		 6	IEEE Engineering in	 UCADITIC
Hofmann		!	0	US 20010001064 A1	!
Holaday	2001		<u>}</u>	! · · · · · · · · · · · · · · · · ·	HCAPLUS
Holmstrm	1998	ļ	 	US 5728281 A	HCAPLUS
Kaali	1992	!	ļ	US 5139684 A	HCAPLUS
Kearney	1995			US 5424209 A	!
Kinosita	1979	554	479	Biochimica et Biophy	
Kobayashi	1989	97	1189	J. Ceram. Soc. Jpn.	•
Kullmann	1993	8	83	Am. J. Respir. Cell	:
Kurtz	1987	15	229	Sol. Energy Mater.	HCAPLUS
Lehninger	1982		181	Principles of Bioche	
Littlehales	1989			US 4840714 A	1
Marshall	1989			US 4849089 A	HCAPLUS
Marshall	1990			US 4906576 A	HCAPLUS
Marshall	1990		1	US 4923814 A	HCAPLUS
Marshall	1990	ĺ	İ	US 4946793 A	HCAPLUS
Matschke	1987	İ	ĺ	US 4699881 A	HCAPLUS
Matschke	1988	İ	İ	US 4764473 A	HCAPLUS
Maurer	1993	11	865	J. Orthop. Res.	HCAPLUS
Merz	1991	941	47	Unfallchirurg, Deter	
Meserol	1998		i	US 5720921 A	HCAPLUS
Meserol	2000	i	İ	US 6074605 A	HCAPLUS
Meserol	2000			US 6090617 A	HCAPLUS
Meserol	2002	1	l I	US 6485961 B1	HCAPLUS
Mochizuki	1989	1	! !	US 4804450 A	HCAPLUS
Mouneimne	1990	275	 117	FEBS Letters	HCAPLUS
*** *****	1	12/5	1 11 /	Ion Bond 16 Zirconiu	
Multi-Arc, Inc	1996		ļ i	•	•
Multi-Arc, Inc	1995	ļ	ļ	Ion Bond 17 Titanium	•
Multi-Arc, Inc	1995			Ion Bond 19 Chromium	,
Multi-Arc, Inc	1995	!	ļ	Ion Bond Coatings fo	•
Multi-Arc, Inc	1995		ļ	Ion Bond Coatings fo	
Multi-Arc, Inc	1995		ļ	The Ion Bond Network	•
Narayan	1994	B25	5	Materials Sciences a	:
Nicolau	1980	!	!	US 4192869 A	HCAPLUS
Nicolau	1982	1	!	US 4321259 A	HCAPLUS
Nicolau	1984			US 4473563 A	HCAPLUS
Nicolau	1997	1		US 5612207 A	HCAPLUS
Nicolau	1985	51	92	Biblthca haemat.	HCAPLUS
Nicolau	1986		265	Phytic Acid: Chemist	HCAPLUS
Pietra	1990	115	1025	Analyst	HCAPLUS
Pohl	1984	Ì	İ	US 4476004 A	Ì
	•	•	•	•	•

Ray	1988	1	1	US 4784737 A	HCAPLUS
Ropars	1987	İ	Ì	US 4652449 A	HCAPLUS
Ropars	1988		1	US 4752586 A	HCAPLUS
Ropars	1985	445	304	Improved oxygen deli	MEDLINE
Sanford	1990			US 4945050 A	
Sanford	1991			US 5036006 A	1
Sanford	1992			US 5100792 A	
Satomi	1988	15	339	Annals Rehab.	HCAPLUS
Schaldach	1989	34	185	Biomed. Technik.	MEDLINE
Schoendorfer	1992			US 5135667 A	HCAPLUS
Shoji	1982	41	1097	Appl. Phys. Lett.	HCAPLUS
Smith	1972			US 3676325 A	HCAPLUS
Sowers	1986			US 4622302 A	
Susuki	1981	19	114	Jpn. J. Med. Electro	MEDLINE
Tada	1992		1.	US 5124259 A	HCAPLUS
Taheri	1994	90	376	Electroencephalograp	MEDLINE
Tait	1991	7	327	Surf. Eng.	HCAPLUS
Takahashi	1991			US 5007995 A	HCAPLUS
Teisseire	1985	58	1810	J. Appl. Phys.	MEDLINE
Teisseire			153	Significance of low	
Teissere	1987	84	6894	Proc. Natl. Acad. Sc	
Therin	1991	2	1	J. Materials Science	-
Vasilenko	1973	13	39	Poroshkovaia Metallu	HCAPLUS
Weiner	1983	47	65	Biol. of the Cell	HCAPLUS
Weisel	1978	83	682	Surgery	MEDLINE
Wisbey	1987	8	477	Biomaterials	HCAPLUS
Wisbey	1989	C384/	9	ImechE	
Wong	1987			US 4663292 A	HCAPLUS
Wong	1989			US 4849355 A	HCAPLUS
Xylander	1978			US 4075076 A	1
Zhao	1991	42	1109	Vacuum	HCAPLUS
Zhu	1994	9	295	Biosensors and Bioel	!
Ziegler	1991		!	US 4995957 A	HCAPLUS
Zimmermann	1978	ļ		US 4081340 A	HCAPLUS

L98 ANSWER 9 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN 2003:683276 HCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER:

140:122445

TITLE:

Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-

Gly-D-Ala-Gly-NH2 (ZP123): In vivo and in vitro studies

AUTHOR (S):

Kjolbye, Anne Louise; Knudsen, Carsten Boye; Jepsen, Trine; Larsen, Bjarne Due; Petersen, Jorgen Soberg

CORPORATE SOURCE:

Department of Pharmacology, Zealand Pharma A/S,

Smedeland, Den.

SOURCE:

Journal of Pharmacology and Experimental Therapeutics

(2003), 306(3), 1191-1199 CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER:

American Society for Pharmacology and Experimental

Therapeutics

DOCUMENT TYPE:

Journal

LANGUAGE: English

Antiarrhythmic peptides (AAPs) are a group of compds. with antiarrhythmic AΒ properties; however, their use has been hampered by very low plasma stability. The aim of this study was to compare the in vitro and in vivo stability of our new stable AAP analog Ac-D-Tyr-D-Pro-D-Hyp-Gly -D-Ala-Gly-NH2 (ZP123) with the previously described AAP analog AAP10. Moreover, the effect of the two compds. was examined in a murine in vivo model of ouabain-induced second degree AV-block, and the effect on dispersion of action potential duration

(APD dispersion) was studied during hypokalemic-ischemia in isolated perfused rabbit hearts. The in vitro t1/2 of ZP123 in rat and human plasma was about 1,700 times longer than t1/2 of AAP10. Due to rapid elimination, it was not possible to obtain an in vivo pharmacokinetic characterization of AAP10; however, calcns. suggested that the clearance of ZP123 was at least 140 times slower than for AAP10. AAP10 and ZP123 produced a dose-dependent delay in onset of ouabain-induced AV-block in mice at doses of 10-11 to 10-7 mol/kg i.v. ZP123 and 10-11 to 10-6 mol/kg i.v. AAP10. Maximal efficacy of ZP123 was reached at a 10-fold lower dose (10-8 mol/kg i.v.) than with AAP10. In the isolated rabbit hearts, ZP123 and AAP10 had no effect on dispersion during control conditions. The increased APD dispersion during hypokalemic ischemia is considered a major arrhythmic substrate and only ZP123 prevented the increase in APD dispersion. In conclusion, ZP123 is a new potent AAP analog with improved stability.

1-8 (Pharmacology)

```
with improved stability.
CC
     1-8 (Pharmacology)
     Section cross-reference(s): 14, 63
     Peptides, biological studies
ΙT
     RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT
     (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (antiarrhythmics; pharmacol. characterization with in vivo and in vitro
        studies of new stable antiarrhythmic peptide analog
        Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2
        (ZP123))
IT
    Cardiovascular agents
     Cytoprotective agents
        (cardioprotective agents; pharmacol. characterization with in vivo and
        in vitro studies of new stable antiarrhythmic peptide analog
        Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2
        (ZP123))
IT
    Drug delivery systems
        (injections, i.v.; pharmacol. characterization with in vivo and in
        vitro studies of new stable antiarrhythmic peptide analog
        Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2
        (ZP123))
    Antiarrhythmics
IT
    Disease models
    Human
        (pharmacol. characterization with in vivo and in vitro studies of new
        stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly
        -D-Ala-Gly-NH2 (ZP123))
IT
    355151-12-1
    RL: DMA (Drug mechanism of action); PAC (Pharmacological
     activity); PKT (Pharmacokinetics); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (ZP 123; pharmacol. characterization with in vivo and in vitro studies
        of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-
        Gly-D-Ala-Gly-NH2 (ZP123))
IT
    355151-12-1
    RL: DMA (Drug mechanism of action); PAC (Pharmacological
    activity); PKT (Pharmacokinetics); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
        (ZP 123; pharmacol. characterization with in vivo and in vitro studies
        of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-
        Gly-D-Ala-Gly-NH2 (ZP123))
    355151-12-1 HCAPLUS
RN
    Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-
CN
```

Absolute stereochemistry.

alanyl- (9CI) (CA INDEX NAME)

RETABLE					
Referenced Author	Year	AOT	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
=,=====================================	+=====	+=====	+=====	+===============	+=======
Aonuma, S	1980	28	3332	Chem Pharm Bull (Tok	HCAPLUS
Aonuma, S	1982	5	40	J Pharmacobiodyn	HCAPLUS
Argentieri, T	1989	45	737	Experientia	HCAPLUS
Dhein, S	1994	350	174	Naunyn-Schmiedeberg'	HCAPLUS
Dikshit, M	1988	26	874	Indian J Exp Biol	HCAPLUS
Echt, D	1991	324	781	N Engl J Med	MEDLINE
Gabrielson, J	2000		21	Pharmacokinetic and	
Hjalmarson, A	1984	29	145	Cardiologia	MEDLINE
ISIS-1	1986	2	57	Lancet	
Kjolbye, A	2002	40	770	J Cardiovasc Pharmac	HCAPLUS
Kohama, Y	1987	35	3928	Chem Pharm Bull (Tok	HCAPLUS
Kohama, Y	1988	36	4597	Chem Pharm Bull (Tok	HCAPLUS
Muller, A	1997	327	65	Eur J Pharmacol	MEDLINE
Muller, A	1997	356	76	Naunyn-Schmiedeberg'	MEDLINE
Naccarelli, G	2000	15	64	Curr Opin Cardiol	MEDLINE
Ronsberg, M	1986	14	350	Med Sci	HCAPLUS
Rowland, M	1989		438	Clinical Pharmacokin	
Waldo, A	1996	348	7	Lancet	HCAPLUS
Waldo, A	1996	348	416	published erratum ap	
Xing, D	2003	14	510	J Cardiovasc Electro	

L98 ANSWER 10 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2004:116197 HCAPLUS Full-text

DOCUMENT NUMBER:

141:167468

TITLE:

Effects of the new antiarrhythmic peptide ZP123 on epicardial activation and repolarization pattern

Dhein, Stefan; Larsen, Bjarne D.; Petersen, Jorgen S.;

Mohr, Friedrich-Wilhelm

CORPORATE SOURCE:

Clinic for Cardiac Surgery, Heart Center, University

of Leipzig, Leipzig, Germany

SOURCE:

Cell Communication & Adhesion (2003), 10(4-6), 371-378

CODEN: CCAEBH; ISSN: 1541-9061

PUBLISHER:

AUTHOR (S):

Taylor & Francis, Inc.

DOCUMENT TYPE:

Journal

English LANGUAGE:

AB Antiarrhythmic peptides such as AAP10 (Gly-Ala- Gly-4Hyp-Pro-Tyr-CONH2) have antiarrhythmic properties related to their stimulatory effect on gap junctional coupling. However, most of these peptides are not stable in enzymic environment which limits studies with these compds. in vivo. ZP123 is a new antiarrhythmic peptide constructed using a retro-all-D-amino acid design of the AAP10 template (Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D-Ala-Gly-NH2): The aim of this study was to compare the effects of AAP10 and ZP123 on epicardial

activation and repolarization patterns in isolated perfused rabbit hearts. addition, we tested the effect of these compds. on PKC activation in cultured HeLa-Cx43 cells. Rabbit hearts were perfused according to the Langendorff technique with Tyrode solution at constant pressure (70 cm H2O). After 45 min equilibration, either AAP10 (n = 7) or ZP123 (n = 7) was infused intracoronarily in concns. of 0.1, 1, 10, 100, and 1000 nM (15 min for each concentration) in the presence of 0.05% bovine serum albumine. 256 AgCl electrodes were attached to the hearts surface and connected to the inputs of a 256 channel mapping system in a unipolar circuit (4 kHz/channel, 0.04 mV vertical resolution, 1 mm spatial resolution). For each electrode the activation and repolarization timepoint were determined We found that both peptides significantly reduced epicardial dispersion by a maximum of about 20% thereby enhancing the homogeneity of epicardial action potential duration, while the action potential duration itself was not affected. The beat-to-beat variability of the epicardial activation pattern was stabilized by both peptides as compared to an untreated time-control series. Other parameters such as LVP, CF, heart rate, or total activation time were not effected by either of the peptides. In a second protocol, rectangular pulses were delivered to the back wall and the propagation velocity was determined longitudinal and transversal to the fiber axis. We found an increase in both longitudinal and transversal conduction velocity. Using a com. PKC assay on HeLa-Cx43 cells we found that 50 nM AAP10 and 50 nM ZP123 increased activity by $99\pm6\%$ and $146\pm54\%$, resp. The PKC activation induced by either of these compds. was completely blocked using the selective PKC α inhibitor GCP54345. We conclude that AAP10 and ZP123 have similar effects in vitro, but the superior enzymic stability of ZP123 makes this compound the preferred substance for in vivo studies of antiarrhythmic peptides.

CC 1-8 (Pharmacology)

IT 159503-65-8 355151-12-1, ZP123

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ZP123, AAP10 reduced epicardial dispersion, increased longitudinal and transversal conduction velocity without affecting cardiac parameters in rabbit and induced PKC α activity in HeLA-Cx43 cell but ZP123 , showed better enzymic stability)

IT 159503-65-8 355151-12-1, ZP123

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ZP123, AAP10 reduced epicardial dispersion, increased longitudinal and transversal conduction velocity without affecting cardiac parameters in rabbit and induced PKC α activity in HeLA-Cx43 cell but ZP123 showed better enzymic stability)

RN 159503-65-8 HCAPLUS

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & &$$

RN 355151-12-1 HCAPLUS

CN Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RETABLE

Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
	+====-	+====-	+=====-	+=====================================	+========
Arisi, G	1983	52	706	Circ Res	MEDLINE
Buchanan, J	1985	56	696	Circ Res	HCAPLUS
Dhein, S	1999	128	1375	Br J Pharmacol	HCAPLUS
Dhein, S	2001	8	257	Cell Commun Adhesion	HCAPLUS
Dhein, S	1993	87	617	Circulation	HCAPLUS
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1994	350	174	Naunyn Schmiedeberg	HCAPLUS
Grover, R	2001	22	1011	Peptides '	HCAPLUS
Hofmann, J	1997	11	649	FASEB J	HCAPLUS
Joyner, R	1982	50	192	Circ Res	MEDLINE
Kjolbye, A	2003	306	1191	J Pharmacol Exp Ther	HCAPLUS
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Muller, A	1997	356	76	Naunyn Schmiedeberg	MEDLINE
Weingart, R	1988	63	72	Circ Res	MEDLINE
Weng, S	2002	16	1114	FASEB J	HCAPLUS
Wit, A	1993		127	Cardiac Mapping	
Xing, D	2003	14	510	J Cardiovasc Electro	

L98 ANSWER 11 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2002:829575 HCAPLUS Full-text

DOCUMENT NUMBER:

138:378882

TITLE:

Anti-arrhythmic peptide N-3-(4-Hydroxyphenyl)propionyl

Pro-Hyp-Gly-Ala-Gly-OH

reduces dispersion of action potential duration during

ischemia/reperfusion in rabbit hearts

AUTHOR (S): Kjolbye, Anne Louise; Holstein-Rathlou, Niels-Henrik;

Petersen, Jorgen Soberg

CORPORATE SOURCE:

Zealand Pharma, Glostrup, Den.

SOURCE:

Journal of Cardiovascular Pharmacology (2002), 40(5),

770-779

CODEN: JCPCDT; ISSN: 0160-2446 Lippincott Williams & Wilkins

PUBLISHER: DOCUMENT TYPE:

Journal

LANGUAGE: English AB

During ischemia, cardiac gap junctions close and neighboring cells uncouple. This leads to slow conduction, increased dispersion of APD (duration from action potential beginning to 90% of repolarization), nonuniform anisotropy, and unidirectional conduction block, all of which favor the induction of reentry arrhythmias. It was suggested that anti-arrhythmic peptides increase gap junction conductance during states of reduced coupling. The aim of this study was to test the effect of the anti-arrhythmic peptide N-3-(4hydroxyphenyl)propionyl Pro-Hyp-Gly -Ala-Gly-OH (HP-5) (10-10 M) on dispersion of epicardial APD during both normokalemic and hypokalemic ischemia/reperfusion in isolated perfused rabbit hearts. HP-5 did not affect average APD , heart rate, left ventricular contractility (LVP dP/dtmax), or mean coronary flow. HP-5 significantly reduced the epicardial APD dispersion during hypokalemic ischemia (HP-5 treated: 24.1 ms, untreated: 33.9 ms) and during normokalemic reperfusion but not during normokalemic ischemia or control conditions. In addition, among untreated hearts subjected to hypokalemic ischemia/reperfusion, 7 of 10 developed ventricular fibrillation, whereas only 3 of 9 hearts perfused with HP-5 developed ventricular fibrillation. These results show that HP-5 is able to reduce APD90 dispersion during hypokalemic ischemia in rabbit hearts.

CC 1-8 (Pharmacology)

Section cross-reference(s): 2

IT 111915-92-5

RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(antiarrhythmic peptide HP-5 reduces dispersion of action potential duration)

IT 111915-92-5

RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(antiarrhythmic peptide HP-5 reduces dispersion of action potential duration)

RN 111915-92-5 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium), 1-deglycine-2-[1-[3-(4hydroxyphenyl)-1-oxopropyl]-L-proline]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RETABLE					
Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
	+=====-	+=====	+======	+==================	+=======
Anon	1998	97	651	Circulation	
Aonuma, S	1980	28	3332	Chem Pharm Bull (Tok	HCAPLUS
Aonuma, S	1982	5	40	J Pharmacobiodyn	HCAPLUS
Argentieri, T	1989	45	737	Experientia	HCAPLUS
Dhein, S	1999	128	1375	Br J Pharmacol	HCAPLUS
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1994	350	174	Naunyn Schmiedebergs	HCAPLUS
Dikshit, M	1988	26	874	Indian J Exp Biol	HCAPLUS
Gottwald, E	1998	79	474	Heart	MEDLINE
Kohama, Y	1987	35	3928	Chem Pharm Bull (Tok	HCAPLUS
Kohama, Y	1988	36	4597	Chem Pharm Bull (Tok	HCAPLUS
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Merx, W	1977	94	603	Am Heart J	MEDLINE
Muller, A	1997	327	65	Eur J Pharmacol	MEDLINE
Muller, A	1997	356	76	Naunyn Schmiedebergs	MEDLINE
Peters, N	1993	88	864	Circulation	HCAPLUS
Peters, N	1997	95	988	Circulation	MEDLINE
Wolk, R	1999	84	20,7	Pharmacol Ther	HCAPLUS
L98 ANSWER 12 OF 37 H	CAPLUS	COPY	RIGHT 2	007 ACS on STN	
ACCESSION NUMBER:	2001	: 93562	6 HCAP	LUS <u>Full-text</u>	
DOCUMENT NUMBER:	136:6	54121			
TITLE:	Pept:	ide com	njugate	s modified n- and/or $\mathfrak c$	c-terminally by
	short	t char	ged pept	tide chains	
INVENTOR(S):	Larse	en, Bja	arne Du	e; Petersen, Jorgen	
	Sobe	rg; Kaj	ousta, 1	Daniel R.; Harlow, Ke	nneth
	Will:				
PATENT ASSIGNEE(S):	Zeala	and Pha	armaceu	ticals A/S, Den.	
SOURCE:	PCT :	Int. A _l	ppl., 7	2 pp.	
	CODE	N: PIX	XD2		

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT	NO.	KIN	D DATE	APPLICATION NO.	DATE
WO 2001	098324	A1	20011227	WO 2001-US19113	20010615 <
W:	AE, AG,	AL, AM,	AT, AU, AZ,	BA, BB, BG, BR, BY,	BZ, CA, CH, CN,
	CO, CR,	CU, CZ,	DE, DK, DM,	DZ, EE, ES, FI, GB,	GD, GE, GH, GM,
	HR, HU,	ID, IL,	IN, IS, JP,	KE, KG, KP, KR, KZ,	LC, LK, LR, LS,
	LT, LU,	LV, MA,	MD, MG, MK,	MN, MW, MX, MZ, NO,	NZ, PL, PT, RO,
	RU, SD,	SE, SG,	SI, SK, SL,	TJ, TM, TR, TT, TZ,	UA, UG, US, UZ,
	VN, YU,	ZA, ZW			
RW:	GH, GM,	KE, LS,	MW, MZ, SD,	SL, SZ, TZ, UG, ZW,	AT, BE, CH, CY,
	DE, DK,	ES, FI,	FR, GB, GR,	IE, IT, LU, MC, NL,	PT, SE, TR, BF,
	BJ, CF,	CG, CI,	CM, GA, GN,	GW, ML, MR, NE, SN,	TD, TG
CA 2410	224	A1	20011227	CA 2001-2410224	20010615 <
EP 1294	746	. A1	20030326	EP 2001-952155	20010615 <
R:	AT, BE,	CH, DE,	DK, ES, FR,	GB, GR, IT, LI, LU,	NL, SE, MC, PT,
	IE, SI,	LT, LV,	FI, RO, MK,	CY, AL, TR	
JP 2004	516811	T	20040610	JP 2002-504279	20010615 <
PRIORITY APP	LN. INFO	. :		DK 2000-944	A 20000616 <
				DK 2000-1485	A 20001005 <

US 2000-251671P P 20001206 <--US 2001-298186P P 20010613 WO 2001-US19113 W 20010615 WO 2001-US41008 A 20010615

OTHER SOURCE(S): MARPAT 136:64121

Disclosed are a variety of peptide conjugates represented by the following general formula R1-Z-X-Z'-R2, wherein X represents a hexapeptide of the formula A1-A2-A3-A4-A5-A6 wherein A1 represents Arg, Lys, or His, A2 represents Tyr, Trp, or Phe, A3 represents Tyr, Asn, Trp or Phe, A4 represents Lys, Arg or His, A5 represents Phe, Tyr, Trp, Leu, Val or Ile, and A6 represents Arq, Lys, or His and wherein each amino acid residue in said hexapeptide may be in the L or D form; Z represents a charged peptide chain of from 4 to 20 amino acid residues having the D or L configuration or is missing; and Z' represents a charged peptide chain of from 4 to 20 amino acid residues having the D or L configuration or is missing, providing that not both of Z and Z' are missing; R1 represents H or an acyl group; R2 represents NR3R4 where each of R3 and R4 independently represents hydrogen, C(1-6)alkoxy, aryloxy, or a lower alkyl as defined herein; or R2 represents OH; the peptide conjugates of formula (I) being optionally further linked to a transport moiety; and salts, hydrates and solvates thereof, and C-terminally amidated or esterified derivs. thereof with suitable organic or inorg. acids, including methods or making and using such conjugates. Also provided are antibodies that specifically bind the peptide conjugates. The present invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides.

IC ICM C07K007-08

ICS C07K014-00; C07K016-44; A61K038-16; C07K007-06; C07K014-575; A61K038-04

CC 1-8 (Pharmacology)

Section cross-reference(s): 15, 34, 63

RETABLE

Referenced Author (RAU)		VOL	(RPG)	Referenced Work	Referenced File
Lapalu, S		+==== 417	+=====· 333	+=====================================	HCAPLUS
Meunier, J	2000	21	893	PEPTIDES	HCAPLUS
Novonordisk As	1999	ļ		WO 9944627 A	HCAPLUS

L98 ANSWER 13 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2001:504962 HCAPLUS Full-text

DOCUMENT NUMBER:

135:298164

TITLE:

Structure-activity relationships of novel peptides related to the antiarrhythmic peptide AAP10 which reduce the dispersion of epicardial action potential

duration

AUTHOR (S):

Grover, R.; Dhein, S.

CORPORATE SOURCE:

Institute of Pharmacology, University of Cologne,

Cologne, 50931, Germany

SOURCE:

Peptides (New York, NY, United States) (2001), 22(7),

1011-1021

CODEN: PPTDD5; ISSN: 0196-9781

PUBLISHER:

Elsevier Science Inc.

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB We report the first study on short peptide structure-activity relationships (SAR) for the antiarrhythmic peptide AAP10 and its putative receptor. Synthetic improvements on the natural antiarrhythmic peptide AAPnat (H-Gly-Pro-Hyp-Gly-Ala-Gly) isolated from bovine atria led us to the synthesis of our lead mol. AAP10 (H-Gly-Ala-Gly-Hyp-Pro-Tyr-NH2) which reduces dispersion of epicardial potential duration and acts antiarrhythmically in isolated rabbit

hearts. The aim of our study was to elucidate structure-activity relationships for AAP10 based on Langendorff expts. and mol. modeling. Mutation of the amino acid sequence led to 11 different peptides which were tested analogous to the lead mol. Among these new synthetic peptides various including the cyclopeptide cAAP10RG, cyclo[CF3C(OH)-Gly-Ala-Gly-Hyp-Pro-Tyr] showed promising activities. (supported by the DFG and Koln-Fortune).

CC 1-3 (Pharmacology)

IT 81771-37-1, Antiarrhythmic peptide (cattle atrium)

159503-65-8 366800-46-6 366800-47-7 366800-48-8

366800-49-9 366800-50-2 366800-51-3 366800-52-4 366800-53-5

366800-54-6 366800-55-7 366800-56-8 366800-57-9 366800-58-0

366800-59-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(structure-activity relationships of novel peptides related to antiarrhythmic peptide AAP10 which reduce dispersion of epicardial action potential duration)

IT 81771-37-1, Antiarrhythmic peptide (cattle atrium)

159503-65-8 366800-53-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(structure-activity relationships of novel peptides related to antiarrhythmic peptide AAP10 which reduce dispersion of epicardial action potential duration)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 366800-53-5 HCAPLUS

CN L-Tyrosinamide, glycyl-L-alanylglycyl-L-prolyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RETABLE					
Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
	+=====	+=====	+=====	+======================================	+========
Atherton, E	1989			Solid phase peptide	
Beck-Sickinger, A	1991	4	88	Pept res	HCAPLUS
Bhacca, N	1962			High resolution NMR	
Carpino, L	1972	37	3404	J Org Chem	HCAPLUS
Curphey, T	1979	44	2805	J Org Chem	HCAPLUS
Dhein, S	1999	128	1375	Br J Pharmacol	HCAPLUS
Dhein, S	1993	87	617	Circulation	HCAPLUS
Dhein, S	1997	96	I-292	Circulation	
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1997	2	51	Exp Clin Cardiol	ļ
Dhein, S	1994	350	174	Naunyn Schmiedebergs	
Dhein, S	1994	349	R55	Naunyn Schmiedebergs	}
Dhein, S	1999	359	R7	Naunyn Schmiedebergs	
Dhein, S	1995	429	R91	Pflug Arch Eur J Phy	
Dhein, S	1998		163	Proceedings of Inter	HCAPLUS
Durrer, D	1954	47	192	Am Heart J	MEDLINE
Friebolin, H	1988			Ein-Und Zweidimensio	
Gottwald, E	1998	79	474	Heart	MEDLINE
Grover, R	1998	19	1725	Peptides	HCAPLUS
Han, J	1964	16	46	Circ Res	
Kjolbye, A	2000	14	A698	The FASEB J	
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Meyer, V	1978		·	Praxis in der HPLC	1
Millar, C	1985	72	1372	Circulation	MEDLINE
Mueller, A	1997	327	65	Eur J Pharmacol	HCAPLUS
Mueller, A	1997	356	76	Naunyn Schmiedebergs	HCAPLUS
Nomizu, M	1994	20	2691	Tetrahedron	
Patrick, G	1995			An introduction to m	
Rink, H	1987	28	3787	Tetrahedron Lett	HCAPLUS
Viswanadhan, V	1989	29	163	J chem inf comput sc	
Wang, S	1973	95	1328	J Amer Chem Soc	HCAPLUS
Wiener, S	1984	106	765	J Am Chem Soc	l

L98 ANSWER 14 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

2000:144722 HCAPLUS Full-text ACCESSION NUMBER: DOCUMENT NUMBER: 132:185454 Use of anti-angiogenic agents for inhibiting vessel TITLE: wall injury Brown, Charles L., III; Gorlin, Steve INVENTOR(S): Global Vascular Concepts, Inc., USA PATENT ASSIGNEE(S): PCT Int. Appl., 29 pp. SOURCE: CODEN: PIXXD2 Patent DOCUMENT TYPE: English LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: APPLICATION NO. KIND DATE PATENT NO. _____ _ _ _ _ -----______ WO 1999-US19218 19990824 <--A2 20000302 WO 2000010552 A3 20001123 WO 2000010552 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG 19990824 <--A1 20000314 AU 1999-56871 AU 9956871 P 19980824 <--US 1998-97579P PRIORITY APPLN. INFO.: WO 1999-US19218 W 19990824 <--Use of anti-angiogenic agents to inhibit an undesirable response to vessel AB wall injury, including stent neointima, dialysis graft neointima, vascular graft-induced neointima, and the treatment of benign hypertrophic scar formation as well as the treatment and passivation of unstable atherosclerotic plaques are provided. The invention provides for the use of catheter-based devices for enhancing the local delivery of anti-angiogenic agents into the endothelial tissues of blood vessels of the living body. IC ICM A61K031-00 63-6 (Pharmaceuticals) CC Section cross-reference(s): 1 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide IT Ascorbic acid, ethers, biological studies 52-01-7, Spironolactone 53-05-4, Tetrahydrocortisone 53-86-1, Indomethacin 60-33-3, Linoleic acid, biological studies 60-54-8, Tetracycline 68-96-2, 17α-Hydroxyprogesterone 128-13-2, Ursodeoxycholic acid 145-63-1, 152-58-9, Cortexolone 302-79-4, Retinoic acid 362-07-2, 2-Methoxyestradiol 446-72-0, Genistein 465-21-4, Bufalin 2609-46-3, Amiloride 4431-00-9, Aurine tricarboxylic acid 10118-90-8, Minocycline 12772-57-5, Radicicol 19545-26-7, Wortmannin 33069-62-4, Taxol 34031-32-8, Auranofin 37270-94-3, Platelet factor 4 38096-31-0, Diaminoanthraquinone 38194-50-2, Sulindac 50903-99-6, L-Name 53902-12-8, Tranilast 57381-26-7, Irsogladine 62571-86-2, Captopril 62996-74-1, Staurosporine 65646-68-6, Fenretinide 70563-58-5, Herbimycin A 79831-76-8, Castanospermine 86090-08-6, Angiostatin 100827-28-9, Erbstatin 103909-75-7, 22-Oxa-1α-25-dihydroxyvitamin D3 105219-56-5, WEB 2086 110124-55-5, MDL 27032 125697-92-9, Lavendustin A 126509-46-4, Eponemycin 129298-91-5, TNP-470 130370-60-4, BB-94 134633-29-7,

Tecogalan sodium 142186-14-9, FR-118487 148717-90-2, Squalamine 154039-60-8, Marimastat 171784-03-5, Louisianine A 171784-04-6, Louisianine B 171784-06-8, Louisianine D 187888-07-9, Endostatin 188417-67-6, CM 101 204005-46-9, SU5416

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anti-angiogenic agents for inhibiting vessel wall injury)

IT 57381-26-7, Irsogladine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anti-angiogenic agents for inhibiting vessel wall injury)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 15 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:37178 HCAPLUS Full-text

DOCUMENT NUMBER: 132:343088

TITLE: Protective effect of irsogladine on

monochloramine-induced gastric mucosal lesions in

rats: a comparative study with Rebamipide

AUTHOR(S): Yamamoto, H.; Umeda, M.; Mizoguchi, H.; Kato, S.;

Takeuchi, K.

CORPORATE SOURCE: Department of Pharmacology and Experimental

Therapeutics, Kyoto Pharmaceutical University, Kyoto,

607-8414, Japan

SOURCE: World Journal of Gastroenterology (1999),

5(6), 477-482

CODEN: WJGAF2; ISSN: 1007-9327

PUBLISHER: World Journal of Gastroenterology

DOCUMENT TYPE: Journal LANGUAGE: English

LANGUAGE: Aim: To examine the effect of irsogladine, a novel antiulcer drug, on the AB mucosal ulcerogenic response to monochloramine (NH2Cl) in rat stomach, in comparison with Rebamipide, another antiulcer drug with cytoprotective activity. Methods and Results: Oral administration of NH2Cl (120 mM) produced severe hemorrhagic lesions in unanesthetized rat stomachs. Both irsogladine (1-10 mg/kg, orally) and Rebamipide (30-100 mg/kg, orally) dose-dependently prevented the development of these lesions in response to NH2Cl; the effect of irsogladine was significant at ≥3 mg/kg and that of Rebamipide only at 100 mg/kg. The protective effect of irsogladine on NH2Cl-induced gastric lesions was significantly reduced by NG-nitro-L-arginine Me ester (L-NAME) but not by indomethacin, while that of Rebamipide was significantly mitigated by indomethacin but not by L-NAME. Topical application of NH2Cl (20 mM) caused a marked reduction of p.d. (PD) in ex-vivo stomachs. This PD reduction was not affected by mucosal application of irsogladine but significantly prevented by Rebamipide. The mucosal exposure to NH4OH (120 mM) also caused a marked PD reduction in the ischemic stomach (bleeding from the carotid artery), resulting in gastric lesions. These ulcerogenic and PD responses caused by NH4OH plus ischemia were also significantly mitigated by Rebamipide, in an indomethacin-sensitive manner, while irsogladine potently prevented such lesions without affecting the PD response, in a L-NAME-sensitive manner. Conclusions: These results suggest that (1) NH2Cl generated either exogenously or endogenously damages the gastric mucosa, (2) both irsogladine and

Rebamipide protect the stomach against injury caused by NH2Cl, and (3) the mechanism underlying the protective action of irsogladine is partly mediated by endogenous nitric oxide while that of Rebamipide is in part mediated by endogenous prostaglandins.

CC 1-9 (Pharmacology)

57381-26-7, Irsogladine 90098-04-7, Rebamipide IT

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(protective effect of irsogladine on monochloramine-induced gastric mucosal lesions in rats compared to Rebamipide)

57381-26-7, Irsogladine IT

> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(protective effect of irsogladine on monochloramine-induced gastric mucosal lesions in rats compared to Rebamipide)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

RETABLE

Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
	+=====-	, }=====	, }======	, +====================================	· -=========
Badwey, J	1980	46	695	Ann Rev Biochem	
Dekigai, H	1995	40	1332	Dig Dis Sci	MEDLINE
Graham, D	1989	96	615	Gastroenterology	
Grisham, M	1986	251	G567	Am J Physiol	HCAPLUS
Grisham, M	1984	259	10404	J Biol Chem	HCAPLUS .
Ishihara, K	1992	42	1462	Arzneimittelforschun	HCAPLUS
Ivy, K	1970	59	683	Gastroenterology	
Kato, S	1977	42	2156	Dig Dis Sci	
Klevanoff, S	1980	93	480	Ann Intern Med	
Marshall, B	1983	1	1273	Lancet	
Marshall, B	1983	1	965	Lancet	
Murakami, M	1995	40	268	Dig Dis Sci	HCAPLUS .
Murakami, M	1993	105	1710	Gastroenterology	HCAPLUS
Nishiwaki, H	1997	29	713	Gen Pharmacol	HCAPLUS
Okabe, S	1984	24	683	Pharmacometrics	
Svanes, K	1982	82	1409	Gastroenterology	HCAPLUS
Takeuchi, K	1989	49	235	Jpn J Pharmacol	HCAPLUS
Tepperman, B	1992	105	171	Br J Pharmacol	HCAPLUS
Ueda, F	1984	34P	474	Arzneimittelforschun	
Ueda, F	1984	34	478	Arzneimittelforschun	HCAPLUS
Whitehead, R	1972	25	1	J Clin Pathol	MEDLINE
Whittle, B	1990	99	607	Br J Pharmacol	HCAPLUS
Yamasaki, K	1987	142	23	Eur J Pharmacol	HCAPLUS
Yoshikawa, T	1993	43	363	Arzneimittelforschun	HCAPLUS

L98 ANSWER 16 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

1998:714418 HCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER: 130:119294

Effects of an antiarrhythmic peptide on intercellular TITLE:

coupling via gap junctions

Dhein, Stefan; Gottwald, Michaela; Schaefer, Thomas; AUTHOR (S):

Muller, Andreas; Tudyka, Tatjana; Krusemann, Kathi;

Grover, Rajiv

Institute of Pharmacology, University of Cologne, CORPORATE SOURCE:

Cologne, D-50931, Germany

Gap Junctions, Proceedings of the International Gap SOURCE:

Junction Conference, 8th, Key Largo, Fla., July 12-17,

1997 (1998), Meeting Date 1997, 163-167.

Editor(s): Werner, Rudolf. IOS Press: Amsterdam,

Neth.

CODEN: 66XYAX

DOCUMENT TYPE:

Conference

LANGUAGE: English We recently reported on a synthetic antiarrhythmic peptide (AAP10, NH2- GLY-

AB ALA-GLY-HYP-PRO-TYR-CONH2) which was found to be effective against arrhythmia in the late ischemic period in isolated rabbit hearts. This peptide enhanced gap junctional current in pairs of adult guinea pig cardiomyocytes. In this study we wanted to investigate whether AAP10 acts on uncoupled guinea pig papillary muscles. After 30 min of equilibration at normoxic conditions the muscles were submitted to hypoxia with glucose free superfusion for 20 min with or without pretreatment with 10 nM AAP10. Under these conditions intracellular action potentials were recorded and the delay between stimulus and propagated action potential (stimulus-response interval, SRI) was evaluated. We found no effect of AAP10 under normoxic conditions on SRI or on action potential morphol. Resting membrane potential, amplitude, action potential duration, dU/dtmax were not altered. However, while in untreated muscles uncoupling occurred after 12 min, this was not the case in muscles treated with AAP10. In addnl. expts., we could demonstrate that uncoupling via 50 mM Na-propionate could be antagonized by 10 nM AAP10 without affecting other parameters than SRI. This AAP10 effect could be fully inhibited by 10 μM genistein and 1 μM bisindolylmaleimide I (a specific inhibitor of PKC), but not by 2 μM H8 (a specific PKA blocker) and not by 5 μM genistein. Using 14Clabeled AAP10 we found that the substance binds to membrane proteins but not to connexin 43. From these results we conclude that AAP10 can enhance intercellular coupling especially in situations with reduced coupling probably via a protein kinase C mediated mechanism.

CC 1-8 (Pharmacology)

IT 159503-65-8, AAP10

> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(effects of an antiarrhythmic peptide on intercellular coupling via gap junctions)

IT 159503-65-8, AAP10

> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(effects of an antiarrhythmic peptide on intercellular coupling via gap junctions)

RN - 159503-65-8 HCAPLUS

retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) CN INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & & & \\ \text{Me} & & & \\ \text{NH} & & & \\ \text{NH} & & & \\ \text{NH} & & & \\ \text{NH} & & & \\ \text{NH} & & & \\ \text{NH} & & & \\ \text{OH} & & & \\ \text{OH} & & & \\ \text{OH} & & & \\ \text{OH} & & & \\ \text{OH} & & & \\ \text{OH} & & & \\ \text{OH} & & & \\ \text{OH} & & & \\ \text{OH} & & & \\ \text{OH} & & & \\ \text{OH} & & & \\ \text{OH} & & & \\ \text{OH} & & & \\ \text{OH} & & \\ \text{OH} & & & \\ \text{OH} & &$$

_			

Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
=======================================	+====-	+=====	+=====	+======================================	+========
Aonuma, S	1980	28	3340		HCAPLUS
Dhein, S	1997	·		Cardiac gap junction	,
Dhein, S	1993	87	617	Circulation	HCAPLUS
Dhein, S	1995	92	I	Circulation	}
Dhein, S	1996	94	I	Circulation	
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1997	2	51	J Clin Exp Cardiol	!
Dhein, S	1994	350	174	Naunyn Schmiedeberg'	HCAPLUS
Echt, D	1991	324	781	New Engl J Med	MEDLINE
Kwak, B	1995	6	1707	Mol Biol Cell	HCAPLUS
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Manjunath, C	1987	142	228	Biochem Biophys Res	HCAPLUS
Muller, A	1993	88	11	Basic Res Cardiol	MEDLINE
Muller, A	1997	327	65	Eur J Pharmacol	MEDLINE
Muller, A	1997	356	76	Naunyn Schmiedeberg'	MEDLINE
Podrid, P	1985	29	33	Drugs	
Spray, D	1981	77	77	J Gen Physiol	MEDLINE
Takens-Kwak, B	1992	422	198	Pfluger's Arch	HCAPLUS
Weingart, R	1986	370	267	J Physiol (Lond)	MEDLINE

L98 ANSWER 17 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN 1997:278971 HCAPLUS Full-text

ACCESSION NUMBER:

DOCUMENT NUMBER:

127:17689

TITLE:

Process for preparation of triazine derivatives by

cyclization

INVENTOR(S):

Yagishita, Kenichi; Sato, Toyozo; Yokogoshi, Kiyonori

PATENT ASSIGNEE(S): SOURCE:

Permachem Asia, Ltd., Japan Jpn. Kokai Tokkyo Koho, 3 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09087256	Α	19970331	JP 1995-276084	19950920 <
PRIORITY APPLN. INFO.:			JP 1995-276084	19950920 <

OTHER SOURCE(S): CASREACT 127:17689

The title compds., useful for prevention and treatment of ulcer (no data), are prepared in an industrial manner efficiently and economically. Thus, 2,5-

dichlorobenzamidine is reacted with NaN(CN)2 in (HOCH2)2 to give 90% 2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine.

IC ICM C07D251-18

ICS C07D251-18; A61K031-53

CC 28-14 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT 57381-26-7P 57381-27-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(process for preparation of triazine derivs. by cyclization)


IT 57381-26-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(process for preparation of triazine derivs. by cyclization)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



L98 ANSWER 18 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1997:693510 HCAPLUS Full-text

DOCUMENT NUMBER:

128:18349

TITLE:

N-oxidation of irsogladine by the CYP2C subfamily in

the rat, dog, monkey and man

AUTHOR (S):

Nakamura, A.; Hirota, T.; Morino, A.; Shimada, T.;

Uematsu, T.

CORPORATE SOURCE:

Research Laboratories, Nippon Shinyaku Co., Ltd.,

Kyoto, 601, Japan

SOURCE:

Xenobiotica (1997), 27(10), 995-1003

CODEN: XENOBH; ISSN: 0049-8254

PUBLISHER:

Taylor & Francis

DOCUMENT TYPE:

Journal

LANGUAGE:

English

1. The metabolism of irsogladine (ISG) was studied in hepatic microsomes from the rat, dog, monkey and man, and marked species differences were observed in N-oxidation of ISG. The rank order of the activity of the N-oxidation was shown to be man < monkey < dog < rat. 2. Anti-NADPH-P 450 reductase antibody inhibited the formation of the N-oxidized metabolite of ISG (ISG-N-oxide) in hepatic microsomes from rats by 74%. Anti-CYP2C11 antibody also inhibited the formation of ISG-N-oxide in hepatic microsomes from rat by 73 %, whereas anti-CYP2E1, 3A2 and 4A1 antibody did not inhibit N-oxidation Thus, CYP2C11 in the rat is at least partially responsible for the N-oxidation of ISG in the rat.

3. Anti-CYP2C11 antibody also inhibited the formation of ISG-N-oxide in hepatic microsomes from the dog and monkey by 61 and 46 % resp. Therefore, a isoform(s) similar to CYP2C11 partially contributed to the N-oxidation of ISG in the dog and monkey. In contrast, human CYP2C9, a member of the human CYP2C subfamily, did not catalyze the N-oxidation of ISG. 4. These findings show

that the marked species difference in the N-oxidation of ISG is caused by the difference in the catalytic properties of CYP2C among the species examined

CC 1-2 (Pharmacology)

Section cross-reference(s): 13

IT 57381-26-7, Irsogladine

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(N-oxidation of irsogladine by CYP2C subfamily in rat, dog, monkey and man)

IT 57381-26-7, Irsogladine

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(N-oxidation of irsogladine by CYP2C subfamily in rat, dog, monkey and man)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

RETABLE					
Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
=======================================	+=====	+=====	+=====	+======================================	
Ando, T	1989	36	1221	Arzneimittel Forschu	
Cashman, J	1993	21	492	Drug Metabolism and	!
Chiba, K	1995	10	391	Xenobiotic Metabolis	!
Funae, Y	1993	1	221	Handbook of Experime	
Gonzalez, F	1993		239	Handbook of Experime	
Imaoka, S	1996	51	1041	Biochemical Pharmaco	
Komori, M	1989	38	235	Biochemical Pharmaco	•
Lowry, O	1981	193	265	Journal of Biologica	
Mani, C	1993	21	645		HCAPLUS
Mani, C	1993	21	657	Drug Metabolism and	HCAPLUS
Miura, T	1989	49 .	365	Japan Journal of Pha	7
Nakashima, M	1984	34	492	Arzneimittel Forschu	!
Nedelcheva, V	1994	24	1151	Xenobiotica	HCAPLUS
Ohta, O	1983	996	142	Biochimica et Biophy	<u>:</u>
Prough, R	1977	180	363	Archives of Biochemi	<u> </u>
Rodrigues, A	1994	22	788	J	HCAPLUS
Rouer, E	1987	15	524	1	HCAPLUS
Shimada, T	1994	270	414	Journal of Pharmacol	!
Smith, D	1991	23	355	Drug Metabolism Revi	!
Sugiyama, M	1989	36	1229	Arzneimittel Forschu	!
Uchida, T	1990	38	644	Molecular Pharmacolo	
Ueda, F	1984	34	474	Arzneimittel Forschu	!
Ueda, F	1984	34	478	Arzneimittel Forschu	•
Ueda, F	1991	57	321	Japan Journal of Pha	
Ueda, F	1994	271	397	Journal of Pharmacol	T .
Weaver, R	1994	47	763	Biochemical Pharmaco	:
Zins, G	1965	150	109	Journal of Pharmacol	HCAPLUS

Zins, G | 1967 | 159 | 194 · | Journal of Pharmacol |

L98 ANSWER 19 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1997:424142 HCAPLUS Full-text

DOCUMENT NUMBER:

127:130662

TITLE:

Actions of the antiarrhythmic peptide AAP10 on

intercellular coupling

AUTHOR (S):

Mueller, Andreas; Schaefer, Thomas; Linke, Werner; Tudyka, Tatjana; Gottwald, Michaela; Klaus, Wolfgang;

Dhein, Stefan

CORPORATE SOURCE:

Institute of Pharmacology, University of Koln, Koln,

D-50931, Germany

SOURCE:

Naunyn-Schmiedeberg's Archives of Pharmacology (

1997), 356(1), 76-82

CODEN: NSAPCC; ISSN: 0028-1298

PUBLISHER: DOCUMENT TYPE: Springer Journal

LANGUAGE: English Disturbances in gap junction distribution and a decrease in the connexin43

content of the heart were shown to occur after myocardial infarction and in ischemic heart disease, resp. These changes are now thought to play an important role in the genesis of arrhythmias associated with these diseases. It is thought that agents that can increase cellular coupling might be beneficial in these situations. Recently, we presented data showing that the synthetic peptide AAP10 acts antiarrhythmically in a model of regional The data suggested that AAP10 might act via an increase in cellular ischemia. The goal of this study was to establish whether AAP10 can interact with cardiac gap junctions. Measurements of the stimulus-response-interval (SRI) in quinea pig papillary muscle showed that high concns. of AAP10 (1 μ M) can decrease the SRI by about 10% under normoxic conditions. At lower concns. (10 nM) AAP10 had no effect on SRI under normoxic conditions but prevented the increase in the SRI induced by perfusion with hypoxic, glucose-free Tyrode's solution Double-cell voltage-clamp expts. confirmed that AAP10 can interact with cardiac gap junctions. 10 NM AAP10 could either diminish or reverse the run-down of gap junction conductance normally observed in pairs of guinea pig ventricular myocytes. During control gap junction conductance decreased with a rate of -2.5±2.0 nS/min. After application of 10 nM AAP10 gap junction conductance increased with a rate of $+1.0\pm0.7$ nS/min. After washout of AAP10 gap junction conductance decreased again with a rate not significantly different from control. Our results show that AAP10 does interact with gap junctions. Because no other effects of AAP10 on other electrophysiol. parameters could be found, this action on gap junctions might be the basis of AAP10's antiarrhythmic effect seen in previous studies.

CC 1-8 (Pharmacology)

159503-65-8, AAP 10

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(actions of antiarrhythmic peptide AAP10 on intercellular coupling)

IT 159503-65-8, AAP 10

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(actions of antiarrhythmic peptide AAP10 on intercellular coupling)

RN159503-65-8 HCAPLUS

retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA CN INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & &$$

L98 ANSWER 20 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1997:331424 HCAPLUS Full-text

CORPORATE SOURCE:

DOCUMENT NUMBER: 127:44651

Increase in gap junction conductance by an TITLE:

antiarrhythmic peptide

Mueller, Andreas; Gottwald, Michaela; Tudyka, Tatjana; AUTHOR (S):

Linke, Werner; Klaus, Wolfgang; Dhein, Stefan Institute of Pharmacology, University of Koeln,

Gleueler Strasse 24, Koln, D-50931, Germany

European Journal of Pharmacology (1997), SOURCE:

327(1), 65-72

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Journal DOCUMENT TYPE: English LANGUAGE:

AB Impaired cellular coupling is thought to be a very important factor for the genesis of cardiac arrhythmia. Cellular coupling is mediated by gap junctions. However, there are no therapeutic agents or exptl. substances yet that increase cellular coupling. In addition, it has been shown that most antiarrhythmic drugs available now possess serious adverse effects. Thus, there is an urgent need for new antiarrhythmic agents. Previous studies using epicardial mapping in isolated rabbit hearts provided indirect evidence supporting the hypothesis that a newly synthesized antiarrhythmic peptide (Gly-Ala-Gly -4Hyp-Pro-Tyr-CONH2 = AAP10) might act via an increase in cellular, i.e., gap junctional coupling. The aim of the present study was to test this hypothesis. Measurement of the stimulus-response interval in papillary muscle showed a decrease of about 10% after application of 1 μM AAP10. These results are compatible with the hypothesis of AAP10 acting on gap junctions. In order to prove this hypothesis, gap junction conductance was measured directly by performing double-cell voltage-clamp expts. in isolated pairs of quinea-pig myocytes. During a 10 min control period gap junction conductance slowly decreased with a rate of -2.5±2.0 nS/min. After application of 10 nM AAP10 this behavior reversed and gap junction conductance now increased with $+1.0\pm0.7$ nS/min. Upon washout of AAP10 gap junction conductance again decreased with a rate similar to that under control conditions. Another important finding was that we could not detect any other actions of AAP10 on cardiac myocytes. All parameters of the transmembrane action potential remained unchanged and, similarly, no changes in the IV relationship of single cardiac myocytes treated with 10 nM AAP10 could be observed We conclude that AAP10 increases gap junction conductance, i.e., cellular coupling in the heart. This finding might be the first step towards the development of a new class of antiarrhythmic agents.

CC 1-8 (Pharmacology)

IT Antiarrhythmics

(antiarrhythmic peptide AAP10 (Gly-Ala-Gly

-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance)

IT Cell junction

(gap junction, coupling; antiarrhythmic peptide AAP10 (Gly-Ala-Gly-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance)

IT 159503-65-8, AAP 10

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiarrhythmic peptide AAP10 (Gly-Ala-Gly

-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance 180268740)

IT 159503-65-8, AAP 10

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiarrhythmic peptide AAP10 (Gly-Ala-Gly

-4Hyp-Pro-Tyr-CONH2) increases gap junction conductance 180268740)

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RETABLE

Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
Aonuma, S	+====- 1980	+====- 28	+===== 3332	Chem Pharm Bull	HCAPLUS
Balke, C	1988	63	879	Circ Res	MEDLINE
Bastide, B	1993	73	1138	Circ Res	HCAPLUS
Cai, D	1994	41	217	IEEE Trans Biomed En	!
Cole, W	1988	53	809	Biophys J	MEDLINE
de-Carvalho, C	1992	70	733	Circ Res	
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1994	350	174	Naunyn-Schmiedeberg'	HCAPLUS
Halliwell, J	1994		17	Microelectrode Techn	
Hamill, O	1981	391	85	Pflug Arch	MEDLINE
Jarolimek, W	1993	425	491	Pflug Arch	HCAPLUS
Kleber, A	1987	61	271	Circ Res	MEDLINE
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Merx, W	1977	94	603	Am Heart J	MEDLINE
Metzger, P	1985	366	177	J Physiol (London)	MEDLINE
Muller, A	1993	88	11	Basic Res Cardiol	MEDLINE
Page, E	1992	!	1003	The Heart and Cardio	!
Peters, N	1993	88	864	Circulation	HCAPLUS

Saffitz, J	1993	87	1742	Circulation	MEDLINE
Severs, N	1994	5	462	J Cardiovasc Electro	MEDLINE
Smith, J	1991	139	801	Am J Pathol	MEDLINE
Spach, M	1994	90	1103	Circulation	MEDLINE
Spray, D	1981	77	77	J Gen Physiol	MEDLINE
Steendijk, P	1993	88	167	Basic Res Cardiol	MEDLINE
Veenstra, R	1990	258	C662	Am J Physiol	MEDLINE
Wang, H	1992	63	139	Biophys J	HCAPLUS
Weingart, R	1988	63	72	Circ Res	MEDLINE
Weingart, R	1986	370	267	J Physiol (London)	MEDLINE
Wilders, R	1992	63	942	Biophys J	MEDLINE

L98 ANSWER 21 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1997:86895 HCAPLUS Full-text

DOCUMENT NUMBER:

126:194926

TITLE:

Triazine derivatives inhibit rat hepatocarcinogenesis

but do not enhance gap junctional intercellular

communication

AUTHOR (S):

Hori, Takaaki; Asamoto, Makoto; Krutovskikh, Vladimir;

Iwahori, Yoshio; Maeda, Mitsuaki; Toriyama-Baba,

Hiroyasu; Takasuka, Nobuo; Tsuda, Hiroyuki

CORPORATE SOURCE:

Chemotherapy Division, National Cancer Center Research

Institute, Tokyo, 104, Japan

SOURCE:

Japanese Journal of Cancer Research (1997),

88(1), 12-17

CODEN: JJCREP; ISSN: 0910-5050

PUBLISHER:

Japanese Cancer Association

DOCUMENT TYPE:

Journal

LANGUAGE: English

AB We report here novel candidate chemopreventive agents active against exptl. hepatocarcinogenesis. The triazine derivs. 6-(2-chlorophenyl)-2,4- diamino-1,3,5-triazine (2CPDAT), 6-(3-chlorophenyl)-2,4-diamino-1,3,5- triazine (3CPDAT), 6-(4-chlorophenyl)-2,4-diamino-1,3,5-triazine (4CPDAT), 6-(4pyridyl)-2,4-diamino-1,3,5-triazine (PyDAT), and 6-(pyridine N-oxid-4-yl)-2,4diamino-1,3,5-triazine (PyNODAT), synthesized in our laboratory, in addition to 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine (DCPDAT), or irsogladine, which is a widely used anti-ulcer drug, were investigated for potential chemopreventive effects in a rat liver medium-term bioassay system. A significant inhibitory influence on enzyme-altered liver foci was found for 2CPDAT, 3CPDAT, 4CPDAT, and PyNODAT, but not for DCPDAT or PyDAT. The involvement of gap junctional intercellular communication in the inhibition was studied, but no change in gap junctional intercellular communication capacity in rat liver cells in vitro or in gap junction protein (connexin 32) expression in rat liver in vivo was noted. These results indicate that, although these irsogladine analogs exert inhibitory effects on rat liver carcinogenesis, their action is independent of modification of gap junctional intercellular communication.

1-6 (Pharmacology) CC

IT 4514-53-8 4514-54-9 29366-77-6 33237-20-6 57381-26-7

187753-86-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(triazine derivs. inhibit hepatocarcinogenesis but do not enhance gap junctional intercellular communication)

IT 57381-26-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(triazine derivs. inhibit hepatocarcinogenesis but do not enhance gap

junctional intercellular communication)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

Referenced Author (RAU) Year VOL FG Referenced Work Referenced (RAU) File	RETABLE					
Asamoto, M 1991 4 322 Mol Carcinog HCAPLUS Bertram, J 1994 234 235 Methods Enzymol HCAPLUS Bertram, J 1989 18 562 Prev Med HCAPLUS Bex, V 1995 13 69 Cell Biochem Funct HCAPLUS Budunova, I 1994 10 71 Cell Biol Toxicol HCAPLUS Budunova, I 1994 10 71 Cell Biol Toxicol HCAPLUS Demilo, A 1981 29 82 Jagric Food Chem HCAPLUS Bex, V 1996 87 549 Jpn J Cancer Res HCAPLUS Hirose, Y 1996 87 549 Jpn J Cancer Res HCAPLUS Holder, J 1993 53 3475 Cancer Res HCAPLUS Holder, J 1993 53 3475 Cancer Res HCAPLUS Holder, J 1998 18 565 J Cancer Res HCAPLUS Holder, N 1988 9 387 Carcinogenesis HCAPLUS HOLDER, N 1988 9 387 Carcinogenesis HCAPLUS HOLDER, N 1996 17 333 Carcinogenesis HCAPLUS HOLDER, MIRCAPLUS H	Referenced Author	Year	VOL	PG	Referenced Work	Referenced
Asamoto, M	(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
Bertram, J	=======================================	+=====-	+=====	+======	+====================================	+==== = =
Bertram, J 1989 18 562 Prev Med HCAPLUS	Asamoto, M	1991	4	322	Mol Carcinog	HCAPLUS
Bex, V 1995 13 69 Cell Biochem Funct HCAPLUS Budunova, I 1994 10 71 Cell Biol Toxicol HCAPLUS Demilo, A 1981 29 82 J Agric Food Chem HCAPLUS El-Fouly, M 1987 168 422 Exp Cell Res HCAPLUS Hirose, Y 1996 87 549 Jpn J Cancer Res HCAPLUS Holder, J 1993 53 3475 Cancer Res HCAPLUS Hosokawa, T 1992 118 565 J Cancer Res Clin On MEDLINE Ito, N 1988 9 387 Carcinogenesis HCAPLUS Jansen, L 1996 17 333 Carcinogenesis HCAPLUS Klaunig, J 1990 62 135 Lab Invest HCAPLUS Kumar, N 1986 103 767 J Cell Biol HCAPLUS Kumar, N 1986 103 767 J Cell Biol Toxicol HCAPLUS McKarns, S 1992	Bertram, J	1994	234	235	Methods Enzymol	HCAPLUS
Budunova, I 1994 10 71 Cell Biol Toxicol HCAPLUS Demilo, A 1981 29 82 J Agric Food Chem HCAPLUS El-Fouly, M 1987 168 422 Exp Cell Res HCAPLUS Hirose, Y 1996 87 549 Jpn J Cancer Res HCAPLUS Holder, J 1993 53 3475 Cancer Res HCAPLUS Hosokawa, T 1993 18 565 J Cancer Res HCAPLUS Ito, N 1988 9 387 Carcinogenesis HCAPLUS Ito, N 1989 17 630 Toxicol Pathol HCAPLUS Ito, N 1989 17 630 Toxicol Pathol HCAPLUS Klaunig, J 1990 62 135 Lab Invest HCAPLUS Klaunig, J 1990 62 135 Lab Invest HCAPLUS Kumar, N 1991 12 1701 Carcinogenesis HCAPLUS Kumar, N 1996	Bertram, J	1989	18	562	Prev Med	HCAPLUS
Demilo, A 1981 29 82	Bex, V	1995	13 .	69	Cell Biochem Funct	HCAPLUS
El-Fouly, M	Budunova, I	1994	10	71	Cell Biol Toxicol	HCAPLUS
Hirose, Y Holder, J Holder, J Hosokawa, T	Demilo, A	1981	29	82	J Agric Food Chem	HCAPLUS
Holder, J 1993 53 3475 Cancer Res HCAPLUS Hosokawa, T 1992 118 565 J Cancer Res Clin On MEDLINE Ito, N 1988 9 387 Carcinogenesis HCAPLUS Ito, N 1989 17 630 Toxicol Pathol HCAPLUS Jansen, L 1996 17 333 Carcinogenesis HCAPLUS Klaunig, J 1990 62 135 Lab Invest HCAPLUS Krutovskikh, V 1991 12 1701 Carcinogenesis HCAPLUS Kwmar, N 1986 103 767 J Cell Biol HCAPLUS Lalezari, I 1971 16 117 J Chem Eng Data HCAPLUS Loewenstein, W 1979 560 1 Biochim Biophys Acta HCAPLUS McKarns, S 1992 8 89 Cell Biol Toxicol HCAPLUS Mesnil, M 1986 165 391 Exp Cell Res HCAPLUS Murray, A 1979 91 395 Biochem Biophys Res HCAPLUS Murray, A 1982 7 587 Carcinogenesis MEDLINE Ogino, A 1980 23 437 J Med Chem HCAPLUS Ruch, R 1987 87 111 Toxicol Appl Pharmac HCAPLUS Ruch, R 1987 87 111 Toxicol Appl Pharmac HCAPLUS Saez, J 1989 257 1 Am J Physiol Sato, Y 1993 322 155 FEBS Lett HCAPLUS Satoh, K 1985 82 3964 Proc Natl Acad Sci U HCAPLUS Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Smyrl, N 1986 36 251 Pharmacometrics Trosko, J 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1994 34 478 Arzneim Forsch HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	El-Fouly, M	1987	168	422	Exp Cell Res	HCAPLUS
Hosokawa, T	Hirose, Y	1996	87	549	Jpn J Cancer Res	HCAPLUS
Ito, N 1988 9 387 Carcinogenesis HCAPLUS Ito, N 1989 17 630 Toxicol Pathol HCAPLUS Jansen, L 1996 17 333 Carcinogenesis HCAPLUS Klaunig, J 1990 62 135 Lab Invest HCAPLUS Krutovskikh, V 1991 12 1701 Carcinogenesis HCAPLUS Kumar, N 1986 103 767 J Cell Biol HCAPLUS Lalezari, I 1971 16 117 J Chem Eng Data HCAPLUS Loewenstein, W 1979 560 1 Biochim Biophys Acta HCAPLUS McKarns, S 1992 8 89 Cell Biol Toxicol HCAPLUS McKarns, S 1992 8 89 Cell Biol Toxicol HCAPLUS McKarns, S 1992 8 89 Cell Biol Toxicol HCAPLUS McKarns, S 1992 8 89 Cell Res HCAPLUS McKarns, S <t< td=""><td>Holder, J</td><td>1993</td><td>53</td><td>3475</td><td>Cancer Res</td><td>HCAPLUS</td></t<>	Holder, J	1993	53	3475	Cancer Res	HCAPLUS
Topic Topi	Hosokawa, T	1992	118	565	J Cancer Res Clin On	MEDLINE
Top. Top.	Ito, N	1988	9	387	Carcinogenesis	HCAPLUS
Rlaunig, J		1989	17	630	Toxicol Pathol	HCAPLUS
Krutovskikh, V 1991 12 1701 Carcinogenesis HCAPLUS Kumar, N 1986 103 767 J Cell Biol HCAPLUS Lalezari, I 1971 16 117 J Chem Eng Data HCAPLUS Loewenstein, W 1979 560 1 Biochim Biophys Acta HCAPLUS McKarns, S 1992 8 89 Cell Biol Toxicol HCAPLUS Mesnil, M 1986 165 391 Exp Cell Res HCAPLUS Murray, A 1979 91 395 Biochem Biophys Res HCAPLUS Murray, A 1982 7 587 Carcinogenesis MEDLINE Ogino, A 1980 23 437 J Med Chem HCAPLUS Ruch, R 1987 87 111 Toxicol Appl Pharmac HCAPLUS Saez, J 1989 257 1 Am J Physiol HCAPLUS Sato, Y 1993 322 155 FEBS Lett HCAPLUS Saboh, K	Jansen, L	1996	17	333	Carcinogenesis	HCAPLUS
Kumar, N 1986 103 767 J Cell Biol HCAPLUS Lalezari, I 1971 16 117 J Chem Eng Data HCAPLUS Loewenstein, W 1979 560 1 Biochim Biophys Acta HCAPLUS McKarns, S 1992 8 89 Cell Biol Toxicol HCAPLUS Mesnil, M 1986 165 391 Exp Cell Res HCAPLUS Murray, A 1976 91 395 Biochem Biophys Res HCAPLUS Murray, A 1982 7 587 Carcinogenesis MEDLINE Ogino, A 1980 23 437 J Med Chem HCAPLUS Ruch, R 1987 87 111 Toxicol Appl Pharmac HCAPLUS Saez, J 1989 257 1 Am J Physiol Sato, Y 1993 322 155 FEBS Lett HCAPLUS Sato, Y 1993 322 155 FEBS Lett HCAPLUS Shaga, T 1981 213 1023 Science HCAPLUS Sumi, N 1982 19 493	Klaunig, J	1990	62	135	Lab Invest	HCAPLUS
Lalezari, I	Krutovskikh, V	1991	12	1701	Carcinogenesis	HCAPLUS
Loewenstein, W 1979 560 1 Biochim Biophys Acta HCAPLUS McKarns, S 1992 8 89 Cell Biol Toxicol HCAPLUS Mesnil, M 1986 165 391 Exp Cell Res HCAPLUS Murray, A 1979 91 395 Biochem Biophys Res HCAPLUS Murray, A 1982 7 587 Carcinogenesis MEDLINE Ogino, A 1980 23 437 J Med Chem HCAPLUS Ruch, R 1987 87 111 Toxicol Appl Pharmac HCAPLUS Saez, J 1989 257 1 Am J Physiol Bart HCAPLUS Sato, Y 1993 322 155 FEBS Lett HCAPLUS Sato, Y 1993 322 155 FEBS Lett HCAPLUS Slaga, T 1981 213 1023 Science HCAPLUS Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Tsushimoto, G 19	Kumar, N	1986	103	767	J Cell Biol	HCAPLUS
McKarns, S 1992 8 89 Cell Biol Toxicol HCAPLUS Mesnil, M 1986 165 391 Exp Cell Res HCAPLUS Murray, A 1979 91 395 Biochem Biophys Res HCAPLUS Murray, A 1982 7 587 Carcinogenesis MEDLINE Ogino, A 1980 23 437 J Med Chem HCAPLUS Ruch, R 1987 87 111 Toxicol Appl Pharmac HCAPLUS Saez, J 1989 257 1 Am J Physiol HCAPLUS Sato, Y 1993 322 155 FEBS Lett HCAPLUS Satoh, K 1985 82 3964 Proc Natl Acad Sci U HCAPLUS Slaga, T 1981 213 1023 Science HCAPLUS Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Sumi, N 1986 36 251 Pharmacometrics Trosko, J 1993 53 1	Lalezari, I	1971	16	117	J Chem Eng Data	HCAPLUS
Mesnil, M 1986 165 391 Exp Cell Res HCAPLUS Murray, A 1979 91 395 Biochem Biophys Res HCAPLUS Murray, A 1982 7 587 Carcinogenesis MEDLINE Ogino, A 1980 23 437 J Med Chem HCAPLUS Ruch, R 1987 87 111 Toxicol Appl Pharmac HCAPLUS Saez, J 1989 257 1 Am J Physiol Sato, Y 1993 322 155 FEBS Lett HCAPLUS Satoh, K 1985 82 3964 Proc Natl Acad Sci U HCAPLUS Slaga, T 1981 213 1023 Science HCAPLUS Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Sumi, N 1986 36 251 Pharmacometrics Trosko, J 1993 53 1 Life Sci HCAPLUS Ueda, F 1984 34 478 Arzneim Forsch HCAPLUS <td>Loewenstein, W</td> <td>1979</td> <td>560</td> <td>1</td> <td>Biochim Biophys Acta</td> <td>HCAPLUS</td>	Loewenstein, W	1979	560	1	Biochim Biophys Acta	HCAPLUS
Murray, A 1979 91 395 Biochem Biophys Res HCAPLUS Murray, A 1982 7 587 Carcinogenesis MEDLINE Ogino, A 1980 23 437 J Med Chem HCAPLUS Ruch, R 1987 87 111 Toxicol Appl Pharmac HCAPLUS Saez, J 1989 257 1 Am J Physiol Sato, Y 1993 322 155 FEBS Lett HCAPLUS Satoh, K 1985 82 3964 Proc Natl Acad Sci U HCAPLUS Slaga, T 1981 213 1023 Science HCAPLUS Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Sumi, N 1986 36 251 Pharmacometrics Trosko, J 1993 53 1 Life Sci HCAPLUS Tsushimoto, G 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1991 57 321 Jpn J Pharmacol	McKarns, S	1992	8	89	Cell Biol Toxicol	HCAPLUS
Murray, A 1982 7 587 Carcinogenesis MEDLINE Ogino, A 1980 23 437 J Med Chem HCAPLUS Ruch, R 1987 87 111 Toxicol Appl Pharmac HCAPLUS Saez, J 1989 257 1 Am J Physiol Sato, Y 1993 322 155 FEBS Lett HCAPLUS Satoh, K 1985 82 3964 Proc Natl Acad Sci U HCAPLUS Slaga, T 1981 213 1023 Science HCAPLUS Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Sumi, N 1986 36 251 Pharmacometrics Trosko, J 1993 53 1 Life Sci HCAPLUS Tsushimoto, G 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1991 57 321 Jpn J Pharmacol HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS	Mesnil, M	1986	165	391	Exp Cell Res	HCAPLUS
Ogino, A 1980 23 437 J Med Chem HCAPLUS Ruch, R 1987 87 111 Toxicol Appl Pharmac HCAPLUS Saez, J 1989 257 1 Am J Physiol Sato, Y 1993 322 155 FEBS Lett HCAPLUS Satoh, K 1985 82 3964 Proc Natl Acad Sci U HCAPLUS Slaga, T 1981 213 1023 Science HCAPLUS Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Sumi, N 1986 36 251 Pharmacometrics HCAPLUS Trosko, J 1993 53 1 Life Sci HCAPLUS Tsushimoto, G 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1994 34 478 Arzneim Forsch HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res<	Murray, A	1979	91	395	Biochem Biophys Res	HCAPLUS
Ruch, R 1987 87 111 Toxicol Appl Pharmac HCAPLUS Saez, J 1989 257 1 Am J Physiol Sato, Y 1993 322 155 FEBS Lett HCAPLUS Satoh, K 1985 82 3964 Proc Natl Acad Sci U HCAPLUS Slaga, T 1981 213 1023 Science HCAPLUS Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Sumi, N 1986 36 251 Pharmacometrics Trosko, J 1993 53 1 Life Sci HCAPLUS Tsushimoto, G 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1984 34 478 Arzneim Forsch HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Murray, A	1982	7	587	Carcinogenesis	MEDLINE
Saez, J 1989 257 1 Am J Physiol Sato, Y 1993 322 155 FEBS Lett HCAPLUS Satoh, K 1985 82 3964 Proc Natl Acad Sci U HCAPLUS Slaga, T 1981 213 1023 Science HCAPLUS Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Sumi, N 1986 36 251 Pharmacometrics Trosko, J 1993 53 1 Life Sci HCAPLUS Tsushimoto, G 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1984 34 478 Arzneim Forsch HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Ogino, A	1980	23	437	J Med Chem	HCAPLUS
Sato, Y 1993 322 155 FEBS Lett HCAPLUS Satoh, K 1985 82 3964 Proc Natl Acad Sci U HCAPLUS Slaga, T 1981 213 1023 Science HCAPLUS Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Sumi, N 1986 36 251 Pharmacometrics Trosko, J 1993 53 1 Life Sci HCAPLUS Tsushimoto, G 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1984 34 478 Arzneim Forsch HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Ruch, R	1987	87 ·	111	Toxicol Appl Pharmac	HCAPLUS
Satoh, K 1985 82 3964 Proc Natl Acad Sci U HCAPLUS Slaga, T 1981 213 1023 Science HCAPLUS Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Sumi, N 1986 36 251 Pharmacometrics Trosko, J 1993 53 1 Life Sci HCAPLUS Tsushimoto, G 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1984 34 478 Arzneim Forsch HCAPLUS Ueda, F 1991 57 321 Jpn J Pharmacol HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Saez, J	1989	257	1	Am J Physiol	
Slaga, T 1981 213 1023 Science HCAPLUS Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Sumi, N 1986 36 251 Pharmacometrics Trosko, J 1993 53 1 Life Sci HCAPLUS Tsushimoto, G 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1984 34 478 Arzneim Forsch HCAPLUS Ueda, F 1991 57 321 Jpn J Pharmacol HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Sato, Y	1993	322	155	FEBS Lett	HCAPLUS
Smyrl, N 1982 19 493 J Heterocycl Chem HCAPLUS Sumi, N 1986 36 251 Pharmacometrics Trosko, J 1993 53 1 Life Sci HCAPLUS Tsushimoto, G 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1984 34 478 Arzneim Forsch HCAPLUS Ueda, F 1991 57 321 Jpn J Pharmacol HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Satoh, K	1985	82	3964	Proc Natl Acad Sci U	HCAPLUS
Sumi, N 1986 36 251 Pharmacometrics Trosko, J 1993 53 1 Life Sci HCAPLUS Tsushimoto, G 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1984 34 478 Arzneim Forsch HCAPLUS Ueda, F 1991 57 321 Jpn J Pharmacol HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Slaga, T	1981	213	1023	Science	HCAPLUS
Trosko, J 1993 53 1 Life Sci HCAPLUS Tsushimoto, G 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1984 34 478 Arzneim Forsch HCAPLUS Ueda, F 1991 57 321 Jpn J Pharmacol HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Smyrl, N	1982	19	493	J Heterocycl Chem	HCAPLUS
Tsushimoto, G 1983 12 721 Arch Environ Contam HCAPLUS Ueda, F 1984 34 478 Arzneim Forsch HCAPLUS Ueda, F 1991 57 321 Jpn J Pharmacol HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Sumi, N	1986	36	251	Pharmacometrics	
Ueda, F 1984 34 478 Arzneim Forsch HCAPLUS Ueda, F 1991 57 321 Jpn J Pharmacol HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Trosko, J	1993	53	1	Life Sci	HCAPLUS
Ueda, F 1991 57 321 Jpn J Pharmacol HCAPLUS Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Tsushimoto, G	1983	12	721	Arch Environ Contam	HCAPLUS
Williams, G 1981 11 339 Cancer Lett HCAPLUS Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Ueda, F	1984	34	478	Arzneim Forsch	HCAPLUS
Yamasaki, H 1995 333 181 Mutat Res HCAPLUS Yotti, L 1979 206 1089 Science HCAPLUS	Ueda, F	1991	57	321	Jpn J Pharmacol	HCAPLUS
Yotti, L 1979 206 1089 Science HCAPLUS	Williams, G	1981	11	339	Cancer Lett	HCAPLUS
	Yamasaki, H	1995	333	181	Mutat Res	HCAPLUS
Zhang, L 1991 12 2109 Carcinogenesis HCAPLUS	Yotti, L	1979	206	1089	Science	HCAPLUS
	Zhang, L	1991	12	2109	Carcinogenesis	HCAPLUS

L98 ANSWER 22 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1996:385934 HCAPLUS Full-text

DOCUMENT NUMBER: 125:41767

Synthesis and formulation of triazine derivatives as TITLE:

hepatitis remedies

INVENTOR (S):

Ueda, Fusao; Ozaki, Takayuki; Nakamura, Ken-ichi

Nippon Shinyaku Co., Ltd., Japan PATENT ASSIGNEE(S):

SOURCE:

GI

PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 9604914	A1 19960222	WO 1995-JP1577	19950808 <
W: AU, BR, CA,	CN, FI, HU, JP,	KR, MX, NO, NZ, RU,	UA, US, VN
RW: AT, BE, CH,	DE, DK, ES, FR,	GB, GR, IE, IT, LU,	MC, NL, PT, SE
CA 2197091	A1 19960222	CA 1995-2197091	19950808 <
AU 9531920	A 19960307	AU 1995-31920	19950808 <
AU 703263	B2 19990325		
EP 775487	A1 19970528	EP 1995-927992	19950808 <
R: AT, BE, CH,	DE, DK, ES, FR,	GB, IT, LI, NL, PT,	SE
CN 1155244	A 19970723	CN 1995-194521	19950808 <
BR 9508539	A 19971028	BR 1995-8539	19950808 <
HU 77735	A2 19980728	HU 1997-355	19950808 <
RU 2147233	C1 20000410	RU 1997-103983	19950808 <
US 5962453	A 19991005	US 1997-776992	19970206 <
PRIORITY APPLN. INFO.:	•	JP 1994-185810	A 19940808 <
•		WO 1995-JP1577	W 19950808 <
OTHER SOURCE(S):	MARPAT 125:4176	7	

AB A medicine useful as a hepatitis remedy is claimed which contains as the active ingredient a triazine derivative represented by general formula (I), a solvate thereof, or a salt thereof, wherein R1 and R2 represent each independently hydrogen or (un) substituted alkyl, aralkyl or alkenyl, or NR1R2 represents a cyclic amino group which may bear, in addition to the pertinent nitrogen atom, nitrogen, oxygen or sulfur as the ring atom and may be substituted, provided the case where NR1R2 represents NH2 is excluded. Studies in mouse and rat models of hepatitis indicate the remedial efficacy of various I.

IC ICM A61K031-53

ICS A61K031-535; A61K031-54; A61K031-55

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 28

57381-26-7DP, derivs. 178105-27-6P ΙT 178105-28-7P 178105-29-8P 178105-32-3P 178105-48-1P 178105-57-2P 178105-31-2P 178105-59-4P

178105-60-7P 178105-61-8P 178105-65-2P 178105-85-6P 178105-91-4P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and formulation of triazine derivs. as hepatitis remedies) 51-35-4, 4-Hydroxyproline 56-40-6, Glycine, reactions 62-53-3, Aniline, reactions 64-04-0, Phenethylamine N, N-Dimethylformamide, reactions 74-89-5, Methylamine, reactions 92-54-6, N-Phenylpiperazine 100-36-7, N,N-Diethylethylenediamine 100-46-9, Benzylamine, reactions 103-67-3, N-Methylbenzylamine 103-76-4, N-(2-Hydroxyethyl)piperazine 107-15-3, 1,2-Ethanediamine, 108-18-9, Diisopropylamine 109-05-7, 2-Methylpiperidine reactions 109-85-3, 2-Methoxyethylamine 109-83-1, N-Methyl-N-(2-hydroxyethyl)amine 109-96-6, 3-Pyrroline 110-85-0, Piperazine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 111-42-2, 123-75-1, Pyrrolidine, reactions 111-49-9, Hexamethylenimine reactions 123-90-0, Thiomorpholine 124-40-3, Dimethylamine, reactions Methanesulfonyl chloride 141-43-5, Ethanolamine, reactions 141-91-3, 2,6-Dimethylmorpholine 147-85-3, (s)-Proline, reactions 503-29-7, Azetidine 535-75-1, 2-Carboxypiperidine 598-41-4, Glycinamide 660-68-4, Diethylamine hydrochloride 841-77-0, 1-Diphenylmethylpiperazine 1499-56-5, trans-4-Hydroxy-L-proline methyl 1664-40-0, N-Phenylethylenediamine 1758-46-9, 2-Phenoxyethylamine 2038-03-1, 4-Morpholineethanamine 4360-51-4, Cinnamylamine 5082-74-6, 3-Hydroxymethylpyrrolidine 5382-16-1, 4-Hydroxypiperidine 5625-67-2, 2-Oxopiperazine 6457-49-4, 4-Hydroxymethylpiperidine 6859-99-0, 3-Hydroxypiperidine 18471-40-4, 3-Amino-1-benzylpyrrolidine 19130-96-2, 1,5-Dideoxy-1,5-imino-D-glucitol 20980-22-7 23356-96-9 24252-67-3 27578-60-5, 2-Piperidinoethylamine 31252-42-3, 4-Benzylpiperidine 40499-83-0, 3-Hydroxypyrrolidine 40807-61-2, 4-Hydroxy-4-phenylpiperidine 41661-47-6, 4-Oxopiperidine 45347-82-8, 3-Azetidinol 55276-43-2 68832-13-3 72351-36-1 81530-73-6 103706-76-9 138304-74-2 149366-79-0 178105-24-3 178105-25-4 178105-26-5 178105-46-9 178105-69-6 RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis and formulation of triazine derivs. as hepatitis remedies) IT 57381-26-7DP, derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and formulation of triazine derivs. as hepatitis remedies) 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

RN

IT

L98 ANSWER 23 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1996:203525 HCAPLUS Full-text DOCUMENT NUMBER: 124:278316

Inhibition of tumor growth and neovascularization by TITLE:

an anti-gastric ulcer agent irsogladine

Ono, Mayumi; Kawahara, Naoyuki; Goto, Daisuke; AUTHOR (S):

Wakabayashi, Yukihiro; Ushiro, Shin; Yoshida, Shigeo;

Izumi, Hiroto; Kuwano, Michihiko; Sato, Yashufumi School Medicine, Kyushu Univ., Fukuoka, 812-82, Japan

CORPORATE SOURCE: SOURCE:

Cancer Research (1996), 56(7), 1512-16

CODEN: CNREA8; ISSN: 0008-5472

American Association for Cancer Research PUBLISHER:

DOCUMENT TYPE: Journal LANGUAGE: English

Irsogladine used clin. as an anti-gastric ulcer agent, at 10-6-10-4 M, AB inhibited cell proliferation and tubular morphogenesis of vascular endothelial cells, but the proliferation of human epidermoid cancer of glioma cells was not inhibited by this drug, even at 10-4 M. In vivo studies demonstrated that p.o. administration of irsogladine significantly inhibited tumor growth of human glioma cells in mice, and histol. anal. showed a dramatic decrease of the neovascularization in the tumors. In mice transplanted with chambers containing human glioma cells or hepatic cancer cells, irsogladine also inhibited angiogenesis. These in vivo and in vitro assays demonstrate that irsogladine may be a unique and potent inhibitor of tumor angiogenesis.

CC 1-6 (Pharmacology)

IT 57381-26-7, Irsogladine

> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibition of tumor growth and neovascularization by irsogladine)

IT 57381-26-7, Irsogladine

> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibition of tumor growth and neovascularization by irsogladine)

RN 57381-26-7 HCAPLUS

CN1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 24 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:387151 HCAPLUS Full-text

DOCUMENT NUMBER: 125:104423

TITLE: Suppressing effects of 6-(2,5-dichlorophenyl)-2,4-

> diamino-1,3,5-triazine and related synthetic compounds on azoxymethane-induced aberrant crypt foci in rat

AUTHOR (S): Hirose, Yoshinobu; Tanaka, Takuji; Makita, Hiroki;

> Yang, Muzheng; Satoh, Kumiko; Hara, Akira; Maeda, Mitsuaki; Toriyama, Hiroyasu Baba; Mori, Hideki;

Tsuda, Hiroyuki

CORPORATE SOURCE: First Dep. Pathol., Gifu Univ. Sch. Med., Gifu, 500,

Japan

SOURCE: Japanese Journal of Cancer Research (1996), 87(6), 549-554

CODEN: JJCREP; ISSN: 0910-5050 Japanese Cancer Association

DOCUMENT TYPE:

PUBLISHER:

Journal

LANGUAGE: English

AB The modifying effects of di

The modifying effects of dietary administration of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and 5 related compds. on the occurrence of azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) were investigated in rats. Male F344 rats were given s.c. injections of AOM (15 mg/kg body weight) once a wk for 3 wks to induce ACF. They also received a diet containing 200 ppm test compound for 5 wks, starting one wk before the first dosing of AOM. At the termination of the experiment, all of the compds. had caused a significant reduction in ACF frequency, which might by associated with suppression of the expression of proliferation biomarkers. The apoptotic index in the colonic mucosal epithelium of rats killed at 6 h after the first AOM exposure revealed no blocking activity of the compds.

CC 1-6 (Pharmacology)

IT 4514-53-8 4514-54-9 29366-77-6 33237-20-6 *57381-26-7* 178991-22-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compds. on azoxymethane-induced aberrant crypt foci in rat colon)

IT 57381-26-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(suppressing effects of 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine and related synthetic compds. on azoxymethane-induced aberrant crypt foci in rat colon)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 25 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1995:750055 HCAPLUS Full-text

DOCUMENT NUMBER:

123:188182

TITLE:

Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine

receptor

AUTHOR(S):

Ueda, Fusao; Ban, Keiko; Ishima, Tsuyoshi

CORPORATE SOURCE:

Discovery Research Laboratories II, Nippon Shinyaku

Co. Ltd., Kyoto, 601, Japan

SOURCE:

Journal of Pharmacology and Experimental Therapeutics

(1995), 274(2), 815-19

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER:

Williams & Wilkins

DOCUMENT TYPE:

Journal

LANGUAGE:

English

Irsogladine, an agent that protects gastric mucosa against various ulcerogenic AB stimuli through increasing cAMP in surface mucous cells, has been reported to dose-dependently (10-7 to 10-5 M) facilitate gap-junctional intercellular communication (GJIC) in gastric epithelial cells. The beta adrenergic agonist, isoproterenol, stimulates GJIC in resting cells and inhibits GJIC in cells activated by 3-isobutyl-1- methylxanthine. In this study, we investigated whether irsogladine acts on GJIC in a manner similar to that shown by isoproterenol. Irsogladine, which bound to M1 muscarinic acetylcholine receptors (mAChR), did not inhibit, but failed to further facilitate the 3-isobutyl-1-methylxanthine- enhanced GJIC, measured by Lucifier yellow transfer. The enhancement of GJIC by irsogladine was inhibited by the M1 mAChR antagonist, pirenzepine. A selective M1 mAChR agonist, McN-A-343, enhanced GJIC. Isoproterenol (10-8 to 10-6 M), which alone did not affect GJIC, inhibited the GJIC enhanced by 10-5 M irsogladine. Conversely, 10-10 to 10-6 M irsogladine, which alone did not affect GJIC, inhibited the GJIC enhanced by 10-5 M isoproterenol. McN-A-343 also converted the action of 10-5 M isoproterenol from facilitation to inhibition of GJIC. These results indicate that GJIC is heterologously down-regulated by crosstalk between M1 mAChR and beta adrenergic receptors. In addition, the effects of irsogladine and isoproterenol at low concns. suggest the involvement of another mechanism for down-regulating GJIC.

CC 1-9 (Pharmacology)

IT 57381-26-7, Irsogladine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor)

IT 57381-26-7, Irsogladine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 26 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:633350 HCAPLUS Full-text

DOCUMENT NUMBER: 123:74593

TITLE: Effects of irsogladine, cimetidine and cetraxate on

prostaglandin biosynthesis in cultured rabbit gastric

epithelial cells

AUTHOR(S): Ueda, Fusao; Ideguchi, Kyoichi

CORPORATE SOURCE: Discovery Res. Lab., Nippon Shinyaku Co. Ltd., Kyoto,

601, Japan

SOURCE: Yakuri to Chiryo (1995), 23(2), 327-31

CODEN: YACHDS; ISSN: 0386-3603

PUBLISHER: Raifu Saiensu Shuppan K.K.

DOCUMENT TYPE: Journal LANGUAGE: Japanese

The effects of antiulcer drugs on prostaglandin (PG) biosynthesis were investigated in 1-14C-arachidonic acid (AA)-prelabeled gastric epithelial cells. Irsogladine and cimetidine did not affect basal PG biosynthesis. Cetraxate decreased the release of polar substances (phospholipids and probably peptide leukotrienes) and increased AA release. All these antiulcer drugs inhibited norepinephrine-induced PGE2 biosynthesis. These results suggest that PGE2 is not important in gastric defense functions. In addition, the inhibition of PGE2 biosynthesis by the antiulcer drugs might be involved in their mechanisms for inhibiting gastric ulcers.

CC 1-9 (Pharmacology)

IT 34675-84-8, Cetraxate 51481-61-9, Cimetidine 57381-26-7,

Irsogladine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effects of irsogladine, cimetidine and cetraxate on prostaglandin biosynthesis in cultured rabbit gastric epithelial cells)

IT 57381-26-7, Irsogladine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effects of irsogladine, cimetidine and cetraxate on prostaglandin biosynthesis in cultured rabbit gastric epithelial cells)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 27 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:954085 HCAPLUS Full-text

DOCUMENT NUMBER: 124:21526

TITLE: Irsogladine inhibits ionomycin-induced decrease in

intercellular communication in cultured rabbit gastric

epithelial cells

AUTHOR(S): kameda, Yukiaki; Ueda, Fusao

CORPORATE SOURCE: Res. Lab., Nippon shinyaku Co., Ltd., Kyoto, 601,

Japan

SOURCE: Japanese Journal of Pharmacology (1995),

69(3), 223-8

CODEN: JJPAAZ; ISSN: 0021-5198 Japanese Pharmacological Society

DOCUMENT TYPE: Journal LANGUAGE: English

PUBLISHER:

Effects of irsogladine on ionomycin-induced decreased in intercellular communication and increase in intracellular concentration of Ca2+ ([Ca2+]i) were investigated in cultured rabbit gastric epithelial cells. Ionomycin (10-7-10-16 M) transiently and concentrate-dependently inhibited intercellular communication concomitantly with the elevation of [Ca2+]i in the presence and

absence of extracellular Ca2+. Irsogladine (0-5 M), which has been shown to facilitate intercellular communication, suppressed the ionomycin-induced elevation of [Ca2+]i and decrease in intercellular communication. The suppression of the ionomycin effects by irsogladine was independent of extracellular Ca2+. TMB-8 [8-(diethylamino)octyl-3,4,5- trimethoxybenzoate hydrochloride] (10-6 M) also suppressed the ionomycin-induced elevation of [Ca2+]i and decrease in intercellular communication. These results indicate that the ionomycin-induced decrease in intercellular communication may be due to Ca2+ mobilization from intracellular stores. Inhibitory effects of irsogladine and TMB-8 on the ionomycin-induced decrease in intercellular communication may be produced by suppressing Ca2+ mobilization.

CC 1-9 (Pharmacology)

IT 57381-26-7, Irsogladine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(irsogladine inhibits ionomycin-induced decrease in intercellular communication in gastric epithelium)

IT *57381-26-7*, Irsogladine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(irsogladine inhibits ionomycin-induced decrease in intercellular communication in gastric epithelium)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 28 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1995:126565 HCAPLUS Full-text

DOCUMENT NUMBER:

122:616

TITLE:

A new synthetic antiarrhythmic peptide reduces

dispersion of epicardial activation recovery interval and diminishes alterations of epicardial activation patterns induced by regional ischemia: a mapping study

AUTHOR(S):

Dhein, S.; Manicone, N.; Muller, A.; Gerwin, R.; Ziskoven, U.; Irankhahi, A.; Minke, C.; Klaus, W.

CORPORATE SOURCE:

Inst. Pharmakologie, Univ. Koln, Koln, D-50931,

Germany

SOURCE:

Naunyn-Schmiedeberg's Archives of Pharmacology (

1994), 350(2), 174-84

CODEN: NSAPCC; ISSN: 0028-1298

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB Common antiarrhythmic agents affect ionic membrane channels and thereby alter cellular elec. activity. Since this accounts for the proarrhythmic effects as well the authors tried to find new substances with different profiles of actions. A new antiarrhythmic peptide, H2,N-Gly- Ala-Gly-4 Hyp-Pro-Tyr-CONH2 (AAP 10), was synthesized using the Fmoc-strategy. This peptide was analyzed for its electrophysiol. profile of action in normal isolated rabbit hearts

perfused according to the Langendorff technique either under control conditions or after induction of a regional ischemia. For this purpose 256 channel epicardial mapping was employed allowing the determination of the time points of activation at each electrode thus identifying the origins of epicardial activation (so called breakthrough-points, BTP). Epicardial spread of activation was then described math. by activation vectors which gave direction and velocity of the epicardial activation wave at each electrode. Single heart beats were analyzed under control conditions and under treatment with AAP10 or under regional ischemia with or without AAP 10-pretreatment (10-8 mol./L). The authors calculated the percentage of similar vectors (VEC) with unaltered direction (deviation <5°) and the percentage of identical breakthrough points (deviation ≤ 1 mm) compared to control conditions. addition, apparent epicardial velocities, total activation time of a given region and activation-recovery interval (ARI) as well as dispersion of ARI (i.e. standard deviation of ARI) and distribution of ARI were analyzed. Under control conditions treatment with AAP 10 (10-10 to 3+10-7 mol/L) led to a significant decrease in ARI-dispersion without alteration of any of the other parameters under investigation. Left ventricular regional ischemia resulted in a marked alteration of the activation patterns (a significant decrease in vector-field- and breakthrough point-similarity) which could be significantly inhibited by pretreatment with AAP10. In addition, the authors found that AAP10 depressed the increase in ARI-dispersion during the first minutes of ischemia and accelerated normalization of ARI-dispersion during reperfusion. In addnl. expts., it could be shown that AAP 10 did not alter action potential duration maximum dU/dt, amplitude or resting membrane potential of isolated quinea pig muscles using a common intracellular action potential recording technique. From these results it is concluded that (a) AAP 10 inhibits ischemia induced alterations of the activation pattern (b) that it decreases ARI-dispersion (c) that this effect seems not to be due to an action on ionic channels (d) that the effect of AAP 10 may be due to an improvement of cellular coupling and finally (e) that AAP 10 may be an interesting new approach to the problem of prophylaxis of ischemia-associated ventricular arrhythmias.

```
CC 1-8 (Pharmacology)
```

IT 159503-65-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(prevention of ischemia-associated ventricular arrhythmias by synthetic peptide AAP 10)

IT 159503-65-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prevention of ischemia-associated ventricular arrhythmias by synthetic peptide AAP 10)

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

L98 ANSWER 29 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1993:38951 HCAPLUS Full-text

DOCUMENT NUMBER:

118:38951

TITLE:

Preparation of 2,4-diamino-6-phenyl-1,3,5-triazine derivatives as anticancer agents and anticancer

pharmaceutical compositions containing them

INVENTOR(S):

Mishina, Hitoshi; Ueda, Fusao

PATENT ASSIGNEE(S):

Nippon Shinyaku Co., Ltd., Japan

SOURCE:

PCT Int. Appl., 46 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

Capanes

PATENT INFORMATION:

PA	TENT NO.		KIN	D DATE	APPLICATION NO.	DATÉ	
						-	
WO	9211247		A1	19920709	WO 1991-JP1734	19911219	<
	W: AU,	BR, CA	, FI,	HU, JP, KR,	NO, SU, US		
	RW: AT,	BE, CH	DE,	DK, ES, FR,	GB, GR, IT, LU, MC,	NL, SE	
UA	9190979		Α	19920722	AU 1991-90979	19911219	<
EP	563386		A1	19931006	EP 1992-901441	19911219	<
	R: AT,	BE, CH	, DE,	DK, ES, FR,	GB, GR, IT, LI, LU,	MC, NL, SE	
PRIORITY	Y APPLN.	INFO.:			JP 1990-413461	A 19901220	<
					JP 1991-96372	A 19910401	< - -
					WO 1991-JP1734	A 19911219	<

OTHER SOURCE(S):

MARPAT 118:38951

-

AΒ The title compds. (I; R1, R2 = H, halo, amino, aralkylamino, NO2, alkyl, alkoxy, alkoxyalkyl, aralkyloxy, acyl; R3, R4 = H, nicotinoyl, Bz, alkoxy; n = 0, 1) are prepared An anticancer pharmaceutical composition contains I. Thus, a mixture of p-HOC6H4CN, PhCH2Cl, and K2CO3 in MeCN was refluxed for 5 h to give p-PhCH2OC6H4CN which was heated with dicyandiamide and KOH in diethylene qlycol di-Me ether at 100° for 8 h to give I (R1 = 4-PhCH2O, R2 = R3 = R4 = H, n = 0). I.maleate (R1 = 2-Cl, R2 = 5-Cl, R3 = R4 = H, n = 0) (irsogladine) (II), administered to mice at 10 mg/kg p.o. per day from day 14 to 18 after implantation of human colon cancer WiDr cells, showed the tumor volume ratio (the tumor volume after 18 days/the initial volume) 1.52 vs. 2.00 (control) and 1.52 for cyclophosphamide administered at 10 mg/kg i.p. once on day 14. also enhanced the antitumor activity of 5-fluorouracil derivs., e.g. Mifurol and Sunfurol, and in vitro inhibited the uptake of 5-fluorouracil in MDCK cells. Clin. trials of II were also described. Tablet, powder, and injection solution formulations containing II were given.

IC ICM C07D251-18 ICS A61K031-53

CC 28-19 (Heterocyclic Compounds (More Than One Hetero Atom)) Section cross-reference(s): 1

27374-29-4P 29366-71-0P 29366-73-2P IT 4514-54-9P 20317-65-1P 30354-89-3P 34095-30-2P 36303-44-3P 57381-26-7P, Irsogladine 57381-33-6P, Irsogladine maleic acid salt 57381-45-0P 57381-50-7P 65052-46-2P 68215-75-8P 57381-58-5P 59386-77-5P 57381-57-4P 81530-52-1P 81530-54-3P 116118-75-3P 145176-29-0P 145176-30-3P 145176-31-4P 145176-32-5P 145176-33-6P 145176-34-7P 145176-37-0P 145176-38-1P 145176-39-2P 145176-36-9P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as anticancer agent)

IT 57381-26-7P, Irsogladine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as anticancer agent)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 30 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1990:515835 HCAPLUS Full-text

DOCUMENT NUMBER:

113:115835

TITLE:

Antiarrhythmic activity of a novel analog of AAP

AUTHOR(S):

Kundu, Bijoy; Rizvi, Shaheena Yasmeen; Mathur, Krishna

Behari; Kar, Karunamoy

CORPORATE SOURCE:

Div. Biopolym., Cent. Drug Res. Inst., Lucknow, 226

001, India

SOURCE:

Collection of Czechoslovak Chemical Communications (

1990), 55(2), 575-80

CODEN: CCCCAK; ISSN: 0010-0765

DOCUMENT TYPE:

Journal English

LANGUAGE: AB Antiarrhythmic peptide (AAP) analogs H-Gly-X-X1-Gly-Ala-Gly-OH [I; X-X1 = Sar-Pro (Sar = MeGly), Pro-Sar, Sar-Sar] have been synthesized in order to obtain peptides with enhanced antiarrhythmic activity. Their antiarrhythmic activity has been evaluated against aconitine induced arrhythmia in rats. I (X-X1 = Sar-Sar) is more active than AAP (I, X-X1 = Pro-Hyp). It is equipotent to the commonly used antiarrhythmic drug quinidine, so far as delay in the onset of ventricular tachycardia, ventricular fibrillation and cardiac arrest are concerned. Relationships of biol. activities of these peptides with their CD spectra are discussed. The spatial structure of I (X-X1 = Sar-Sar) attributed to Sar2-Sar3 linkage might be contributing to its higher antiarrhythmic activity.

34-3 (Amino Acids, Peptides, and Proteins) CC

Section cross-reference(s): 1

IT 81771-37-1DP, Antiarrhythmic peptide (ox atrium), analogs

129164-97-2P 129165-00-0P 129165-01-1P

129165-02-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antiarrhythmic activity of)

IT 81771-37-1DP, Antiarrhythmic peptide (ox atrium), analogs RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antiarrhythmic activity of)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L98 ANSWER 31 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1989:568091 HCAPLUS Full-text

DOCUMENT NUMBER: 111:168091

TITLE: Antiarrhythmic peptide has no direct cardiac actions

AUTHOR (S): Argentieri, T.; Cantor, E.; Wiggins, J. R.

Berlex Lab., Inc., Cedar Knolls, NJ, 07927, USA CORPORATE SOURCE:

Experientia (1989), 45(8), 737-8 SOURCE:

CODEN: EXPEAM; ISSN: 0014-4754

DOCUMENT TYPE: Journal LANGUAGE: English

AB The electrophysiol., inotropic, and muscarinic effects of antiarrhythmic peptide (AAP) were examined in canine cardiac Purkinje fibers, ferret papillary muscle, and canine cardiac membranes, resp. Aside from a prolongation of time to peak force in papillary muscle, no biol. significant effects of AAP could be determined in any preparation, suggesting that its antiarrhythmic effects are not mediated by direct membrane actions.

CC 2-10 (Mammalian Hormones)

IT 81771-37-1, Antiarrhythmic peptide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(heart response to)

IT 81771-37-1, Antiarrhythmic peptide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(heart response to)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L98 ANSWER 32 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1989:147197 HCAPLUS Full-text

DOCUMENT NUMBER:

110:147197

TITLE:

Effect of N-3-(4-hydroxyphenyl)propionyl Pro-Pro-

Gly-Ala-Gly on

calcium-induced arrhythmias

AUTHOR (S):

Kohama, Yasuhiro; Kuwahara, Shigeki; Yamamoto, Koji;

Okabe, Masaru; Mimura, Tsutomu; Fukaya, Chikara;

Watanabe, Masahiro; Yokoyama, Kazumasa

CORPORATE SOURCE:

Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

SOURCE:

Chemical & Pharmaceutical Bulletin (1988),

36(11), 4597-9

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE:

Journal

LANGUAGE:

English

The present investigation was done to examine whether or not the presence of hydroxyproline in N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-Gly- Ala-Gly (HP-5) is essential for its antiarrhythmic activity. Pretreatment of mice with 10 mg/kg of [Pro2]-HP-5 provided better protection against calcium-induced arrhythmias than did pretreatment with HP-5. Thus, the prolyl residue was more favorable than the hydroxyprolyl residue for antiarrhythmic activity of these analogs.

CC 1-3 (Pharmacology)

Section cross-reference(s): 2, 34

IT 111915-92-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(antiarrhythmic activity of, structure in relation to)

IT 111915-92-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiarrhythmic activity of, structure in relation to)

RN 111915-92-5 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium), 1-deglycine-2-[1-[3-(4-hydroxyphenyl)-1-oxopropyl]-L-proline]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$HO_2C$$
 H
 HO_2C
 H
 HO
 R
 HO

L98 ANSWER 33 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1988:16410 HCAPLUS Full-text

DOCUMENT NUMBER:

108:16410

TITLE:

A new antiarrhythmic peptide, N-3-(4-

hydroxyphenyl) propionyl Pro-Hyp-Gly-

Ala-Clv

AUTHOR(S):

Kohama, Yasuhiro; Okimoto, Naotsugu; Mimura, Tsutomu;

Fukaya, Chikara; Watanabe, Masahiro; Yokoyama,

Kazumasa

CORPORATE SOURCE:

Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

SOURCE:

Chemical & Pharmaceutical Bulletin (1987),

35(9), 3928-30

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE:

Journal

LANGUAGE:

English

In order to increase the antiarrhythmic activity of the naturally occurring antiarrhythmic peptide (Pro-Hyp-Gly-Ala- Gly; (P-5)), P-5 analogs with 3 diffeent hydrophobic substituents, N-3-(4-hydroxyphenyl)propionyl (H), N-3-phenylpropionyl (I) and N-3-phenylpropyl (P), were prepared and their activities were evaluated in CaCl2-induced arrhythmias in mice. HP-5 showed potent antiarrhythmic activity at 1 mg/kg, i.v. and its potency was much higher than that of P-5 at 10 mg/kg, i.v. IP-5 showed similar potency to P-5, but PP-5 was inactive. Pro-Hyp-Gly-Ala, Pro-Hyp-Gly and Pro-Hyp with the substituent H, were also ineffective. Thus, 3-(4-hydroxyphenyl)propionylation of the imino nitrogen of Pro in P-5 led to increased potency.

CC 2-2 (Mammalian Hormones)

IT 111915-91-4DP, analogs 111915-92-5P 111915-93-6P
111915-94-7P 111915-95-8P 111915-96-9P 111915-97-0P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation and antiarrhythmic activity of, structure in relation to)

IT 111915-92-5P

RN

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(preparation and antiarrhythmic activity of, structure in relation to) 111915-92-5 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium), 1-deglycine-2-[1-[3-(4hydroxyphenyl)-1-oxopropyl]-L-proline]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L98 ANSWER 34 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1984:133284 HCAPLUS Full-text

DOCUMENT NUMBER:

100:133284

TITLE:

Studies on heart. XXXIV. Inhibitory effect of

antiarrhythmic peptide (AAP) on experimental

thromboses

AUTHOR (S):

Aonuma, Shiqeru; Kohama, Yasuhiro; Makino, Toshitake;

Hattori, Kunihiro; Kawahara, Yusuke

CORPORATE SOURCE:

Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

SOURCE:

Chemical & Pharmaceutical Bulletin (1984),

32(1), 219-27

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE:

Journal

LANGUAGE:

English

The antithrombotic action of antiarrhythmic peptide (Gly -Pro-Hyp-Gly-Ala-AB Gly) (aAP) [81771-37-1] was studied by using various in vivo thrombosis models. AAP (1, 10, or 100 mg/kg, i.v.; 10 mg/kg, i.p.; or 100 mg/kg, orally) significantly inhibited white thrombus formation on a silk thread in the extracorporeal shunt models in rats, its ED50 being about 30 mg/kg, i.v. (10 mg/kg, i.v.) was effective in protecting rats against the decrease in platelet count, against the incidence of electrocardiog. alterations (T-wave inversion and ST-segment depression) typical of myocardial ischemia, and against development of ectopic beats during coronary thromboembolism induced by i.v. infusion of ADP. The peptide (10 mg/kg, i.p.) was also effective in preventing thrombus formation in the lung and the decrease of platelet count induced by lactic acidosis in rats, and it (10 mg/kg, i.v.) clearly inhibited thromboembolic death induced by rapid i.v. injection of collagen in mice. Daily treatments with the peptide (10 mg/kg/d, i.p.) resulted in significant delay of the progression of gangrene and mummification in laurate-induced peripheral arterial occlusive disease in rats. AAP did not affect venous thrombus formation, blood flow through the carotid artery, plasma recalcification time or fibrinolytic activity in rats. It is likely that the potent antithrombotic action of AAP is mainly due to its anti-plateletaggregating action in vivo. Ticlopidine (100 mg/kg, orally) also showed a

comparatively wide antithrombotic spectrum, like AAP, in the present thrombosis models; but ticlopidine, like aspirin (50 mg/kg, s.c.), lacked activity against myocardial ischemia.

CC 2-9 (Mammalian Hormones)

IT 81771-37-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (antithrombotic activity of)

IT 81771-37-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (antithrombotic activity of)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L98 ANSWER 35 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1983:482255 HCAPLUS Full-text

DOCUMENT NUMBER: 99:82255

TITLE: Studies on heart. XXII. Inhibitory effect of an

atrial peptide (AAP) on several drug-induced

arrhythmias in vivo

AUTHOR(S): Aonuma, Shiqeru; Kohama, Yasuhiro; Makino, Toshitake;

Hattori, Kunihiro

CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, 565, Japan

SOURCE: Yakuqaku Zasshi (1983), 103(6), 662-6

CODEN: YKKZAJ; ISSN: 0031-6903

DOCUMENT TYPE: Journal LANGUAGE: Japanese

The effect of an atrial peptide, Gly-Pro-4Hyp-Gly- Ala-Gly (AAP) [81771-37-AB 1], on several drug-induced arrhythmias in anesthetized dogs, rats and mice was investigated. AAP (10 mg/kg, i.v.) significantly reversed the persistent arrhythmias consisting of atrio-ventricular (A-V) block, ectopic beat, and/or ventricular tachycardia induced by aconitine pretreatment prevented development of ventricular fibrillation in dogs and rats. AAP (10, 25 mg/kg, i.v.) prolonged onset time of A-V block or ectopic beat and onset time of ventricular tachycardia induced by aconitine infusion in mice. This peptide (10 mg/kg, i.v.) significantly prolonged the onset time of A-V block or ectopic beat induced by CaCl2 infusion and the time until ventricular fibrillation induced by ouabain infusion in mice, and shortened the duration of arrhythmia induced by ADP in rats, but did not affect the mouse epinephrine-induced arrhythmia. The peptide (25 mg/kg, i.v.) prolonged the OTc interval and had no effect on the PO interval heart rate, respiratory rate, and blood pressure in dogs. AAP (1 g/kg, i.v.v., i.p., and orally) did not show acute toxicity in mice. AAP had antiarrhythmic activity with few side effects.

CC 1-8 (Pharmacology)

Section cross-reference(s): 2

IT 81771-37-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiarrhythmic activity of)

IT 81771-37-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiarrhythmic activity of)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L98 ANSWER 36 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1980:157536 HCAPLUS Full-text

DOCUMENT NUMBER:

92:157536

TITLE:

Structure-activity study of antiulcerous and antiinflammatory drugs by discriminant analysis Ogino, Akio; Matsumura, Shingo; Fujita, Toshio

AUTHOR(S): CORPORATE SOURCE:

Res. Lab., Nippon Shinyaku Co., Ltd., Kyoto, 601,

Japan

SOURCE:

Journal of Medicinal Chemistry (1980),

23(4), 437-44

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE:

LANGUAGE:

Journal English

GI

The structure activity of 34 antiulcer benzoguanamines I (R = H, halogen, Me, NO2, SCF3, etc.; n = 0-2), and that of 22 antiinflammatory phenylacetic acids II (R = H, OH, Me, OEt, Ph, etc.; n = 0-2), and 24 aminouracils III (R1 = Et, Me, Ph, substituted Ph, etc.; R2 = alkyl, CH2CH2OH, etc.; NR3N4 = NHPr, NMe2, NHBu, morpholins, etc.) were studied in rats by discriminant anal. For antiulcer activity the drug effect was evaluated in terms of averaged ulcer indexes and the percent inhibition value against the injury was expressed relative to the averaged index of the control group; the error involved was <10%. For the antiinflammatory activity the inhibitory effect was represented as the percent value relative to the average volume of control; the error in the percent value was <10%. The discriminant variables were selected from the physicochem. parameters used to analyze the variation in hydrophobicity due to structural modifications. The potency scores divided into 3 groups for each of the 3 series of compds. were predicted with >80% accuracy.

CC 1-3 (Pharmacodynamics)

Section cross-reference(s): 22

91-76-9D, derivs. 4514-53-8 4514-54-9 19338-12-6 IT 91-76-9 29366-71-0 29366-72-1 29366-73-2 29366-77-6 30101-52-1 30508-75-9 30508-78-2 30530-43-9 30530-44-0 30530-48-4 57381-26-7 57381-35-8 57381-38-1 57381-40-5 57381-42-7 57381-45-0 57381-46-1 57381-50-7 57381-54-1 57381-57-4 57381-60-9 65052-47-3 65052-49-5 65052-50-8 65052-53-1 65052-55-3 72775-79-2 72775-80-5 72775-81-6 72781-91-0 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiulcer activity of, discriminant anal. in evaluation of)

IT 57381-26-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiulcer activity of, discriminant anal. in evaluation of)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 37 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1975:606332 HCAPLUS Full-text

DOCUMENT NUMBER:

83:206332

TITLE:

Benzoguanamine derivatives

INVENTOR(S):

Murai, Hiromu; Ohata, Katsuya; Aoyagi, Yoshiaki; Ueda,

Fusao; Kitano, Masahiko; Takata, Satoshi; Tada,

Shinichi

PATENT ASSIGNEE(S):

Nippon Shinyaku Co., Ltd., Japan

SOURCE:

Ger. Offen., 24 pp.

DOCUMENT TYPE:

CODEN: GWXXBX Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.	KIND	DATE				
		A1	19750828	DE 1975-2506814		19750218	<
	DE 2506814	C3	19791115	22 13/3 2000011			
	DE 2506814	B2	19790322				
	JP 50111085	A	19750901	JP 1974-19211		19740218	<
	JP 55004751	В	19800131	01 1971 19211		13,10010	•
	JP 50111086	A	19750901	JP 1974-19212		19740218	<i></i> -
	JP 52046955	В	19771129	01 15/4 15212		13/10210	
	US 3966728	A	19760629	US 1975-544176		19750127	< - -
	CH 592638	A5	19771031	CH 1975-1300		19750204	
	CH 592639		19771031	CH 1975-1301		19750204	
	SE 7501273	A	19750819	SE 1975-1273		19750205	
	SE 425245	В	19820913	SE 1975-1274		19750205	
	SE 425245	C	19821230	00 1973 1071		13,30203	
	DK 7500436	A	19751020	DK 1975-436		19750207	<
	DK 138268	Ċ	19790212	DR 1373 130		13/3020/	
	DK 138116	В	19780717	DK 1975-437		19750207	<i>-</i>
	DK 138116	C	19781204	DR 1973 137		13730207	
	NL 7501574	A	19750820	NL 1975-1574		19750211	<i></i> -
	NL 157901	В	19780915	NB 1973 1371		13/30211	
	NL 157902	В	19780915	NL 1975-1575		19750211	<i></i> -
	FR 2261009	A1	19750912	FR 1975-4690		19750214	
	BE 825673	A1	19750616			19750218	
	AT 7501200	A	19770315	AT 1975-1200	•	19750218	
	AT 339909	В	19771110	111 1373 1200		29,30220	
	AT 7501197	A		AT 1975-1197		19750218	<
	AT 340941	В		111 13,3 113,		17.30210	
PRIO	RITY APPLN. INFO.:		13700110	JP 1974-19211	А	19740218	<
INIO	MIII IIIIIIII. IIII O			JP 1974-19212		19740218	
GI	For diagram(s), see	- printe	ed CA Issue.				•
AB	Triazines T $(R = 2)$	-Cl. 2-	F. 2-Br. 3-0	Cl, R1 = 5-Cl; R = 2-	-Cl.	R1 = 5-Br	. 4-Cl.
				5-F, 5-Br, 4-Cl; R =			
				vith dicyandiamide or			
				ceration. Thus 20 m			
				oition of Shay ulcers			·
IC	C07D	3		•			
CC	28-21 (Heterocyclic	Compoi	inds (More T	han One Hetero Atom))		
IT	57381-26-7P 57381						
	57381-42-7P 57381	L-45-0P	57381-46-	1P 57381-50-7P 5	7381	-53-0P	
		L-55-2P					
	RL: BAC (Biological	activ	ity or effec	tor, except adverse)	; BS	U	
				(Synthetic preparat			
	(Biological study);						
	(preparation and						
IT	57381-26-7P			_			
	RL: BAC (Biological	activ	ity or effec	tor, except adverse)	; BS	U	
			_	(Synthetic preparat			
	(Biological study);						
	(preparation and	antiu	lcer activit	y of)			
RN	57381-26-7 HCAPLUS	3					
CN '	1.3.5-Triazine-2.4-	diamine	e. 6-(2.5-di	chlorophenvl) - (9CI)	(0	A INDEX N	AME)

CN '1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

GIVEN BY EXAMINER*****

=> d que 14

42 SEA FILE=REGISTRY ABB=ON PLU=ON [G'SAR'] A [G'SAR'] ['HYP'P] ['HY L2

P'P]YN/SQSFP

L3 36 SEA FILE=HCAPLUS ABB=ON PLU=ON L2

14 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND (AY<2001 OR PY<2001 OR L4

PRY<2001)

=> d ibib abs hitind hitstr retable 14 tot

ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2004:546915 HCAPLUS Full-text

DOCUMENT NUMBER:

141:83631

TITLE:

Rice nucleic acid molecules and encoded proteins and

their uses for plant improvement

INVENTOR(S):

La Rosa, Thomas J.; Kovalic, David K.; Zhou, Yihua; Cao, Yongwei; Wu, Wei; Boukharov, Andrey A.; Barbazuk,

Brad W.

PATENT ASSIGNEE(S):

USA

SOURCE:

U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S.

Ser. No. 837,604.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004123343	A1	20040624	US 2003-437963	20030514 <
US 2004123343	A1	20040624	US 2003-437963	20030514 <
PRIORITY APPLN. INFO.:		•	US 2000-197872P	P 20000419 <
			US 2001-837604	A2 20010418
			US 2003-437963	A 20030514

AΒ The present invention provides 102,483 cDNA sequences and their encoded protein sequences from rice (Oryza sativa). Bioinformatic anal. identified putative functions and uses for the nucleic acids/polypeptides. The disclosed polynucleotides and polypeptides find use in production of transgenic plants to produce plants having improved properties. [This abstract record is one of forty-one records for this document necessitated by the large number of index

entries required to fully index the document and publication system constraints.].. IC ICM A01H001-00 C12N015-82; C07H021-04; C12N009-24; C12N005-04 INCL 800278000; 435069100; 435200000; 435201000; 435419000; 536023200 3-3 (Biochemical Genetics) Section cross-reference(s): 6, 11 716607-04-4 IT 716607-00-0 716607-01-1 716607-02-2 716607-03-3 716607-07-7 716607-08-8 716607-09-9 716607-05-5 716607-06-6 716607-10-2 716607-11-3 716607-12-4 716607-13-5 716607-14-6 716607-15-7 716607-16-8 716607-17-9 716607-18-0 716607-19-1 716607-20-4 716607-21-5 716607-22-6 716607-23-7 716607-24-8 716607-25-9 716607-26-0 716607-27-1 716607-28-2 716607-29-3 716607-30-6 716607-31-7 716607-32-8 716607-33-9 716607-34-0 716607-35-1 716607-36-2 716607-37-3 716607-38-4 716607-39-5 716607-40-8 716607-41-9 716607-42-0 716607-43-1 716607-44-2 716607-49-7 716607-45-3 716607-46-4 716607-47-5 716607-48-6 716607-50-0 *716607-51-1* 716607-52-2 716607-53-3 716607-54-4 716607-55-5 716607-56-6 716607-57-7 716607-58-8 716607-61-3 716607-62-4 716607-63-5 716607-59-9 716607-60-2 716607-64-6 716607-65-7 716607-66-8 716607-67-9 716607-68-0 716607-69-1 716607-70-4 716607-71-5 716607-72-6 716607-73-7 716607-74-8 716607-75-9 716607-76-0 716607-77-1 716607-78-2 716607-79-3 716607-80-6 716607-81-7 716607-82-8 716607-83-9 716607-84-0 716607-85-1 716607-86-2 716607-87-3 716607-88-4 716607-89-5 716607-90-8 716607-91-9 716607-92-0 716607-93-1 716607-94-2 716607-95-3 716607-96-4 716607-97-5 716607-98-6 716608-01-4 716608-02-5 716607-99-7 716608-00-3 716608-03-6 716608-05-8 716608-06-9 716608-07-0 716608-08-1 716608-04-7 716608-09-2 716608-10-5 716608-11-6 716608-12-7 716608-13-8 716608-14-9 716608-16-1 716608-17-2 716608-18-3 716608-15-0 716608-19-4 716608-20-7 716608-21-8 716608-22-9 716608-23-0 716608-27-4 716608-28-5 716608-24-1 716608-25-2 716608-26-3 716608-32-1 716608-33-2 716608-30-9 716608-31-0 716608-29-6 716608-37-6 716608-38-7 716608-34-3 716608-35-4 716608-36-5 716608-39-8 716608-40-1 716608-41-2 716608-42-3 716608-43-4 716608-47-8 716608-48-9 716608-44-5 716608-45-6 716608-46-7 716608-52-5 716608-53-6 716608-49-0 716608-50-3 716608-51-4 716608-54-7 716608-55-8 716608-56-9 716608-57-0 716608-58-1 716608-59-2 716608-60-5 716608-61-6 716608-62-7 716608-63-8 716608-65-0 716608-66-1 716608-67-2 716608-68-3 716608-64-9 716608-71-8 716608-72-9 716608-73-0 716608-69-4 716608-70-7 716608-74-1 716608-75-2 716608-76-3 716608-77-4 716608-78-5 716608-83-2 716608-79-6 716608-80-9 716608-81-0 716608-82-1 716608-85-4 716608-86-5 716608-87-6 716608-88-7 716608-84-3 716608-89-8 716608-90-1 716608-91-2 716608-92-3 716608-93-4 716608-94-5 716608-95-6 716608-96-7 716608-97-8 716608-98-9 716608-99-0 716609-00-6 716609-01-7 716609-02-8 716609-03-9 716609-08-4 716609-04-0 716609-05-1 716609-06-2 716609-07-3 716609-11-9 716609-12-0 716609-13-1 716609-09-5 716609-10-8 716609-14-2 716609-15-3 716609-16-4 716609-17-5 716609-18-6 716609-22-2 716609-23-3 716609-19-7 716609-20-0 716609-21-1 716609-27-7 716609-28-8 716609-24-4 716609-25-5 716609-26-6 716609-32-4 716609-33-5 716609-29-9 716609-30-2 716609-31-3 716609-34-6 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses) (amino acid sequence; rice nucleic acid mols. and encoded proteins and their uses for plant improvement) IT 716607-51-1

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses) (amino acid sequence; rice nucleic acid mols. and encoded proteins and their uses for plant improvement)

RN 716607-51-1 HCAPLUS

CN Protein (Oryza sativa clone PAT_MRT4530_21015C.1.pep fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2004:80331 HCAPLUS Full-text

DOCUMENT NUMBER:

140:140710

TITLE:

cDNAs encoding human NOVX proteins and their

diagnostic and therapeutic use

INVENTOR(S):

Shimkets, Richard A.; Patturajan, Meera; Vernet, Corine A. M.; Casman, Stacie J.; Malyankar, Uriel M.; Shenoy, Suresh G.; Spytek, Kimberly A.; Gangolli, Esha A.; Miller, Charles E.; Boldog, Ferenc L.; Li, Li; Taupier, Raymond J.; Kekuda, Ramesh; Smithson, Glennda; Zerhusen, Bryan D.; Liu, Xiaohong; Colman, Steven D.; Tchernev, Velizar T.; Si, Jingsheng; Edinger, Shlomit R.; Stone, David J.; Sciore, Paul;

Millet, Isabelle; Rothenberg, Mark E.

PATENT ASSIGNEE(S):

IISA

SOURCE:

U.S. Pat. Appl. Publ., 240 pp., Cont.-in-part of U.S.

Ser. No. 28,248.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

173

PATENT INFORMATION:

PATENT NO.		APPLICATION NO.	
US 2004018970		US 2002-107782	
		US 2001-28248	
US 2003203363		US 2002-94466	
		CA 2002-2440337	
		CA 2002-2440345	
		EP 2002-713788	
R: AT, BE, CH,	DE, DK, ES, FR,	GB, GR, IT, LI, LU, N	L, SE, MC, PT,
	LV, FI, RO, MK,		
AU 2005200106	A1 20050210	AU 2005-200106	20050112 <
AU 2006201467	A1 20060504	AU 2006-201467	20060407 <
PRIORITY APPLN. INFO.:		US 2000-256619P	P 20001219 <
		US 2001-262959P	P 20010119
		US 2001-272408P	P 20010228
		US 2001-279344P	P 20010328
		US 2001-285189P	P 20010420
		US 2001-308039P	P 20010726
	•	US 2001-311266P	P 20010809
		US 2001-28248	A2 20011219
		AU 2000-37360	A3 20000309 <
		AU 2000-78680	A3 20001006 <
		US 2001-274191P	P 20010308
		US 2001-274194P	P 20010308
	•	US 2001-274281P	
	•	US 2001-274322P	
		US 2001-274849P	

```
US 2001-275235P
                   P
                      20010312
US 2001-275578P
                   P 20010313
US 2001-275579P
                   P 20010313
US 2001-275601P
                   P 20010313
US 2001-276000P
                   P
                      20010314
US 2001-276776P
                   P
                      20010316
US 2001-276994P
                   P
                      20010319
US 2001-277239P
                   P 20010320
                   P 20010320
US 2001-277321P
                   P 20010320
US 2001-277327P
US 2001-277338P
                   P 20010320
US 2001-277791P
                   P 20010321
                   P 20010322
US 2001-277833P
US 2001-278152P
                   Ρ
                      20010323
US 2001-278894P
                   Р
                      20010326
US 2001-278999P
                   P 20010327
US 2001-279036P
                   P 20010327
US 2001-279995P
                   P 20010330
US 2001-280233P
                   P 20010330
                   P 20010402
US 2001-280802P
US 2001-280822P
                   P 20010402
US 2001-280900P
                   P 20010402
US 2001-281194P
                  P 20010404
US 2001-283675P
                   P 20010413
US 2001-287424P
                   P 20010430
US 2001-288066P
                   P 20010502
US 2001-288148P
                   P
                      20010502
US 2001-288342P
                   Ρ
                      20010503
US 2001-288528P
                   P
                      20010503
US 2001-291190P
                   Ρ
                      20010515
US 2001-291099P
                   P
                      20010516
US 2001-291240P
                   P 20010516
US 2001-294485P
                   P 20010530
US 2001-294821P
                   P 20010531
                   P
US 2001-294889P
                      20010531
                   P
US 2001-294899P
                      20010531
US 2001-335302P
                   P
                      20011031
US 2001-338375P
                   P 20011204
```

```
AB The present invention provides cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use.
```

IC ICM C12Q001-68

ICS G01N033-53; C07K014-47; C12P021-02; C12N005-06; A61K038-17; C07K016-22; C07H021-04

INCL 514012000; 435069100; 435320100; 435325000; 530350000; 536023500; 530388150; 435006000; 435007100

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 13, 14

651798-64-0 651798-65-1 IT 651798-56-0 651798-57-1 651798-58-2 651798-73-1, Protein NOV4b (human) 651798-79-7 651798-66-2 651798-93-5 651798-87-7 651798-94-6 651798-80-0 651798-81-1 651799-07-4 651799-12-1 651799-18-7 651799-00-7 651799-01-8 651799-23-4 651799-29-0

RL: PRP (Properties)

(unclaimed protein sequence; cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use)

IT 651799-18-7

RL: PRP (Properties)

(unclaimed protein sequence; cDNAs encoding human NOVX proteins and their diagnostic and therapeutic use)

RN 651799-18-7 HCAPLUS

CN 103: PN: US20040018970 SEQID: 102 unclaimed protein (9CI) (CA INDEX NAME)

```
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

L4 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2002:781492 HCAPLUS Full-text

DOCUMENT NUMBER: 138:1096

TITLE: Essential genes in microorganisms and their use as

targets for antisense inhibition of proliferation and

antibiotic screening

INVENTOR(S):
Wang, Liangus; Zamudio, Carlos; Malone, Cheryl;

Haselbeck, Robert; Ohlsen, Kari L.; Zyskind, Judith W.; Wall, Daniel; Trawick, John D.; Carr, Grant J.; Yamamoto, Robert; Forsyth, R. Allyn; Xu, H. Howard

PATENT ASSIGNEE(S): Elitra Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 1766 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

```
PATENT NO.
                       KIND DATE
                                        APPLICATION NO.
                                                              DATE
                       ----
                                         _____
                              -----
    WO 2002077183
                       A2
                              20021003 WO 2002-XO9107
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
            LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
            PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
            UG, US, UZ, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
            CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                       US 2001-815242
    US 2002061569
                       A1
                              20020523
                                                             20010321 <--
    WO 2002077183
                        A2
                              20021003
                                       WO 2002-US9107
                                                               20020321
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
            CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                         US 2001-815242 A 20010321
                                         US 2001-948993
                                                           A 20010906
                                         US 2001-342923P
                                                           P 20011025
                                         US 2002-72851
                                                           A 20020208
                                         US 2002-362699P
                                                            P 20020306
                                                            A 20020321
                                         WO 2002-US9107
                                                           P 20000321 <--
                                         US 2000-191078P
                                                          P 20000523 <--
                                         US 2000-206848P
                                         US 2000-207727P
                                                           P 20000526 <--
                                         US 2000-242578P
                                                           P 20001023 <--
                                         US 2000-253625P
                                                          P 20001127 <--
                                         US 2000-257931P
                                                           P 20001222 <--
                                                         P 20010216
                                         US 2001-269308P
```

AB The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Thus, 6213 nucleic acid fragments are identified

for which expression inhibits proliferation or is required for proliferation in Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium, and Staphylococcus aureus. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate mols. for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than Staphylococcus aureus, Salmonella typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The invention provides 38,184 such proliferation-required gene sequences (plus their encoded protein sequences). The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms. [This abstract record is one of twenty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IC ICM C12N

IT

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 10

477094-57-8 477094-58-9 477094-59-0 477094-60-3 477094-61-4 477094-62-5 477094-63-6 477094-64-7 477094-65-8 477094-66-9 477094-67-0 477094-68-1 477094-69-2 477094-70-5 477094-71-6 477094-72-7 477094-73-8 477094-74-9 477094-75-0 477094-76-1 477094-77-2 477094-78-3 477094-79-4 477094-80-7 477094-81-8 477094-82-9 477094-83-0 477094-84-1 477094-85-2 477094-86-3 477094-87-4 477094-88-5 477094-89-6 477094-90-9 477094-91-0 477094-93-2 477094-92-1 477094-94-3 477094-95-4 477094-96-5 477094-97-6 477094-98-7 477094-99-8 477095-00-4 477095-01-5 477095-02-6 477095-03-7 477095-04-8 477095-05-9 477095-06-0 477095-07-1 477095-08-2 477095-09-3 477095-10-6 477095-11-7 477095-12-8 477095-13-9 477095-14-0 477095-15-1 477095-16-2 477095-20-8 477095-17-3 477095-18-4 477095-19-5 477095-21-9 477095-23-1 477095-24-2 477095-25-3 477095-22-0 477095-26-4 477095-27-5 477095-28-6 477095-29-7 477095-30-0 477095-31-1 477095-32-2 477095-33-3 477095-34-4 477095-35-5 477095-36-6 477095-37-7 477095-38-8 477095-39-9 477095-40-2 477095-41-3 477095-42-4 477095-43-5 *477095-44-6* 477095-45-7 477095-46-8 477095-47-9 477095-48-0 477095-49-1 477095-50-4 477095-51-5 477095-52-6 477095-53-7 477095-54-8 477095-55-9 477095-56-0 477095-57-1 477095-59-3 477095-58-2 477095-60-6 477095-61-7 477095-62-8 477095-63-9 477095-64-0 477095-65-1 477095-68-4 477095-69-5 477095-66-2 477095-67-3 477095-70-8 477095-71-9 477095-72-0 477095-73-1 477095-74-2 477095-75-3 477095-76-4 477095-77-5 477095-78-6 477095-79-7 477095-80-0 477095-81-1 477095-82-2 477095-83-3 477095-84-4 477095-85-5 477095-86-6 477095-87-7 477095-88-8 477095-89-9 477095-90-2 477095-93-5 477095-91-3 477095-92-4 477095-94-6 477095-95-7 477095-96-8 477095-97-9 477095-98-0 477095-99-1 477096-00-7 477096-01-8 477096-02-9 477096-03-0 477096-04-1 477096-05-2 477096-06-3 477096-07-4 477096-08-5 477096-09-6 477096-10-9 477096-11-0 477096-13-2 477096-14-3 477096-12-1 477096-15-4 477096-16-5 477096-17-6 477096-18-7 477096-19-8 477096-20-1 477096-21-2 477096-22-3 477096-23-4 477096-24-5 477096-25-6 477096-26-7 477096-27-8 477096-28-9 477096-29-0 477096-30-3 477096-31-4 477096-32-5 477096-33-6 477096-34-7 477096-35-8 477096-36-9 477096-37-0 477096-38-1 477096-39-2 477096-40-5 477096-41-6 477096-42-7 477096-43-8 477096-44-9 477096-45-0 477096-46-1 477096-47-2 477096-48-3 477096-49-4 477096-50-7

```
477096-51-8
              477096-52-9
                            477096-53-0
                                          477096-54-1
                                                        477096-55-2
477096-56-3
              477096-57-4
                            477096-58-5
                                          477096-59-6
                                                        477096-60-9
477096-61-0
              477096-62-1
                            477096-63-2
                                          477096-64-3
                                                        477096-65-4
              477096-67-6
477096-66-5
                            477096-68-7
                                          477096-69-8
                                                        477096-70-1
477096-71-2
              477096-72-3
                            477096-73-4
                                          477096-74-5
                                                        477096-75-6
477096-76-7
              477096-77-8
                            477096-78-9
                                          477096-79-0
                                                        477096-80-3
477096-81-4
              477096-82-5
                            477096-83-6
                                          477096-84-7
                                                        477096-85-8
477096-86-9
              477096-87-0
                            477096-88-1
                                          477096-89-2
                                                        477096-90-5
RL: BSU (Biological study, unclassified); BUU (Biological use,
unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological
study); USES (Uses)
   (amino acid sequence; essential genes in microorganisms and their use
   as targets for antisense inhibition of proliferation and antibiotic
```

IT 477095-44-6

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; essential genes in microorganisms and their use as targets for antisense inhibition of proliferation and antibiotic screening)

RN 477095-44-6 HCAPLUS

screening)

CN Protein (Mycobacterium avium clone MAV104574 essential) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2002:754415 HCAPLUS Full-text

DOCUMENT NUMBER:

137:263304

TITLE:

Synthesis of peptides and medical uses of

intracellular communication facilitating compounds Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier, Eddie; Kjolbye, Anne Louise; Jorgensen, Niklas Rye; Nielsen, Morten Schak; Holstein-Rathlou, Niels-Henrik;

Martins, James B.

PATENT ASSIGNEE(S):

Zealand Pharmaceuticals A/S, Den.

SOURCE:

INVENTOR(S):

PCT Int. Appl., 233 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PAT	PATENT NO.				KIND DA				;	APPLICATION NO.						DATE			
WO	2002	 0770:	 17		A2	-	20021003			WO 2	 002-	US57	73		20020222				
WO	2002	0770	17		A3		2003	1009											
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	AZ,	BA,	BB,	ВG,	BR,	BY,	ΒZ,	CA,	CH,	CN,		
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,		
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,		
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,		
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,		
		UA,	ŪĠ,	US,	UZ,	VN,	YU,	ZA,	ZM,	ZW									
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZM,	ZW,	AM,	ΑZ,	BY,		
		KG,	ΚZ,	MD,	RU,	TJ,	TM,	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,		
		GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,		
		GN,	GQ,	GW,	ML,	MR,	ΝĒ,	SN,	TD,	TG									
WO	2001	0627	75		A2		2001	0830	1	WO 2	001-	DK12	7		2	0010	222 <		
WO	WO 2001062775 A3				2002	0131													

```
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
            CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 2003092609
                         A1
                                20030515
                                           US 2001-792286
                                                                   20010222 <--
     CA 2439101
                         A1-
                                20021003
                                            CA 2002-2439101
    EP 1370276
                         A2
                                20031217
                                           EP 2002-723240
                                                                   20020222
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                         Т
                                20050303
                                            JP 2002-576275
     JP 2005506295
                                                                   20020222
    BR 2002007476
                         Α
                                20060124
                                           BR 2002-7476
                                                                   20020222
                                           NO 2003-3641
    NO 2003003641
                         A
                                20031020
                                                                   20030815
    US 2005113293
                         A1
                                20050526
                                           US 2003-646294
                                                                   20030822 <--
     IN 2003DN01336
                         Α
                                20050527
                                           IN 2003-DN1336
                                                                   20030822
                         A1
                                20050407
                                           US 2004-772774
                                                                   20040204 <--
     US 2005075280
PRIORITY APPLN. INFO.:
                                            US 2001-792286
                                                               A 20010222
                                                               A 20010222
                                            WO 2001-DK127
                                            US 2001-314470P
                                                               P 20010823
                                            DK 2000-288
                                                               A 20000223 <--
                                            DK 2000-738
                                                               A 20000504 <--
                                            US 2000-251659P
                                                              P 20001206 <--
                                            WO 2002-US5773
                                                               W 20020222
OTHER SOURCE(S):
                        MARPAT 137:263304
     The invention relates to novel peptides, including novel antiarrhythmic
AΒ
     peptides of linear or cyclic structure, having improved stability in vitro
     and/or in vivo, to compns. comprising these peptides, and to uses of the
     peptides for the preparation of medicaments. The invention also relates to
     the use of compds. that facilitate the intercellular communication for the
     preparation of medicaments for the treatment of a range of diseases
   characterized in impaired intercellular gap junctional communication.
     invention further relates to a method of treating diseases, such as bladder
     incontinence, disorders of alveolar tissue and bronchial tissue, impaired
     hearing due to diseases of the cochlea, endothelial lesions, diabetic
     retinopathy and diabetic neuropathy, ischemia of the central nervous system
     and spinal cord, dental tissue disorders including periodontal disease, kidney
     diseases leading to hypertension, and a method of preventing failures of bone
     marrow transplantation. Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D-Ala-Gly-NH2 (Hyp =
     hydroxyprolyl) was prepared by the solid-phase method and assayed for biol.
     activity. Graphs include those for relative cell-to-cell conductance, PI-
     turnover in neonatal rat cardiomyocytes, and ventricular APD90 dispersion.
IC
    ICM C07K007-00
CC
     34-3 (Amino Acids, Peptides, and Proteins)
    Section cross-reference(s): 1, 6, 63
     81771-37-1P, Antiarrhythmic peptide (cattle atrium)
                                                          111915-92-5P
    159503-65-8P
                   355151-11-0P
                                355151-12-1P
                                                 355151-13-2P
                                                                 355151-14-3P
     355151-15-4P
                   355151-16-5P
                                  355151-17-6P
                                                 355151-18-7P
                                                                 355151-19-8P
     355151-20-1P
                   355151-23-4P
                                  355151-25-6P
                                                 355151-26-7P
                                                                 355151-27-8P
     355151-29-0P
                   355151-30-3P
                                  355151-31-4P
                                                 355151-32-5P
    355151-33-6P
                   355151-34-7P
                                  355151-35-8P
                                                 355151-36-9P
                                  355151-39-2P
    355151-37-0P
                   355151-38-1P
                                                 355151-40-5P
                                                                 355151-41-6P
    355151-43-8P 355151-45-0P 355151-46-1P
    355151-47-2P
                   355151-49-4P 355151-50-7P
                                                 355151-51-8P
    355151-52-9P
                   355151-53-0P
                                  355151-54-1P 355151-55-2P
                                                                355151-56-3P
    355151-74-5P
                   463362-31-4P
                                  463362-32-5P
                                                 463362-33-6P
                                                                 463362-34-7P
    463362-35-8P
                   463362-36-9P
                                  463362-37-0P
                                                 463362-38-1P
                                                                 463362-40-5P
```

463362-42-7P

463944-96-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

IT 35919-99-4 212570-15-5 366800-53-5 463362-43-8 463362-44-9

463362-45-0 463362-46-1 463362-47-2 463362-48-3 463362-49-4

463362-50-7 463362-51-8 463362-52-9 463362-53-0 463362-54-1

463362-55-2 463362-56-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

IT 355151-33-6P 355151-45-0P 355151-46-1P

355151-47-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

RN 355151-33-6 HCAPLUS

CN D-Asparagine, glycyl-D-alanylglycyl-(4S)-4-hydroxy-D-prolyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 355151-45-0 HCAPLUS

CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-glutaminylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 355151-46-1 HCAPLUS

CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 355151-47-2 HCAPLUS

CN Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 463362-44-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL . (Biological study); USES (Uses)

(synthesis of peptides and medical uses of intracellular communication facilitating compds.)

RN 463362-44-9 HCAPLUS

CN L-Aspartamide, glycyl-L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2002:575239 HCAPLUS Full-text

DOCUMENT NUMBER:

137:136135

TITLE:

Human cDNA sequences and their encoded proteins and

diagnostic and therapeutic uses

INVENTOR(S):

Shimkets, Richard A.; Patturajan, Meera; Vernet, Corine A. M.; Casman, Stacie J.; Malyankar, Uriel; Shenoy, Suresh; Spytek, Kimberly A.; Gangolli, Esha; Miller, Charles; Boldog, Ferenc; Li, Li; Taupier, Raymond J., Jr.; Kekuda, Ramesh; Smithson, Glennda; Zerhusen, Bryan D.; Liu, Xiaohong; Colman, Steven D.; Tchernev, Velizar; Si, Jingsheng; Edinger, Schlomit;

Stone, David; Sciore, Paul; Millet, Isabelle;

Rothenberg, Mark

PATENT ASSIGNEE(S):

SOURCE:

Curagen Corporation, USA PCT Int. Appl., 363 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

Patent English

173

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	PATENT NO.				KIN	KIND DATE				APPL	ICAT:	ION 1	NO.		D	DATE			
WO	2002	0593	15		A2	_	2002	0801	,	WO 2	001-1	US50	076		20011219 <-				
WO	2002	0593	15		A3		2003	1009											
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,		
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DΖ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,		
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,		
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,		
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,		
		UG,	US,	UΖ,	VN,	YU,	ZA,	ZW	•		•								
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,		
		KG,	ΚZ,	MD,	RU,	TJ,	TM,	ΑT,	ΒE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,		
		GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,		
		GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG									
AU	2002	2468	80		A1		2002	0806		AU 2	002-	2468	80		20	0011	219 <		
AU	2005	2001	06		A1		2005	0210		AU 2	005-3	2001	06		20	0050	112 <		
AU	2006	2014	67		A1		2006	0504		AU 2	006-	2014	67		20	060	407 <		
PRIORIT	Y APP	LN.	INFO	. :					1	US 2	000-	2566	19P	3	P 20	0001	219 <		

```
US 2001-262959P
                      20010119
US 2001-272408P
                   Р
                      20010228
US 2001-285189P
                   P 20010420
US 2001-308039P
                   P 20010726
US 2001-311266P
                   P 20010809
                   A3 20000309 <--
AU 2000-37360
AU 2000-78680
                   A3 20001006 <--
WO 2001-US50076
                   W 20011219
```

Disclosed herein are 20 cDNA sequences that encode novel human polypeptides that are members of the following protein families: stabilin, CD44-like precursor/fascilin domain, polydom, transmembrane IIIb protein, serine proteinase, Wnt-7a protein, apical endosomal glycoprotein, ADAM13, leucinerich F box-containing protein, steroid-binding protein, steroid dehydrogenase, myosin heavy chain, and pancreatitis-associated protein. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

IC ICM C12N015-12

ICS C07K014-47

3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 13

TT 444213-89-2 444213-92-7 444213-96-1 444213-97-2 444213-98-3 444214-00-0 444214-01-1 444214-02-2 444214-03-3 444214-04-4 44214-05-5 444214-06-6 444214-07-7

RL: PRP (Properties)

(unclaimed protein sequence; human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses)

IT 444214-05-5

RL: PRP (Properties)

(unclaimed protein sequence; human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses)

RN 444214-05-5 HCAPLUS

CN 50: PN: WO02059315 SEQID: 102 unclaimed protein (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2002:293812 HCAPLUS Full-text

DOCUMENT NUMBER:

136:290020

TITLE:

CC

Nucleic acids and their encoded polypeptides from

human tissues

INVENTOR(S):

Tang, Y. Tom; Liu, Chenghua; Zhou, Ping; Asundi,
Vinod; Zhang, Jie; Zhao, Qing A.; Ren, Feiyan; Xue,
Aidong J.; Yang, Yonghong; Wehrman, Tom; Drmanac,

Radoje T.

PATENT ASSIGNEE(S):

Hyseq, Inc., USA

SOURCE:

PCT Int. Appl., 357 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

127

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
				
WO 2002031111	A2	20020418	WO 2001-US27760	20011011 <
WO 2002031111	A3	20021017		·

```
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2425827
                          A1
                                20020418
                                            CA 2001-2425827
                                                                    20011011 <--
    AU 200196235
                          Α
                                20020422
                                             AU 2001-96235
                                                                    20011011 <--
     EP 1325120
                          Α2
                                20030709
                                             EP 2001-977088
                                                                    20011011 <--
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.:
                                             US 2000-687527
                                                                 A2 20001012 <--
                                             WO 2001-US27760
                                                                 W 20011011
     The present invention provides novel nucleic acids, novel polypeptide
AB
     sequences encoded by these nucleic acids and uses thereof. Thus, 446 novel
     nucleic acids were obtained from cDNA libraries prepared from various human
     tissues and in some cases isolated from a genomic library derived from human
     chromosomes using standard PCR, SBH (sequencing-by-hybridization) sequence
     signature anal., and Sanger sequencing techniques. Novel contigs of the
     invention were assembled from sequences that were obtained from a cDNA library
     by the above methods, and in some cases sequences obtained from one or more
     public databases, using a recursive algorithm to extend the seed EST into an
     extended assemblage. Tissue expression profiles and nearest neighbor sequence
     homologies are provided. The sequences of this invention have applications in
     nucleic acid or polypeptide arrays, in the identification of binding mols.,
     and in treatment of diseases.
     ICM C12N
IC
CC
     3-3 (Biochemical Genetics)
     Section cross-reference(s): 6, 13, 63
                                                   408551-80-4P
                                                                  408551-81-5P
IT
     408551-77-9P
                    408551-78-0P
                                    408551-79-1P
                                                   408551-85-9P
                                                                  408551-86-0P
     408551-82-6P
                    408551-83-7P
                                    408551-84-8P
                                                                  408551-91-7P
                                                   408551-90-6P
     408551-87-1P
                    408551-88-2P
                                    408551-89-3P
     408551-92-8P
                    408551-93-9P
                                    408551-94-0P
                                                   408551-95-1P
                                                                  408551-96-2P
                                                                  408552-01-2P
     408551-97-3P
                    408551-98-4P
                                    408551-99-5P
                                                   408552-00-1P
                                                 408552-05-6P
     408552-02-3P 408552-03-4P
                                 408552-04-5P
     408552-06-7P
                    408552-07-8P
                                    408552-08-9P
                                                   408552-09-0P
                                                                  408552-10-3P
     408552-11-4P
                    408552-12-5P
                                    408552-13-6P
                                                   408552-14-7P
                                                                  408552-15-8P
                                    408552-18-1P
                                                   408552-19-2P
                                                                  408552-20-5P
     408552-16-9P
                    408552-17-0P
                                                   408552-24-9P
                                                                  408552-25-0P
                    408552-22-7P
                                    408552-23-8P
     408552-21-6P
     408552-26-1P
                    408552-27-2P
                                    408552-28-3P
                                                   408552-29-4P
                                                                  408552-30-7P
     408552-31-8P
                    408552-32-9P
                                    408552-33-0P
                                                   408552-34-1P
                                                                  408552-35-2P
                                                                  408552-40-9P
     408552-36-3P
                    408552-37-4P
                                    408552-38-5P
                                                   408552-39-6P
                                    408552-43-2P
                                                   408552-44-3P
                                                                  408552-45-4P
     408552-41-0P
                    408552-42-1P
     408552-46-5P
                    408552-47-6P
                                    408552-48-7P
                                                   408552-49-8P
                                                                  408552-50-1P
     408552-51-2P
                    408552-52-3P
                                    408552-53-4P
                                                   408552-54-5P
                                                                  408552-55-6P
                                    408552-58-9P
                                                   408552-59-0P
                                                                  408552-60-3P
     408552-56-7P
                    408552-57-8P
                                                                  408552-65-8P
     408552-61-4P
                    408552-62-5P
                                    408552-63-6P
                                                   408552-64-7P
                                    408552-68-1P
                                                   408552-69-2P
                                                                  408552-70-5P
     408552-66-9P
                    408552-67-0P
                    408552-72-7P
                                    408552-73-8P
                                                   408552-74-9P
                                                                  408552-75-0P
     408552-71-6P
                                    408552-78-3P
                                                   408552-79-4P
                                                                  408552-80-7P
     408552-76-1P
                    408552-77-2P
     408552-81-8P
                    408552-82-9P
                                    408552-83-0P
                                                   408552-84-1P
                                                                  408552-85-2P
                                                   408552-89-6P
                                                                  408552-90-9P
     408552-86-3P
                    408552-87-4P
                                    408552-88-5P
                                    408552-93-2P
                                                   408552-94-3P
                                                                  408552-95-4P
     408552-91-0P
                    408552-92-1P
     408552-96-5P
                    408552-97-6P
                                    408552-98-7P
                                                   408552-99-8P
                                                                  408553-00-4P
     408553-01-5P
                    408553-02-6P
                                    408553-03-7P
                                                   408553-04-8P
                                                                  408553-05-9P
                                                                  408553-10-6P
                                                   408553-09-3P
     408553-06-0P
                    408553-07-1P
                                    408553-08-2P
```

408553-13-9P

408553-14-0P

408553-12-8P

408553-11-7P

408553-15-1P

```
408553-18-4P
                                                                408553-20-8P
     408553-16-2P
                   408553-17-3P
                                                 408553-19-5P
                                  408553-23-1P
     408553-21-9P
                   408553-22-0P
                                                 408553-24-2P
                                                                408553-25-3P
                                                                408553-30-0P
     408553-26-4P
                   408553-27-5P
                                  408553-28-6P
                                                 408553-29-7P
     408553-31-1P
                   408553-32-2P
                                  408553-33-3P
                                                 408553-34-4P
                                                                408553-35-5P
                                  408553-38-8P
                                                                408553-40-2P
     408553-36-6P
                   408553-37-7P
                                                 408553-39-9P
     408553-41-3P
                   408553-42-4P
                                  408553-43-5P
                                                 408553-44-6P
                                                                408553-45-7P
     408553-46-8P
                   408553-47-9P
                                  408553-48-0P
                                                 408553-49-1P
                                                                408553-50-4P
                                                 408553-54-8P
    408553-51-5P
                   408553-52-6P 408553-53-7P
                                                                408553-55-9P
     408553-56-0P
                   408553-57-1P 408553-58-2P
                                                 408553-59-3P
                                                                408553-60-6P
     408553-61-7P
                   408553-62-8P 408553-63-9P
                                                 408553-64-0P
                                                                408553-65-1P
     408553-66-2P
                   408553-67-3P
                                  408553-68-4P
                                                 408553-69-5P
                                                                408553-70-8P
     408553-71-9P
                   408553-72-0P
                                  408553-73-1P
                                                 408553-74-2P
                                                                408553-75-3P
                   408553-77-5P 408553-78-6P
    408553-76-4P
                                                 408553-79-7P
                                                                408553-80-0P
     408553-81-1P
                   408553-82-2P
                                  408553-83-3P
                                                 408553-84-4P
                                                                408553-85-5P
    408553-86-6P
                   408553-87-7P
                                  408553-88-8P 408553-89-9P
                                                                408553-90-2P
    RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
    unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical
     study); BIOL (Biological study); PREP (Preparation); USES (Uses)
        (amino acid sequence; nucleic acids and their encoded polypeptides from
       human tissues)
     408552-03-4P
    RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study,
    unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical
     study); BIOL (Biological study); PREP (Preparation); USES (Uses)
        (amino acid sequence; nucleic acids and their encoded polypeptides from
       human tissues)
     408552-03-4 HCAPLUS
    Protein (human clone WO0231111-SEQID-704) (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
    ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
                        2001:828442 HCAPLUS Full-text
ACCESSION NUMBER:
DOCUMENT NUMBER:
                        136:396989
                        Human nucleic acids and polypeptides and their
TITLE:
                        diagnostic and therapeutic uses
                        Drmanac, Rodoje T.; Liu, Chenghua; Tang, Y. Tom
INVENTOR(S):
                        Hyseq, Inc., USA
PATENT ASSIGNEE(S):
                        PCT Int. Appl., 103 pp.
SOURCE:
                        CODEN: PIXXD2
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                        English
FAMILY ACC. NUM. COUNT:
                        127
PATENT INFORMATION:
```

IT

RN

CN

PAT	PATENT NO.		KIN	D	DATE			APPL	ICAT	ION I	NO.		D	ATE			
WO	2001	 0750:	- 67		A2	- ·	2001	1011	1	WO 2	 001-:	 XF86	· 3 1		2	0010	 330 <
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		CR,	ĊŪ,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,
		HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,
		LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	ΡĻ,	PT,	RO,	RU,
		SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VN,
•		YU,	ZA,	ZW													
	RW:	GH,	GM,	KE,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	TZ.,	ŪĠ,	ZW,	AT,	BE,	CH,	CY,
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,
		ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG		
WO	2001	0750	67		A2		2001	1011	1	WO 2	001-	US86	31		2	0010	330 <
WO	2001	0750	67	A3		20020404											
WO	2001	0750	67		A9		2002	1031									

```
WO 2001075067
                          A8
                                20041014
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                             US 2000-540217
                                                                A 20000331 <--
                                             US 2000-649167
                                                                 A 20000823 <--
                                             WO 2001-US8631
                                                                 W 20010330
     The present invention provides 30,368 nucleic acids and the 30,368 novel human
AB
     polypeptide sequences encoded by these nucleic acids. A plurality of novel
     nucleic acids are obtained from cDNA libraries prepared from various human
     tissues and in some cases isolated from a genomic library derived from human
     chromosomes using standard PCR, sequencing by hybridization signature anal.,
     and Sanger sequencing techniques. Nearest neighbor results are identified by
     sequence homol. searching. The invention also relates to therapeutic,
     diagnostic, and research utilities for these polynucleotides and proteins.
      [This abstract record is one of 10 records for this document necessitated by
     the large number of index entries required to fully index the document and
     publication system constraints.].
IC
     ICM C12N
     3-3 (Biochemical Genetics)
CC
     Section cross-reference(s): 6, 13, 63
IT
                                 429717-76-0
                                                429717-77-1
                                                              429717-78-2
     429717-74-8
                   429717-75-9
     429717-79-3
                   429717-80-6
                                 429717-81-7
                                                429717-82-8
                                                              429717-83-9
                                 429717-86-2
                                                429717-87-3
                                                              429717-88-4
     429717-84-0
                   429717-85-1
     429717-89-5
                   429717-90-8
                                 429717-91-9
                                                429717-92-0
                                                              429717-93-1
                                 429717-96-4
                                                429717-97-5
                                                              429717-98-6
     429717-94-2
                   429717-95-3
                                 429718-01-4
                                                429718-02-5
                                                              429718-03-6
     429717-99-7
                   429718-00-3
                                                429718-07-0
                                                              429718-08-1
     429718-04-7
                   429718-05-8
                                 429718-06-9
     429718-09-2
                   429718-10-5
                                 429718-11-6
                                                429718-12-7
                                                              429718-13-8
     429718-14-9
                   429718-15-0
                                 429718-16-1
                                                429718-17-2
                                                              429718-18-3
                                                429718-22-9
                                                              429718-23-0
     429718-19-4
                   429718-20-7
                                 429718-21-8
                                                429718-27-4
                                                              429718-28-5
     429718-24-1
                   429718-25-2
                                 429718-26-3
                   429718-30-9
                                 429718-31-0
                                                429718-32-1
                                                              429718-33-2
     429718-29-6
                   429718-35-4
                                 429718-36-5
                                                429718-37-6
                                                              429718-38-7
     429718-34-3
                                                429718-42-3
     429718-39-8
                   429718-40-1
                                 429718-41-2
                                                429718-46-7
                                                              429718-47-8
     429718-43-4
                   429718-44-5
                                 429718-45-6
                                 429718-50-3
                                                429718-51-4
                                                              429718-52-5
     429718-48-9
                   429718-49-0
                                 429718-55-8
                                                429718-56-9
                                                              429718-57-0
     429718-53-6
                   429718-54-7
                                                429718-61-6
                                                              429718-62-7
                   429718-59-2
                                 429718-60-5
     429718-58-1
     429718-63-8
                   429718-64-9
                                 429718-65-0
                                                429718-66-1
                                                              429718-67-2
                                 429718-70-7
                                                429718-71-8
                                                              429718-72-9
     429718-68-3
                   429718-69-4
                                 429718-75-2
                                                429718-76-3
                                                              429718-77-4
     429718-73-0
                   429718-74-1
                                                429718-81-0
                                                              429718-82-1
                   429718-79-6
                                 429718-80-9
     429718-78-5
     429718-83-2
                   429718-84-3
                                 429718-85-4
                                                429718-86-5
                                                              429718-87-6
                                                429718-91-2
                                                              429718-92-3
     429718-88-7
                   429718-89-8
                                 429718-90-1
                                 429718-95-6
                                                429718-96-7
                                                              429718-97-8
     429718-93-4
                   429718-94-5
                   429718-99-0
                                 429719-00-6
                                                429719-01-7
                                                              429719-02-8
     429718-98-9
     429719-03-9
                   429719-04-0
                                 429719-05-1
                                                429719-06-2
                                                              429719-07-3
     429719-08-4
                   429719-09-5
                                 429719-10-8
                                                429719-11-9
                                                              429719-12-0
                                                              429719-17-5
                                                429719-16-4
                   429719-14-2
                                 429719-15-3
     429719-13-1
                                 429719-20-0
     429719-18-6
                   429719-19-7
                                                429719-21-1
                                                              429719-22-2
     429719-23-3
                   429719-24-4
                                 429719-25-5
                                                429719-26-6
                                                              429719-27-7
                                                429719-31-3
```

429719-30-2

429719-35-7

429719-36-8

429719-28-8

429719-33-5

429719-29-9

429719-34-6

429719-32-4

429719-37-9

```
429719-40-4
    429719-38-0
                  429719-39-1
                                            429719-41-5
                                                          429719-42-6
    429719-43-7 429719-44-8
                               429719-45-9
                                            429719-46-0 429719-47-1
    429719-48-2 429719-49-3
                               429719-50-6 429719-51-7 429719-52-8
                               429719-55-1 429719-56-2 429719-57-3
    429719-53-9
                 429719-54-0
                               429719-60-8 429719-61-9
    429719-58-4
                 429719-59-5
                                                         429719-62-0
                                           429719-66-4
    429719-63-1
                 429719-64-2
                               429719-65-3
                                                          429719-67-5
    429719-68-6
                 429719-69-7
                               429719-70-0
                                            429719-71-1
                                                         429719-72-2
                                           429719-76-6
    429719-73-3 429719-74-4
                              429719-75-5
                                                         429719-77-7
    429719-78-8 429719-79-9
                              429719-80-2 429719-81-3 429719-82-4
    429719-83-5 429719-84-6 429719-85-7 429719-86-8 429719-87-9
    429719-88-0 429719-89-1 429719-90-4 429719-91-5 429719-92-6
    429719-93-7 429719-94-8 429719-95-9 429719-96-0 429719-97-1
                               429720-00-3 429720-01-4
    429719-98-2
                 429719-99-3
                                                          429720-02-5
    429720-03-6 429720-04-7 429720-05-8 429720-06-9
    RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
    THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study);
    USES (Uses)
       (amino acid sequence; human nucleic acids and polypeptides and their
       diagnostic and therapeutic uses)
    429718-39-8
    RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties);
    THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study);
       (amino acid sequence; human nucleic acids and polypeptides and their
       diagnostic and therapeutic uses)
    429718-39-8 HCAPLUS
    Protein (human clone WO0175067-SEQID-32147) (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
    ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:781081 HCAPLUS Full-text
DOCUMENT NUMBER:
                       135:314493
TITLE:
                       Novel nucleic acids encoding human bone
                       marrow-expressed polypeptides
                       Ford, John E.; Boyle, Bryan J.; Tang, Y. Tom; Asundi,
INVENTOR(S):
                       Vinod; Yang, Yonghong; Liu, Chenghua; Drmanac, Radoje
PATENT ASSIGNEE(S):
                       Hyseq, Inc., USA
SOURCE:
                       PCT Int. Appl., 203 pp.
                       CODEN: PIXXD2
DOCUMENT TYPE:
                       Patent
LANGUAGE:
                       English
FAMILY ACC. NUM. COUNT: 127
PATENT INFORMATION:
                       KIND DATE
    PATENT NO.
                                        APPLICATION NO.
                                                              DATE
    _____
                                         -----
                       ----
                              -----
    WO 2001079447
                       A2
                              20011025
                                        WO 2001-US12607
                                                               20010418 <--
    WO 2001079447
                       A8 20030724
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
            HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
            LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
            RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
            VN. YU. ZA. ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
```

KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,

GW, ML, MR, NE, SN, TD, TG

IT

RN

CN

```
20010418 <--
    AU 200155454
                         Α
                               20011030
                                           AU 2001-55454
    US 2003113847
                        A1
                               20030619
                                           US 2002-232484
                                                                 20020830 <--
PRIORITY APPLN. INFO.:
                                           US 2000-552929
                                                              A 20000418 <--
                                           US 2000-695783
                                                              A 20001024 <--
                                                              P 20001130 <--
                                           US 2000-250583P
                                                              A 20010126
                                           US 2001-770160
                                           WO 2001-US12607
                                                              W 20010418
AΒ
     The present invention provides 67 novel bone marrow-expressed nucleic acids,
     novel polypeptide sequences encoded by these nucleic acids, and uses thereof.
     The novel nucleic acids were assembled from expressed sequence tags (ESTs)
     isolated mainly by sequencing by hybridization, Sanger sequencing techniques,
     and in some cases, sequences obtained from one or more public databases. A
     recursive algorithm was used to extend some of the seed ESTs into an extended
     assemblage, by pulling addnl. sequences from different databases. Clusters
     were identified which were expressed in bone marrow tissue cDNA libraries, but
     not in other tissues. The polynucleotides and polypeptides of the invention
     have uses in diagnosis and therapy, detecting bone-marrow cells or tissues,
     and in arrays to screen for binding agents.
IC
    ICM C12N
     3-3 (Biochemical Genetics)
CC
    Section cross-reference(s): 6, 13, 63
    218776-18-2 321453-13-8
                                367452-08-2
                                              367620-05-1
                                                           367620-06-2
IT
                  367620-08-4
                                367620-09-5
                                              367620-10-8
                                                           367620-11-9
    367620-07-3
    367620-12-0 367620-13-1 367620-14-2 367620-15-3
    367620-16-4
                367620-17-5 367620-18-6
                                             367620-19-7
                                                           367620-20-0
                                              367620-48-2
    367620-21-1 367620-22-2
                                367620-47-1
                                                           367620-49-3
    367620-50-6
                                367620-52-8
                  367620-51-7
                                              367620-53-9
                                                           367620-54-0
    367620-55-1
                                367620-57-3
                  367620-56-2
                                              367620-58-4
                                                           367620-59-5
                                             367620-63-1
    367620-60-8 367620-61-9
                                367620-62-0
                                                           367620-64-2
    367620-65-3 367620-66-4
                                367620-67-5 367935-34-0
                                                           367935-37-3
    367935-43-1 367935-50-0
                                367935-54-4 367935-57-7
                                                           367935-63-5
    367935-65-7 367935-71-5
                                367935-78-2 367935-81-7 367943-61-1
    367943-64-4 367943-67-7
    RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
    unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical
    study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
        (amino acid sequence; nucleic acids encoding human bone
       marrow-expressed polypeptides)
    367620-13-1
IT
    RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study,
    unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical
    study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
        (amino acid sequence; nucleic acids encoding human bone
       marrow-expressed polypeptides)
    367620-13-1 HCAPLUS
RN
    Bone marrow-specific protein (human clone WO0179447-SEQID-38 precursor)
CN
           (CA INDEX NAME)
     (9CI)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
    ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:
                        2001:636085 HCAPLUS Full-text
DOCUMENT NUMBER:
                        135:180957
                        Preparation of novel antiarrhythmic peptides
TITLE:
                        Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier,
INVENTOR (S):
                        Eddi; Kjolbye, Anne Louise; Jorgensen, Niklas Rye;
                        Nielsen, Morten Schak; Holstein-Rathlou, Niels-Henrik;
                        Martins, James B.
```

Zealand Pharmaceuticals A/S, Den.

PCT Int. Appl., 189 pp.

PATENT ASSIGNEE(S):

SOURCE:

87

CODEN: PIXXD2 .

DOCUMENT TYPE:

Patent

LANGUAGE:

FAMILY ACC. NUM. COUNT:

English

PATENT INFORMATION:

2

PATENT	INFORMATION:			
PA	ATENT NO.	KIND DATE	APPLICATION NO.	
	2001062775 2001062775	A2 20010830 A3 20020131	WO 2001-DK127	20010222 <
WC			BB, BG, BR, BY, CA,	CH. CN. CR. CU.
			GB, GD, GE, GH, GM,	
			KZ, LC, LK, LR, LS,	
	MD, MG,	MK, MN, MW, MX, NO,	NZ, PL, PT, RO, RU,	SD, SE, SG, SI,
			UA, UG, US, UZ, VN,	
	RW: GH, GM,	KE, LS, MW, MZ, SD,	SL, SZ, TZ, UG, ZW,	AT, BE, CH, CY,
	DE, DK,	ES, FI, FR, GB, GR,	IE, IT, LU, MC, NL,	PT, SE, TR, BF,
	BJ, CF,	CG, CI, CM, GA, GN,	GW, ML, MR, NE, SN,	TD, TG
CA	A 2385659	A1 20010830	CA 2001-2385659	
EF	2 1226160	A2 20020731	EP 2001-907393	20010222 <
EF	2 1226160	B1 20041215		
			GB, GR, IT, LI, LU,	NL, SE, MC, PT,
		LT, LV, FI, RO, MK,		
	2003528826	T 20030930	JP 2001-562556	20010222 <
	284896	T 20050115		20010222 <
	3 2228807	T3 , 20050416	ES 2001-1907393	20010222 <
	1226160	T 20050429		20010222 < 20010222 <
	J 781674 A 2439101	B2 20050602 A1 20021003		
		A2 20021003 A2 20021003		20020222
	2002077017	A3 20031009		20020222
"			BÀ, BB, BG, BR, BY,	BZ, CA, CH, CN,
			DZ, EC, EE, ES, FI,	
			JP, KE, KG, KP, KR,	
	•	, , , , , ,	MK, MN, MW, MX, MZ,	
			SI, SK, SL, TJ, TM,	
	UA, UG,	US, UZ, VN, YU, ZA,	ZM, ZW	
	RW: GH, GM,	KE, LS, MW, MZ, SD,	SL, SZ, TZ, UG, ZM,	ZW, AM, AZ, BY,
,	KG, KZ,	MD, RU, TJ, TM, AT,	BE, CH, CY, DE, DK,	ES, FI, FR, GB,
	GR, IE,	IT, LU, MC, NL, PT,	SE, TR, BF, BJ, CF,	CG, CI, CM, GA,
	GN, GQ,	GW, ML, MR, NE, SN,		
E	2 1370276	A2 20031217		20020222
			GB, GR, IT, LI, LU,	NL, SE, MC, PT,
	• •	LT, LV, FI, RO, MK,	•	2002022
	2005506295	T 20050303	JP 2002-576275	20020222 20020222
	R 2002007476 D 2003003641	A 20060124 A 20031020	BR 2002-7476 NO 2003-3641	20020222
	3 2005113293	A1 20050526	US 2003-646294	20030813
	3 2005113293 3 2005075280	A1 20050407	US 2004-772774	20030022 <
	J 2005275285	A1 20050929	AU 2005-205785	20050902 <
	TY APPLN. INFO.		DK 2000-288	A 20000223 <
			DK 2000-738	A 20000504 <
			US 2000-251659P	P 20001206 <
		,	US 2001-792286	A 20010222
			WO 2001-DK127	W 20010222
			US 2001-314470P	P 20010823
			WO 2002-US5773	W 20020222
		1/20020 125 1000	F -9	

OTHER SOURCE(S): MARPAT 135:180957

AB Peptides X-A-B-Y and cyclo(X-A-B-Y) [A and B represents chemical moieties having an amino group (radical) and a carboxy group; X represents a peptide

sequence of 1 to 3 D- or L-amino acid residues or an N-terminal modification of the group A-B when Y represents a C-terminal peptide sequence of 2 to 5 D- or L-amino acid residues; X represents a peptide sequence of 2 to 5 D- or L-amino acid residues when Y represents a C-terminal peptide sequence of 1 to 3 D- or L-amino acid residues; for the linear peptide, X is optionally chemical modified at its N-terminal and has an optional linking group comprising 0-8 backbone atoms] and their mirror image or a retro analogs or pharmaceutically acceptable derivs. were prepared for treating cardiac arrhythmias. Thus, Ac-D-Tyr-D-pro-D-4Hyp-Gly- D-Ala-Gly-NH2 (4Hyp = 4-hydroxyprolyl) was prepared by the solid-phase method using TentaGel-S-Ram and examined for biol. activity [assays included effect on gap junction intercellular communication (GJIC) in cardiomyocytes, binding to tissue prepns. of murine heart, and effect on cAMP formation in CHO cells].

IC ICM C07K007-00

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 1, 63

IT 81771-37-1P, Antiarrhythmic peptide (cattle atrium) 355151-11-0P 355151-14-3P 355151-15-4P 355151-16-5P 355151-17-6P 355151-18-7P 355151-19-8P 355151-20-1P 355151-21-2P 355151-22-3P 355151-23-4P 355151-24-5P 355151-25-6P 355151-26-7P 355151-27-8P 355151-28-9P 355151-29-0P 355151-30-3P 355151-31-4P 355151-32-5P 355151-33-6P 355151-34-7P 355151-35-8P 355151-36-9P 355151-37-0P 355151-38-1P 355151-39-2P 355151-40-5P 355151-42-7P 355151-44-9P 355151-45-0P 355151-46-1P 355151-47-2P 355151-48-3P 355151-49-4P 355151-50-7P 355151-51-8P 355151-52-9P 355151-53-0P 355151-54-1P 355151-55-2P 355151-56-3P 355151-57-4P .355151-58-5P 355151-59-6P 355151-60-9P 355151-61-0P 355151-62-1P 355151-63-2P 355151-64-3P 355151-65-4P 355151-66-5P 355151-67-6P 355151-68-7P 355151-69-8P 355151-70-1P 355151-71-2P 355151-72-3P 355151-73-4P 355151-74-5P RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel antiarrhythmic peptides)

IT 355151-33-6P 355151-45-0P 355151-46-1P 355151-47-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel antiarrhythmic peptides)

RN 355151-33-6 HCAPLUS

CN

D-Asparagine, glycyl-D-alanylglycyl-(4S)-4-hydroxy-D-prolyl-D-prolyl-D-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 355151-45-0 HCAPLUS CN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-(CA INDEX NAME) glutaminylglycyl] (9CI) *** STRUCTURE DIAGRAM IS NOT AVAILABLE *** 355151-46-1 HCAPLUS RN Cyclo[L-alanylglycyl-(4R)-4-hydroxy-L-prolyl-L-prolyl-L-tyrosyl-L-CN asparaginylglycyl] (9CI) (CA INDEX NAME) *** STRUCTURE DIAGRAM IS NOT AVAILABLE *** RN 355151-47-2 HCAPLUS Cyclo(L-alanylglycyl-L-prolyl-L-prolyl-L-tyrosyl-L-asparaginylglycyl) CN (9CI) (CA INDEX NAME) *** STRUCTURE DIAGRAM IS NOT AVAILABLE *** ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN L4 ACCESSION NUMBER: 2000:325646 HCAPLUS Full-text DOCUMENT NUMBER: 133:247911 TITLE: Prediction of the coding sequences of unidentified human genes. XVII. the complete sequences of 100 new cDNA clones from brain which code for large proteins AUTHOR (S): Nagase, Takahiro; Kikuno, Reiko; Ishikawa, Ken-Ichi; Hirosawa, Makoto; Ohara, Osamu Kazusa DNA Research Institute, Chiba, 292-0812, Japan CORPORATE SOURCE: DNA Research (2000), 7(2), 143-150 SOURCE: CODEN: DARSE8; ISSN: 1340-2838 PUBLISHER: Universal Academy Press DOCUMENT TYPE: Journal LANGUAGE: English To provide information regarding the coding sequences of unidentified human AB genes, the authors have conducted a sequencing project of human cDNAs which encode large proteins. The authors herein present the entire sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from two sets of size-fractionated human adult and fetal brain cDNA libraries. The average sizes of the inserts and corresponding open reading frames of cDNA clones analyzed here were 4.4 kb and 2.6 kb (856 amino acid residues), resp. Database searches of the predicted amino acid sequences classified 53 predicted gene products into the following five functional categories: cell signaling/communication, nucleic acid management, cell structure/motility, protein management and metabolism It was also revealed that homologues for 32 KIAA gene products were detected in the databases, which were similar in sequence through almost their entire regions. Addnl., the chromosomal loci of the genes were determined by using human-rodent hybrid panels unless their chromosomal loci were already assigned in the public databases. expression levels of the genes were monitored in spinal cord, fetal brain and fetal liver, as well as in 10 human tissues and 8 brain regions, by reverse transcription-coupled polymerase chain reaction, products of which were quantified by ELISA. 3-3 (Biochemical Genetics) CC TТ 295808-10-5 295808-11-6 295808-12-7 295808-13-8 295808-14-9 295808-15-0 295808-16-1 295808-17-2 295808-18-3 295808-19-4 295808-23-0 295808-24-1 295808-20-7 295808-21-8 295808-22-9 295808-25-2 295808-26-3 295808-27-4 295808-28-5 295808-29-6 295808-31-0 *295808-32-1* 295808-33-2 295808-30-9 295808-34-3 295808-35-4 295808-36-5 295808-37-6 295808-38-7 295808-42-3 295808-39-8 295808-40-1 295808-41-2 295808-43-4 295808-46-7 295808-47-8 295808-44-5 295808-45-6 295808-48-9

295808-49-0

295808-50-3

295808-51-4

295808-52-5

295808-53-6

```
295808-56-9
295808-54-7
             295808-55-8
                                       295808-57-0
                                                    295808-58-1
                          295808-61-6
295808-59-2
            295808-60-5
                                       295808-62-7
                                                    295808-63-8
            295808-65-0
                          295808-66-1
                                       295808-67-2
                                                    295808-68-3
295808-64-9
295808-69-4
            295808-70-7
                          295808-71-8
                                       295808-72-9 295808-73-0
295808-74-1
            295808-75-2
                          295808-76-3
                                       295808-77-4
                                                    295808-78-5
            295808-80-9
                          295808-81-0
295808-79-6
                                       295808-82-1
                                                    295808-83-2
                          295808-86-5
295808-84-3
           295808-85-4
                                       295808-87-6
                                                    295808-88-7
           295808-90-1
                          295808-91-2
                                       295808-92-3
295808-89-8
                                                    295808-93-4
295808-94-5 295808-95-6
                          295808-96-7 295808-97-8 295808-98-9
295808-99-0 295809-00-6
                          295809-01-7
                                       295809-02-8 295809-03-9
295809-04-0
            295809-05-1 295809-06-2
                                      295809-07-3 295809-08-4
295809-09-5
```

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from human adult and fetal brain cDNA libraries)

IT 295808-32-1

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; sequences of 100 cDNA clones of unknown human genes, named KIAA1444 to KIAA1543, from human adult and fetal brain cDNA libraries)

RN 295808-32-1 HCAPLUS

CN Protein (human clone fj01441 gene KIAA1466 fragment) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RETABLE

AUTHOR (S):

Referenced Author	Year	VOT	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
=======================================	+=====	+=====	+=====	+======================================	+=======
Anon	1998	282	2012	Science	
Bateman, A	1999	27	260	Nucleic Acids Res	HCAPLUS
Bleasby, A	1994	22	3574	Nucleic Acids Res	HCAPLUS
Deguchi, M	1998	273	26269	J Biol Chem	HCAPLUS
Dunham, I	1999	402	489	Nature	HCAPLUS
Goffeau, A	1996	274	546	Science	HCAPLUS
Gyapay, G	1996	5	339	Hum Mol Genet	HCAPLUS
Hirosawa, M	1999	6	329	DNA Res	HCAPLUS
Ishikawa, K	1997	4	307	DNA Res	HCAPLUS .
Kikuno, R	2000	28	331	Nucleic Acids Res	HCAPLUS
Nagase, T	1998	5	277	DNA Res	HCAPLUS
Nagase, T	1998	5	31	DNA Res	HCAPLUS
Nagase, T	2000	7	65	DNA Res	HCAPLUS
Nomura, N	1994	1	27	DNA Res	HCAPLUS
Ohara, O	1997	4	53	DNA Res	HCAPLUS
Taguchi, A	1996	35	31	Brain Res Mol Brain	HCAPLUS

L4 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1999:379001 HCAPLUS Full-text

DOCUMENT NUMBER: 131:54612

TITLE: Complete genome sequence of an aerobic

hyper-thermophilic crenarchaeon, Aeropyrum pernix K1 Kawarabayasi, Yutaka; Hino, Yumi; Horikawa, Hiroshi; Yamazaki, Syuji; Haikawa, Yuji; Jin-No, Koji; Takahashi, Mikio; Sekine, Mitsuo; Baba, Sin-Ichi; Ankai, Akiho; Kosugi, Hiroki; Hosoyama, Akira; Fukui, Shiqehiro; Nagai, Yoshimi; Nishijima, Keiko; Nakazawa,

Hidekazu; Takamiya, Minako; Masuda, Sayaka; Funahashi,

Tomomichi; Tanaka, Toshihiro; Kudoh, Yutaka; Yamazaki, Jun; Kushida, Norihiro; Oguchi, Akio; Aoki, Ken-ichi; Kubota, Kenji; Nakamura, Yoshinobu; Nomura, Norimichi;

Sako, Yoshihiko; Kikuchi, Hisasi

CORPORATE SOURCE: National Institute of Technology and Evaluation,

Tokyo, 151-0066, Japan

SOURCE: DNA Research (1999), 6(2), 83-101, 145-152

CODEN: DARSE8; ISSN: 1340-2838

PUBLISHER: Universal Academy Press

DOCUMENT TYPE: Journal LANGUAGE: English

The complete sequence of the genome of an aerobic hyper-thermophilic AB crenarchaeon, Aeropyrum pernix K1, which optimally grows at 95°, was determined by the whole genome shotgun method with some modifications. entire length of the genome was 1,669,695 bp. The authenticity of the entire sequence was supported by restriction anal. of long PCR products, which were directly amplified from the genomic DNA. As the potential protein-coding regions, a total of 2694 open reading frames (ORFs) were assigned. By similarity search against public databases, 633 (23.5%) of the ORFs were related to genes with putative function and 523 (19.4%) to the sequences registered but with unknown function. All the genes in the TCA cycle except for that of α -ketoglutarate dehydrogenase were included, and instead of the α ketoglutarate dehydrogenase gene, the genes coding for the 2 subunits of 2oxoacid:ferredoxin oxidoreductase were identified. The remaining 1538 ORFs (57.1%) did not show any significant similarity to the sequences in the databases. Sequence comparison among the assigned ORFs suggested that a considerable member of ORFs were generated by sequence duplication. The RNA genes identified were a single 16S-23S rRNA operon, two 5S rRNA genes, and 47 tRNA genes including 14 genes with intron structures. All the assigned ORFs and RNA coding regions occupied 89.12% of the whole genome. The data presented in this paper are available on the internet homepage (http://www.mild.nite.go.jp).

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 6, 10

```
IT
     227780-17-8
                   227780-18-9
                                 227780-19-0
                                               227780-20-3
                                                              227780-21-4
     227780-22-5
                  227780-23-6
                                 227780-24-7
                                               227780-25-8
                                                              227780-26-9
    227780-27-0
                                               227780-30-5
                                                              227780-32-7
                  227780-28-1
                                 227780-29-2
                                               227780-49-6
                                                              227780-50-9
     227780-34-9
                   227780-35-0
                                 227780-45-2
                                               227780-54-3
                                                              227780-55-4
     227780-51-0
                   227780-52-1
                                 227780-53-2
                                 227780-59-8
                                               227780-63-4
                                                              227780-68-9
     227780-56-5
                   227780-57-6
                                               227780-72-5
                   227780-70-3
                                 227780-71-4
                                                              227780-73-6
    227780-69-0
     227780-74-7
                   227780-75-8
                                 227780-76-9
                                               227780-77-0
                                                              227780-78-1
     227780-92-9
                   227781-11-5
                                 227781-12-6
                                               227781-13-7
                                                              227781-14-8
                                                              227781-19-3
                                               227781-18-2
                   227781-16-0
                                 227781-17-1
     227781-15-9
                                 227781-22-8
                                               227781-23-9
                                                              227781-24-0
     227781-20-6
                   227781-21-7
     227781-25-1
                   227781-33-1
                                 227781-45-5
                                               227781-54-6
                                                              227781-62-6
     227781-74-0
                   227781-76-2
                                 227781-77-3
                                               227781-78-4
                                                              227781-79-5
                                                              227781-91-1
                   227781-81-9
                                 227781-83-1
                                               227781-88-6
    227781-80-8
                                               227782-05-0
                                                              227782-15-2
     227781-95-5
                   227781-96-6
                                 227782-00-5
     227782-16-3
                   227782-17-4
                                 227782-18-5
                                               227782-19-6
                                                              227782-20-9
    227782-24-3
                   227782-25-4
                                 227782-26-5
                                               227782-27-6
                                                              227782-28-7
                                               227782-32-3
    227782-29-8
                   227782-30-1
                                 227782-31-2
                                                              227782-33-4
                                 227782-36-7
                                               227782-37-8
                                                              227782-38-9
    227782-34-5
                   227782-35-6
    227782-39-0
                   227782-40-3
                                 227782-41-4
                                               227782-42-5
                                                              227782-43-6
    227782-44-7
                   227782-45-8
                                 227782-46-9
                                               227782-47-0
                                                              227782-48-1
    227782-49-2 . 227782-50-5
                                 227782-51-6
                                               227782-52-7
                                                              227782-53-8
    227782-54-9
                   227782-55-0
                                 227782-56-1
                                               227782-57-2
                                                              227782-58-3
    227782-59-4
                   227782-60-7
                                 227782-61-8
                                               227782-62-9
                                                              227782-63-0
                                               227782-70-9
                                                              227782-71-0
    227782-65-2
                   227782-66-3
                                 227782-69-6
     227782-72-1
                   227782-73-2
                                 227782-74-3
                                               227782-75-4
                                                              227782-78-7
```

```
227782-79-8
             227782-81-2
                           227782-82-3
                                        227782-83-4
                                                      227782-89-0
227782-93-6
             227782-94-7
                           227782-95-8
                                        227782-97-0
                                                      227783-01-9
227783-11-1
             227783-18-8
                           227783-19-9
                                        227783-20-2
                                                      227783-21-3
             227783-23-5
                           227783-24-6
                                        227783-25-7
                                                      227783-27-9
227783-22-4
                           227783-32-6
                                        227783-33-7
                                                      227783-34-8
227783-29-1
             227783-31-5
             227783-36-0
                           227783-37-1
                                        227783-38-2
                                                      227783-39-3
227783-35-9
             227783-41-7
                           227783-42-8
                                        227783-43-9
                                                      227783-44-0
227783-40-6
                           227783-47-3
                                        227783-48-4
                                                      227783-49-5
227783-45-1
             227783-46-2
                                                      227783-54-2
227783-50-8
             227783-51-9
                           227783-52-0
                                        227783-53-1
                                        227783-58-6
                                                      227783-59-7
227783-55-3
             227783-56-4
                           227783-57-5
                           227783-62-2
                                        227783-64-4
                                                      227783-65-5
227783-60-0
             227783-61-1
             227783-67-7
                           227783-68-8
                                        227783-69-9
                                                      227783-70-2
227783-66-6
227783-71-3
             227783-72-4
                           227783-73-5
                                        227783-74-6
                                                      227783-75-7
227783-76-8
             227783-77-9
                           227783-78-0
                                        227783-79-1
                                                      227783-80-4
                                        227783-84-8
             227783-82-6
                           227783-83-7
                                                      227783-88-2
227783-81-5
227783-90-6
             227783-91-7 227783-92-8
                                      227783-93-9
227783-94-0
             227783-95-1
                           227783-96-2
                                        227783-97-3
                                                      227783-98-4
                           227784-01-2
227783-99-5
             227784-00-1
                                        227784-02-3
                                                      227784-03-4
227784-04-5
                                        227784-07-8
                                                      227784-08-9
             227784-05-6
                           227784-06-7
227784-09-0
             227784-10-3
                           227784-11-4
                                        227784-12-5
                                                      227784-13-6
                           227784-16-9
                                        227784-17-0
                                                      227784-18-1
227784-14-7
             227784-15-8
             227784-20-5
                           227784-21-6
227784-19-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
   (amino acid sequence; complete genome sequence of Aeropyrum pernix K1)
```

227783-92-8

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; complete genome sequence of Aeropyrum pernix K1) 227783-92-8 HCAPLUS

132Aa long protein (Aeropyrum pernix strain K1 gene APE1292) (9CI) (CA CN INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE *** RETABLE

IT

RN

RETABLE					
Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
	+====-	+====-	}=====-	+====================================	+========
Bult, C	1996	273	1058	Science	HCAPLUS
Ewing, B	1998	8	175	Genome Res	HCAPLUS
Ewing, B	1998	8	186	Genome Res	HCAPLUS
Hirata, R	1990	265	6726	J Biol Chem	HCAPLUS
Kane, P	1990	250	651	Science	HCAPLUS
Kawarabayasi, Y	ĺ		147	DNA Res	
Kawarabayasi, Y	1998	5	55	DNA Res	HCAPLUS
Klenk, H	1997	390	364	Nature	HCAPLUS
Lowe, T	1997	25	955	Nuc Acids Res	HCAPLUS
Nakamura, Y	1997	2	299	Microbial & Comparat	HCAPLUS
Niehaus, F	1997	204	153	Gene	HCAPLUS
Nomura, N	1998	180	3635	J Bacteriol	HCAPLUS
Peler, F	1992	89	5577	Proc Natl Acad Sci	
Perler, F	1997	25	1087	Nuc Acids Res	HCAPLUS
Pietrokovski, S	1994	3	2340	Protein Science	HCAPLUS
Riera, J	1990	94	475	Proc Natl Acad Sci	
Sako, Y	1996	46	1070	International Journa	MEDLINE
Smith, C	1987	236	1448	Science	HCAPLUS
Smith, D .	1997	179	7135	J Bacteriol	HCAPLUS
Smith, T	1981	147	195	J Mol Biol	MEDLINE
Takagi, M	1997	63	4504	Appl Environ Microbi	HCAPLUS
Xu, M	1993	75	1371	Cell	HCAPLUS

Zhang, Q | 1996 | 120 | 587 | J Biochem | HCAPLUS

L4 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1997:474887 HCAPLUS Full-text

DOCUMENT NUMBER: 127:174474

TITLE: In vivo evidence of the critical role of cadherin-5 in

murine vascular integrity

AUTHOR(S): Matsuyoshi, Norihisa; Toda, Ken-Ichi; Horiguchi, Yuji;

Tanaka, Toshihiro; Nakagawa, Shinichi; Takeichi,

Masatoshi; Imamura, Sadao

CORPORATE SOURCE: Department of Dermatology, Graduate School of

Medicine, Faculty of Science, Kyoto University, Kyoto,

606-01, Japan

SOURCE: Proceedings of the Association of American Physicians

(**1997**), 109(4), 362-371

CODEN: PAAPFD; ISSN: 1081-650X

PUBLISHER: Blackwell
DOCUMENT TYPE: Journal
LANGUAGE: English

ΔR Vascular endothelial cell-cell adhesion is crucial for the regulation of vascular functions and is associated with many circulatory disorders. We isolated a rat monoclonal antibody (VECD1) recognizing the mouse vascular endothelial cell adhesion mol. and found that it inhibited vascular endothelial cell-cell association We sequenced a full-length cDNA of the antigen that was identical to mouse cadherin-5. L-cells transfected with its cDNA acquired cell-cell adhesiveness, and these transfectants reacted with VECD1 at cell-cell contact areas. We studied the role of mouse cadherin-5 in vascular functions. The addition of VECD1 antibody to a cultured vascular endothelial cell line (F-2) caused the detachment of each cell. Although normal F-2 cells formed tubular structures on Matrigel, VECD1 disturbed the tubulogenesis. VECD1 also increased the permeability through the F-2 cell layer. To clarify the in vivo function of mouse cadherin-5, we i.p. injected the hybridomas producing VECD1 into adult mice. Severe venous stasis and s.c. hemorrhage were induced within several days after the injection, resulting in the early death of the animals. These findings are evidence of an essential role of cadherin-5 in the regulation of vascular endothelial cell-cell adhesion in vivo.

CC 13-6 (Mammalian Biochemistry)

Section cross-reference(s): 6

IT 193843-04-8, Cadherin 5 (mouse F-2 cell)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

IT 173432-45-6, Cadherin 5, prepro- (Mus musculus)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

IT 193843-04-8, Cadherin 5 (mouse F-2 cell)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; in vivo evidence of critical role of cadherin-5 in murine vascular integrity)

RN 193843-04-8 HCAPLUS

CN Cadherin 5 (mouse F-2 cell) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 173432-45-6, Cadherin 5, prepro- (Mus musculus)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); PRP (Properties); BIOL (Biological study)
 (in vivo evidence of critical role of cadherin-5 in murine vascular
 integrity)

RN 173432-45-6 HCAPLUS

CN Cadherin 5, prepro- (Mus musculus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 1996:556341 HCAPLUS Full-text

DOCUMENT NUMBER:

125:239971

TITLE:

A novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA

binding domain

AUTHOR (S):

Jacquemin, Patrick; Hwang, Jung-Joo; Martial, Joseph

A.; Dolle, Pascal; Davidson, Irwin

CORPORATE SOURCE:

Inst. Genetique Biologie Moleculaire Cellulaire,

College France, Illkirch, 163-67404, Fr. Journal of Biological Chemistry (1996),

271(36), 21775-21785

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER:

LANGUAGE:

SOURCE:

American Society for Biochemistry and Molecular

Biology

DOCUMENT TYPE:

Journal English

AB The authors describe the mol. cloning of two novel human and murine transcription factors containing the TEA/ATTS DNA binding domain and related to transcriptional enhancer factor-1 (TEF-1). These factors bind to the consensus TEA/ATTS cognate binding site exemplified by the GT-IIC and Sph enhansons of the SV40 enhancer but differ in their ability to bind cooperatively to tandemly repeated sites. The human TEFs are differentially expressed in cultured cell lines and the mouse (m) TEFs are differentially expressed in embryonic and extra-embryonic tissues in early post-implantation embryos. Strikingly, at later stages of embryogenesis, mTEF-3 is specifically expressed in skeletal muscle precursors, whereas mTEF-1 is expressed not only in developing skeletal muscle but also in the myocardium. Together with previous data, these results point to important, partially redundant, roles for these TEF proteins in myogenesis and cardiogenesis. In addition, mTEF-1 is strongly coexpressed with mTEF-4 in mitotic neuroblasts, while accentuated mTEF-4 expression is also observed in the qut and the nephrogenic region of the kidney. These observations suggest addnl. roles for the TEF proteins in central nervous system development and organogenesis.

CC 3-4 (Biochemical Genetics)

Section cross-reference(s): 6, 13

IT 181829-00-5 181829-01-6 181829-02-7 181829-03-8

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; a novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain)

IT 181829-01-6

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; a novel family of developmentally regulated

mammalian transcription factors containing the TEA/ATTS DNA binding domain)

RN 181829-01-6 HCAPLUS

CN RNA formation factor TEF-5 (human fragment reduced) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L4 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:49097 HCAPLUS Full-text

DOCUMENT NUMBER: 124:137260

TITLE: Molecular cloning and expression of murine vascular

endothelial-cadherin in early stage development of

cardiovascular system

AUTHOR(S): Breier, G.; Breviario, F.; Caveda, L.; Berthier, R.;

Schnuerch, H.; Gotsch, U.; Vestweber, D.; Risau, W.;

Dejana, E.

CORPORATE SOURCE: Max-Planck-Institut physiologische klinische

Forschung, Bad Nauheim, Germany

SOURCE: Blood (1996), 87(2), 630-41

CODEN: BLOOAW; ISSN: 0006-4971

PUBLISHER: Saunders
DOCUMENT TYPE: Journal
LANGUAGE: English

An early step in the formation of the extraembryonic and intraembryonic AB vasculature is endothelial cell differentiation and organization in blood islands and vascular structures. This involves the expression and function of specific adhesive mols. at cell-to-cell junctions. Previous work showed that endothelial cells express a cell-specific cadherin (vascular endothelial [VE]cadherin, or 7B4/cadherin-5) that is organized at cell-to-cell contacts in cultured cells and is able to promote intercellular adhesion. In this study, we investigated whether VE-cadherin could be involved in early cardiovascular development in the mouse embryo. We first cloned and sequenced the mouse VEcadherin cDNA. At the protein level, murine VE-cadherin presented 75% identity (90%, considering conservative amino acid substitutions) with the human homolog. Transfection of murine VE-cadherin cDNA in L cells induced Ca++dependent cell-to-cell aggregation and reduced cell detachment from monolayers. In situ hybridization of adult tissues showed that the murine mol. is specifically expressed by endothelial cells. In mouse embryos, VEcadherin transcripts were detected at the very earliest stages of vascular development (E7.5) in mesodermal cells of the yolk sac mesenchyme. At E9.5, expression of VE-cadherin was restricted to the peripheral cell layer of blood islands that gives rise to endothelial cells. Hematopoietic cells in the center of blood islands were not labeled. At later embryonic stages, VEcadherin transcripts were detected in vascular structures of all organs examined, e.g., in the ventricle of the heart, the inner cell lining of the atrium and the dorsal aorta, in intersomitic vessels, and in the capillaries of the developing brain. A comparison with flk-1 expression during brain angiogenesis revealed that brain capillaries expressed relatively low amts. of VE-cadherin. In the adult brain, the level of VE-cadherin transcript was further reduced. By immunohistochem., murine VE-cadherin protein was detected at cell-to-cell junctions of endothelial cells. Overall, these data demonstrate that VE-cadherin is an early, constitutive, and specific marker of endothelial cells. This distinguishes this mol. from other cadherins and suggests that its expression is associated with the early assembly of vascular structures.

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 6, 13

IT 173432-45-6, Cadherin 5, prepro- (Mus musculus)

173432-46-7, Cadherin 5 (Mus musculus)

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)

(amino acid sequence; cDNA sequence and tissue distribution of murine vascular endothelial-cadherin in early stage development of cardiovascular system)

IT 173432-45-6, Cadherin 5, prepro- (Mus musculus)

173432-46-7, Cadherin 5 (Mus musculus)

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)

(amino acid sequence; cDNA sequence and tissue distribution of murine vascular endothelial-cadherin in early stage development of cardiovascular system)

RN 173432-45-6 HCAPLUS

CN Cadherin 5, prepro- (Mus musculus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 173432-46-7 HCAPLUS

CN Cadherin 5 (Mus musculus) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

******BELOW ARE REFERENCES TO QUERY ON CLAIM 41, WHERE A AND B ARE EQUAL TO 1 NOT A RANGE OF 0-1********

=> d que 160

L52

STR

Structure attributes must be viewed using STN Express query preparation.

L54 2075 SEA FILE=REGISTRY SSS FUL L52

L57 STR

Structure attributes must be viewed using STN Express query preparation.

L59 4 SEA FILE=REGISTRY SUB=L54 SSS FUL L57 L60 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L59

=> d ibib abs hitind hitstr retable 160 tot

L60 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2006:465364 HCAPLUS Full-text

DOCUMENT NUMBER:

144:460820

TITLE:

Peptide antitumor agents

INVENTOR(S):

Rosenberg, Martin Jay New York University, USA

PATENT ASSIGNEE(S):

PCT Int. Appl., 44 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.					KIND DATE					APPL	ICAT:	ION I	NO.		D	DATE					
	WO	2006	0527	 75		A2	-	2006	0518		WO 2	005-1	US40	078		2	0051	104				
	WO	2006	0527	75		A 3		2006	0720				•									
		W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	ВB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,				
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,				
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KN,	ΚP,	KR,				
			ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	MW,	MX,				
			MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,				
			SG,	SK,	SL,	SM,	SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,				
			VN,	YU,	ZA,	ZM,	ZW															
		RW:	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,				
			IS,	IT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,				
			CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG,	BW,	GH,				
			GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,				
			KG,	ΚŻ,	MD,	RU,	ТJ,	TM														
	US	2006	2585	73		A1		2006	1116	1	US 2	005-3	2646	84		2	0051	031				
	US	7173	110		•	B2		2007	0206													
PRIO	RITY	APP:	LN.	INFO	.:					1	US 2	004-	6262	20P		P 2	0041	108				

AB Disclosed herein are isolated, purified peptides, biol. active fragments and analogs of the peptides having anti-tumor activity in mammals, pharmaceutical

formulations comprising the peptides, fragments and analogs and methods of treating mammals suffering from tumors using such materials.

CC 1-6 (Pharmacology)

Section cross-reference(s): 34, 63

IT 886751-53-7P 886751-54-8P 886751-55-9P 886751-56-0P

886751-57-1P 886751-58-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide antitumor agents)

IT 886751-53-7P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide antitumor agents)

RN 886751-53-7 HCAPLUS

CN Cyclo[(2S)-2-amino-4-(methylsulfinyl)butanoyl-(2S)-2-amino-4-(methylsulfinyl)butanoyl-L-cysteinyl-L-valyl-L-threonyl-L-histidyl-L-cysteinyl-L-asparaginylglycylglycyl], cyclic (3→7)-disulfide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L60 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

1995:615187 HCAPLUS Full-text

DOCUMENT NUMBER:

123:27638

TITLE:

Peptides for neutralizing the toxicity of lipid A

INVENTOR(S):

Porro, Massimo

PATENT ASSIGNEE(S):

Biosynth S.r.L., Italy

SOURCE:

PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PA'	TENT	NO.					DATE		1	APPL	ICAT:	ION I	NO.		D	ATE		
						-			-						-			
WO	9503	327			A2		1995	0202	7	NO 1	994-1	EP24	13		1:	9940	721	
WO	9503	327			A3		1995	0504										
	W:	AM,	AT,	ΑU,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CZ,	DE,	DK,	ES,	FI,	GB,	
		GE,	HU,	JP,	KE,	KG,	ΚP,	KR,	KΖ,	LK,	LT,	LU,	LV,	MD,	MG,	MN,	MW,	
		NL,	NO,	NZ,	PL,	PT,	RO,	RU,	SD,	SE,	SI,	SK,	ТJ,	TT,	UA,	US,	UZ,	VN
	RW:	KE,	MW,	SD,	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	
		NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	ML,	MR,	NE,	SN,	TD,	TG
US	5652	211			Α		1997	0729	Ţ	JS 1:	993-	9783	0		1:	9930	726	
CA	2167	087			A1		1995	0202	(CA 1:	994-	2167	087		1:	9940	721	
AU	9474	602			Α		1995	0220	7	AU 1	994-	7460	2		1:	9940	721	
AU	6839	20			B2		1997	1127										
EP	7113	07			A1		1996	0515	1	EP 1:	994-	9242	72		1:	9940	721	
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙE,	IT,	LI,	LU,	MC,	NL,	PT,	SE
JP	0950	3489			T		1997	0408	Ċ	JP 1:	994-	5049	48		1:	9940	721	
PRIORIT	Y APP	LN.	INFO	.:					τ	JS 1	993-	9783	0	7	A 1:	9930	726	
									τ	JS 1	991-	6587	44]	32 1	9910	211	
									τ	JS 1	992-	8198	93	7	A2 1	9920	116	
									τ	JS 1:	993-	4987	1	7	A2 1	9930	419	
									1	NO 1	994-1	EP24	13	, ,	W 1:	9940	721	
		-			_								_	a .				

AB A peptide composition for neutralizing the toxicity of lipid A exhibits the formula: (1) (A)n (A= Lys, Arg; n=integer ≥7); (2) (AB)m (A as in (1); B= Val,

```
Leu, Ile, Tyr, Phe, Try; m=integer ≥3); or (3) (ABC)p (A=Lys, Arg; B, C=Leu,
     Ile, Tyr, Phe, Try; p=integer ≥2). The composition binds lipid-A of
     endotoxins and provides therapeutic and prophylactic uses. Novel 29 peptides
     capable of neutralizing the toxicity of lipid A are provided and their use on
     treating septic shock is claimed.
IC
    ICM C07K014-00
    ICS C07K007-00
CC
     4-9 (Toxicology)
     Section cross-reference(s): 1
IT
    25104-18-1, Polylysine
                            38000-06-5, Polylysine
                                                       163912-71-8
                                               164123-03-9
    164123-00-6 164123-01-7
                                 164123-02-8
                                                             164123-04-0
    164123-05-1
                  164123-06-2
                                 164123-07-3
                                               164123-08-4
                                                             164123-09-5
    164123-10-8 164123-11-9 164123-12-0
    164123-13-1 164123-14-2
                                 164123-15-3
                                               164123-16-4
                                                             164123-17-5
     164123-18-6
                  164123-19-7
                                 164123-20-0
                                               164123-21-1
                                                             164123-22-2
                                 164176-08-3
    164123-23-3
                  164123-24-4
                                               164176-09-4
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (peptides for neutralizing the toxicity of lipid A of endotoxins)
    164123-10-8 164123-11-9 164123-12-0
IT
    RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (peptides for neutralizing the toxicity of lipid A of endotoxins)
    164123-10-8 HCAPLUS
RN.
    Cyclo(L-cysteinyl-L-lysyl-L-phenylalanyl-L-lysyl-L-cysteinyl-L-lysyl-L-
CN
    phenylalanyl-L-lysyl-L-phenylalanyl-L-lysyl), cyclic (1\rightarrow 5)-
    disulfide (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
    164123-11-9 HCAPLUS
RN
    Cyclo(L-cysteinyl-L-lysyl-L-leucyl-L-lysyl-L-cysteinyl-L-lysyl-L-leucyl-L-
CN
     lysyl-L-leucyl-L-lysyl), cyclic (1->5)-disulfide (9CI) (CA INDEX
    NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN
     164123-12-0 HCAPLUS
CN
    Cyclo(L-arginyl-L-arginyl-L-cysteinyl-L-arginyl-L-threonyl-L-arginyl-L-
     cysteinyl-L-arginyl-L-phenylalanyl-L-lysyl), cyclic (3→7)-disulfide
     (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
=> d his full
     (FILE 'HOME' ENTERED AT 13:10:47 ON 12 MAR 2007)
     FILE 'REGISTRY' ENTERED AT 13:11:19 ON 12 MAR 2007.
     FILE 'LREGISTRY' ENTERED AT 13:13:27 ON 12 MAR 2007
              O SEA ABB=ON PLU=ON [G'SAR'] A [G'SAR'] ['HYP'P] ['HYP'P] YN/SQSFP
L1
    FILE 'REGISTRY' ENTERED AT 13:15:31 ON 12 MAR 2007
             42 SEA ABB=ON PLU=ON [G'SAR'] A [G'SAR'] ['HYP'P] ['HYP'P] YN/SQSFP
L2
     FILE 'HCAPLUS' ENTERED AT 13:17:13 ON 12 MAR 2007
L3
             36 SEA ABB=ON PLU=ON L2
             14 SEA ABB=ON PLU=ON L3 AND (AY<2001 OR PY<2001 OR PRY<2001)
L4
     FILE 'REGISTRY' ENTERED AT 13:18:16 ON 12 MAR 2007
L5
              O SEA ABB=ON PLU=ON L2 AND MEDLINE/LC
```

L6 0 SEA ABB=ON PLU=ON L2 AND EMBASE/LC L7 0 SEA ABB=ON PLU=ON L2 AND BIOSIS/LC L8 0 SEA ABB=ON PLU=ON L2 AND CAOLD/LC

FILE 'STNGUIDE' ENTERED AT 13:18:53 ON 12 MAR 2007

FILE 'HCAPLUS' ENTERED AT 13:19:30 ON 12 MAR 2007 E US2004-772774/APPS

L9 2 SEA ABB=ON PLU=ON US2004-772774/AP
D SCAN
SEL RN L9

FILE 'REGISTRY' ENTERED AT 13:20:34 ON 12 MAR 2007

107 SEA ABB=ON PLU=ON (159503-65-8/BI OR 355151-11-0/BI OR L10 355151-12-1/BI OR 355151-13-2/BI OR 355151-14-3/BI OR 355151-15 -4/BI OR 355151-16-5/BI OR 355151-17-6/BI OR 355151-18-7/BI OR 355151-19-8/BI OR 355151-20-1/BI OR 355151-23-4/BI OR 355151-25 -6/BI OR 355151-26-7/BI OR 355151-27-8/BI OR 355151-29-0/BI OR 355151-30-3/BI OR 355151-31-4/BI OR 355151-32-5/BI OR 355151-33 -6/BI OR 355151-34-7/BI OR 355151-35-8/BI OR 355151-36-9/BI OR 355151-37-0/BI OR 355151-38-1/BI OR 355151-39-2/BI OR 355151-40 -5/BI OR 355151-41-6/BI OR 355151-43-8/BI OR 355151-45-0/BI OR 355151-46-1/BI OR 355151-47-2/BI OR 355151-49-4/BI OR 355151-50 -7/BI OR 355151-51-8/BI OR 355151-52-9/BI OR 355151-53-0/BI OR 355151-54-1/BI OR 355151-55-2/BI OR 355151-56-3/BI OR 355151-74 -5/BI OR 81771-37-1/BI OR 111915-92-5/BI OR 133294-37-8/BI OR 212570-15-5/BI OR 355151-21-2/BI OR 355151-22-3/BI OR 355151-24 -5/BI OR 355151-28-9/BI OR 355151-42-7/BI OR 355151-44-9/BI OR 355151-48-3/BI OR 355151-57-4/BI OR 355151-58-5/BI OR 355151-59 -6/BI OR 355151-60-9/BI OR 355151-61-0/BI OR 355151-62-1/BI OR 355151-63-2/BI OR 355151-64-3/BI OR 355151-65-4/BI OR 355151-66 -5/BI OR 355151-67-6/BI OR 355151-68-7/BI OR 355151-69-8/BI OR 355151-70-1/BI OR 355151-71-2/BI OR 355151-72-3/BI OR 355151-73 -4/BI OR 355151-75-6/BI OR 355151-76-7/BI OR 35919-99-4/BI OR 366800-53-5/BI OR 463362-31-4/BI OR 463362-32-5/BI OR 463362-33 -6/BI OR 463362-34-7/BI OR 463362-35-8/BI OR 463362-36-9/BI OR 463362-37-0/BI OR 463362-38-1/BI OR 463362-40-5/BI OR 463362-42 -7/BI OR 463362-43-8/BI OR 463362-44-9/BI OR 463362-45-0/BI OR 463362-46-1/BI OR 463362-47-2/BI OR 463362-48-3/BI OR 463362-49 -4/BI OR 463362-50-7/BI OR 463362-51-8/BI OR 463362-52-9/BI OR 463362-53-0/BI OR 463362-54-1/BI OR 463362-55-2/BI OR 463362-56 -3/BI OR 463362-57-4/BI OR 463362-58-5/BI OR 463362-59-6/BI OR 463944-96-9/BI OR 476-70-0/BI OR 50-99-7/BI OR 501-36-0/BI OR 57381-26-7/BI OR 602-07-3/BI OR 7782-44-7/BI) Lll 5 SEA ABB=ON PLU=ON L10 AND L2

FILE 'STNGUIDE' ENTERED AT 13:21:01 ON 12 MAR 2007

FILE 'HCAPLUS' ENTERED AT 13:22:00 ON 12 MAR 2007

E LARSEN B/AU

L12

L13

177 SEA ABB=ON PLU=ON ("LARSEN B"/AU OR "LARSEN B DUE"/AU OR "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR "LARSEN BJARNE DUE"/AU)

E PETERSEN J/AU

L*** DEL 0 S E3, E29, E122, E127, E129, E169, E175-E177.

262 SEA ABB=ON PLU=ON ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR "PETERSEN JOERGEN"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN JORGEN SOEBERG"/AU)

		E MEIER E/AU
L14	118	SEA ABB=ON PLU=ON ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER
		E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M
		M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR "MEIER EDDI"/AU
		OR "MEIER EDDIE"/AU)
L15	7	E KJOLBYE A/AU SEA ABB=ON PLU=ON "KJOLBYE ANNE LOUISE"/AU
птэ	,	E JORGENSEN N/AU
L16	31	SEA ABB=ON PLU=ON ("JORGENSEN N"/AU OR "JORGENSEN N R"/AU OR
210	31	"JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU OR "JORGENSEN
		NIKLAS RYE"/AU)
		E NIELSEN M/AU
L17	495	SEA ABB=ON PLU=ON ("NIELSEN M"/AU OR "NIELSEN M S"/AU OR
		"NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR "NIELSEN
		MORTEN S"/AU OR "NIELSEN MORTEN SCHAK"/AU)
		E MARTINS J/AU
L18	138	SEA ABB=ON PLU=ON ("MARTINS J"/AU OR "MARTINS J B"/AU OR
		"MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS JAMES
		B"/AU)
710	76	E HOLSTEIN R/AU SEA ABB=ON PLU=ON ("HOLSTEIN R"/AU OR "HOLSTEIN RATHLOU N
L19	76	H"/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN RATHLOU N
		NIELS H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)
L20	2	SEA ABB=ON PLU=ON L12 AND L13 AND L14 AND L15 AND L16 AND
	_	L17 AND L18 AND L19
L21	13	SEA ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15 OR L16 OR L17
		OR L18 OR L19)
L22	15	SEA ABB=ON PLU=ON L13 AND (L14 OR L15 OR L16 OR L17 OR L18
		OR L19)
L23		SEA ABB=ON PLU=ON L14 AND (L15 OR L16 OR L17 OR L18 OR L19)
L24		SEA ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR L19)
L25		SEA ABB=ON PLU=ON L16 AND (L17 OR L18 OR L19)
L26 L27		SEA ABB=ON PLU=ON L17 AND (L18 OR L19) SEA ABB=ON PLU=ON L18 AND L19
L28		SEA ABB=ON PLU=ON (L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR
1120	21	L26 OR L27)
L29	4	SEA ABB=ON PLU=ON L28 AND (AY<2001 OR PY<2001 OR PRY<2001)
	FILE 'HCAP	LUS, MEDLINE, EMBASE, BIOSIS, DRUGU, WPIX' ENTERED AT 13:29:40
	ON 12 MAR	
L30		SEA ABB=ON PLU=ON LARSEN B?/AU
L31		SEA ABB=ON PLU=ON PETERSEN J?/AU
L32		SEA ABB=ON PLU=ON MEIER E?/AU
L33		SEA ABB=ON PLU=ON KJOLBYE A?/AU
L34 L35		SEA ABB=ON PLU=ON JORGENSEN N?/AU SEA ABB=ON PLU=ON NIELSEN M?/AU
L36		SEA ABB=ON PLU=ON MARTINS J?/AU
L37		SEA ABB=ON PLU=ON HOLSTEIN R?/AU
L38		SEA ABB=ON PLU=ON L30 AND L31 AND L32 AND L33 AND L34 AND
		L35 AND L36 AND L37
L39	0	SEA ABB=ON PLU=ON (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
		L36 OR L37) AND (ANTI(2A) ARRYTHMIC?)
L40	2	SEA ABB=ON PLU=ON (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
		L36 OR L37) AND (ANTIARRYTHMIC?)
L41		SEA ABB=ON PLU=ON (L38 OR L40)
L42	856	SEA ABB=ON PLU=ON (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR
L43	1	L36 OR L37) AND (PEPTIDE?) SEA ABB=ON PLU=ON L42 AND (ARRYTHM?)
L43 L44		SEA ABB=ON PLU=ON (L43 OR L41)
	-	

	FILE	'STNGUIDE' ENTERED AT 13:33:02 ON 12 MAR 2007
L45 L46 L47 L48		'REGISTRY' ENTERED AT 13:34:05 ON 12 MAR 2007 STRUCTURE UPLOADED STRUCTURE UPLOADED 0 SEA SSS SAM L46 0 SEA SSS FUL L46
	FILE	'STNGUIDE' ENTERED AT 13:35:38 ON 12 MAR 2007
L49	FILE	'BEILSTEIN' ENTERED AT 13:35:43 ON 12 MAR 2007 0 SEA SSS FUL L46
	FILE	'MARPAT' ENTERED AT 13:35:57 ON 12 MAR 2007
	FILE	'STNGUIDE' ENTERED AT 13:36:04 ON 12 MAR 2007
	FILE	'REGISTRY' ENTERED AT 13:38:12 ON 12 MAR 2007
	FILE	'STNGUIDE' ENTERED AT 14:02:36 ON 12 MAR 2007
L50	FILE	'REGISTRY' ENTERED AT 14:03:19 ON 12 MAR 2007 D QUE L46 D QUE L45 STRUCTURE UPLOADED D QUE L50
	FILE	'STNGUIDE' ENTERED AT 14:04:58 ON 12 MAR 2007
L51 L52 L53		'REGISTRY' ENTERED AT 14:12:47 ON 12 MAR 2007 STRUCTURE UPLOADED STRUCTURE UPLOADED 50 SEA SSS SAM L52 D QUE L52 2075 SEA SSS FUL L52 SAVE L54 TELLER/A TEMP 0 SEA ABB=ON PLU=ON L54 AND L10
		'HCAPLUS' ENTERED AT 14:16:01 ON 12 MAR 2007
L56		1861 SEA ABB=ON PLU=ON L54
		'STNGUIDE' ENTERED AT 14:16:08 ON 12 MAR 2007
L57 L58 L59	FILE	'REGISTRY' ENTERED AT 14:22:05 ON 12 MAR 2007 STRUCTURE UPLOADED 0 SEA SUB=L54 SSS SAM L57 4 SEA SUB=L54 SSS FUL L57
L60	FILE	'HCAPLUS' ENTERED AT 14:23:05 ON 12 MAR 2007 2 SEA ABB=ON PLU=ON L59 D BIB D BIB 2
L61 L62 L63 L64 L65	FILE	'REGISTRY' ENTERED AT 14:23:30 ON 12 MAR 2007 0 SEA ABB=ON PLU=ON L59 AND MEDLINE/LC 0 SEA ABB=ON PLU=ON L59 AND EMBASE/LC 0 SEA ABB=ON PLU=ON L59 AND BIOSIS/LC 0 SEA ABB=ON PLU=ON L59 AND CAOLD/LC 528 SEA ABB=ON PLU=ON L54 AND (ALA OR ALANIN? OR GLY OR GLYCINE OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DOAMINOBUT?

OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)

	FILE '		LUS' ENTERED AT 14:25:47 ON 12 MAR 2007
L66			SEA ABB=ON PLU=ON L65
L***	DEL 59	8742	
			D SCAN L9
L67		56	SEA ABB=ON PLU=ON L65 (L) (THU OR PKT OR BAC OR PAC OR
			DMA)/RL
			D KWIC
L68		1	SEA ABB=ON PLU=ON L66 AND (?ARRYTHM? OR ?THROMB? OR OSTEOPORO
			SIS? OR CANCER?)
L69			SEA ABBEON PLUEON (L67 OR L68)
L70			SEA ABB=ON PLU=ON L69 AND (AY<2001 OR PY<2001 OR PRY<2001)
L71			SEA ABB=ON PLU=ON L69 AND (AY<2000 OR PY<2000 OR PRY<2000) SEA ABB=ON PLU=ON L70 AND (ALA OR ALANIN? OR GLY OR GLYCINE
L/2		36	OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DOAMINOBUT?
			OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
			GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
			D KWIC
L73		38	SEA ABB=ON PLU=ON L70 AND (ALA OR ALANIN? OR GLY OR GLYCINE
			OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT?
			OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR
			GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)
L74			SEA ABB=ON PLU=ON (L68 OR L72 OR L73)
L75		38	SEA ABB=ON PLU=ON L74 NOT (L29 OR L4 OR L9)
	FILE '		STEIN' ENTERED AT 14:32:13 ON 12 MAR 2007
L76		U	SEA SSS FUL L57
	FILE '	MARPA	AT' ENTERED AT 14:32:29 ON 12 MAR 2007
			
	FILE '	REGIS	STRY' ENTERED AT 14:33:37 ON 12 MAR 2007
L77	•	0	SEA ABB=ON PLU=ON L65 AND L10
L78		0	SEA ABB=ON PLU=ON L10 AND SQL/CI
	FILE '	STNG	JIDE' ENTERED AT 14:36:57 ON 12 MAR 2007
	י שודם	REGIS	STRY' ENTERED AT 14:38:24 ON 12 MAR 2007
L79	1 1 1 1 1		SEA ABB=ON PLU=ON L10 AND SQL
L80			SEA ABB=ON PLU=ON L10 AND SQL?
L81			SEA ABB=ON PLU=ON L10 AND SOL<10
L82		23	SEA ABB=ON PLU=ON L10 NOT L81
			D SCAN L82
L83		106	SEA ABB=ON PLU=ON L10 NOT O2/MF
L84		104	SEA ABB=ON PLU=ON L83 NOT C14H12O3
L85		104	SEA ABB=ON PLU=ON L83 NOT C14H12O3/MF
L86			SEA ABB=ON PLU=ON L85 NOT C19H21NO4/MF
L87			SEA ABB=ON PLU=ON L86 NOT C9H7C12N5/MF
L88			SEA ABB=ON PLU=ON L87 NOT C20H19NO6
L89		101	SEA ABB=ON PLU=ON L88 NOT C6H12O6/MF
	ं स्वाप्त	нсарі	LUS' ENTERED AT 14:43:59 ON 12 MAR 2007
L90			SEA ABB=ON PLU=ON L89
L91			SEA ABB=ON PLU=ON L89 (L) (THU OR BAC OR PAC OR DMA OR
		-	PKT)/RL
L92		26	SEA ABB=ON PLU=ON L91 AND (AY<2001 OR PY<2001 OR PRY<2001)
			D QUE L73
L93		20	SEA ABB=ON PLU=ON L91 AND (ALA OR ALANIN? OR GLY OR GLYCINE
			OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT?

OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)

L94 35 SEA ABB=ON PLU=ON (L92 OR L93)

L95 33 SEA ABB=ON PLU=ON L94 NOT (L4 OR L29)

L96 14 SEA ABB=ON PLU=ON (L9 OR L4)

FILE 'STNGUIDE' ENTERED AT 14:46:29 ON 12 MAR 2007

D QUE L29

D QUE L44

D QUE L4

D QUE L60

FILE 'HCAPLUS, WPIX' ENTERED AT 14:46:57 ON 12 MAR 2007

L97 18 DUP REM L29 L44 L4 L60 (6 DUPLICATES REMOVED)

ANSWERS '1-18' FROM FILE HCAPLUS

D QUE L29

D QUE L41

D QUE L29

D QUE L44

D QUE L95

L98 37 DUP REM L29 L44 L95 (4 DUPLICATES REMOVED)

ANSWERS '1-37' FROM FILE HCAPLUS

D IBIB ABS HITIND HITSTR RETABLE L98 TOT

D QUE L4

D IBIB ABS HITIND HITSTR RETABLE L4 TOT

D OUE L60

D IBIB ABS HITIND HITSTR RETABLE L60 TOT

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 MAR 2007 HIGHEST RN 926007-42-3 DICTIONARY FILE UPDATES: 11 MAR 2007 HIGHEST RN 926007-42-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE LREGISTRY

LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE HCAPLUS

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Mar 2007 VOL 146 ISS 12 FILE LAST UPDATED: 11 Mar 2007 (20070311/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 9, 2007 (20070309/UP).

FILE MEDLINE

FILE LAST UPDATED: 10 Mar 2007 (20070310/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE

FILE COVERS 1974 TO 12 Mar 2007 (20070312/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 7 March 2007 (20070307/ED)

FILE DRUGU

FILE LAST UPDATED: 9 MAR 2007 <20070309/UP>

>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<

>>> THESAURUS AVAILABLE IN /CT <<<

FILE WPIX

FILE LAST UPDATED:

5 MAR 2007 <20070305/UP>

MOST RECENT THOMSON SCIENTIFIC UPDATE: 200716 <200716/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

- >>> YOU ARE IN THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX <<<
- >>> New display format FRAGHITSTR available <<< SEE ONLINE NEWS and

http://www.stn-international.de/archive/stn_online_news/fraghitstr ex.pdf

>>> IPC Reform reclassification data for the backfile is being
loaded into the database during January 2007.
There will not be any update date (UP) written for the reclassified
documents, but they can be identified by 20060101/UPIC. <<<</pre>

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE http://scientific.thomson.com/support/patents/coverage/latestupdates/

PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE http://www.stn-international.de/stndatabases/details/ipc reform.html and http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf

>>> FOR DETAILS ON THE NEW AND ENHANCED DERWENT WORLD PATENTS INDEX PLEASE SEE

http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<

FILE BEILSTEIN
FILE LAST UPDATED ON JANUARY 10, 2007

FILE COVERS 1771 TO 2006.

FILE CONTAINS 9,780,003 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

- * PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.
- * SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE
- * ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE
- * ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.
- * FOR PRICE INFORMATION SEE HELP COST

NEW

* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.

* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

FILE MARPAT

FILE CONTENT: 1961-PRESENT VOL 146 ISS 11 (20070309/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES (COVERAGE TO THESE DATES IS NOT COMPLETE):

US 2007020715 25 JAN 2007
DE 102005032918 18 JAN 2007
EP 1743897 17 JAN 2007
JP 2007016265 25 JAN 2007
WO 2007012422 01 FEB 2007
GB 2427406 27 DEC 2006
FR 2888248 12 JAN 2007
RU 2291880 20 JAN 2007
CA 2551930 08 JAN 2007

Expanded G-group definition display now available.

chain nodes : 31 32 33 34 35 36 37 38 39 40 ring nodes : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 41 chain bonds : 2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35 ring bonds : 1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28 27-30 28-29 29-30 exact/norm bonds : 1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38 18-19 19-20 20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 21:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS 33:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:Atom

Uploading 12.str

chain nodes : 38 39 31 32 33 34 35 36 37 ring nodes : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 24 25 26 27 28 29 30 41 chain bonds : 2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35 ring bonds : 1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28 27-30 28-29 29-30 exact/norm bonds : 1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11 14-39 14-41 15-16 16-17 17-18 17-38 11-25 11-34 12-13 12-24 13-14 14-15 18-19 19-20 25-26 26-28 27-30 27-36 28-29 20-21 20-37 21-22 22-27 23-24 24-40 29-30

Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS

33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:Atom

chain nodes :

31 32 33 34 35 36 37 38 39 40

ring nodes :

24 25 26 27 28 29 30 41

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

 $1-2^{-}$ 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-24

13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24

25-26 26-28

27-30 28-29 29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11

11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38

18-19 19-20

20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35

29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

20:Atom 21:Atom

22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom

31:CLASS 32:CLASS

33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

41:Atom

chain nodes :

31 32 33 34 35 36 37 38 39 40

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

24 25 26 27 28 29 30 41

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-

24

13-14 14-15 14-41 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24

25-26 26-28


27-30 28-29 29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 14-41 15-16 16-17 17-18 17-38 18-19 19-20 20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS 33:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:Atom



chain nodes :

31 32 33 34 35 36 37 38 39 40

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-14

14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28 27-30 28-29

27-30 2 29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20 20-21 20-37

21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom

22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS

33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

chain nodes:
31 32 33 34 35 36 37 38 39 40
ring nodes:

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-

14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28 27-30 28-29

29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20 20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS 33:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

Uploading 152.str

chain nodes :

31 32 33 34 35 36 37 38 39 40

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

24 25 26 27 28 29 30

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-

14

14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28

27-30 28-29

29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25

11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20

20-21 20-37

21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom


11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

20:Atom 21:Atom

22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom

31:CLASS 32:CLASS

33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS



chain nodes :

31 32 33 34 35 36 37 38 39 40

ring nodes :

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-25 12-13 12-24 13-

14-15 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24 25-26 26-28

27-30 28-29

29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 8-9 8-33 9-10 10-11 11-25

11-34 12-13 12-24 13-14 14-15 14-39 15-16 16-17 17-18 17-38 18-19 19-20


20-21 20-37

21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 23:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:CLASS 32:CLASS

33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS



chain nodes :

31 32 33 34 35 36 37 38 39 40

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 41

chain bonds :

2-31 5-32 8-33 11-34 14-39 17-38 20-37 24-40 27-36 28-35

ring bonds :

1-2 1-23 2-3 3-4 4-5 5-6 6-7 7-8 7-41 8-9 9-10 10-11 11-25 12-13 12-24

13-14 14-15 15-16 15-41 16-17 17-18 18-19 19-20 20-21 21-22 22-27 23-24

25-26 26-28

27-30 28-29 29-30

exact/norm bonds :

1-2 1-23 2-3 2-31 3-4 4-5 5-6 5-32 6-7 7-8 7-41 8-9 8-33 9-10 10-11 11-25 11-34 12-13 12-24 13-14 14-15 14-39 15-16 15-41 16-17 17-18 17-38 18-19 19-20

20-21 20-37 21-22 22-27 23-24 24-40 25-26 26-28 27-30 27-36 28-29 28-35 29-30

Match level :

- 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
- 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
- 31:CLASS 32:CLASS
- 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS

41:Atom

=> d que 129

*****BELOW ARE INVENTOR RESULTS ALONG WITH INVENTOR REGISTRY NUMBERS LIMITED BY THERAPEUTIC USE*****

=> d que	129	
L12	177	SEA FILE=HCAPLUS ABB=ON PLU=ON ("LARSEN B"/AU OR "LARSEN B
		DUE"/AU OR "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR
		"LARSEN BJARNE DUE"/AU)
L13	262	SEA FILE=HCAPLUS ABB=ON PLU=ON ("PETERSEN J"/AU OR "PETERSEN
		J S"/AU OR "PETERSEN JOERGEN"/AU OR "PETERSEN JOERGEN S"/AU OR
		"PETERSEN JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN"/AU OR
		"PETERSEN JORGEN S"/AU OR "PETERSEN JORGEN SOBERG"/AU OR
		"PETERSEN JORGEN SOEBERG"/AU)
L14	118	SEA FILE=HCAPLUS ABB=ON PLU=ON ("MEIER E"/AU OR "MEIER E
		A"/AU OR "MEIER E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU
		OR "MEIER E M M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR
		"MEIER EDDI"/AU OR "MEIER EDDIE"/AU)
L15	7	SEA FILE=HCAPLUS ABB=ON PLU=ON "KJOLBYE ANNE LOUISE"/AU
L16	31	SEA FILE=HCAPLUS ABB=ON PLU=ON ("JORGENSEN N"/AU OR "JORGENSE
		N N R"/AU OR "JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU
		OR "JORGENSEN NIKLAS RYE"/AU)
L17	495	SEA FILE=HCAPLUS ABB=ON PLU=ON ("NIELSEN M"/AU OR "NIELSEN M
		S"/AU OR "NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR
		"NIELSEN MORTEN S"/AU OR "NIELSEN MORTEN SCHAK"/AU)
L18	138	SEA FILE=HCAPLUS ABB=ON PLU=ON ("MARTINS J"/AU OR "MARTINS J
		B"/AU OR "MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS
		JAMES B"/AU)
L19	76	SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLSTEIN R"/AU OR "HOLSTEIN
		RATHLOU N H"/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN
		RATHLOU NIELS H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)
L20	2	SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND L13 AND L14 AND L15
		AND L16 AND L17 AND L18 AND L19
L21	13	SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15 OR
		L16 OR L17 OR L18 OR L19)
L22	15	SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L14 OR L15 OR L16 OR
		L17 OR L18 OR L19)
L23	4	SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND (L15 OR L16 OR L17 OR
	_	L18 OR L19)
L24	5	SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR
	_	L19) SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND (L17 OR L18 OR L19)
L25		
L26	3	SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L18 OR L19)

```
2 SEA FILE=HCAPLUS ABB=ON
                                         PLU=ON L18 AND L19
L27
             21 SEA FILE=HCAPLUS ABB=ON PLU=ON (L20 OR L21 OR L22 OR L23 OR
L28
                L24 OR L25 OR L26 OR L27)
              4 SEA FILE=HCAPLUS ABB=ON PLU=ON L28 AND (AY<2001 OR PY<2001
L29
                OR PRY<2001)
=> d que 144
          2579 SEA LARSEN B?/AU
L30
          5774 SEA PETERSEN J?/AU
L31
          1629 SEA MEIER E?/AU
L32
             42 SEA KJOLBYE A?/AU
L33
           977 SEA JORGENSEN N?/AU
L34
          5171 SEA NIELSEN M?/AU
L35
          2182 SEA MARTINS J?/AU
L36
           595 SEA HOLSTEIN R?/AU
L37
              2 SEA L30 AND L31 AND L32 AND L33 AND L34 AND L35 AND L36 AND
L38
              2 SEA (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37) AND
L40
                (ANTIARRYTHMIC?)
L41
              4 SEA (L38 OR L40)
           856 SEA (L30 OR L31 OR L32 OR L33 OR L34 OR L35 OR L36 OR L37) AND
L42
                (PEPTIDE?)
              1 SEA L42 AND (ARRYTHM?)
L43
              4 SEA (L43 OR L41)
L44
=> d que 195
             42 SEA FILE=REGISTRY ABB=ON PLU=ON [G'SAR']A[G'SAR']['HYP'P]['HY
L2
                P'P]YN/SQSFP
             36 SEA FILE=HCAPLUS ABB=ON PLU=ON L2
L3
             14 SEA FILE=HCAPLUS ABB=ON PLU=ON L3 AND (AY<2001 OR PY<2001 OR
L4
                PRY<2001)
            107 SEA FILE=REGISTRY ABB=ON PLU=ON (159503-65-8/BI OR 355151-11-
L10
                0/BI OR 355151-12-1/BI OR 355151-13-2/BI OR 355151-14-3/BI OR
                355151-15-4/BI OR 355151-16-5/BI OR 355151-17-6/BI OR 355151-18
                -7/BI OR 355151-19-8/BI OR 355151-20-1/BI OR 355151-23-4/BI OR
                355151-25-6/BI OR 355151-26-7/BI OR 355151-27-8/BI OR 355151-29
                -0/BI OR 355151-30-3/BI OR 355151-31-4/BI OR 355151-32-5/BI OR
                355151-33-6/BI OR 355151-34-7/BI OR 355151-35-8/BI OR 355151-36
                -9/BI OR 355151-37-0/BI OR 355151-38-1/BI OR 355151-39-2/BI OR
                355151-40-5/BI OR 355151-41-6/BI OR 355151-43-8/BI OR 355151-45
                -0/BI OR 355151-46-1/BI OR 355151-47-2/BI OR 355151-49-4/BI OR
                355151-50-7/BI OR 355151-51-8/BI OR 355151-52-9/BI OR 355151-53
                -0/BI OR 355151-54-1/BI OR 355151-55-2/BI OR 355151-56-3/BI OR
                355151-74-5/BI OR 81771-37-1/BI OR 111915-92-5/BI OR 133294-37-
                8/BI OR 212570-15-5/BI OR 355151-21-2/BI OR 355151-22-3/BI OR
                355151-24-5/BI OR 355151-28-9/BI OR 355151-42-7/BI OR 355151-44
                -9/BI OR 355151-48-3/BI OR 355151-57-4/BI OR 355151-58-5/BI OR
                355151-59-6/BI OR 355151-60-9/BI OR 355151-61-0/BI OR 355151-62
                -1/BI OR 355151-63-2/BI OR 355151-64-3/BI OR 355151-65-4/BI OR
                355151-66-5/BI OR 355151-67-6/BI OR 355151-68-7/BI OR 355151-69
                -8/BI OR 355151-70-1/BI OR 355151-71-2/BI OR 355151-72-3/BI OR
                355151-73-4/BI OR 355151-75-6/BI OR 355151-76-7/BI OR 35919-99-
                4/BI OR 366800-53-5/BI OR 463362-31-4/BI OR 463362-32-5/BI OR
                463362-33-6/BI OR 463362-34-7/BI OR 463362-35-8/BI OR 463362-36
                -9/BI OR 463362-37-0/BI OR 463362-38-1/BI OR 463362-40-5/BI OR
                463362-42-7/BI OR 463362-43-8/BI OR 463362-44-9/BI OR 463362-45
                -0/BI OR 463362-46-1/BI OR 463362-47-2/BI OR 463362-48-3/BI OR
                463362-49-4/BI OR 463362-50-7/BI OR 463362-51-8/BI OR 463362-52
```

		10//2//4
L12	177	-9/BI OR 463362-53-0/BI OR 463362-54-1/BI OR 463362-55-2/BI OR 463362-56-3/BI OR 463362-57-4/BI OR 463362-58-5/BI OR 463362-59 -6/BI OR 463944-96-9/BI OR 476-70-0/BI OR 50-99-7/BI OR 501-36-0/BI OR 57381-26-7/BI OR 602-07-3/BI OR 7782-44-7/BI) SEA FILE=HCAPLUS ABB=ON PLU=ON ("LARSEN B"/AU OR "LARSEN B"
DIZ		DUE"/AU OR "LARSEN BJARNE"/AU OR "LARSEN BJARNE D"/AU OR "LARSEN BJARNE DUE"/AU)
L13		SEA FILE=HCAPLUS ABB=ON PLU=ON ("PETERSEN J"/AU OR "PETERSEN J S"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN JOERGEN S"/AU OR "PETERSEN JOERGEN SOEBERG"/AU OR "PETERSEN JORGEN S"/AU OR "PETERSEN JORGEN SOBERG"/AU OR "PETERSEN JORGEN SOEBERG"/AU)
L14		SEA FILE=HCAPLUS ABB=ON PLU=ON ("MEIER E"/AU OR "MEIER E A"/AU OR "MEIER E F"/AU OR "MEIER E G"/AU OR "MEIER E J J"/AU OR "MEIER E M M"/AU OR "MEIER E P"/AU OR "MEIER E V"/AU OR "MEIER EDDI"/AU OR "MEIER EDDIE"/AU
L15	7	SEA FILE=HCAPLUS ABB=ON PLU=ON "KJOLBYE ANNE LOUISE"/AU
L16		SEA FILE=HCAPLUS ABB=ON PLU=ON ("JORGENSEN N"/AU OR "JORGENSEN N R"/AU OR "JORGENSEN N RYE"/AU OR "JORGENSEN NIKLAS R"/AU OR "JORGENSEN NIKLAS RYE"/AU)
L17		SEA FILE=HCAPLUS ABB=ON PLU=ON ("NIELSEN M"/AU OR "NIELSEN M S"/AU OR "NIELSEN M S WEBER"/AU OR "NIELSEN MORTEN"/AU OR "NIELSEN MORTEN S"/AU OR "NIELSEN MORTEN SCHAK"/AU)
L18		SEA FILE=HCAPLUS ABB=ON PLU=ON ("MARTINS J"/AU OR "MARTINS J B"/AU OR "MARTINS J B L"/AU OR "MARTINS JAMES"/AU OR "MARTINS JAMES B"/AU) SEA FILE=HCAPLUS ABB=ON PLU=ON ("HOLSTEIN R"/AU OR "HOLSTEIN
L19		RATHLOU N H"/AU OR "HOLSTEIN RATHLOU N H N H"/AU OR "HOLSTEIN RATHLOU NIELS H"/AU OR "HOLSTEIN RATHLOU NIELS HENRIK"/AU)
L20		SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND L13 AND L14 AND L15 AND L16 AND L17 AND L18 AND L19
L21		SEA FILE=HCAPLUS ABB=ON PLU=ON L12 AND (L13 OR L14 OR L15 OR L16 OR L17 OR L18 OR L19) SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND (L14 OR L15 OR L16 OR
L22		L17 OR L18 OR L19)
L23		SEA FILE=HCAPLUS ABB=ON PLU=ON L14 AND (L15 OR L16 OR L17 OR L18 OR L19) SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18 OR
L24		L19)
L25		
L26		SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L18 OR L19)
L27		SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND L19
L28	21	SEA FILE=HCAPLUS ABB=ON PLU=ON (L20 OR L21 OR L22 OR L23 OR
		L24 OR L25 OR L26 OR L27)
L29		SEA FILE=HCAPLUS ABB=ON PLU=ON L28 AND (AY<2001 OR PY<2001 OR PRY<2001) SEA FILE=REGISTRY ABB=ON PLU=ON L10 NOT O2/MF
L83		
L85		SEA FILE=REGISTRY ABB=ON PLU=ON L83 NOT C14H12O3/MF
L86		SEA FILE=REGISTRY ABB=ON PLU=ON L85 NOT C19H21NO4/MF
L87		SEA FILE=REGISTRY ABB=ON PLU=ON L86 NOT C9H7C12N5/MF
L88	102	SEA FILE=REGISTRY ABB=ON PLU=ON L87 NOT C20H19NO6
L89	101	SEA FILE=REGISTRY ABB=ON PLU=ON L88 NOT C6H12O6/MF
L91	66	SEA FILE=HCAPLUS ABB=ON PLU=ON L89 (L) (THU OR BAC OR PAC OR DMA OR PKT)/RL
L92		SEA FILE=HCAPLUS ABB=ON PLU=ON L91 AND (AY<2001 OR PY<2001 OR PRY<2001)
L93	20	SEA FILE=HCAPLUS ABB=ON PLU=ON L91 AND (ALA OR ALANIN? OR GLY OR GLYCINE OR GLU OR GLUTAMIC? OR ASP OR ASPARTIC? OR DAB OR DIAMINOBUT? OR DAPA OR LYS OR LYSINE OR ASP OR ASPARAGINE OR GLN OR GLUTAMINE OR ORN OR ORNITHINE OR CYS OR CYSTEINE)

L94 35 SEA FILE=HCAPLUS ABB=ON PLU=ON (L92 OR L93)
L95 33 SEA FILE=HCAPLUS ABB=ON PLU=ON L94 NOT (L4 OR L29)

=> dup rem 129,144,195
PROCESSING COMPLETED FOR L29
PROCESSING COMPLETED FOR L44
PROCESSING COMPLETED FOR L95

L98 37 DUP REM L29 L44 L95 (4 DUPLICATES REMOVED)

ANSWERS '1-37' FROM FILE HCAPLUS

=> d ibib abs hitind hitstr retable 198 tot

L98 ANSWER 1 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1

ACCESSION NUMBER:

2002:754415 HCAPLUS Full-text

DOCUMENT NUMBER:

137:263304

TITLE:

Synthesis of peptides and medical uses of

intracellular communication facilitating compounds

INVENTOR(S):

Larsen, Bjarne Due; Petersen, Jorgen

Soberg; Meier, Eddie; Kjolbye, Anne Louise; Jorgensen, Niklas Rye; Nielsen, Morten Schak; Holstein-Rathlou,

Niels-Henrik; Martins, James B. Zealand Pharmaceuticals A/S, Den.

PATENT ASSIGNEE(S):

PCT Int. Appl., 233 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

2

PATENT INFORMATION:

PAT	CENT 1	NO.			KINI	o :	DATE		1	APPL.						ATE	
	2002				A2		2002: 2003:		,	WO 20		JS57'				0020	
WO	2002 W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	ΝZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,
		UA,	ŪĠ,	US,	UΖ,	VN,	YU,	ZA,	ZM,	ZW							
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
		KG,	KZ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	CH,	CY,	DE,	DK,	ES,	FI,	FR,	GB,
		GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,
		GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD;	TG -							
WO	2001	0627	75		A2		2001	0830	1	WO 2	001-	DK12	7		2	0010	222 <
WO	2001				A 3		2002										
	W:	ΑE,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CR,	CU,
		CZ,	DE,	DK,	DM,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,
		IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,
		MD,	MG,	MK,	MN,	MW,	MX,	NO,	ΝZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,
		SK,	SL,	TJ,	TM,	TR,	TT,	ΤZ,	UA,	ŪĠ,	US,	UΖ,	VN,	YU,	ZA,	ZW	
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	ΤZ,	ŪG,	ZW,	AT,	BE,	CH,	CY,
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,
		ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,									
US	2003	0926	09		A1		2003			US 2					_		222 <
CA	2439	101			A1		2002										
EP	1370				A2		2003									0020	
	R:						ES,					LI,	LU,	NL,	SE,	MC,	PT,
		ΙĖ,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR						

```
20020222
                        Т
                              20050303
                                         JP 2002-576275
    JP 2005506295
                                                               20020222
                                        BR 2002-7476
                        Α
                              20060124
    BR 2002007476
                                                               20030815
                                         NO 2003-3641
    NO 2003003641
                        Α
                              20031020
                                                               20030822 <--
                                         US 2003-646294
                        A1
                              20050526
    US 2005113293
                                                               20030822
                                         IN 2003-DN1336
                              20050527
    IN 2003DN01336
                        Α
                                                               20040204 <--
                                         US 2004-772774
    US 2005075280
                        A1
                              20050407
                                                            A 20010222
                                         US 2001-792286
PRIORITY APPLN. INFO.:
                                                           A 20010222
                                         WO 2001-DK127
                                         US 2001-314470P
                                                           P 20010823
                                         DK 2000-288
                                                            A 20000223 <--
                                                            A 20000504 <--
                                         DK 2000-738
                                         US 2000-251659P
                                                            P 20001206 <--
                                         WO 2002-US5773
                                                            W 20020222
```

OTHER SOURCE(S): MARPAT 137:263304

The invention relates to novel peptides, including novel antiarrhythmic AB peptides of linear or cyclic structure, having improved stability in vitro and/or in vivo, to compns. comprising these peptides, and to uses of the peptides for the preparation of medicaments. The invention also relates to the use of compds. that facilitate the intercellular communication for the preparation of medicaments for the treatment of a range of diseases characterized in impaired intercellular gap junctional communication. invention further relates to a method of treating diseases, such as bladder incontinence, disorders of alveolar tissue and bronchial tissue, impaired hearing due to diseases of the cochlea, endothelial lesions, diabetic retinopathy and diabetic neuropathy, ischemia of the central nervous system and spinal cord, dental tissue disorders including periodontal disease, kidney diseases leading to hypertension, and a method of preventing failures of bone marrow transplantation. Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D-Ala-Gly-NH2 (Hyp = hydroxyprolyl) was prepared by the solid-phase method and assayed for biol. activity. Graphs include those for relative cell-to-cell conductance, PIturnover in neonatal rat cardiomyocytes, and ventricular APD90 dispersion.

IC ICM C07K007-00

CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 6, 63

L98 ANSWER 2 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2001:636085 HCAPLUS Full-text

DOCUMENT NUMBER: 135:180957

TITLE: Preparation of novel antiarrhythmic peptides

INVENTOR(S): Larsen, Bjarne Due; Petersen, Jorgen Soberg; Meier, Eddi; Kjolbye, Anne

Louise: Jorgensen, Niklas Rye;

Nielsen, Morten Schak; Holstein-Rathlou,

Niels-Henrik; Martins, James B.

PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S, Den.

SOURCE: PCT Int. Appl., 189 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PAT	rent :	NO.			KIN	D	DATE		1	APPL	ICAT	ION I	NO.		D	ATE	
						-											
WO	2001	0627	75		A2		2001	0830	1	WO 2	001-	DK12	7		2	0010	222 <
WO	2001				A3		2002										
	W:	ΑE,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CR,	CU,
										GD,							
		IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,
	•	MD,	MG,	MK,	MN,	MW,	MX,	NO,	ΝZ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,

```
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                                                   20010222 <--
                                20010830
                                            CA 2001-2385659
    CA 2385659
                         A1
                                20020731
                                            EP 2001-907393
                                                                   20010222 <--
    EP 1226160
                         A2
                                20041215
    EP 1226160
                         B1
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                                                   20010222 <--
                                           JP 2001-562556
                                20030930
                         Т
                                                                   20010222 <--
                                            AT 2001-907393
    AT 284896
                         Т
                                20050115
                                                                   20010222 <--
                                            ES 2001-1907393
    ES 2228807
                         Т3
                                20050416
                                                                   20010222 <--
                                            PT 2001-907393
                         T
                                20050429
    PT 1226160
                                                                   20010222 <--
                                            AU 2001-35362
                         B2
                                20050602
    AU 781674
                                                                   20020222
                         A1
                                20021003
                                            CA 2002-2439101
    CA 2439101
                                           WO 2002-US5773
                                                                   20020222
                         A2
                                20021003
    WO 2002077017
                                20031009
    WO 2002077017
                         A3
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
            GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
            GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                                                   20020222
                                20031217
                                          EP 2002-723240
                         A2
    EP 1370276
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                                                   20020222
                                20050303
                                            JP 2002-576275
    JP 2005506295
                         Т
                                                                   20020222
                                            BR 2002-7476
                                20060124
    BR 2002007476
                         Α
                                                                   20030815
                                20031020
                                            NO 2003-3641
                         Α
    NO 2003003641
                                20050526
                                            US 2003-646294
                                                                   20030822 <--
                         A1
    US 2005113293
                                                                   20040204 <--
                                            US 2004-772774
                                20050407
    US 2005075280
                         A1
                                                                   20050902 <--
                                            AU 2005-205785
                                20050929
    AU 2005205785
                         A1
                                                                A 20000223 <--
                                            DK 2000-288
PRIORITY APPLN. INFO.:
                                            DK 2000-738
                                                                A 20000504 <--
                                            US 2000-251659P
                                                                P 20001206 <--
                                                                A 20010222
                                            US 2001-792286
                                            WO 2001-DK127
                                                                W 20010222
                                            US 2001-314470P
                                                                P 20010823
                                            WO 2002-US5773
                                                                W 20020222
```

OTHER SOURCE(S): MARPAT 135:180957

Peptides X-A-B-Y and cyclo(X-A-B-Y) [A and B represents chemical moieties having an amino group (radical) and a carboxy group; X represents a peptide sequence of 1 to 3 D- or L-amino acid residues or an N-terminal modification of the group A-B when Y represents a C-terminal peptide sequence of 2 to 5 D- or L-amino acid residues; X represents a peptide sequence of 2 to 5 D- or L-amino acid residues; K represents a C-terminal peptide sequence of 1 to 3 D- or L-amino acid residues; for the linear peptide, X is optionally chemical modified at its N-terminal and has an optional linking group comprising 0-8 backbone atoms] and their mirror image or a retro analogs or pharmaceutically acceptable derivs. were prepared for treating cardiac arrhythmias. Thus, Ac-D-Tyr-D-pro-D-4Hyp-Gly- D-Ala-Gly-NH2 (4Hyp = 4-hydroxyprolyl) was prepared by the solid-phase method using TentaGel-S-Ram and examined for biol. activity [assays included effect on gap junction intercellular communication (GJIC) in cardiomyocytes, binding to tissue prepns. of murine heart, and effect on cAMP formation in CHO cells].

CC 34-3 (Amino Acids, Peptides, and Proteins) Section cross-reference(s): 1, 63

L98 ANSWER 3 OF 37 HCAPLUS COPYRIGHT 2007 ACS ON STN ACCESSION NUMBER: 2006:100738 HCAPLUS Full-text

DOCUMENT NUMBER: 144:198849

TITLE: Novel dosage form comprising modified-release and

immediate-release active ingredients

INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil;

Gupta, Vinod Kumar

PATENT ASSIGNEE(S): India

SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S.

Ser. No. 630,446.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
	- -				
US 2006024365	A1	20060202	US 2005-134633		20050519
IN 193042	A1	20040626	IN 2002-MU697		20020805
IN 2003MU00080	Α	20050204	IN 2003-MU80		20030122
IN 2003MU00082	A	20050204	IN 2003-MU82		20030122
US 2004096499	A1	20040520	US 2003-630446		20030729
PRIORITY APPLN. INFO.:			IN 2002-MU697	Α	20020805
			IN 2002-MU699	Α	20020805
			IN 2003-MU80	A	20030122
			IN 2003-MU82	Α	20030122
			US 2003-630446	A2	20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

INCL 424468000

CC 63-6 (Pharmaceuticals)

50-04-4, Cortisone acetate 50-06-6, 50-02-2, Dexamethasone IT Phenobarbital, biological studies 50-12-4, Mephenytoin 50-18-0, Cyclophosphamide 50-19-1, Meperidine hydrochloride 50-23-7, Hydrocortisone 50-24-8, Prednisolone Hydroxyphenamate 50-28-2, Estra-1,3,5(10)-triene-3,17-diol (17 β)-, 50-27-1, Estriol biological studies 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline bromide 50-35-1, Thalidomide 50-36-2, Cocaine 50-53-3, Chlorpromazine, biological studies 50-52-2, Thioridazine 50-55-5, Reserpine 50-56-6, Oxytocin, biological studies 50-58-8, Phendimetrazine tartrate 50-59-9, Cephaloridine 50-76-0, Dactinomycin 50-78-2, Aspirin 50-65-7, Niclosamide 51-15-0, Pralidoxime 51-05-8, Procaine hydrochloride Floxuridine 51-30-9, Isoproterenol hydrochloride 51-21-8, Fluorouracil chloride 51-40-1, Norepinephrine bitartrate 51-43-4, Epinephrine 51-55-8, Atropine, biological studies Propylthiouracil 51-57-0, Methamphetamine hydrochloride Homatropine hydrobromide 51-83-2, Carbachol 52-01-7, Spironolactone 51-64-9, Dextroamphetamine 52-24-4, Thiotepa 52-49-3, Trihexyphenidyl hydrochloride 52-68-6, 52-76-6, Lynestrenol 52-86-8, Haloperidol 52-88-0, Metrifonate

52-89-1, Cysteine hydrochloride Methylatropine nitrate 53-19-0, Mitotane 53-16-7D, Estrone, esters 53-03-2, Prednisone 53-39-4, Oxandrolone 53-43-0, 53-34-9, Fluprednisolone 53-73-6, Dehydroepiandrosterone 53-60-1, Promazine hydrochloride 53-79-2, Puromycin 53-84-9, Nadide 53-86-1, Angiotensin amide 54-05-7, Chloroquine 54-21-7, 54-03-5, Hexobendine Indometacin 54-35-3, Penicillingprocaine Sodium salicylate 54-31-9, Furosemide 54-36-4, Metyrapone 54-42-2, Idoxuridine 54-64-8, Thimerosal 54-84-2, Cinanserin hydrochloride 54-85-3, Isoniazid 54-91-1, 55-03-8, Levothyroxine sodium 55-06-1, Liothyronine sodium Pipobroman 55-63-0, Nitroglycerin 55-86-7, Mechlorethamine hydrochloride 55-91-4, 55-98-1, Busulfan 56-45-1, Serine, biological studies Isoflurophate 56-53-1, Diethylstilbestrol 56-47-3, Desoxycorticosterone acetate 56-75-7, Chloramphenicol 56-84-8, 56-59-7, Felypressin Aspartic acid, biological studies 56-87-1, Lysine, biological studies 56-89-3, Cystine, biological studies 56-94-0, Demecarium bromide 57-13-6, Urea, biological studies 57-41-0, 57-63-6, 57-53-4, Meprobamate 57-47-6, Physostigmine Phenytoin Ethinyl estradiol 57-65-8, Thyromedan hydrochloride 57-66-9, 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological Probenecid 57-91-0, 17-α Estradiol 57-94-3, Tubocurarine chloride studies 57-96-5, Sulfinpyrazone 58-08-2, Caffeine, biological studies 58-22-0, Testosterone 58-18-4, Methyltestosterone Pyrimethamine 58-28-6, Desipramine hydrochloride 58-25-3, Chlordiazepoxide 58-33-3, Promethazine hydrochloride 58-38-8, Dipyridamole 58-54-8, Ethacrynic acid 58-39-9, Perphenazine Prochlorperazine 58-71-9, Cephalothin sodium 58-55-9, Theophylline, biological studies 58-86-6, Xylose, biological studies 58-93-5, Hydrochlorothiazide 59-30-3, Folic acid, 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-52-9, Dimercaprol 59-33-6, Pyrilamine maleate biological studies 59-63-2, Isocarboxazid 59-67-6, Niacin, biological studies 59-97-2, Nitrofurazone 59-92-7, Levodopa, biological studies Tolazoline hydrochloride 60-13-9, Amphetamine sulfate 60-18-4, Tyrosine, biological studies 60-23-1, Cysteamine 60-29-7, Ether, biological studies 60-45-7, Fenimide 60-54-8, Tetracycline 60-80-0, Antipyrine 60-99-1, Methotrimeprazine 61-25-6, Methimazole Papaverine hydrochloride 61-56-3, Sulthiame 61-57-4, Niridazole 61-73-4, Methylene blue 61-75-6, Bretylium 61-68-7, Mefenamic acid 61-76-7, Phenylephrine hydrochloride 61-90-5, Leucine, tosylate biological studies 62-51-1, Methacholine chloride 62-68-0, Proadifen 62-90-8, Nandrolone phenpropionate 62-73-7, Dichlorvos hydrochloride 63-12-7, Benzquinamide 63-39-8, Uridine 63-05-8, Androstenedione 63-45-6, Primaquine phosphate 63-68-3, Methionine, triphosphate 63-89-8, Colfosceril palmitate 63-91-2, biological studies Phenylalanine, biological studies 63-92-3, Phenoxybenzamine 64-31-3, Morphine sulfate 63-98-9, Phenacemide hydrochloride 64-43-7, Amobarbital sodium 64-55-1, Mebutamate 64-77-7, Tolbutamide 65-28-1, Phentolamine mesylate 65-29-2, Gallamine 64-86-8, Colchicine 65-45-2, Salicylamide 66-75-1, Uracil mustard triethiodide 66-81-9, Cycloheximide 67-20-9, Nitrofurantoin 67-43-6, Dicumaról 67-45-8, Furazolidone 67-63-0, Isopropyl alcohol, Pentetic acid 67-68-5, Dimethyl sulfoxide, biological studies biological studies 67-92-5, Dicyclomine hydrochloride 67-73-2, Fluocinolone acetonide 67-96-9, Dihydrotachysterol 68-22-4, 67-95-8, Quingestrone 68-35-9, Sulfadiazine 68-23-5, Norethynodrel Norethindrone 68-89-3, Dipyrone 68-91-7, Trimethaphan camsylate Cycloserine 68-96-2, 17 Hydroxy progesterone 69-44-3, Amodiaquine hydrochloride 69-53-4, Ampicillin 69-57-8, Penicillingsodium 69-65-8, Mannitol 69-72-7, Salicylic acid, biological studies 69-74-9, Cytarabine hydrochloride 70-00-8, Trifluridine 70-10-0, Ticlatone

10772774 71-00-1, Histidine, biological studies

Hexachlorophene

71-58-9, Medroxyprogesterone acetate Succinylcholine chloride Digitoxin 71-68-1, Hydromorphone hydrochloride 71-73-8, Thiopental 71-81-8, Isopropamide iodide 72-18-4, Valine, biological sodium 72-19-5, Threonine, biological studies 72-33-3, Mestranol studies 72-44-6, Methaqualone 73-09-6, Etozolin 73-22-3, Tryptophan, biological studies 73-31-4, Melatonin 73-32-5, Isoleucine, biological studies 73-48-3, Bendroflumethiazide 74-79-3, Arginine, biological 75-00-3, Ethyl chloride 75-19-4, Cyclopropane Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-73-3, Secobarbital 76-74-4, Pentobarbital 76-90-4, Codeine 77-26-9, Butalbital 77-21-4, Glutethimide Mepenzolate bromide 77-36-1, Chlorthalidone 77-41-8, Methsuximide 77-27-0, Thiamylal 77-46-3, Acedapsone 77-67-8, Ethosuximide 77-86-1, Trometamol 78-11-5, Pentaerythritol tetranitrate 78-44-4, Carisoprodol Propionic acid, biological studies 79-17-4, Pimagedine 79-57-2, 79-64-1, Dimethisterone 80-08-0, Dapsone 80-50-2, Oxvtetracycline 81-04-9, 1,5-Naphthalenedisulfonic acid Anisotropine methylbromide 81-23-2, Dehydrocholic acid 81-54-9, Purpurin 81-13-0, Dexpanthenol 82-92-8, Cyclizine 83-43-2, Methylprednisolone 83-73-8, Iodoquinol 83-74-9, Ibogaine 84-17-3, Dienestrol RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (novel dosage form comprising modified-release and immediate-release active ingredients) 55294-15-0, Muzolimine 55298-68-5, Neomycin 55268-75-2, Cefuroxime IT 55453-87-7, Isoxepac 55560-96-8, Tixocortol pivalate 55694-87-6, Pentizidone sodium 55695-56-2, Cloroperone hydrochloride 55779-18-5, 55774-33-9, Azathioprine sodium 55721-11-4, Secalciferol 55837-27-9, Piretanide 55837-29-1, Tiropramide Arprinocid 55870-64-9, Pentisomicin 55881-07-7, Miokamycin 55905-53-8, Clebopride 56030-54-7, Sufentanil 56049-88-8, 55981-09-4, Nitazoxanide Indacrinone 56079-80-2, Ropitoin hydrochloride 56093-45-9, Selenium 56119-96-1, Furodazole 56187-89-4, Ximoprofen 56208-01-6, 56281-36-8, 56211-40-6, Torasemide 56219-57-9, Arildone Pifarnine Motretinide 56290-94-9, Medroxalol 56383-05-2, Zindotrine 56391-55-0, Octazamide 56391-57-2, Netilmicin sulfate 56420-45-2, Epirubicin 56430-99-0, Flumecinol 56470-64-5, Anordrin 56605-16-4D, Spiromustine, di-Ph derivs. 56611-65-5, Oxagrelate 56689-42-0, Repromicin 56689-44-2, Nitramisole hydrochloride 56717-18-1, Isotiquimide 56741-95-8, Bropirimine 56784-39-5, Ozolinone 56980-93-9, Celiprolol 56796-20-4, Cefmetazole 56917-29-4, Fluretofen 56995-20-1, Flupirtine 57010-32-9, Tiapamil hydrochloride 57041-67-5, 57067-46-6, Isamoxole 57109-90-7, Clorazepate dipotassium Desflurane 57166-13-9, Napactadine hydrochloride 57149-07-2, Naftopidil 57248-88-1, Pamidronate disodium 57262-94-9, Setiptiline 57285-09-3, Folliculostatin 57381-26-7, Irsogladine 57432-61-8, 57441-90-4, Nivimedone sodium 57540-79-1, Methylergonovine maleate 57653-26-6, Fenobam Nisbuterol mesylate 57645-05-3, Sermetacin 57666-60-1, Nitrafudam hydrochloride 57726-65-5, Nufenoxole 57773-63-4, Triptorelin 57773-65-6, Deslorelin 57775-22-1, Etoperidone hydrochloride 57781-15-4, Halopredone 57801-81-7, Brotizolam 57808-65-8, Closantel 57982-78-2, Budipine 57998-68-2, Diaziquone 58019-50-4, Menabitan hydrochloride 58019-65-1, Nabazenil 58066-85-6, 58152-03-7, Isepamicin 58167-78-5, Tandamine hydrochloride Miltefosine 58239-89-7, Moxazocine 58261-91-9, Mefenidil 58473-74-8, Cinromide 58493-49-5, Olvanil 58497-00-0, Procinonide 58503-79-0, Meobentine 58524-83-7, Ciprocinonide 58525-82-9, Azatyrosine 58581-89-8, Azelastine 58712-69-9, Traxanox 58795-03-2, Apalcillin sodium 58934-46-6, Lorcainide hydrochloride 58944-73-3, Sinefungin 58957-92-9, Idarubicin 58970-76-6, Ubenimex 59017-64-0, Ioxaglic acid

59018-13-2, Ioxaglate meglumine 59070-06-3, Ticarcillin cresyl sodium 59122-46-2, Misoprostol 59160-29-1, Lidofenin 59170-23-9, Bevantolol 59227-89-3, Laurocapram 59263-76-2, Meptazinol 59179-95-2, Lorzafone 59467-96-8, hydrochloride 59333-90-3, Exaprolol hydrochloride Midazolam hydrochloride 59497-39-1, Naflocort 59653-73-5, Teroxirone 59703-84-3, Piperacillin sodium 59729-33-8, Citalopram 59756-39-7, Enolicam sodium 59794-18-2, Paulomycin Butikacin 59803-98-4, Brimonidine 59804-37-4, Tenoxicam 59831-63-9, Doconazole 59831-64-0, Milenperone 59831-65-1, Halopemide 59917-39-4, Vindesine 59937-28-9, Malotilate 59954-01-7, Pamatolol sulfate 60019-19-4, Iotetric acid 60050-95-5, Sulfoxamine 60084-10-8, Tiazofurin 60086-22-8, Clopipazan mesylate 60135-22-0, Flumoxonide 60142-96-3, Gabapentin 60166-93-0, Iopamidol 60200-06-8, Clorsulon 60282-87-3, Gestodene 60207-31-0, Azaconazole 60209-20-3, Lycetamine 60325-46-4, Sulprostone 60398-23-4, Iodoamiloride 60400-92-2, Proxicromil 60525-15-7, Zimelidine hydrochloride 60560-33-0, Pinacidil 60569-19-9, Propiverine 60607-34-3, Oxatomide 60607-35-4, Topterone 60628-96-8, Bifonazole 60653-25-0, Orpanoxin 60719-84-8, Amrinone 60719-85-9, Ciprefadol succinate 60762-57-4, Pirlindole 60857-08-1, Prostratin 60925-61-3, Ceforanide 60940-34-3, Ebselen 60976-05-8 61036-62-2, Teicoplanin 61177-45-5, Clavulanate potassium 61220-69-7, 61260-05-7, Prenalterol hydrochloride 61263-35-2, Meteneprost 61270-78-8, Cefonicid sodium 61318-91-0, Sulconazole nitrate 61379-65-5, Rifapentine 61380-27-6, 61325-80-2, Flumezapine Carfentanil citrate 61380-41-4, Lofentanil oxalate 61413-54-5, 61444-62-0, Nifluridide 61477-94-9, Pirmenol hydrochloride Rolipram 61481-30-9, Dicranin 61484-39-7, Pareptide sulfate 61489-71-2, Menotropin 61570-90-9, Tioxidazole 61622-34-2, Cefotiam 61825-94-3, Oxaliplatin 61849-14-7, Epoprostenol sodium 61869-08-7, Paroxetine 62013-04-1, Dirithromycin 62087-72-3, Pentigetide 62134-34-3, Butoprozine hydrochloride 62220-58-0, Bipenamol hydrochloride 62265-68-3, Quinfamide 62304-98-7, Thymalfasin 62435-42-1, Perfosfamide 62488-57-7 62571-86-2, Captopril 62571-87-3, Minaxolone 62587-73-9, Cefsulodin 62613-82-5, Oxiracetam 62625-19-8, Pirogliride 62658-63-3, Bopindolol 62666-20-0, Progabide 62732-44-9, tartrate Ipidacrine 62816-98-2, Ormaplatin 62851-43-8, Zidometacin 62893-20-3, Cefoperazone sodium 62928-11-4, Iproplatin 62929-91-3, Procaterol hydrochloride 62973-76-6, Azanidazole 62973-77-7, Parconazole hydrochloride 62989-33-7, Sapropterin 62996-74-1, Staurosporine 63119-27-7, Anitrazafen 63198-97-0, Viroxime 63204-23-9, Oxmetidine hydrochloride 63245-28-3, Etifenin 63251-39-8, Sulfinalol hydrochloride 63269-31-8, Ciramadol 63358-49-6, Aspoxicillin 63534-64-5, Iosulamide meglumine 63585-09-1, Foscarnet 63612-50-0, 63590-19-2, Balanol 63590-64-7, Terazosin sodium Nilutamide 63659-18-7, Betaxolol 63659-19-8, Betaxolol hydrochloride 63675-72-9, Nisoldipine 63774-77-6, Somatomedin B 63941-73-1, Ioglucol 63950-06-1, Esorubicin hydrochloride 63941-74-2, Ioglucomide 64019-93-8, Dipivefrin hydrochloride 64059-66-1, Cetaben sodium 64092-48-4, Zomepirac sodium 64063-83-8, Picotrin diolamine 64221-86-9, Imipenem 64228-81-5, Atracurium 64211-45-6, Oxiconazole 64379-93-7, Cinflumide 64420-40-2, besylate 64318-79-2, Gemeprost 64461-82-1, Tizanidine hydrochloride 64485-93-4, Etibendazole 64808-48-6, Lobenzarit sodium 64706-54-3, Bepridil Cefotaxime sodium 64872-77-1, Butoconazole nitrate 64924-67-0, Halofuginone hydrobromide 64953-12-4, Moxalactam disodium 65009-35-0, Lidamidine hydrochloride 65043-22-3, Indeloxazine hydrochloride 65052-63-3, Cefetamet 65057-90-1, Talisomycin 65093-40-5, Cytarabine ocfosfate 65141-46-0, Nicorandil 65222-35-7, Pazelliptine 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 65322-72-7, Endralazine mesylate Lateritin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (novel dosage form comprising modified-release and immediate-release active ingredients)

IT 57381-26-7, Irsogladine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (novel dosage form comprising modified-release and immediate-release active ingredients)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 4 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2004:1036916 HCAPLUS Full-text

DOCUMENT NUMBER:

142:33307

TITLE:

Stable analogs of peptide and polypeptide therapeutics

INVENTOR(S): Bachovo

Bachovchin, William W.; Lai, Hung-Sen; Sanford, David

George

PATENT ASSIGNEE(S):

Trustees of Tufts College, USA

SOURCE:

PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE			
WO 2004103390	A2 20041202	WO 2004-US15488	20040517			
WO 2004103390	A3 20050630					
		BA, BB, BG, BR, BW,				
CN, CO, CR,	CU, CZ, DE, DK,	DM, DZ, EC, EE, EG,	ES, FI, GB, GD,			
		IN, IS, JP, KE, KG,				
LK, LR, LS,	LT, LU, LV, MA,	MD, MG, MK, MN, MW,	MX, MZ, NA, NI,			
NO, NZ, OM,	PG, PH, PL, PT,	RO, RU, SC, SD, SE,	SG, SK, SL, SY,			
TJ, TM, TN,	TR, TT, TZ, UA,	UG, US, UZ, VC, VN,	YU, ZA, ZM, ZW			
RW: BW, GH, GM,	KE, LS, MW, MZ,	NA, SD, SL, SZ, TZ,	UG, ZM, ZW, AM,			
		TM, AT, BE, BG, CH,				
EE, ES, FI,	FR, GB, GR, HU,	IE, IT, LU, MC, NL,	PL, PT, RO, SE,			
SI, SK, TR,	BF, BJ, CF, CG,	CI, CM, GA, GN, GQ,	GW, ML, MR, NE,			
SN, TD, TG						
AU 2004240630		AU 2004-240630				
CA 2525574	A1 20041202	CA 2004-2525574	20040517			
US 2005049177	A1 20050303	US 2004-847220	20040517			
EP 1633384		EP 2004-752496				
R: AT, BE, CH,	DE, DK, ES, FR,	GB, GR, IT, LI, LU,	NL, SE, MC, PT,			
		CZ, EE, HU, PL, SK				
CN 1822851	A 20060823	CN 2004-80019850	20040517			
PRIORITY APPLN. INFO.:		US 2003-471411P	P 20030515			
		WO 2004-US15488	W 20040517			

- The present invention relates to compns. of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof. The peptide and polypeptide analogs are resistant to cleavage by proteinases, i.e., a serine proteinase, metalloproteinase, aspartic proteinase, or cysteine e proteinase. For example, two substitutions at the P'l glutamic acid of GLP1-(7-37) were made to obtain GLP-1 (3DMA), wherein the P'l substitution was 3-dimethylaspartate, and GLP-1-(BM), wherein the P'l substitution was 3-butylmethylglycine. Both GLP-1 (3DMA) and GLP-1-(BM) displayed robust resistance to degradation by the serine protease dipeptidyl peptidase IV (DPP IV) and retained biol. activities of native glucagon-like peptide 1 (GLP-1). They both retained the ability to bind to GLP-1 receptors of COS-7 cells, as well as to potentiate GLP-1 signaling via the GLP-1 receptor to an extent indistinguishable from native GLP-1.
- IC ICM A61K038-00
- CC 2-10 (Mammalian Hormones)
 Section cross-reference(s): 1, 63
- 58-82-2D, Bradykinin, analogs 581-05-5D, 50-56-6D, Oxytocin, analogs IT 1393-25-5D, Secretin, analogs α-Melanotropin (swine), analogs 2002-44-0D, analogs 3397-23-7D, 1405-97-6D, Gramicidin, analogs 9002-60-2D, Adrenocorticotropic hormone, analogs Ornipressin, analogs 9002-76-0D, Gastrin, analogs 9002-72-6D, Growth hormone, analogs 9004-10-8D, Insulin, 9002-79-3D, Melanocyte stimulating hormone, analogs 9007-12-9D, Calcitonin, analogs 9007-92-5D, Glucagon, analogs 9014-42-0D, Thrombopoietin, analogs 9011-97-6D, Cholecystokinin, analogs 9015-71-8D, Corticotropin-releasing factor, analogs 9034-39-3D, Growth 9034-40-6D, Gonadotropin-releasing hormone releasing factor, analogs 9034-50-8D, Vasotocin, analogs 9041-90-1D, hormone, analogs 11000-17-2D, Vasopressin, analogs 11002-13-4D, Angiotensin I, analogs Angiotensinogen, analogs 11096-26-7D, Erythropoietin, analogs 11128-99-7D, Angiotensin II, analogs 24305-27-9D, Thyrotropin-releasing 33507-63-0D, Substance P, analogs 39379-15-2D, hormone, analogs 40077-57-4D, Vasoactive intestinal octacosapeptide Neurotensin, analogs 51110-01-1D, Somatostatin, analogs 52232-67-4D, Human (swine), analogs 52906-92-0D, Motilin, analogs parathyroid hormone (1-34), analogs 58569-55-4D, Met-enkephalin, analogs 55123-66-5D, Leupeptin, analogs 59392-49-3D, GIP, analogs 58822-25-6D, Leu-enkephalin, analogs 60118-07-2D, Endorphin, 59763-91-6D, Pancreatic polypeptide, analogs 61912-98-9D, Insulin-like growth factor, analogs 62229-50-9D, analogs 64190-70-1D, FMRF-amide, analogs Epidermal growth factor, analogs 69431-45-4D, 67382-96-1D, Melanin-concentrating hormone, analogs δ -Sleep inducing peptide, analogs 70904-56-2D, Kyotorphin, analogs 74913-18-1D, Dynorphin, analogs 80043-53-4D, Gastrin-releasing peptide, 80448-90-4D, Dynorphin A (swine), analogs 80802-79-5D, analogs Cecropin, analogs 81608-30-2D, Neuromedin C, analogs 81771-37-1D , Antiarrhythmic peptide, analogs 82785-45-3D, Neuropeptide Y, analogs 83150-76-9D, Octreotide, analogs 83335-41-5D, Dynorphin B (swine), 83652-28-2D, Calcitonin gene-related peptide, analogs 86933-74-6D, Neurokinin A, analogs 85637-73-6D, Atriopeptin, analogs 86933-75-7D, Neurokinin B (swine spinal cord), analogs 87616-84-0D, 88526-44-7D, Paracelsin, Growth hormone-releasing peptide 6, analogs 89105-94-2, Fibrinogen-binding inhibitor peptide analogs 89750-15-2D, Glucagon-like peptide II, analogs GLP 1, analogs 98084-68-5D, Atriopeptin I, 97793-28-7D, Atriopeptin III, analogs 98084-69-6D, Atriopeptin II, analogs 98824-26-1D, Calcitonin 99566-27-5D, Neuropeptide FF (cattle), gene-related peptide II, analogs 102577-25-3D, Neuromedin N, analogs 103131-69-7D, Kinetensin (human), analogs 103220-14-0D, Corticostatin, analogs 103370-86-1D, Parathyroid hormone related peptide, analogs 106021-96-9D, analogs 106388-42-5D, Peptide YY, analogs 106441-70-7D, Neuropeptide K, analogs 111745-44-9D, Neuromedin U, analogs 114471-18-0D, Brain natriuretic

peptide, analogs 115150-59-9D, Antagonist G, analogs 116243-73-3D, 119418-04-1D, Galanin, analogs 122752-15-2D, Endothelin, analogs 122752-16-3D, Deltorphin II, analogs Deltorphin I, analogs 127830-04-0D, C-type natriuretic peptide, analogs 128245-93-2D, analogs 133249-66-8D, Elafin, analogs 137061-48-4D, Pituitary adenylate cyclase activating polypeptide, analogs 140896-21-5D, Indolicidin, analogs 141636-44-4, GR 83074 141801-26-5D, Endomorphin-2, analogs 151039-33-7D, PD-142893, analogs 151039-37-1D, PD-145065, analogs 154835-90-2D, Adrenomedullin, analogs 168317-35-9D, Guamerin, analogs 169494-85-3D, Leptin, analogs 170713-75-4D, Nociceptin, analogs 180201-29-0D, analogs 186901-48-4D, Cortistatin 14, analogs 189388-22-5D, Endomorphin-1, analogs 188627-80-7D, Eptifibatide, analogs 800379-40-2 800379-41-3D, analogs 309247-07-2D, analogs RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (proteinase-resistant analogs of peptide and polypeptide therapeutics) 37259-58-8, Serine proteinase 37353-41-6, 9002-04-4, Thrombin IT 54249-88-6, Dipeptidyl peptidase IV Cysteine proteinase 81669-70-7 78169-47-8, Aspartic proteinase RL: BSU (Biological study, unclassified); BIOL (Biological study) (resistance to; proteinase-resistant analogs of peptide and polypeptide therapeutics) 81771-37-1D, Antiarrhythmic peptide, analogs IT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (proteinase-resistant analogs of peptide and polypeptide therapeutics) 81771-37-1 HCAPLUS

Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L98 ANSWER 5 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2004:394338 HCAPLUS Full-text

DOCUMENT NUMBER:

140:400107

TITLE:

RN

CN

Compositions and methods for modulating connexin

hemichannels for treating diseases

INVENTOR(S):

Jensen, Peter Holme; Larsen, Bjarne Due; Hansen, Lars Bo Laurenborg; Petersen, Jorgen Soberg; Neve, Soren;

Nielsen, Morten Schak; Meier, Eddi; Steiness, Eva

PATENT ASSIGNEE(S):

Zealand Pharma A/S, Den.

SOURCE:

U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S.

Provisional Ser. No. 352,717.

CODEN: USXXCO

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

KIND DATE APPLICATION NO.

DATE

US 2004092429	A1	20040513	US 2003-353549	20030129
US 7153822	B2	20061226		
CN 1638790	A	20050713	CN 2003-804968	20030129
US 2007042964	A1	20070222	US 2006-501402	20060809
PRIORITY APPLN. INFO.:			US 2002-352717P P	20020129
			US 2003-353549 A3	3 20030129

Disclosed are compns. and methods for modulating hemichannel function in a cell, tissue or organ. The invention also relates to useful screens for detecting such compds., particularly those capable of modulating connexin phosphorylation. Further provided are therapeutic methods for preventing or treating conditions impacted by undesired hemichannel function in a mammal such as heart arrhythmia. Rats subjected to myocardial infarction but treated with Compound 1 (Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D- Ala-Gly-NH2) for three weeks, had an improved cardiac function with less congestion in the left ventricle as demonstrated by a reduced left ventricular end-diastolic pressure.

IC ICM A61K038-17

INCL 514002000

CC 1-12 (Pharmacology)

Section cross-reference(s): 9

IT 355151-12-1 355151-50-7

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(peptide compns. and methods for modulating connexin hemichannels for treating diseases)

IT 355151-12-1 355151-50-7

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(peptide compns. and methods for modulating connexin hemichannels for treating diseases)

RN 355151-12-1 HCAPLUS

CN Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 355151-50-7 HCAPLUS

CN L-Tyrosinamide, N-acetylglycyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RETABLE	1	1	l ===	l Deferenced March	Referenced
Referenced Author	Year	VOL V	PG (PPG)	Referenced Work	Referenced File
(RAU)	•	(RVL)	•	(RWK)	-====================================
=======================================		+====- !		+=====================================	HCAPLUS
Abdullah, K	1999	10	35		I UCAPLUS
Actions	1997	356	76	Naunyn Schmiedebergs	HCAPLUS
Adibi	1982	ļ i		US 4340592 A	I TCAPIUS
Alexandre Stewart	2001			Abstract from Americ	
Alford, A	2001	208	L680	Am J Physiol Lung Ce	
Anon					HCAPLUS
Anon	1993	 	 	DE 4122885 A1	HCAPLUS
Anon	1993			WO 9314777	HCAPLUS HCAPLUS
Anon	1994		 	CA 2156618	
Anon	1994			DE 4314260 A1	HCAPLUS
Anon	1994	ļ		WO 9403468	HCAPLUS
Anon	1994	ļ	!	WO 9412181	HCAPLUS
Anon	1994	!		WO 9414817	HCAPLUS
Anon	1994	ļ	!	WO 9415908	HCAPLUS
Anon	1995	!	!	WO 9513069	HCAPLUS
Anon	1996	!	!	WO 9619494	HCAPLUS
Anon	1996		<u> </u>	WO 9621674 A1	HCAPLUS
Anon	1996			WO 9630395	HCAPLUS
Anon	1996	ļ		WO 9633209	HCAPLUS
Anon	1997	ļ		WO 9705889	HCAPLUS
Anon	1998	1		WO 9810653	HCAPLUS
Anon	1998			WO 9831359	HCAPLUS
Anon	1999			DE 19816932 A1	HCAPLUS
Anon	1999	1		WO 9911606	HCAPLUS
Anon	1999	1		WO 9931049	HCAPLUS
Anon	2000			WO 0075286	HCAPLUS
Anon	2001	1		WO 0100610 A1	HCAPLUS
Anon	2001	1		WO 0162775	HCAPLUS
Anon	2001			WO 0190085 A1	HCAPLUS
Anon	2001	[WO 0192236 A1	HCAPLUS
Anon	2002			WO 02077017 A2	HCAPLUS
Anon	2002		!	WO 02077017 .	HCAPLUS
Anon	2002	ĺ		WO 02101007 A2	HCAPLUS
Anon	2004	İ		WO 2004028466 A2	HCAPLUS
Anon	2004	ĺ	1	WO 2004048400 A1	HCAPLUS
Ashino, Y	2000	279	L5	Am J Physiol Lung Mo	HCAPLUS
Audia	2005	ĺ	ĺ	US 6888022 B1	HCAPLUS
Bailey	2001	İ	j	US 6291640 B1	HCAPLUS
Bascom	1996	İ	1	US 5492894 A	HCAPLUS
Beardslee, M	2000	87	656	Circ. Res.	HCAPLUS
Bennett, M	1991	6	305	Neuron	HCAPLUS
Beny	1994	266	H1465	Physiol Heart Circ P	MEDLINE
Black	2000	i	İ	US 6136787 A	ĺ
Blasits, S	2000	440	710	Phlugers Arch	HCAPLUS
			•		•

Dalamag	1996	66	2019	J Neurochem	
Bolanos Bommarius	2001	1	1 2010	US 6251625 B1	HCAPLUS
Brudnak	2001	! 	l İ	US 20040005304 A1	HCAPLUS
	1996	 238	1	Eur. J. Biochem.	HCAPLUS
Bruzzone, R	1997	238 9	1 1	J Eur Neurosci	MEDLINE
Bruzzone, R	!	5 11	1 287	Curr Eye Res	MEDLINE
Bursell	1992	 	20 /	US 20030092634 A1	
Buysse	2003	 ! > >	 957	J Mol Cell Cardiol	HCAPLUS
Cai	2001	33	93 / 686	Journal of Cardiovas	_
Campos De Carvalbo	1994	5	000 917	Physiol Rev	HCAPLUS
Carmeliet, E	1999	79	91 /	US 20030114387 A1	HCAL EGS
Castro Pineiro	2003	1240	1 4 6 7	Am Rev Respir Dis	MEDLINE
Charash, W	1993	148	467	US 20040102609 A1	MEDDINE
Chatterjee	2004	!	<u> </u>	US 5492920 A	HCAPLUS
Chen	1996			•	IICAFIOS
Chen, X	1998	111	263	Chem Biol Interact	HCAPLUS
Christ, G	1996	79	631	Circ Res.	HCAPLOS
Christ, G	2000	12	s15	Int J Import Res	
Colarusso	2004		!	US 20040142876 A1	
Collier	2003			US 20030202989 A1	MARIOT TAIR
Colwell, C	2000	43	379	J Neurobiol	MEDLINE
Cook	1973	ļ		US 3740438 A	HCAPLUS
Cotrina, M	2000	20	2835	J Neurosci	HCAPLUS
Cotrina, M	1998	95	15735	Proc Natl Acad. Sci.	HCAPLUS
Cowsar	2003			US 20030228353 A1	
Cunha-Vaz	1975	59	649	Br J Ophthalmol	MEDLINE
Dankwardt	2002		j	US 20020169133 A1	
Darrow, B	1995	76		Circulation Research	HCAPLUS
Demuth	2002			US 20020049164 A1	!
Demuth	2003			US 20030135023 A1	ļ
Demuth	2004		1	US 20040171555 A1	
Do Carmo, A	1998	67	569	Exp Eye Res	HCAPLUS
Drauz	1996			US 5534538 A	HCAPLUS
Drauz	1996			US 5543397 A	HCAPLUS
Duerig, J	2000	111	416	Brit J Haematol]
Duggan	2000			US 6017925 A	HCAPLUS
Endo, K	1995	10	589	J Gastroenterol Hepa	
Eugenin	2001	98	4190	Proc. Natl. Acad. Sc	HCAPLUS
Fukuda	2000	İ		US 6162828 A	HCAPLUS
Fukumoto, M	2001	69	247	Life Sciences	HCAPLUS
Gallant	1998	İ	ĺ	US 5798442 A	HCAPLUS
Gluckman	2001	İ	İ	US 6187906 B1	HCAPLUS
Gluckman	2004	İ	1	US 6780848 B1	HCAPLUS
Gordon	1993	İ	ĺ	US 5223486 A	HCAPLUS
Griffith	2003	i	İ	US 20030105165 A1	1
Grubb	1991	i	İ	US 5037957 A	HCAPLUS
Guerineau, N	1998	273	10389	J Biol Chem.	HCAPLUS
Guerrero	1997	99	1991	J Clin Invest	HCAPLUS
Gupta, P	1998	91	3724	Blood	HCAPLUS
Haefliger	2001	60	190	Kidney Int	HCAPLUS
Hagendorff, A	1999	99	1508	Circulation	MEDLINE
Hans-Ulrich	2001			US 20010020006 A1	İ
Hansson, L	2000	36	122	Nutrition and Cancer	İ
Hashitani, H	2001	530	273	J Physiol	HCAPLUS
Haslanger	1991		- / -	US 5061710 A	HCAPLUS
Henriques, J	2002	23	1112	Eur Heart J	MEDLINE
Iguchi, Y	1984	29	489	Arch Oral Biol	İ
Jarvinen	2005	1		US 20050059608 A1	İ
Jensen Jensen	2003	i		US 20040092429 A1	HCAPLUS
Johnstone, B	1989	408	77	J Physiol	MEDLINE
Kaprielian, R	1998	97	651	Circulation	MEDLINE
rapricitan, r	12200	1	,	1	•

			t	1770 4636400 B	HCAPLUS
Kettner	1987			US 4636492 A	!
Kettner	1987]	!	US 4652552 A	HCAPLUS
Kitaura	1987]		US 4666890 A	HCAPLUS
Klaunig, J	1990	62	135		HCAPLUS
Knuetter	2004	21	61	European Journal of	
Koenig, W		ļ	ļ	Succinimidbildung be	
Kohner, E	1995	44	603	Diabetes	HCAPLUS
Kondo	2000	32	1859	J. Mol. Cell. Cardio	:
Kotake	2001			US 6255285 B1	HCAPLUS
Kuhner	2003	1		US 20030050247 A1	
Kuhner	2003	1		US 20030194445 Al	HCAPLUS
Kumar, N	1996	84	381	Cell	HCAPLUS
Kurtz	1997	ĺ	ĺ	US 5643955 A	HCAPLUS
Kwak, B	2001	12	831	Molec Biol Cell	HCAPLUS
Kyung-Sun Kang	2001	166	147	Cancer Letters	
Lagostena, L	2001	531	693	J Physiol	HCAPLUS
Lampe	2000	384	205	Archives of Biochemi	HCAPLUS
Larsen	2002		i	US 6353023 B1	HCAPLUS
Larsen	2002	1		US 6410585 B1	HCAPLUS
	2003	<u>'</u>	ì	US 20030092609 A1	
Larsen	2005	<u> </u>	l	US 20050075280 A1	
Larsen	2005	! !	l I	US 20050113293 A1	
Larsen	2003	1	Ì	US 6342481 B1	HCAPLUS
Leoni	1999	260	207	Neurosci Lett	HCAPLUS
Levy, D		1	2145	J. Mol. Cell. Cardio	•
Li, F	2001	33	815	The Journal Of Cell	•
Lin, R	2001	154	1912	US 5047401 A	HCAPLUS
Lipsky	1991		ļ	•	HCAPLUS
Lipsky	1993			US 5206221 A	!
Low, P	1991	40	873	Diabetes	HCAPLUS
Lynch, J	1981	3	49	J Cardiovasc. Pharma	 WEDTINE
Madar	2004	ļ	į	US 20040121964 A1	1
Masaya Tanno	2001	!	ļ	Abstract from Americ	!
Masuda, M	2001	262	137	Anat Rec	HCAPLUS
Meier, E	2001	1		International Gap Ju	
Melman, A	2001	28	217	Urol Clinic North Am	
Mohammad Hossain	2000		ļ	Science's Stke, Pers	
Morriello	1996			US 5492916 A	HCAPLUS
Morriello	1996			US 5494919 A	HCAPLUS
Morriello	1997			US 5622973 A	HCAPLUS
Munoz	1999	ŀ		US 5872101 A	HCAPLUS
Murakami, S	2001	203	367	Anat Embryol	HCAPLUS
Myers	1993			US 5252560 A	HCAPLUS
Nadya Lumelsky	2001	292	1389	Science	1
Nagy, J	1996	7	745	Cell Growth Diff	HCAPLUS
Nargund	1999	İ.	İ	US 5877182 A	HCAPLUS
Nicolson, G	1998	85	473	Proc. Natl Acad Sci	İ
Oku, H	2001	142	1915	Invest Ophthalmol Vi	İ
Orlic	2001	410	701	Nature	HCAPLUS
Oviedo-Orta	2001	15	768	FASEB	HCAPLUS
Oviedo-Orta	2000	99	578	Immunology	HCAPLUS
Pavia	1995		1	US 5446023 A	HCAPLUS
	1997	}	ì	US 5637564 A	HCAPLUS
Pavia	1997		i	US 5650393 A	HCAPLUS
Pavia	1999	1	1	US 5980913 A	HCAPLUS
Penney	1	1 97	 1746	Circulation	MEDLINE
Peters	1998	97	864	Circulation	HCAPLUS
Peters, N	1993	88	:	J Pharmacol. Esp. Th	•
Petersen, J	1991	258	1	-	ICAE BOS
Phipps	2005	1202	100	US 20050020482 A1	 HCAPLUS
Pitre, D	2001	303	67	Neurosci Lett	TCAFLUS
Pitt	2004	I	1	US 20040235752 A1	1

Polacek, D	1997	34	119	J Vasc Res	HCAPLUS
Posposilik	2005			US 20050107308 A1	
Powers	1996	¦ 	1	US 5514694 A	HCAPLUS
Powers	1997	i i	! 	US 5610297 A	HCAPLUS
Powers	1997	İ	! 	US 5650508 A	HCAPLUS
	2001	i i	! 	US 6235929 B1	HCAPLUS
Powers	2001) 	! 	US 20040127427 A1	
Powers	2000	148	1063	J. Cell Biol	HCAPLUS
Quist, A Rehman, J	1997	272	H1960	AM J Physiol	HCAPLUS
Repolles Moliner	1995	~ / ~ 	111700	US 5432159 A	
Riniker	1975	! 		US 3862113 A	HCAPLUS
Ritzeler	2002	! !		US 6358978 B1	HCAPLUS
	2002	! •	1	US 20040167106 A1	
Rodriguez	1991	 23	457	Tissue Cell	MEDLINE
Rosendaal, M	1999	42	309	Cardiovascular Resea	!
Saffitz, J	!	1 2 521	637	J Physiol (Lond)	HCAPLUS
Sakagami, K	1999	521 61	1765	Cancer Res	HCAPLUS
Saunders, M	2001	101	1 1 1 0 5	Abstract from Americ	l meni beb
Sawa Kostin	2001	1000	! Н1088	Am J Physiol Heart C	ן ארשטז.זזכ
Schuster, A	2001	280	LHIOSS	US 20040167201 A1	HCAPLUS
Sharma	2004	<u> </u>		Abstract from Americ	Į.
Shigeto Kanno	2001		1	1	HCAPLUS
Shinohara, K	2000	286	107	Neurosci Lett.	:
Simon	1998			US 5811387 A	HCAPLUS
Simon, A	1998	8	295	Curr Biol	HCAPLUS
Stammler	2002	!		US 6384272 B1	HCAPLUS
Stevens, R	1999	2777	C448	Am J Physiol	<u> </u>
Sundstrom	2004	ļ	1	US 20040106560 A1	1
Szeto	2004			US 20040029796 A1	
Taugner, R	1980	206	65	Cell Tissue Res	MEDLINE
Teetz	1989	ļ		US 4797471 A	HCAPLUS
Teilman, S	2001]		International Gap Ju	
Thiele	1997	!	!	US 5602102 A	HCAPLUS
Todt, I	2001	181	107	J Membrane Biol	HCAPLUS
Tomoko Nao	2001		ļ	Abstract from Americ	:
Torikata, C	1985	52	399	Lab Invest	HCAPLUS
Tung	1998		!	US 5849711 A	HCAPLUS
Turner, W	1997	75	77	Pharmacol Therap	HCAPLUS
Vitale, M	2001	64	625	Biol Reporo	HCAPLUS
Wang	2001	281	C75	Am J Physiol Cell Ph	
Wang	2002	55	25	Cardiovasc Res	HCAPLUS
Wang	2001	6A	111	Urology	
Wang, Y	1995	270	26581	The Journal Of Biolo	:
Weisheng Bao	2001			Abstract from Americ	
Wolburg, H	1995	157	315	Int Rev Cytol	HCAPLUS
Wright, A	1998	80	89	Pharmacol Ther	HCAPLUS
Yamanaka, I	1997	72	166	European Journal Of	HCAPLUS
Yeh	1997	17	3174	Arterioscle Thromb V	HCAPLUS
Yoshida, M	1998	72	192	Arch Toxicol	HCAPLUS
Zhou, Z	2001	102	959	Neuroscience	HCAPLUS
-		•	•	•	

```
L98 ANSWER 6 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2003:155086 HCAPLUS Full-text
```

DOCUMENT NUMBER: 138:188077

TITLE: Preparation of novel peptide conjugates INVENTOR(S): Larsen, Bjarne Due; Petersen, Jorgen

Soberg; Kapusta, Daniel R.; Harlow, Kenneth W.

PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S, Den.

SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S.

Provisional Ser. No. 298,186.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	- -			
US 2003040472	A1	20030227	US 2001-882291	20010615 <
US 2006052284	A1	20060309	US 2005-102564	- 20050408 <
PRIORITY APPLN. INFO.:			DK 2000-944 A	20000616 <
			DK 2000-1485 A	20001005 <
			US 2000-251671P P	20001206 <
			US 2001-298186P P	20010613
			US 2001-882291 A	1 20010615

OTHER SOURCE(S): MARPAT 138:188077

Disclosed are peptide conjugates R1-Z-A1-A2-A3-A4-A5-A6-Z'-R2 (A1, A4, R6 = Arg, Lys, His; A2 = Tyr, Trp, Phe; A3 = Tyr, Asn, Trp, Phe; A5 = Phe, Tyr, Trp, Leu, Val, Ile, where each amino acid residue in the hexapeptide may be in the L or D form; Z, Z' each represent a charged peptide chain of 4 to 20 amino acid residues having the D or L configuration or is missing, provided that not both Z and Z' are missing; R1 = H, acyl group; R2 is an amino group or OH) which are optionally further linked to a transport moiety, as well as their salts, hydrates, solvates, and C-terminally amidated or esterified derivs. Also provided are antibodies that specifically bind the peptide conjugates. The invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides. Thus, Ac-Arg-Tyr-Tyr-Arg-Trp-Lys-Lys-Lys-Lys-Lys-Lys-NH2 was prepared on TentaGel resin and assayed for antibody production

IC ICM A61K038-16

ICS A61K038-10; A61K038-08; C07K007-08; C07K007-06

INCL 514012000; 514013000; 514014000; 514015000; 530324000; 530325000; 530326000; 530327000; 530328000

CC 34-3 (Amino Acids, Peptides, and Proteins) Section cross-reference(s): 1, 15, 63

L98 ANSWER 7 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2003:610285 HCAPLUS Full-text

DOCUMENT NUMBER:

139:144011

TITLE:

Compositions and methods for modulating connexin

hemichannels for disease treatment

INVENTOR(S):

Petersen, Jorgen Soberg; Neve, Soren; Nielsen, Morten Schak; Meier, Eddi; Steiness, Eva; Jensen, Peter

Holme; Larsen, Bjarne Due; Hansen, Lars Bo Laurenborg

PATENT ASSIGNEE(S):

SOURCE:

Zealand Pharma A/S, Den.
PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:
FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.			KIND DATE			APPLICATION NO.						DATE					
WO 2003063891			A1 20030807		1	WO 2003-DK56					20030129						
	W:	AE,	AG,				AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,
																OM,	
		PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,
		UA.	UG.	US.	UZ.	VC,	VN,	YU,	ZA,	ZM,	zw						

```
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                 20030807
                                             CA 2003-2474788
                                                                    20030129
     CA 2474788
                          A1
                                             EP 2003-701478
                                                                    20030129
                                 20041027
     EP 1469875
                           A1
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
         R:
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                                             BR 2003-7279
                                                                    20030129
                                 20041228
     BR 2003007279
                           Α
                                             JP 2003-563580
                                                                    20030129
                           Т
                                 20050602
     JP 2005516054
                                                                    20030129
                          Α
                                 20050713
                                             CN 2003-804968
     CN 1638790
                                             NO 2004-3590
                                                                    20040827
                                 20040827
                          Α
     NO 2004003590
                                             US 2002-352717P"
                                                                 P
                                                                    20020129
PRIORITY APPLN. INFO.:
                                             WO 2003-DK56
                                                                 W 20030129
      Disclosed are compns. and methods for modulating hemichannel function in a
AΒ
      cell, tissue or organ. The invention also relates to useful screens for
      detecting such compds., particularly those capable of modulating connexin
      phosphorylation. Further provided are therapeutic methods for preventing or
      treating conditions impacted by undesired hemichannel function in a mammal
      such as heart arrhythmia. More preferred compds. suitable for use with the
      present invention include those represented by the following Formula (I,
      R1(NHR2(CH2)s(CO)p)aNHR3(CH2)t(CO)qNHR4COR5) wherein R1= H or Ac; R2,R4= a
      sidechain of one of the amino acids G, Y, D-Y, F and D-F; R3 = any amino acid
      sidechain; R5 = OH or NH2; and a, S, T, P and Q are integers and independently
      = 0 or 1. More specific compds. include those having the following Formula
      (II, R1-X1-X2-X3-R2) wherein X1 = 0, Ala, Gly, \beta-Ala, Tyr, D-Tyr, Asp; X2 is
      0, Ala-Gly-T4c-Pro, Ala-Sar-Hyp-Pro, Ala-Asn, D-Asn-D-Ala, D-Asn, Gly, Ala,
      D-Ala, \beta-Ala, Asn; X3 = Tyr, D-Tyr, Gly, or Phe; R1 = H or Ac, with the
      proviso that X1 and X2 are not both 0; and R2= OH, NH2.
IC
     ICM A61K038-08
     ICS A61P009-06
     1-12 (Pharmacology)
CC
     355151-12-1 355151-50-7
\cdotIT
     RL: PAC (Pharmacological activity); THU (Therapeutic
```

use); BIOL (Biological study); USES (Uses)

(immunoassay method for screening compds. that modulate connexin

hemichannel function for use in disease treatment)

355151-12-1 355151-50-7 IT

RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(immunoassay method for screening compds. that modulate connexin hemichannel function for use in disease treatment)

355151-12-1 HCAPLUS RN

Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-CN alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

355151-50-7 HCAPLUS RN

L-Tyrosinamide, N-acetylglycyl-L-asparaginyl- (9CI) (CA INDEX NAME) CN

Absolute stereochemistry.

RETABLE

Referenced Author (RAU)	Year	•	Referenced File
Henrik, H Holstein-Rathlou, N	2001	WO 0162775 A WO 02077017 A	HCAPLUS HCAPLUS

L98 ANSWER 8 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:

2003:241921 HCAPLUS Full-text

DOCUMENT NUMBER:

138:260539

TITLE:

Apparatus and method for flow electroporation of

biological samples

INVENTOR(S):

Dzekunov, Sergey M.; Lee, Hyung J.; Li, Linhong;

Singh, Vininder; Liu, Linda; Holaday, John W.

PATENT ASSIGNEE(S):

Maxcyte, Inc., USA

SOURCE:

U.S. Pat. Appl. Publ., 59 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003059945	A1	20030327	US 2002-80272		20020221
US 7029916	B2	20060418			
PRIORITY APPLN. INFO.:			US 2001-269867P	P	20010221
			US 2001-269868P	P	20010221

The present invention relates to methods and apparatus for the encapsulation AB of biol.-active substances in various cell populations. More particularly, the present invention relates to a method and apparatus for the encapsulation of biol.-active substances in various cell populations in blood by electroporation to achieve therapeutically desirable changes in the phys. characteristics of the various cell populations in blood. Primary lymphocytes were suspended in B and K buffer (125 mM KCl, 15 mM NaCl, 1.2 mM MgCl2, 3 mM glucose, 25 mM Hepes, pH 7.4) and cell concentration was set from 1x107 cells/mL to 6x108 cells/mL together with DNA plasmid from 50 to 1 mg/mL. Electroporation, 2.3 kV/cm, 400 μs , 4 pulses for small volume expts. (15 μl) or 2.2 kV/cm, 1.6 ms, 1 pulse for large volume expts. (0.5 mL-2 mL) was performed at room temperature Following electroporation, cells were incubated in B&K buffer for 20 min at 37° C. for small volume expts., or diluted by 10+ volume of culture medium (RPMI-1640+10% fetal bovine serum+1% Pen-strep+2 mM

L-glutamine) for large volume expts. Cells were cultured in culture medium for various periods (up to 72 h) and the transfection efficiency was analyzed. Primary quiescence lymphocytes were shown refractory to retrovirus based gene transfer. HIV-based vector could transduce primary lymphocytes, but the efficiency is extremely low in the absence of HIV accessory genes. Other nonviral transfection methods also gave very low transfection efficiency. is the first demonstration of high efficiency of transfection of primary lymphocytes by a non-viral method. ICM C12M001-42 ICS C12N015-87

IC INCL 435461000; X43-528.52 63-7 (Pharmaceuticals) Section cross-reference(s): 3, 9 50-35-1D, Thalidomide, derivs. 50-81-7D, Ascorbic acid, ethers, IT 53-05-4, biological studies 52-01-7, Spironolactone Tetrahydrocortisone 60-33-3, Linoleic acid, biological studies 68-96-2, 17α-Hydroxyprogesterone 60-54-8D, Tetracycline, derivs. 128-13-2, Ursodeoxycholic acid 145-63-1, Suramin 152-58-9, Cortexolone 362-07-2, 2-Methoxyestradiol 446-72-0, 302-79-4, Retinoic acid 465-21-4, Bufalin 566-35-8 1406-16-2D, Vitamin D, derivs. Genistein 2609-46-3, Amiloride 4431-00-9, Aurintricarboxylic acid 10118-90-8, Minocycline 11096-26-7, 9061-61-4, NGF Plasminogen 12772-57-5, Radicicol 19545-26-7, Wortmannin Erythropoietin 34031-32-8, Auranofin 37270-94-3, Platelet factor 4 33069-62-4, Taxol 38096-31-0, Diaminoanthraquinone 37300-21-3, Pentosan polysulfate 50903-99-6, L-NAME 57381-26-7, Irsogladine 62031-54-3, 62571-86-2, Captopril 62683-29-8, Colony Fibroblast growth factor 62996-74-1, Staurosporine 65646-68-6, Fenretinide stimulating factor 81627-83-0, M-CSF 79831-76-8, Castanospermine 70563-58-5, Herbimycin A 83869-56-1, GM-CSF 86090-08-6, Angiostatin 86102-31-0, TIMP 98724-27-7, Proliferin-related protein 99519-84-3 100827-28-9, 103909-75-7, 22-0xa-1α,25-dihydroxyvitamin D3 106096-93-9, Basic fibroblast growth factor 105219-56-5, WEB 2086 110124-55-5, MDL 27032 125697-92-9, Lavendustin A 126509-46-4, 127464-60-2, Vascular endothelial growth factor Eponemycin 129298-91-5, AGM-1470 130370-60-4, Batimastat 134633-29-7, Tecogalan 143011-72-7, G-CSF 148717-90-2, 142186-14-9, FR-118487 sodium 169494-85-3, Leptin 171784-03-5, 154039-60-8, Marimastat Squalamine 171784-05-7, Louisianine C 171784-06-8, Louisianine D Louisianine A 187888-07-9, Endostatin 188417-67-6, CM101 204005-46-9, SU5416 271597-12-7, Myostatin RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (apparatus and method for flow electroporation of biol. samples) 57381-26-7, Irsogladine IT RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (apparatus and method for flow electroporation of biol. samples)

57381-26-7 HCAPLUS RN

1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME) CN

RETABLE Referenced Author (RAU)		VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
	•	•	+======	' +====================================	+=======
Abatti	1992	39	43	IEEE Trans. Biomed.	MEDLINE
Achelpohl	1984	j		US 4440386 A	
Andal Corp	j	ĺ		Multi-Arc Scientific	
Anon	1975	ĺ		DE 2405119	HCAPLUS
Anon	1985			EP 0137504	HCAPLUS
Anon	1987	İ		DE 3603029	HCAPLUS
Anon	1987	ĺ		JP 62151174	
Anon	1987			JP 62171687	HCAPLUS
Anon	1987			JP 62228277	HCAPLUS
Anon	1987			JP 62265975	
Anon	1988			JP 63141587	
Anon	1988	<u> </u>		WO 8804322	
Anon	1989			EP 0343783	HCAPLUS
Anon	1989			JP 1141582	
Anon	1989			WO 8902464	HCAPLUS
Anon	1989			WO 8903426	HCAPLUS
Anon	1990			EP 0362758	HCAPLUS
Anon	1990			JP 2131584	
Anon	1990			JP 2131585	
Anon	1990	ĺ		JP 2186993	
Anon	1991			JP 3195485	HCAPLUS
Anon	1991			WO 9118103	HCAPLUS
Anon	1992			EP 0472772	HCAPLUS
Anon	1992	1		JP 4027393	
Anon	1994			JP 6349068	
Anon	1994	<u> </u>		AT 680890	
Anon	1994			WO 9421117	HCAPLUS
Anon	1995			JP 7180029	
Anon	1995			JP 7320720	!
Anon	1996			DE 4440386	HCAPLUS
Anon	1996			WO 9628199	HCAPLUS
Anon	1997			EP 0798309	HCAPLUS
Anon	1998			CN 1195997	HCAPLUS
Anon	1998	ļ		WO 9824490	HCAPLUS
Anon	2001			WO 0124830	HCAPLUS
Anon	2002	!	}	CA 2214800	HCAPLUS
Anon	1975	ļ	598	Preparation of certa	
Asakami	1990	9	892	J. Mater. Sci. Lett.	
Baer	1992	!	!	US 5128257 A	HCAPLUS
Barsoum	1990			US 4956288 A	HCAPLUS
Behrndt	1991	A139	58	Materials Sciences a	1
Bertoncini	1992	ļ		US 5114681 A	HCAPLUS
Boulton	1981	ļ	!	US 4252628 A	HCAPLUS
Buican	1992	ļ	ļ	US 5100627 A	HCAPLUS
Busta	1992	ļ		US 5137817 A	HCAPLUS
CRC Press	1995		1650	Biological Buffers,	
Calvin	1992			US 5098843 A	HCAPLUS
Capizzi	1993	72	3495	Cancer	HCAPLUS
Casnig	1992	<u> </u>	<u> </u>	US 5134070 A	 HCAPLUS
Chang	1989	Į		US 4822470 A	HCAPLUS
Chang	1990	1		US 4970154 A Trends in Biotechnol	
Chassy	1988	6	303	Trends in Blotechnol Metallurgical and Tr	•
Coll	1992	1	 	US 4910140 A	 HCAPLUS
Dower	1990	 	1067	BIO/Technology	HCMETIOS
Dunican	1998	7	1067	US 20030073238 Al	i
Dzekunov	2003	l	I	100 20000075250 AL	I

_ ,	10004	ı	I	US 20040197883 A1	
Dzekunov	2004		705	Sov. Powder Metall M	
Egorov	1991	29	•	Tissue Oxygenation i	
Einck	1998		357		HCAPLUS
Firth	1993			US 5232856 A	
Franco	1984	ļ		US 4478824 A	HCAPLUS
Franco	1990		<u> </u>	US 4931276 A	HCAPLUS
Gersonde	1980	46	81	Biblthca Haemat.	
Gersonde	1979	39	1	Blut, Improvement of	
Gersonde	1982		277	Origins of Cooperati	
Gersonde	1982	22	279	Toxicology	HCAPLUS
Goodrich	1989	1		US 4874690 A	HCAPLUS
Goodrich	1991	ĺ		US 5043261 A	HCAPLUS
Gossling	1960	ĺ	ĺ	US 2955076 A	
Hibi	1989	Ī	İ	US 4800163 A	
Hilliard	1987	i	i	US 4695547 A	HCAPLUS
Hilliard	1989	Ï	İ	US 4882281 A	HCAPLUS
Hirai	1987	40	607	J. of Antibiotics	HCAPLUS
Hofmann	1996	1		US 5501662 A	
	1996	!	i	US 5545130 A	
Hofmann	1997	† [1 	US 5676646 A	
Hofmann	1986	 	6	IEEE Engineering in	HCAPLUS
Hofmann	!	1	0	US 20010001064 A1	HCAPLUS
Holaday	2001	1	!	US 5728281 A	HCAPLUS
Holmstrm	1998			1 ** * : = : = :	HCAPLUS
Kaali	1992	1	1	US 5139684 A	HCAFIOS
Kearney	1995	!		US 5424209 A	i Lucantuc
Kinosita ,	1979	554	479	Biochimica et Biophy	
Kobayashi	1989	97	1189	J. Ceram. Soc. Jpn.	
Kullmann	1993	8	83	Am. J. Respir. Cell	
Kurtz	1987	15	229	Sol. Energy Mater.	HCAPLUS
Lehninger	1982	ļ	181	Principles of Bioche	
Littlehales	1989			US 4840714 A	!
Marshall	1989		1	US 4849089 A	HCAPLUS
Marshall	1990			US 4906576 A	HCAPLUS
Marshall	1990			US 4923814 A	HCAPLUS
Marshall	1990			US 4946793 A	HCAPLUS
Matschke	1987	ĺ	1	US 4699881 A	HCAPLUS
Matschke	1988	İ	Ì	US 4764473 A	HCAPLUS
Maurer	1993	11	865	J. Orthop. Res.	HCAPLUS
Merz	1991	941	47	Unfallchirurg, Deter	
Meserol	1998	İ	İ	US 5720921 A	HCAPLUS
Meserol	2000	Ì	İ	US 6074605 A	HCAPLUS
Meserol	2000	i	i	US 6090617 A	HCAPLUS
Meserol	2002	i	i	US 6485961 B1	HCAPLUS
Mochizuki	1989	i	i	US 4804450 A	HCAPLUS
Mouneimne	1990	275	117	FEBS Letters	HCAPLUS
Multi-Arc, Inc	1996			Ion Bond 16 Zirconiu	
	1995	i	1	Ion Bond 17 Titanium	
Multi-Arc, Inc	1995		1	Ion Bond 19 Chromium	
Multi-Arc, Inc	•	1		Ion Bond Coatings fo	•
Multi-Arc, Inc	1995	1		Ion Bond Coatings fo	•
Multi-Arc, Inc	1995	1	-	The Ion Bond Network	
Multi-Arc, Inc	1995			Materials Sciences a	•
Narayan	1994	B25	5	•	 HCAPLUS
Nicolau	1980	!		US 4192869 A	HCAPLUS
Nicolau	1982		!	US 4321259 A	HCAPLUS
Nicolau	1984	1	!	US 4473563 A	:
Nicolau	1997	!		US 5612207 A	HCAPLUS
Nicolau	1985	51	92	Biblthca haemat.	HCAPLUS
Nicolau	1986		265	Phytic Acid: Chemist	:
Pietra	1990	115	1025	Analyst	HCAPLUS
Pohl	1984		1	US 4476004 A	1

_	11000	1	l	lus 4784737 A	HCAPLUS
Ray	1988			US 4652449 A	HCAPLUS
Ropars	1987			lus 4752586 A	HCAPLUS
Ropars	1988		1204		
Ropars	1985	445	304	Improved oxygen deli	 MEDDIINE
Sanford	1990			US 4945050 A	
Sanford	1991			US 5036006 A	
Sanford	1992			US 5100792 A	
Satomi	1988	15	339	Annals Rehab.	HCAPLUS
Schaldach	1989	34	185	Biomed. Technik.	MEDLINE
Schoendorfer	1992			US 5135667 A	HCAPLUS
Shoji	1982	41	1097	Appl. Phys. Lett.	HCAPLUS
Smith	1972			US 3676325 A	HCAPLUS
Sowers	1986	İ		US 4622302 A	
Susuki	1981	19	114	Jpn. J. Med. Electro	MEDLINE
Tada	1992	į		US 5124259 A	HCAPLUS
Taheri	1994	90	376	Electroencephalograp	MEDLINE
Tait	1991	7	327	Surf. Eng.	HCAPLUS
Takahashi	1991	į	İ	US 5007995 A	HCAPLUS
Teisseire	1985	58	1810	J. Appl. Phys.	MEDLINE
Teisseire			153	Significance of low	ĺ
Teissere	1987	84	6894	Proc. Natl. Acad. Sc	İ
Therin	1991	2	1	J. Materials Science	į
Vasilenko	1973	13	- 39	Poroshkovaia Metallu	
Weiner	1983	47	65	Biol. of the Cell	HCAPLUS
Weisel	1978	83	682	Surgery	MEDLINE
	1987	18	477	Biomaterials	HCAPLUS
Wisbey	1989	C384/	9	ImechE	
Wisbey	1987	10304/	1	US 4663292 A	HCAPLUS
Wong		 -	<u>}</u>	US 4849355 A	HCAPLUS
Wong	1989	1	!	US 4075076 A	l morni Bob
Xylander	1978	1.0	11100		HCAPLUS
Zhao	1991	42	1109	Vacuum Biosensors and Bioel	1
Zhu	1994	9	295	•	HCAPLUS
Ziegler	1991	ļ	1	US 4995957 A	!
Zimmermann	1978	1		US 4081340 A	HCAPLUS

L98 ANSWER 9 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2003:683276 HCAPLUS Full-text

DOCUMENT NUMBER:

140:122445

TITLE:

Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-

Gly-D-Ala-Gly-NH2 (ZP123):
In vivo and in vitro studies

AUTHOR(S):

Kjolbye, Anne Louise; Knudsen, Carsten Boye; Jepsen, Trine; Larsen, Bjarne Due; Petersen, Jorgen Soberg

CORPORATE SOURCE:

Department of Pharmacology, Zealand Pharma A/S,

Smedeland, Den.

SOURCE:

Journal of Pharmacology and Experimental Therapeutics

(2003), 306(3), 1191-1199 CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER:

American Society for Pharmacology and Experimental

Therapeutics

DOCUMENT TYPE:

Journal English

LANGUAGE:

AB

Antiarrhythmic peptides (AAPs) are a group of compds. with antiarrhythmic properties; however, their use has been hampered by very low plasma stability. The aim of this study was to compare the in vitro and in vivo stability of our new stable AAP analog Ac-D-Tyr-D-Pro-D-Hyp-Gly -D-Ala-Gly-NH2 (ZP123) with the previously described AAP analog AAP10. Moreover, the effect of the two compds. was examined in a murine in vivo model of ouabain-induced second degree AV-block, and the effect on dispersion of action potential duration

(APD dispersion) was studied during hypokalemic-ischemia in isolated perfused rabbit hearts. The in vitro t1/2 of ZP123 in rat and human plasma was about 1,700 times longer than t1/2 of AAP10. Due to rapid elimination, it was not possible to obtain an in vivo pharmacokinetic characterization of AAP10; however, calcns. suggested that the clearance of ZP123 was at least 140 times slower than for AAP10. AAP10 and ZP123 produced a dose-dependent delay in onset of ouabain-induced AV-block in mice at doses of 10-11 to 10-7 mol/kg i.v. ZP123 and 10-11 to 10-6 mol/kg i.v. AAP10. Maximal efficacy of ZP123 was reached at a 10-fold lower dose (10-8 mol/kg i.v.) than with AAP10. In the isolated rabbit hearts, ZP123 and AAP10 had no effect on dispersion during control conditions. The increased APD dispersion during hypokalemic ischemia is considered a major arrhythmic substrate and only ZP123 prevented the increase in APD dispersion. In conclusion, ZP123 is a new potent AAP analog with improved stability. 1-8 (Pharmacology) Section cross-reference(s): 14, 63 Peptides, biological studies RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (antiarrhythmics; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123)) Cardiovascular agents Cytoprotective agents (cardioprotective agents; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123)) Drug delivery systems (injections, i.v.; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123)) Antiarrhythmics Disease models Human (pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly -D-Ala-Gly-NH2 (ZP123)) 355151-12-1 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ZP 123; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123)) 355151-12-1 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ZP 123; pharmacol. characterization with in vivo and in vitro studies of new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123))

Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-D-

Absolute stereochemistry.

355151-12-1 HCAPLUS

alanyl- (9CI) (CA INDEX NAME)

CC

IT

IT

IT

IT

IT

IT

RN

CN

RETABLE		_			
Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
=======================================	+=====	 -=== -	+=====·	+======================================	
Aonuma, S	1980	28	3332	Chem Pharm Bull (Tok	
Aonuma, S	1982	5	40	J Pharmacobiodyn	HCAPLUS
Argentieri, T	1989	45	737	Experientia	HCAPLUS
Dhein, S	1994	350	174	Naunyn-Schmiedeberg'	HCAPLUS
Dikshit, M	1988	26	874	Indian J Exp Biol	HCAPLUS
Echt, D	1991	324	781	N Engl J Med	MEDLINE
Gabrielson, J	2000		21	Pharmacokinetic and	
Hjalmarson, A	1984	29	145	Cardiologia	MEDLINE
ISIS-1	1986	2	57	Lancet	
Kjolbye, A	2002	40	770	J Cardiovasc Pharmac	•
Kohama, Y	1987	35	3928	Chem Pharm Bull (Tok	•
Kohama, Y	1988	36	4597	Chem Pharm Bull (Tok	HCAPLUS
Muller, A	1997	327	65	Eur J Pharmacol	MEDLINE
Muller, A	1997	356	76	Naunyn-Schmiedeberg'	MEDLINE
Naccarelli, G	2000	15	64	Curr Opin Cardiol	MEDLINE
Ronsberg, M	1986	14	350	Med Sci	HCAPLUS
Rowland, M	1989	ĺ	438	Clinical Pharmacokin	
Waldo, A	1996	348	7	Lancet	HCAPLUS
Waldo, A	1996	348	416	published erratum ap	İ
Xing, D	2003	14	510	J Cardiovasc Electro	l

L98 ANSWER 10 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN 2004:116197 HCAPLUS Full-text ACCESSION NUMBER:

141:167468 DOCUMENT NUMBER:

Effects of the new antiarrhythmic peptide ZP123 on TITLE:

epicardial activation and repolarization pattern

Dhein, Stefan; Larsen, Bjarne D.; Petersen, Jorgen S.; AUTHOR (S):

Mohr, Friedrich-Wilhelm

Clinic for Cardiac Surgery, Heart Center, University CORPORATE SOURCE:

of Leipzig, Leipzig, Germany

Cell Communication & Adhesion (2003), 10(4-6), 371-378 SOURCE:

CODEN: CCAEBH; ISSN: 1541-9061

Taylor & Francis, Inc. PUBLISHER:

DOCUMENT TYPE: Journal English LANGUAGE:

Antiarrhythmic peptides such as AAP10 (Gly-Ala- Gly-4Hyp-Pro-Tyr-CONH2) have AB antiarrhythmic properties related to their stimulatory effect on gap junctional coupling. However, most of these peptides are not stable in enzymic environment which limits studies with these compds. in vivo. ZP123 is a new antiarrhythmic peptide constructed using a retro-all-D-amino acid design of the AAP10 template (Ac-D-Tyr-D-Pro-D-4Hyp-Gly-D-Ala-Gly-NH2). The aim of this study was to compare the effects of AAP10 and ZP123 on epicardial

activation and repolarization patterns in isolated perfused rabbit hearts. In addition, we tested the effect of these compds. on PKC activation in cultured HeLa-Cx43 cells. Rabbit hearts were perfused according to the Langendorff technique with Tyrode solution at constant pressure (70 cm H2O). After 45 min equilibration, either AAP10 (n = 7) or ZP123 (n = 7) was infused intracoronarily in concns. of 0.1, 1, 10, 100, and 1000 nM (15 min for each concentration) in the presence of 0.05% bovine serum albumine. 256 AgCl electrodes were attached to the hearts surface and connected to the inputs of a 256 channel mapping system in a unipolar circuit (4 kHz/channel, 0.04 mV vertical resolution, 1 mm spatial resolution). For each electrode the activation and repolarization timepoint were determined We found that both peptides significantly reduced epicardial dispersion by a maximum of about 20% thereby enhancing the homogeneity of epicardial action potential duration, while the action potential duration itself was not affected. The beat-to-beat variability of the epicardial activation pattern was stabilized by both peptides as compared to an untreated time-control series. Other parameters such as LVP, CF, heart rate, or total activation time were not effected by either of the peptides. In a second protocol, rectangular pulses were delivered to the back wall and the propagation velocity was determined longitudinal and transversal to the fiber axis. We found an increase in both longitudinal and transversal conduction velocity. Using a com. PKC assay on HeLa-Cx43 cells we found that 50 nM AAP10 and 50 nM ZP123 increased activity by $99\pm6\%$ and $146\pm54\%$, resp. The PKC activation induced by either of these compds. was completely blocked using the selective PKC α inhibitor GCP54345. We conclude that AAP10 and ZP123 have similar effects in vitro, but the superior enzymic stability of ZP123 makes this compound the preferred substance for in vivo studies of antiarrhythmic peptides.

CC 1-8 (Pharmacology)

IT 159503-65-8 355151-12-1, ZP123

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(ZP123, AAP10 reduced epicardial dispersion, increased longitudinal and transversal conduction velocity without affecting cardiac parameters in rabbit and induced PKC α activity in HeLA-Cx43 cell but ZP123 showed better enzymic stability)

IT 159503-65-8 355151-12-1, ZP123

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ZP123, AAP10 reduced epicardial dispersion, increased longitudinal and transversal conduction velocity without affecting cardiac parameters in rabbit and induced PKC α activity in HeLA-Cx43 cell but ZP123 showed better enzymic stability)

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 355151-12-1 HCAPLUS CN Glycinamide, N-acetyl-D-tyrosyl-D-prolyl-(4S)-4-hydroxy-D-prolylglycyl-Dalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RETABLE					
Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
	+=====-	+=====	+=====	+======================================	
Arisi, G	1983	52	706	Circ Res	MEDLINE
Buchanan, J	1985	56	696	Circ Res	HCAPLUS
Dhein, S	1999	128	1375	Br J Pharmacol	HCAPLUS
Dhein, S	2001	8	257	Cell Commun Adhesion	HCAPLUS
Dhein, S	1993	87	617	Circulation	HCAPLUS
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1994	350	174	Naunyn Schmiedeberg'	HCAPLUS
Grover, R	2001	22	1011	Peptides	HCAPLUS
Hofmann, J	1997	11	649	FASEB J	HCAPLUS
Joyner, R	1982	50	192	Circ Res	MEDLINE
Kjolbye, A	2003	306	1191	J Pharmacol Exp Ther	HCAPLUS
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Muller, A	1997	356	76	Naunyn Schmiedeberg'	MEDLINE
Weingart, R	1988	63	72	Circ Res	MEDLINE
Weng, S	2002	16	1114	FASEB J	HCAPLUS
Wit, A	1993		127	Cardiac Mapping	
Xing, D	2003	14	510	J Cardiovasc Electro	

L98 ANSWER 11 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN 2002:829575 HCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER:

138:378882

TITLE:

Anti-arrhythmic peptide N-3-(4-Hydroxyphenyl)propionyl

Pro-Hyp-Gly-Ala-Gly-OH

reduces dispersion of action potential duration during

ischemia/reperfusion in rabbit hearts

Kjolbye, Anne Louise; Holstein-Rathlou, Niels-Henrik; AUTHOR (S):

Petersen, Jorgen Soberg

CORPORATE SOURCE: Zealand Pharma, Glostrup, Den.

Journal of Cardiovascular Pharmacology (2002), 40(5), SOURCE:

770-779

CODEN: JCPCDT; ISSN: 0160-2446 Lippincott Williams & Wilkins

PUBLISHER: DOCUMENT TYPE:

Journal LANGUAGE: English

During ischemia, cardiac gap junctions close and neighboring cells uncouple. AB This leads to slow conduction, increased dispersion of APD (duration from action potential beginning to 90% of repolarization), nonuniform anisotropy, and unidirectional conduction block, all of which favor the induction of reentry arrhythmias. It was suggested that anti-arrhythmic peptides increase gap junction conductance during states of reduced coupling. The aim of this study was to test the effect of the anti-arrhythmic peptide N-3-(4hydroxyphenyl)propionyl Pro-Hyp-Gly -Ala-Gly-OH (HP-5) (10-10 M) on dispersion of epicardial APD during both normokalemic and hypokalemic ischemia/reperfusion in isolated perfused rabbit hearts. HP-5 did not affect average APD , heart rate, left ventricular contractility (LVP dP/dtmax), or mean coronary flow. HP-5 significantly reduced the epicardial APD dispersion during hypokalemic ischemia (HP-5 treated: 24.1 ms, untreated: 33.9 ms) and during normokalemic reperfusion but not during normokalemic ischemia or control conditions. In addition, among untreated hearts subjected to hypokalemic ischemia/reperfusion, 7 of 10 developed ventricular fibrillation, whereas only 3 of 9 hearts perfused with HP-5 developed ventricular fibrillation. These results show that HP-5 is able to reduce APD90 dispersion during hypokalemic ischemia in rabbit hearts.

1-8 (Pharmacology) CC

Section cross-reference(s): 2

111915-92-5 IT

RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(antiarrhythmic peptide HP-5 reduces dispersion of action potential duration)

111915-92-5 IT

RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(antiarrhythmic peptide HP-5 reduces dispersion of action potential duration)

111915-92-5 HCAPLUS RN

Antiarrhythmic peptide (cattle atrium), 1-deglycine-2-[1-[3-(4-CN hydroxyphenyl)-1-oxopropyl]-L-proline]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RETABLE											
Referenced Author	Year	VOL	PG	Referenced Work	Referenced						
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File						
=======================================			+===== <i>c=a</i>	+======================================	+=====================================						
Anon	1998	97	651	Circulation Chem Pharm Bull (Tok	HCADIJIS						
Aonuma, S	1980	28 5	3332 40	·	HCAPLUS						
Aonuma, S	1982 1989	145	4 0 73 7	Experientia	HCAPLUS						
Argentieri, T Dhein, S	1999	128	73	Br J Pharmacol	HCAPLUS						
Dhein, S	1995	49	851	Drugs	HCAPLUS						
Dhein, S	1994	350	174	Naunyn Schmiedebergs	HCAPLUS						
Dikshit, M	•	26	874	Indian J Exp Biol	HCAPLUS						
Gottwald, E	1998	79	474	Heart	MEDLINE						
Kohama, Y	1987	35	3928	Chem Pharm Bull (Tok	:						
Kohama, Y	1988	36	4597	Chem Pharm Bull (Tok	}						
Kuo, C	1983	67	1356	Circulation	MEDLINE						
Lesh, M	1989	65	1426	Circ Res	MEDLINE						
Merx, W	1977	94	603	Am Heart J	MEDLINE						
Muller, A	1997	327	65	Eur J Pharmacol	MEDLINE						
Muller, A		356	76	Naunyn Schmiedebergs	HCAPLUS						
Peters, N	1993	88	864	Circulation Circulation	MEDLINE						
Peters, N	1997 1999	95 84	988 207	Pharmacol Ther	HCAPLUS						
Wolk, R	1222	104	1207	Filat macor Ther	1.01.12.20.0						
L98 ANSWER 12 OF 37 F	CAPLUS	COPY	RIGHT 2	007 ACS on STN							
ACCESSION NUMBER:		: 93562									
DOCUMENT NUMBER:		64121									
TITLE:				s modified n- and/or	c-terminally by						
	shor	t char	ged pep	tide chains							
INVENTOR(S):	Lars	en, Bj	arne Du	e; Petersen, Jorgen							
Soberg; Kapusta, Daniel R.; Harlow, Kenneth											
			pusta,	Daniel R.; Harlow, Ke	nneth						
	Will	iam			nneth						
PATENT ASSIGNEE(S):	Will Zeal	iam and Ph	armaceu	ticals A/S, Den.	nneth						
PATENT ASSIGNEE(S): SOURCE:	Will Zeal PCT	iam and Ph Int. A	armaceu ppl., 7	ticals A/S, Den.	nneth						
SOURCE:	Will Zeal PCT CODE	iam and Ph Int. A N: PIX	armaceu ppl., 7	ticals A/S, Den.	nneth						
SOURCE: DOCUMENT TYPE:	Will Zeal PCT CODE Pate	iam and Ph Int. A N: PIX nt	armaceu ppl., 7	ticals A/S, Den.	nneth						
SOURCE: DOCUMENT TYPE: LANGUAGE:	Will Zeal PCT CODE Pate Engl	iam and Ph Int. A N: PIX nt	armaceu ppl., 7	ticals A/S, Den.	nneth						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT:	Will Zeal PCT CODE Pate Engl	iam and Ph Int. A N: PIX nt	armaceu ppl., 7	ticals A/S, Den.	nneth						
SOURCE: DOCUMENT TYPE: LANGUAGE:	Will Zeal PCT CODE Pate Engl	iam and Ph Int. A N: PIX nt	armaceu ppl., 7	ticals A/S, Den.	nneth						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT:	Will Zeal PCT CODE Pate Engl 3	iam and Ph Int. A N: PIX nt ish	armaceu ppl., 7 XD2	ticals A/S, Den.	DATE						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:	Will Zeal PCT CODE Pate Engl 3	iam and Ph Int. A N: PIX nt ish DAT	armaceu ppl., 7 XD2 E	ticals A/S, Den. 2 pp. APPLICATION NO.	DATE						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO	Will Zeal PCT CODE Pate Engl 3	iam and Ph Int. A N: PIX nt ish DAT 200	armaceu ppl., 7 XD2 E 11227	ticals A/S, Den. 2 pp. APPLICATION NO. WO 2001-US19113	DATE 20010615 <						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI	Will Zeal PCT CODE Pate Engl 3 KIND	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU	armaceu ppl., 7 XD2 E 11227 , AZ, B	ticals A/S, Den. 2 pp. APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ	DATE 20010615 < , CA, CH, CN,						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU	Will Zeal PCT CODE Pate Engl 3 KIND Al	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU DE, DK	armaceu ppl., 7 XD2 E 11227 , AZ, B	ticals A/S, Den. 2 pp. APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ Z, EE, ES, FI, GB, GD	DATE 20010615 < , CA, CH, CN, , GE, GH, GM,						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU HR, HU, II	Will Zeal PCT CODE Pate Engl 3 KIND Al J, AM, J, CZ,	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU DE, DK IN, IS	armaceu ppl., 7 XD2 E 11227 , AZ, B , DM, D , JP, K	ticals A/S, Den. 2 pp. APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ Z, EE, ES, FI, GB, GD E, KG, KP, KR, KZ, LC	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS,						
DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU HR, HU, II LT, LU, LY	Will Zeal PCT CODE Pate Engl 3 KIND Al AM, J, CZ, J, IL, J, MA,	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU DE, DK IN, IS MD, MG	armaceu ppl., 7 XD2 E 11227 , AZ, B , DM, D , JP, K , MK, M	ticals A/S, Den. 2 pp. APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ Z, EE, ES, FI, GB, GD E, KG, KP, KR, KZ, LC N, MW, MX, MZ, NO, NZ	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS, , PL, PT, RO,						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU HR, HU, II LT, LU, LV RU, SD, SE	Will Zeal PCT CODE Pate Engl 3 KIND Al A, AM, CZ, J, IL, MA, SG,	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU DE, DK IN, IS MD, MG	armaceu ppl., 7 XD2 E 11227 , AZ, B , DM, D , JP, K , MK, M	ticals A/S, Den. 2 pp. APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ Z, EE, ES, FI, GB, GD E, KG, KP, KR, KZ, LC	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS, , PL, PT, RO,						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU HR, HU, II LT, LU, LV RU, SD, SE VN, YU, ZA	Will Zeal PCT CODE Pate Engl 3 KIND Al AM, CZ, I, IL, MA, SG, ZW	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU DE, DK IN, IS MD, MG SI, SK	E 11227 , AZ, B , DM, D , JP, K , MK, M	APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ, EE, ES, FI, GB, GD, E, KG, KP, KR, KZ, LC, N, MW, MX, MZ, NO, NZ, TM, TR, TT, TZ, UA	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS, , PL, PT, RO, , UG, US, UZ,						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU HR, HU, II LT, LU, LV RU, SD, SE VN, YU, ZA RW: GH, GM, KE	Will Zeal PCT CODE Pate Engl 3 KIND Al AM, CZ, J, IL, MA, SG, ZW LS,	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU DE, DK IN, IS MD, MG SI, SK MW, MZ	E 11227 , AZ, B , DM, D , JP, K , MK, M , SL, T	APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ E, EE, ES, FI, GB, GD E, KG, KP, KR, KZ, LC N, MW, MX, MZ, NO, NZ J, TM, TR, TT, TZ, UA L, SZ, TZ, UG, ZW, AT	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS, , PL, PT, RO, , UG, US, UZ, , BE, CH, CY,						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU HR, HU, II LT, LU, LV RU, SD, SE VN, YU, ZA RW: GH, GM, KE DE, DK, ES	Will Zeal PCT CODE Pate Engl 3 KIND Al , AM, CZ, , IL, MA, CZ, , LS, , FI,	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU DE, DK IN, IS MD, MG SI, SK MW, MZ FR, GB	E 11227 , AZ, B , DM, D , JP, K , MK, M , SL, T	APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ E, EE, ES, FI, GB, GD E, KG, KP, KR, KZ, LC N, MW, MX, MZ, NO, NZ J, TM, TR, TT, TZ, UA L, SZ, TZ, UG, ZW, AT E, IT, LU, MC, NL, PT	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS, , PL, PT, RO, , UG, US, UZ, , BE, CH, CY, , SE, TR, BF,						
DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU HR, HU, II LT, LU, LV RU, SD, SE VN, YU, ZA RW: GH, GM, KE DE, DK, ES BJ, CF, CO	Will Zeal PCT CODE Pate Engl 3 KIND Al AM, CZ, IL, MA, SG, ZW LS, FI, G, CI,	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU DE, DK IN, IS MD, MG SI, SK MW, MZ FR, GB CM, GA	E 11227 , AZ, B , DM, D , JP, K , MK, M , SL, T , SD, S , GR, I	APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ E, EE, ES, FI, GB, GD E, KG, KP, KR, KZ, LC N, MW, MX, MZ, NO, NZ J, TM, TR, TT, TZ, UA L, SZ, TZ, UG, ZW, AT	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS, , PL, PT, RO, , UG, US, UZ, , BE, CH, CY, , SE, TR, BF,						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU HR, HU, II LT, LU, LV RU, SD, SE VN, YU, ZA RW: GH, GM, KE DE, DK, ES BJ, CF, CO	Will Zeal PCT CODE Pate Engl 3 KIND Al , AM, CZ, , IL, MA, CZ, , LS, , FI,	iam and Ph Int. A Int. A Int. A Int Int Ish DAT 200 AT, AU DE, DK IN, IS MD, MG SI, SK MW, MZ FR, GB CM, GA 200	E 11227	APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ Z, EE, ES, FI, GB, GD E, KG, KP, KR, KZ, LC N, MW, MX, MZ, NO, NZ J, TM, TR, TT, TZ, UA L, SZ, TZ, UG, ZW, AT E, IT, LU, MC, NL, PT W, ML, MR, NE, SN, TD CA 2001-2410224	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS, , PL, PT, RO, , UG, US, UZ, , BE, CH, CY, , SE, TR, BF, , TG 20010615 <						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU HR, HU, II LT, LU, LV RU, SD, SE VN, YU, ZA RW: GH, GM, KE BJ, CF, CO CA 2410224 EP 1294746	Will Zeal PCT CODE Pate Engl 3 KIND Al AM, CZ, IL, MA, SG, ZW LS, FI, CI, Al Al	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU DE, DK IN, IS MD, MG SI, SK MW, MZ FR, GB CM, GA 200 200	E 11227 , AZ, B , DM, D , JP, K , SL, T , SD, S , GR, I , GN, G 11227 30326	APPLICATION NO. APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ Z, EE, ES, FI, GB, GD E, KG, KP, KR, KZ, LC N, MW, MX, MZ, NO, NZ J, TM, TR, TT, TZ, UA L, SZ, TZ, UG, ZW, AT E, IT, LU, MC, NL, PT W, ML, MR, NE, SN, TD CA 2001-2410224 EP 2001-952155	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS, , PL, PT, RO, , UG, US, UZ, , BE, CH, CY, , SE, TR, BF, , TG 20010615 < 20010615 <						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU HR, HU, II LT, LU, LV RU, SD, SE VN, YU, ZA RW: GH, GM, KE BJ, CF, CO CA 2410224 EP 1294746	Will Zeal PCT CODE Pate Engl 3 KIND Al AM, CZ, IL, MA, SG, ZW LS, FI, CI, Al Al Al DE,	iam and Ph Int. A Int.	E 11227 , AZ, B , DM, D , JP, K , MK, M , SL, T , SD, S , GR, I , GN, G 11227 30326 , FR, G	APPLICATION NO. APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ Z, EE, ES, FI, GB, GD E, KG, KP, KR, KZ, LC N, MW, MX, MZ, NO, NZ J, TM, TR, TT, TZ, UA L, SZ, TZ, UG, ZW, AT E, IT, LU, MC, NL, PT W, ML, MR, NE, SN, TD CA 2001-2410224 EP 2001-952155 B, GR, IT, LI, LU, NL	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS, , PL, PT, RO, , UG, US, UZ, , BE, CH, CY, , SE, TR, BF, , TG 20010615 < 20010615 <						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU HR, HU, II LT, LU, LV RU, SD, SE VN, YU, ZA RW: GH, GM, KE DE, DK, ES BJ, CF, CO CA 2410224 EP 1294746 R: AT, BE, CH IE, SI, LT	Will Zeal PCT CODE Pate Engl 3 KIND Al AM, CZ, IL, MA, SG, ZW LS, FI, CI, Al Al Al DE,	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU DE, DK IN, IS MD, MG SI, SK MW, MZ FR, GB CM, GA 200 DK, ES FI, RO	E 11227 , AZ, B , DM, D , JP, K , MK, M , SL, T , SD, S , GR, I , GN, G 11227 30326 , FR, G , MK, C	APPLICATION NO. APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ Z, EE, ES, FI, GB, GD E, KG, KP, KR, KZ, LC N, MW, MX, MZ, NO, NZ J, TM, TR, TT, TZ, UA L, SZ, TZ, UG, ZW, AT E, IT, LU, MC, NL, PT W, ML, MR, NE, SN, TD CA 2001-2410224 EP 2001-952155 B, GR, IT, LI, LU, NL Y, AL, TR JP 2002-504279	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS, , PL, PT, RO, , UG, US, UZ, , BE, CH, CY, , SE, TR, BF, , TG 20010615 < 20010615 <						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO. PATENT NO. WO 2001098324 W: AE, AG, AI CO, CR, CU HR, HU, II LT, LU, LV RU, SD, SE VN, YU, ZA RW: GH, GM, KE BJ, CF, CO CA 2410224 EP 1294746 R: AT, BE, CH IE, SI, LT	Will Zeal PCT CODE Pate Engl 3 KIND Al AM, CZ, IL, MA, SG, ZW LS, FI, CI, Al Al I, DE, LV,	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU DE, DK IN, IS MD, MG SI, SK MW, MZ FR, GB CM, GA 200 DK, ES FI, RO	E 11227 , AZ, B , DM, D , JP, K , MK, M , SL, T , SD, S , GR, I , GN, G 11227 30326 , FR, G , MK, C	APPLICATION NO. APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ Z, EE, ES, FI, GB, GD E, KG, KP, KR, KZ, LC N, MW, MX, MZ, NO, NZ J, TM, TR, TT, TZ, UA L, SZ, TZ, UG, ZW, AT E, IT, LU, MC, NL, PT W, ML, MR, NE, SN, TD CA 2001-2410224 EP 2001-952155 B, GR, IT, LI, LU, NL TY, AL, TR	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS, , PL, PT, RO, , UG, US, UZ, , BE, CH, CY, , SE, TR, BF, , TG 20010615 < 20010615 < , SE, MC, PT, 20010615 < A 20000616 <						
SOURCE: DOCUMENT TYPE: LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: PATENT NO.	Will Zeal PCT CODE Pate Engl 3 KIND Al AM, CZ, IL, MA, SG, ZW LS, FI, CI, Al Al I, DE, LV,	iam and Ph Int. A N: PIX nt ish DAT 200 AT, AU DE, DK IN, IS MD, MG SI, SK MW, MZ FR, GB CM, GA 200 DK, ES FI, RO	E 11227 , AZ, B , DM, D , JP, K , MK, M , SL, T , SD, S , GR, I , GN, G 11227 30326 , FR, G , MK, C	APPLICATION NO. APPLICATION NO. WO 2001-US19113 A, BB, BG, BR, BY, BZ Z, EE, ES, FI, GB, GD E, KG, KP, KR, KZ, LC N, MW, MX, MZ, NO, NZ J, TM, TR, TT, TZ, UA L, SZ, TZ, UG, ZW, AT E, IT, LU, MC, NL, PT W, ML, MR, NE, SN, TD CA 2001-2410224 EP 2001-952155 B, GR, IT, LI, LU, NL Y, AL, TR JP 2002-504279	DATE 20010615 < , CA, CH, CN, , GE, GH, GM, , LK, LR, LS, , PL, PT, RO, , UG, US, UZ, , BE, CH, CY, , SE, TR, BF, , TG 20010615 < 20010615 <						

US 2000-251671P P 20001206 <-US 2001-298186P P 20010613
WO 2001-US19113 W 20010615
WO 2001-US41008 A 20010615

OTHER SOURCE(S): MARPAT 136:64121

Disclosed are a variety of peptide conjugates represented by the following general formula R1-Z-X-Z'-R2, wherein X represents a hexapeptide of the formula A1-A2-A3-A4-A5-A6 wherein A1 represents Arg, Lys, or His, A2 represents Tyr, Trp, or Phe, A3 represents Tyr, Asn, Trp or Phe, A4 represents Lys, Arg or His, A5 represents Phe, Tyr, Trp, Leu, Val or Ile, and A6 represents Arg, Lys, or His and wherein each amino acid residue in said hexapeptide may be in the L or D form; Z represents a charged peptide chain of from 4 to 20 amino acid residues having the D or L configuration or is missing; and Z' represents a charged peptide chain of from 4 to 20 amino acid residues having the D or L configuration or is missing, providing that not both of Z and Z' are missing; R1 represents H or an acyl group; R2 represents NR3R4 where each of R3 and R4 independently represents hydrogen, C(1-6)alkoxy, aryloxy, or a lower alkyl as defined herein; or R2 represents OH; the peptide conjugates of formula (I) being optionally further linked to a transport moiety; and salts, hydrates and solvates thereof, and C-terminally amidated or esterified derivs. thereof with suitable organic or inorg. acids, including methods or making and using such conjugates. Also provided are antibodies that specifically bind the peptide conjugates. The present invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides.

IC ICM C07K007-08

ICS C07K014-00; C07K016-44; A61K038-16; C07K007-06; C07K014-575; A61K038-04

CC 1-8 (Pharmacology)

Section cross-reference(s): 15, 34, 63

RETABLE

Referenced Author (RAU)	Year (RPY)		•	Referenced Work (RWK)	Referenced File +=======
Lapalu, S Meunier, J		-	333 893	FEBS LETTERS PEPTIDES	HCAPLUS HCAPLUS
Novonordisk As	1999			WO 9944627 A	HCAPLUS

L98 ANSWER 13 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 2001:504962 HCAPLUS Full-text

DOCUMENT NUMBER: 135:298164

TITLE: Structure-activity relationships of novel peptides

related to the antiarrhythmic peptide AAP10 which reduce the dispersion of epicardial action potential

duration

AUTHOR(S): Grover, R.; Dhein, S.

CORPORATE SOURCE: Institute of Pharmacology, University of Cologne,

Cologne, 50931, Germany

SOURCE: Peptides (New York, NY, United States) (2001), 22(7),

1011-1021

CODEN: PPTDD5; ISSN: 0196-9781

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal LANGUAGE: English

We report the first study on short peptide structure-activity relationships (SAR) for the antiarrhythmic peptide AAP10 and its putative receptor. Synthetic improvements on the natural antiarrhythmic peptide AAPnat (H-Gly-Pro-Hyp-Gly-Ala-Gly) isolated from bovine atria led us to the synthesis of our lead mol. AAP10 (H-Gly-Ala-Gly-Hyp-Pro-Tyr-NH2) which reduces dispersion of epicardial potential duration and acts antiarrhythmically in isolated rabbit

hearts. The aim of our study was to elucidate structure-activity relationships for AAP10 based on Langendorff expts. and mol. modeling. Mutation of the amino acid sequence led to 11 different peptides which were tested analogous to the lead mol. Among these new synthetic peptides various including the cyclopeptide cAAP10RG, cyclo[CF3C(OH)-Gly-Ala-Gly-Hyp-Pro-Tyr] showed promising activities. (supported by the DFG and Koln-Fortune).

CC 1-3 (Pharmacology)

IT 81771-37-1, Antiarrhythmic peptide (cattle atrium)
159503-65-8 366800-46-6 366800-47-7 366800-48-8
366800-49-9 366800-50-2 366800-51-3 366800-52-4 366800-53-5
366800-54-6 366800-55-7 366800-56-8 366800-57-9 366800-58-0

366800-59-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(structure-activity relationships of novel peptides related to antiarrhythmic peptide AAP10 which reduce dispersion of epicardial action potential duration)

IT 81771-37-1, Antiarrhythmic peptide (cattle atrium) 159503-65-8 366800-53-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(structure-activity relationships of novel peptides related to antiarrhythmic peptide AAP10 which reduce dispersion of epicardial action potential duration)

RN 81771-37-1 HCAPLUS

CN Antiarrhythmic peptide (cattle atrium) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 159503-65-8 HCAPLUS

CN retro-Antiarrhythmic peptide (cattle atrium), 6-L-tyrosinamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & & & \\ \text{Me} & & & \\ \text{NH} & & & \\ \text{HO} & & & \\ \end{array}$$

RN 366800-53-5 HCAPLUS

CN L-Tyrosinamide, glycyl-L-alanylglycyl-L-prolyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RETABLE					
Referenced Author	Year	VOL	PG	Referenced Work	Referenced
(RAU)	(RPY)	(RVL)	(RPG)	(RWK)	File
=======================================	+=====	== -	+=====·	•	-======================================
Atherton, E	1989			Solid phase peptide	
Beck-Sickinger, A	1991	4	88	Pept res	HCAPLUS
Bhacca, N	1962			High resolution NMR	
Carpino, L	1972	37	3404	J Org Chem	HCAPLUS
Curphey, T	1979	44	2805	J Org Chem	HCAPLUS
Dhein, S	1999	128	1375	Br J Pharmacol	HCAPLUS
Dhein, S	1993	87	617	Circulation	HCAPLUS
Dhein, S	1997	96	I-292	Circulation	
Dhein, S	1995	49	851	Drugs	HCAPLUS
Dhein, S	1997	2	51	Exp Clin Cardiol	
Dhein, S	1994	350	174	Naunyn Schmiedebergs	
Dhein, S	1994	349	R55	Naunyn Schmiedebergs	
Dhein, S	1999	359	R7	Naunyn Schmiedebergs	
Dhein, S	1995	429	R91	Pflug Arch Eur J Phy	•
Dhein, S	1998		163	Proceedings of Inter	
Durrer, D	1954	47	192	Am Heart J	MEDLINE
Friebolin, H	1988		İ	Ein-Und Zweidimensio	l
Gottwald, E	1998	79	474	Heart	MEDLINE
Grover, R	1998	19	1725	Peptides	HCAPLUS
Han, J	1964	16	46	Circ Res	
Kjolbye, A	2000	14	A698	The FASEB J	'
Kuo, C	1983	67	1356	Circulation	MEDLINE
Lesh, M	1989	65	1426	Circ Res	MEDLINE
Meyer, V	1978	İ	<u> </u>	Praxis in der HPLC	
Millar, C	1985	72	1372	Circulation	MEDLINE
Mueller, A	1997	327	65	Eur J Pharmacol	HCAPLUS
Mueller, A	1997	356	76	Naunyn Schmiedebergs	HCAPLUS
Nomizu, M	1994	20	2691	Tetrahedron	
Patrick, G	1995	ĺ	ĺ	An introduction to m	
Rink, H	1987	28	3787	Tetrahedron Lett	HCAPLUS
Viswanadhan, V	1989	29	163	J chem inf comput sc	HCAPLUS
Wang, S	1973	95	1328	J Amer Chem Soc	HCAPLUS
Wiener, S	1984	106	765	J Am Chem Soc	1
•	•	•			

L98 ANSWER 14 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

10772774 2000:144722 HCAPLUS Full-text ACCESSION NUMBER: 132:185454 DOCUMENT NUMBER: Use of anti-angiogenic agents for inhibiting vessel TITLE: wall injury Brown, Charles L., III; Gorlin, Steve INVENTOR (S): Global Vascular Concepts, Inc., USA PATENT ASSIGNEE(S): PCT Int. Appl., 29 pp. SOURCE: CODEN: PIXXD2 Patent DOCUMENT TYPE: English LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: DATE APPLICATION NO. KIND DATE PATENT NO. _____ _____ _ _ _ _ _____ 20000302 WO 1999-US19218 19990824 <--A2 WO 2000010552 **A**3 20001123 WO 2000010552 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG 19990824 <--AU 1999-56871 A1 20000314 AU 9956871 P 19980824 <--US 1998-97579P PRIORITY APPLN. INFO.: W 19990824 <--WO 1999-US19218 Use of anti-angiogenic agents to inhibit an undesirable response to vessel AB wall injury, including stent neointima, dialysis graft neointima, vascular graft-induced neointima, and the treatment of benign hypertrophic scar formation as well as the treatment and passivation of unstable atherosclerotic plaques are provided. The invention provides for the use of catheter-based devices for enhancing the local delivery of anti-angiogenic agents into the endothelial tissues of blood vessels of the living body. ICM A61K031-00 IC 63-6 (Pharmaceuticals) CC Section cross-reference(s): 1 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide 50-81-7D, IT Ascorbic acid, ethers, biological studies 52-01-7, Spironolactone 53-05-4, Tetrahydrocortisone 53-86-1, Indomethacin 60-33-3, Linoleic acid, biological studies 60-54-8, Tetracycline 68-96-2, 17α-Hydroxyprogesterone 128-13-2, Ursodeoxycholic acid 145-63-1, Suramin 152-58-9, Cortexolone 302-79-4, Retinoic acid 362-07-2, 2-Methoxyestradiol 446-72-0, Genistein 465-21-4, Bufalin 566-35-8 2609-46-3, Amiloride 4431-00-9, Aurine tricarboxylic acid 10118-90-8, Minocycline 12772-57-5, Radicicol 19545-26-7, Wortmannin 33069-62-4, Taxol 34031-32-8, Auranofin 37270-94-3, Platelet factor 4 38096-31-0, Diaminoanthraquinone 38194-50-2, Sulindac 50903-99-6, 53902-12-8, Tranilast 57381-26-7, Irsogladine 62571-86-2, Captopril 62996-74-1, Staurosporine 65646-68-6, Fenretinide 70563-58-5, Herbimycin A 79831-76-8, Castanospermine 86090-08-6, Angiostatin 100827-28-9, Erbstatin 103909-75-7,

105219-56-5, WEB 2086

110124-55-5, MDL 27032 125697-92-9, Lavendustin A 126509-46-4, Eponemycin 129298-91-5, TNP-470 130370-60-4, BB-94 134633-29-7, Tecogalan sodium 142186-14-9, FR-118487 148717-90-2, Squalamine 154039-60-8, Marimastat 171784-03-5, Louisianine A 171784-04-6, Louisianine B 171784-06-8, Louisianine D 187888-07-9, Endostatin

22-Oxa-1α-25-dihydroxyvitamin D3

188417-67-6, CM 101 204005-46-9, SU5416

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anti-angiogenic agents for inhibiting vessel wall injury)

IT 57381-26-7, Irsogladine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anti-angiogenic agents for inhibiting vessel wall injury)

RN 57381-26-7 HCAPLUS

CN 1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

L98 ANSWER 15 OF 37 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:37178 HCAPLUS Full-text

DOCUMENT NUMBER: 13

132:343088

TITLE:

Protective effect of irsogladine on

monochloramine-induced gastric mucosal lesions in

rats: a comparative study with Rebamipide

AUTHOR (S):

Yamamoto, H.; Umeda, M.; Mizoguchi, H.; Kato, S.;

Takeuchi, K.

CORPORATE SOURCE:

Department of Pharmacology and Experimental

Therapeutics, Kyoto Pharmaceutical University, Kyoto,

607-8414, Japan

SOURCE:

World Journal of Gastroenterology (1999),

5(6), 477-482

CODEN: WJGAF2; ISSN: 1007-9327 World Journal of Gastroenterology

PUBLISHER:

Journal

DOCUMENT TYPE:

English

LANGUAGE: Aim: To examine the effect of irsogladine, a novel antiulcer drug, on the mucosal ulcerogenic response to monochloramine (NH2Cl) in rat stomach, in comparison with Rebamipide, another antiulcer drug with cytoprotective activity. Methods and Results: Oral administration of NH2Cl (120 mM) produced severe hemorrhagic lesions in unanesthetized rat stomachs. Both irsogladine (1-10 mg/kg, orally) and Rebamipide (30-100 mg/kg, orally) dose-dependently prevented the development of these lesions in response to NH2Cl; the effect of irsogladine was significant at ≥ 3 mg/kg and that of Rebamipide only at 100 mg/kg. The protective effect of irsogladine on NH2Cl-induced gastric lesions was significantly reduced by NG-nitro-L-arginine Me ester (L-NAME) but not by indomethacin, while that of Rebamipide was significantly mitigated by indomethacin but not by L-NAME. Topical application of NH2Cl (20 mM) caused a marked reduction of p.d. (PD) in ex-vivo stomachs. This PD reduction was not affected by mucosal application of irsogladine but significantly prevented by Rebamipide. The mucosal exposure to NH4OH (120 mM) also caused a marked PD reduction in the ischemic stomach (bleeding from the carotid artery), resulting in gastric lesions. These ulcerogenic and PD responses caused by NH4OH plus ischemia were also significantly mitigated by Rebamipide, in an indomethacin-sensitive manner, while irsogladine potently prevented such lesions without affecting the PD response, in a L-NAME-sensitive manner. Conclusions: These results suggest that (1) NH2Cl generated either exogenously or endogenously damages the gastric mucosa, (2) both irsogladine and